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Summary 
Background: Psoriasis is a common chronic immunological inflammatory skin disease. 
The most usual phenotype, vulgaris type, has characteristic lesions known as plaques on 
the surface of the skin. The precise trigger of psoriasis vulgaris is yet to be fully 
elucidated; however, factors such as an inherited genetic component and smoking 
increase likelihood of its development. At cellular level, inflammatory factors are 
present in dermal and epidermal skin layers and excessive skin cell proliferation occurs. 
Sufferers of psoriasis vulgaris often experience psychological illness, with quality of life 
(QoL) measures employed along with symptomatic measures to determine disease 
severity. Recently, psoriasis has been shown to be associated with increased risk of 
serious co-morbidities such as cardiovascular disease and diabetes. 
With no cure available, current recommended therapies only manage symptoms 
associated with the disease. Although newer biological therapies provide effective 
symptom management, they are commonly expensive and due to their reduced safety 
profile, recommended only for severe psoriasis cases. The costs of psoriasis 
management for individuals and the health system are high. Hence, further effective, 
and safer therapies are needed. Chinese herbal medicine (CHM) has been utilised for 
centuries for the management of numerous health conditions including symptoms 
associated with psoriasis.  
Methods: Firstly, two systematic reviews and meta-analyses were conducted to 
examine published CHM research for psoriasis. 1), Using the Cochrane Library 
Systematic Review Method, major English and Chinese databases were searched for 
randomised controlled trials (RCTs) of oral CHM for psoriasis vulgaris compared with 
placebo. Included studies were pooled for meta-analysis and risk of bias was assessed 
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using the Cochrane risk of bias tool. 2), Further systematic review using the same 
rigorous methods was undertaken for RCTs combining oral CHM with conventional 
therapy for psoriasis vulgaris.  
Secondly, in vitro and in vivo data were reviewed in regard to commonly used CHM 
formulation of herbal ingredients. This review aimed to evaluate the biological 
mechanisms of the major constituents of each herb that potentially impact on the 
molecular pathways of psoriasis. Taking the same methods further, in-depth review was 
undertaken of the chief ingredient chi shao and its simile bai shao. Botany and 
ethnopharmacology of the constituents of botanical species referred to as chi shao and 
bai shao were compared to determine the source product for an oral CHM formulation 
(PSORI-CM01).  
From review of RCT data, available CHM treatment guidelines and consultation 
with experts, an optimised oral CHM formulation (PSORI-CM01) was developed for 
psoriasis vulgaris. To clinically evaluate the oral CHM formula PSORI-CM01, a pilot RCT 
was developed based on the methodological strengths and weaknesses of reviewed 
RCTs and using available trial design recommendations such as pragmatic–explanatory 
continuum indicator summary, consolidated standards of reporting trials (CONSORT) 
and the extensions to CONSORT for herbal studies.  
Results: Literature review indicated mild–moderate psoriasis is currently undertreated, 
and that topical treatments, while being affordable, have limited efficacy. Systematic 
review found oral CHM has benefit for psoriasis compared with placebo; however, the 
effect size is relatively small. Considering this effect was relatively low, a further 
systematic review was undertaken to evaluate the effects of CHM combined with 
conventional therapy. Results from this review indicated increased effect for 
conventional therapies when combined with CHM, and reduced adverse events.  
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The subsequent pilot RCT is to investigate oral CHM formulation PSORI-CM01 in a 
mild to moderate psoriasis vulgaris (psoriasis area severity index (PASI) 7–12) 
population. The pilot study is designed as a double-blinded, randomised, placebo-
controlled trial. Thirty participants are to be randomised to receive PSORI-CM01 plus 
calcipotriol or placebo plus calcipotriol. Eligible participants undergo a two-week run-in 
phase followed by a 12-week treatment phase and 12-week follow-up phase. The pilot 
study is to determine the feasibility of the design for an adequately powered RCT, as 
well as to gather preliminary outcome data for further trial sample size estimation. The 
primary outcome measure is psoriasis severity (PASI) change (%) and secondary 
measures are: PASI 75 rate, QoL change using dermatology life quality index (DLQI) and 
Skindex 29 acceptability of treatment and change to psoriasis-related cytokines (such as 
TNF-α and IL-23). Safety of oral CHM is also assessed via reporting of adverse events as 
well as monitoring liver and kidney function via blood pathology changes. 
 Outcomes are measured at baseline (week 0), mid-treatment (week 6), end of 
treatment (week 12) and at the end of the follow-up phase (week 24). Between 
assessments, fortnightly compliance and safety phone calls are conducted, and a daily 
diary of medication use as well as adverse event reporting is self-completed by 
participants. Outcome measure data are analysed using the intention-to-treat principle 
and missing data substituted with the last observation carried forward method. Using 
SPSS software, tests for equivalence between the treatment and control group are 
undertaken with P-values <0.05 considered statistically significant. Blood plasma 
samples are collected at week –2, week 12 and week 24 and concentrations of 
inflammatory cytokines measured via multi-assay techniques (Bio-Plex® Multiplex 
System). 
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Subsequent review of in vitro and in vivo evidence recognised PSORI-CM01 
constituents act on pathways similar to those of conventional drug therapies. Review of 
botanical species commonly used as primary ingredient chi shao recognised it was 
sourced predominantly from two peony species, Paeonia. lactiflora Pallas and Paeonia 
veitchii Lynch A review of the literature indicated that Radix Paeoniae Rubra (chi shao) 
included in the formulation was of high quality and contained the required active 
constituents for psoriasis. 
The developed pilot RCT is currently ongoing. Fourteen eligible participants 
commenced run-in phase; three of these participants withdrew during the run-in phase 
due to abnormal liver function pathology results. The remaining 11 participants were 
randomised to treatment at baseline, however two of these dropped out during the 
treatment phase – one was lost prior to week 12 (end of treatment assessment) and the 
other withdrew due to time constraints before end of week 6 (mid-treatment 
assessment). Baseline analysis revealed the mean PASI score of the 11 participants was 
9.0±2.4, and DLQI score was 10±7.6. One occasion of serious adverse event was 
reported with itch requiring medical intervention. Most adverse events were otherwise 
reported mild and include itch, dizziness, headache and nausea; however, it is not yet 
known what group these events were reported in. Trial recruitment continues and full 
data analysis will be conducted when the last recruited participant finishes their follow-
up phase. 
Conclusion: Oral CHM has promising efficacy for psoriasis and enhances the efficacy of 
conventional treatments when combined. Evidence suggests combined treatment is safe; 
however, long-term follow-up data are limited. Efficacy of CHM is related to the 
mechanistic actions of contained constituents, some of which coincide with 
conventional drug treatment targets. CHM PSORI-CM01 has in vitro and in vivo evidence 
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indicating that therapeutic benefit is via modulation of known psoriatic biological 
pathways. The current pilot study will provide data on the feasibility of a larger-scale 
study and provide preliminary data for PSORI-CM01 efficacy and safety. 
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Chapter 1 – General introduction 
The suffix of psoriasis, ‘psora’ meaning ‘to itch’, gained its name from Hippocrates (460–
377 BCE) (Nickoloff and Nestle, 2004). Historically, psoriasis was mistaken for leprosy, 
biblical texts detailing the unfortunate and unwarranted isolation of sufferers to avoid 
spread of what was thought to be a contagious disease (Glickman, 1986). Modern 
medicine has determined since that psoriasis is a non-communicable disease, with no 
relationship to leprosy (World Health Organization (WHO), 2013). Today psoriasis is 
the broad term used for a disease encompassing many phenotypes, each differing in 
morphology and prevalence. Most commonly psoriasis sufferers present with thickened 
skin regions, known as ‘plaques’ on the extensor surfaces of arms and legs, however, 
other body locations can also be afflicted. Psoriasis is understood to develop from 
hyperactive immune function, with excessive inflammation and the hyper-proliferation 
of abnormal skin cells in affected areas. The precise trigger is not known, but many 
aetiological factors have been implicated. Sufferers commonly report physical 
discomfort such as itching, bleeding and skin irritation. The visual appearance of lesions 
is unsightly and sufferers commonly experience psychological distress as a result. There 
is currently no cure for psoriasis and many treatments have limited use due to risk of 
side effects and/or their high cost. The efficacy of treatments is also limited by the 
potential development of tolerance and/or resistance to drug therapy.  
Although, historically, the use of CHM for psoriasis has been documented to be 
effective, scientific evidence of its efficacy and safety is inconclusive. Hence, currently no 
international treatment guidelines recommend CHM for psoriasis. 
The aims of this study are to: evaluate available evidence for the efficacy and 
safety of CHM for psoriasis; evaluate available evidence for the efficacy and safety of 
combining CHM and conventional pharmacotherapy for psoriasis; develop an evidence-
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based CHM formulation for psoriasis; review the potential biological activity of 
phytochemicals in the CHM formulation for psoriasis; develop the protocol for a clinical 
trial to investigate the developed CHM formulation; and undertake a pilot study to 
evaluate the feasibility of the trial design. 
This thesis presents: results of associated systematic reviews; explanation of how 
the evidence-based oral CHM formulation (PSORI-CM01) was developed; investigation 
of key phytochemicals with potential to act on psoriasis pathogenic pathways; and the 
protocol design and implementation of a pilot double-blind, randomised, placebo-
controlled study ‘integrative medicine for psoriasis study’ ((IMPPS) Australian New 
Zealand Clinical Trials Registry ACTRN12614000493640). The study includes 
participants with mild to moderate psoriasis vulgaris severity and is currently ongoing; 
however, analyses of interim study data are presented. 
Chapter 2 explores the aetiology and pathogenesis of the psoriatic disease. A 
literature review presents the current understanding of psoriasis, citing published 
scientific research for potential triggers and risk factors of disease development. 
Chapter 2 also identifies psoriasis research gaps, where further scientific investigation 
is needed to better understand the development of psoriasis. The chapter then goes on 
to differentiate between psoriasis phenotypes and reviews the global prevalence, 
incidence and health cost implications of psoriatic disease. Referring to international 
treatment guidelines, the significance of disease severity is then explained. For accurate 
and consistent measure of psoriasis severity, the available psoriasis-specific severity 
instruments are evaluated, presenting the strengths and weaknesses of their use in 
clinical study. The impacts of psoriasis on QoL are also discussed, and again relevant 
instruments are reviewed for their suitability in clinical study.  
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A number of potential co-morbidities have growing association with psoriasis. Chapter 
2 reviews the available evidence for the co-morbidities most often identified. Current 
first and second line conventional therapy options are then reviewed, exploring where 
available, their mechanistic actions and any associated physiological risks. Newer ‘third 
line’ biologic drugs are also described, as are future emerging therapies and the 
direction of future drug development. 
Lastly, the chapter discusses the scientific evidence for herbal psoriasis therapies. 
Historical use of CHM for psoriasis is described and its potential benefits for modern use 
are explored.  
Chapter 2 defined the characteristics of the population to be targeted in the clinical 
study; psoriasis type, severity, age group and any excluding factors.  
Review in this chapter assisted to determine the conventional therapy utilised in 
the IMPPS, and guided development of clinically relevant outcome measures for the 
study, aiding selection of suitable instruments. The chapter also assists identify 
potential psoriasis-related biological markers for analyte assay of clinical study 
participant plasma samples. 
In Chapter 3 via systematic review of published randomised controlled trials 
(RCTs) and subsequent meta-analyses of extracted data, the efficacy and safety of oral 
CHM is evaluated for psoriasis vulgaris compared to placebo. The systematic review 
also evaluates trial design of previous RCTs to assess their strengths and weaknesses. 
From the included RCTs, the most common utilised CHM are identified and their 
phytochemicals are explored for potential psoriasis-related pathway activity. The 
results of this chapter assist development; of the trial design; of the investigative 
formulation ingredients, assessment of the general safety of oral CHM and provides 
insight into potential psoriasis biological pathway targets. 
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Further review is presented in Chapter 4, which examines the potential add-on 
effects of oral CHM to conventional therapy. Systematic review and meta-analyses are 
presented on the safety and efficacy of RCTs integrating oral CHM and conventional 
therapy for psoriasis vulgaris. Again, trial designs of included RCTs are evaluated and 
the most commonly utilised CHM again presented for identification of phytochemicals 
with potential psoriatic activity. This chapter further assists selection of a suitable 
conventional therapy for the pilot study and confirms the safety of combined therapies 
for further study.  
Chapter 5 utilises data from the previous chapter reviews along with Chinese 
medicine theory (textbook and recommended treatment guidelines), phytochemical 
evidence and expert opinion to develop an oral CHM, using an evidence-based approach, 
for further clinical investigation. Chinese medicine syndrome differentiation in Chinese 
medicine theory is discussed along with its relevance to selection of herbal ingredients 
and how such selection may influence treatment outcomes. The chapter then describes 
early development of a CHM formulation and presents evidence supporting its potential 
use for psoriasis disease. The ingredients of the final formulation (PSORI-CM01) are 
then described. The main phytochemicals the early developed and final formulations 
are also reviewed, briefly presenting, where available, evidence for their biological 
activity with potential anti-psoriatic action. This chapter primarily describes selection 
of psoriasis vulgaris targeting CHM formula PSORI-CM01 and provides a review of the 
key therapeutic phytochemical markers for the final manufactured product. The chapter 
also describes the development of an instrument, which assesses Chinese medicine 
syndrome for use in the subsequent study. 
Chapter 6 explores PSORI-CM01’s main herbal ingredient, Radix Paeoniae Rubra 
(chi shao). The chapter reviews the two official botanical sources of Radix Paeoniae 
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Rubra, comparing their general characteristics as well as their constituent 
phytochemicals. Review of the published scientific evidence for these phytochemicals 
presents their potential therapeutic biological activities. Results of this chapter assisted 
in determining the species to utilise as Radix Paeoniae Rubra for PSORI-CM01. This 
section also provides a comprehensive review of the phytochemical biological activity of 
each Radix Paeoniae Rubra species for future investigation.  
Chapter 7 describes the development of the clinical study protocol to evaluate 
PSORI-CM01 for psoriasis. Initially, the pros and cons of pragmatic and explanatory 
study designs for oral CHM are discussed, compared with pharmaceutical therapies. The 
chapter also details how the results of previous chapters influenced design of the pilot 
study. Details of the pilot protocol are presented in full according to the population, 
intervention, control, and outcomes (PICO) structure. The chapter then goes on to detail 
the standard operating procedures for the study and strategies employed for 
advertisement and recruitment. The chapter primarily presents development of the 
protocols of the pilot and provides justification for the final design. 
Chapter 8 presents preliminary results of the pilot study and discusses the 
progress of the study to date. It summarises current study progress and preliminarily 
evaluates the strengths and weaknesses of the study design. Study limitations are also 
discussed and methods are suggested to improve study design for future larger-scale 
studies. Adverse event data are reported and the feasibility of the trial protocol is 
preliminarily evaluated.  
Chapter 9 presents a summary of the main findings of the thesis. It presents a brief 
overview of the results of each chapter. This last section identifies the overall 
significance of the thesis and provides researchers and clinicians with 
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recommendations for integrating oral CHM and conventional therapy in clinical therapy 
and research. 
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Chapter 2 – Psoriasis disease review 
This chapter reviews the phenotypes of psoriasis, the aetiology and pathogenesis of 
psoriasis, the epidemiology and socioeconomic burden of the disease, measurement of 
psoriasis severity, associated co-morbidities, available therapies based on major 
therapeutic guidelines and their biological actions on psoriatic disease. It then reviews 
herbal therapies for psoriasis including CHM. 
2.1 The phenotypes of psoriasis  
A number of different psoriasis phenotypes have been identified, each with unique 
visual and symptomatic characteristics. This section differentiates each of the main 
phenotypes.  
2.1.1 Psoriasis vulgaris  
Of psoriasis phenotypes, vulgaris is the most common, presenting in about 80% of 
psoriasis cases (Biondi Oriente et al., 1989). Vulgaris type lesions are predominantly 
elevated and linear, most commonly on elbows, knees, scalp, hands and feet 
(Dermatology Expert Group, 2004). Accompanying symptoms may include itching, 
irritation, stinging and/or pain (World Health Organization (WHO), 2013). The raised 
red lesions typically have an adherent, thick, silver, scaly appearance from which 
itderived the more common name ‘plaque’ psoriasis (Figure 2.1)(Clarke, 2011, 
Weisshaar, 2012). Although rare for vulgaris type, psoriasis skin surface effects over the 
entire body can be fatal. Extensive inflammation and peeling of the skin can in turn 
reduce the skin’s barrier function and subsequently the body is unable to its regulate 
temperature (Fitzpatrick et al., 2009). 
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2.1.2 Guttate psoriasis  
Red in appearance and typically tear-shaped with central body distribution, guttate 
psoriasis has the highest incidence in children, where typically it follows bacterial 
infection, such as streptococcal pharyngitis (Figure 2.2: Guttate psoriasis)(Henley, 
2012).  
2.1.3 Inverse (flexural) psoriasis  
Presenting in flexural folds such as axilla and inguinal regions, inverse psoriasis is also 
known as flexural psoriasis. Unlike psoriasis vulgaris, its lesions appear shinier and are 
more moist. As their location is exposed to more sweat and friction, irritation is typical 
in sufferers (Figure 2.3: Flexural psoriasis) (Syed and Khachemoune, 2011) 
2.1.4 Erythrodermic psoriasis  
Deemed to be the most severe form of psoriasis, erythrodermic psoriasis sufferers 
present with diffuse erythema and typically extensive fine scaling over the body. 
Subsequent inflammation can affect the body’s ability to regulate temperature and 
fluids, where patients risk death from severe fever or infection (Figure 2.4: 
Erythrodermic psoriasis)(Boyd and Menter, 1989).  
2.1.5 Pustular psoriasis  
Pustular psoriasis has a number of patterns distinguished by their appearance and 
development: generalised (or von Zumusch), annular, exanthematic or localised. A key 
feature is an erythematous area consisting of surface pustules, which may or may not be 
painful (Figure 2.5: Pustular psoriasis)(Baker and Ryan, 1968). 
2.1.6 Further phenotyping 
Psoriasis phenotypes may be further classified based on their location, such as the scalp, 
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genitals, or palms of the hand and soles of the feet (palmoplantar) (Ayala, 2007, 
Raychaudhuri et al., 2014). Psoriasis location can influence disease severity and in some 
circumstances, such as palmoplantar, it can be debilitating (Figure 2.6: Acral 
psoriasis)(Janagond et al., 2013, Ayala, 2007, Burfield and Burden, 2013). 
 
 
Figure 2.1: Psoriasis vulgaris lesion (DermNet New Zealand Trust, 2014) 
 
 
Figure 2.2: Guttate psoriasis (DermNet New Zealand Trust, 2014) 
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Figure 2.3: Flexural psoriasis (DermNet New Zealand Trust, 2014) 
 
 
Figure 2.4: Erythrodermic psoriasis (DermNet New Zealand Trust, 2014) 
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Figure 2.5: Pustular psoriasis (DermNet New Zealand Trust, 2014) 
 
. 
Figure 2.6: Acral psoriasis (DermNet New Zealand Trust, 2014) 
 
2.1.7 Psoriatic arthritis 
A common co-symptom found in psoriasis sufferers is arthritis of joints, in which as well 
as lesion development there is gradual increasing damage to joints from inflammation. 
The damage leads to associated pain, stiffness and joint deformity, which for some can 
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be debilitating (Figure 2.7: Psoriasis-associated arthritis). Associated incidence of 
arthritis is found in 30–40% of psoriasis sufferers (Haroon et al., 2013, Boehncke and 
Menter, 2013). Over 86% of psoriatic arthritis sufferers report psoriatic lesion 
development prior to psoriatic arthritis and diagnosis of psoriasis on average precedes 
the arthritis by 14.6 years (Armstrong et al., 2012). 
 
 
Figure 2.7: Psoriasis-associated arthritis (DermNet New Zealand Trust, 2014) 
 
2.2 Aetiology and pathogenic mechanisms of psoriasis 
Theory of psoriatic aetiology and pathogenesis has guided development of new 
therapies however there is still conjecture about the precise mechanisms involved. This 
section reviews the current understanding and evidence for factors affecting psoriatic 
pathogenesis and aetiology, identifing mechanistic gaps where further research is 
needed. 
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2.2.1 A general understanding of psoriasis aetiology 
Until recently, scientists believed psoriasis to be a relatively benign disease, with the 
unsightly appearance and discomfort thought to be the only risks to sufferers. With 
clinical pathologic and histological study improving over the years, understanding of the 
pathophysiology of psoriasis has improved significantly (Murphy et al., 2007). Now, 
researchers understand that psoriasis is likely a systemic disease of the body, with 
increased risk to a number of associated co-morbidities (Kimball et al., 2008).  
The main differences between psoriatic and healthy skin are increased presence of 
inflammatory cells and increased proliferation of abnormal skin cells. Although the 
precise cause of psoriasis has not been elucidated, much is known of the psoriasis 
cellular response and progression once activated. Likely following ‘trigger’ (activation) 
by an antigen of some type (external or autoimmune), initially CD4+ type T-lymphocyte 
cells (also known as T-cells) infiltrate, going on to develop into specific T-cell subsets 
(Korn et al., 2009). One theory is that in some people the skin’s barrier function is 
reduced leaving them more susceptible to antigen attack and psoriasis development 
(Feingold, 2014). Research suggests the initial triggers may vary, as they are shown to 
be inconsistent for psoriasis development. Another plausible, yet unsubstantiated, 
theory suggests genetic immune system mutation potentiates psoriasis (Fry et al., 2014). 
Research indicates that further investigation of psoriasis triggering antigens is needed 
as well as how they might link to genetic polymorphisms (Ryan et al., 2013). However, 
substantial research has been carried out on the biological processes, which follow the 
onset of psoriasis.  
Looking at the visual features of psoriatic skin under a microscope and reconising 
the physiological changes occurring, can identify the stage of lesion development. Early 
dermal changes see an increase of T-cell infiltrate, neutrophils, activated mast cells and 
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plasmacytoid dendritic cells. Identified as important in subsequent upstream 
development of psoriasis lesions, the plasmacytoid dendritic cells produce key psoriasis 
related cytokine, interferon-α (IFN-α). Later, plasmacytoid dendritic cells differentiate 
into dendritic cells (DCs), and it has been proposed that drug development should 
target this phase, preventing IFN-α release for earlier treatment and/or preventing 
psoriasis (Nestle et al., 2005).  
Dendritic cells are antigen detection and presenting cells originating from bone 
marrow. In psoriasis they circulate in the bloodstream and migrate to peripheral tissues 
where they process antigens and present them to circulating T-cells and B-lymphocytes 
(B-cells), further triggering psoriasis immunological response (Boehncke et al., 2010, 
Bowcock and Krueger, 2005). Likely acting as auto-antigens, research has shown that 
adenosine triphosphate, induced by an antimicrobial peptide known as LL37 and 
receptor P2X7, further increases DC maturation and inflammation (Killeen et al., 2013, 
Lande et al., 2014). Interestingly, in psoriatic patients, DCs located at psoriatic regions 
are stronger stimulators of T-cell proliferation than DCs derived from non-psoriatic 
peripheral blood or skin (Nestle et al., 1994). The DCs also secrete known psoriasis-
associated cytokines, such as tumour necrosis factor alpha (TNF-), interferon gamma 
(IFN-), and interleukins 12, 23 and 15 (IL-12, IL-23 and IL-15). These cytokines then 
further stimulate and proliferate T-cells, likely locally maintaining the initial triggered 
response. Development of lesions likely then ensues due to continued dermal 
inflammation and epidermal hyperplasia (Boyman et al., 2007).  
Keratinocytes secreting various cytokines likely recruit T-cells for activation in 
affected areas (Jariwala, 2007). Stimulated T-cells then release TNF-, IFN- and other 
cytokines that induce further downstream gene responses and activate further signal 
pathways. This leads to migration of leukocytes to inflammatory regions and 
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subsequent vasodilation representing the common erythema characteristic of psoriatic 
skin (Chamian and Krueger, 2004). Conventional treatments such as cyclosporine and 
alefacept were developed to act on these T-cell pathways, while other therapies such as 
infliximab and etanercept are TNF- antagonists, aimed at decreasing pro-inflammatory 
cytokines and reducing infiltration of characteristic psoriasis cells (see 7.6.8 Cytokine 
concentrations) (Boyman et al., 2007). 
In psoriasis, IFN- production decreases expression of enzymes required for 
production of ultra-long-chain ceramides. Found in the stratum corneum, these 
ceramides play a key role in maintaining the skin’s permeable barrier (Feingold, 2014). 
Despite a host of available anti-TNF- drugs to treat psoriasis, drugs aimed at IFN- 
have not proven to be efficacious (Harden et al., 2014).  
Like T-cells, mast cells infiltrate early in psoriatic plaque development, peaking at 
around 14 days, before more T-cells infiltrate followed closely by macrophages. These 
lead to large production of TNF, IFN-γ, IL-8 and mediators, such as vascular endothelial 
growth factor (Ghoreschi et al., 2007, Toruniowa and Jablonska, 1988). Contributing to 
this, dendritic cells are also known to secrete psoriasis-active cytokines (TNF-, IFN- γ, 
IL-12, IL-23 and IL-15)(Lowes et al., 2007). Contrasting with the apparent contributing 
effect of dendritic cells on psoriasis, it seems in vivo, antigen-presenting cells 
(Langerhans cells) suppress psoriasis severity (Glitzner et al., 2014). During psoriasis 
development, antigen-presenting cells and T-cells continue to interact, forming surface 
complexes known as lymphocyte function-associated antigen-1 (LFA-1). These bind to 
adjacent cells, such as keratinocytes, via intercellular adhesion molecule 1 (ICAM-1). 
This ICAM-1 is another common drug target for psoriasis. When such adhesion is 
prevented, this further prevents T-cell activation and release of inflammatory cytokines, 
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chemokines and growth factors known to be implicated in development, proliferation 
and altered differentiation of psoriatic keratinocytes (Boehncke et al., 2010).  
Acting as the first line of defence against pathogens, cathelicidin, S100 proteins 
and defensins are also implicated in psoriasis pathogenesis, evidenced to aid in the 
recruitment and attraction of chemokines identified as key to pathogenesis of psoriasis 
(Batycka-Baran et al., 2014). 
Found predominantly in the upper dermis of psoriatic skin, research indicates that 
CD4+ T-cells are mostly involved in early psoriasis pathogenesis. In the epidermis, CD8+ 
cells are more predominant and their influx corresponds with latter psoriatic lesion 
progression (Nickoloff and Wrone-Smith, 1999, Paukkonen et al., 1992). It is suggested 
that fluctuation in levels and ratios of CD4+ and CD8+ T-cells reflects patterns of acute 
psoriasis exacerbation and subsequent remission (Gudjonsson et al., 2004). While T-cell 
processes occur, mast cells of the upper dermis continue to be activated, continually 
producing inflammatory cells and assisting with lesion perpetuation (Harvima et al., 
2008).  
Regulating T-cells (Tregs) have been identified as important in suppressing 
inflammation processes and maintaining homeostasis. Although Treg levels are found to 
be raised in psoriatic skin, it has been recognised that people with psoriasis have 
reduced ability to suppress and inhibit immune response against self-antigens 
(Sugiyama et al., 2005, Mattozzi et al., 2013). The decreased expression of transcription 
factor forkhead box P3 (FOXP3) likely decreases development and differentiation of 
these Tregs, which reduces their function. People with psoriasis have increased 
expression of microRNA (miRNA) miR-210 in CD4+ cells, which is implicated in this 
decrease (Zhao et al., 2013). Subsequently, there has been an increase in research on 
the development of miRNA-targeted therapies (Guinea-Viniegra et al., 2014). Newer 
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biologic drugs elevate Treg subsets, which may contribute to their therapeutic effects 
for psoriasis (Figure 2.8)(Quaglino et al., 2009).  
 
Figure 2.8: Biological activation and pathological pathways of psoriasis (Adapted from 
(Nickoloff and Nestle, 2004, Kaffenberger et al., 2014)) 
 
The triggered immune response in psoriasis is understood to follow the T helper 
type 1 (Th1) cell-mediated delayed hypersensitivity pathway. This differs from other 
common dermatological conditions such as atopic dermatitis, which follow the T helper 
type 2 (Th2) pathway (Uyemura et al., 1993). Interesting research shows allergic 
contact dermatitis reaction is delayed in people with psoriasis, peaking in intensity 
around day 7, compared with the typical 3–5 day peak of non-psoriatic people. However, 
the clinical course of psoriasis following a dermatitis trigger does not change (Quaranta 
et al., 2014).  
More recently, innate lymphoid cells (ILCs) such as natural killer (NK) cells that 
are non-antigen specific, have been implicated in psoriasis. An increased proportion of 
NCR+ ILC3 is present in the affected skin and peripheral blood of people with psoriasis 
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compared with non-psoriatic people. This NCR+ ILC3 produces IL-22, indicated as 
important in epidermal thickening of psoriasis lesions (Teunissen et al., 2014). The level 
of ILCs is shown to decrease after treatment with anti-TNF- therapy. Interestingly, 
drugs targeting IL-22 likely also reduce ILC3, yet clinically they have not been shown to 
improve psoriasis symptoms(Ward and Umetsu, 2014).  
Another key pathway relatively unique to psoriasis is that of the Th17 cell line 
(stimulated by transforming growth factor (TGF)-β1, IL-6, IL-23 and IL-15), which is 
involved in clearance of pathogens undetectable to Th1 and Th2 (Michalak-Stoma et al., 
2013, Asarch et al., 2008). Interestingly, T-cells extracted from psoriatic skin lesions are 
predominantly of this Th17 phenotype (Pene et al., 2008). Leading to production of key 
chemokines, IL-17, IL-17F and IL-22, which further activiate inflammatory pathways 
and mediate other known psoriatic cytokines such as IL-23 (Lowes et al., 2008, Zheng et 
al., 2007). Th22 line cytokines are now also implicated in psoriatic development and 
express distinctive chemokine receptors compared with Th1 and Th2 lines (Michalak-
Stoma et al., 2013) (Pene et al., 2008). 
Despite evidence that psoriasis follows Th1 and Th17 pathways, research suggests 
there are decreased levels of IgM, IgA and IgG against Candida species C. albicans. This 
may indicate psoriatic people have a reduced humoral immune response to Candida 
(Taheri Sarvtin et al., 2014).  
Following such immune response dilated and elongated blood capillaries form 
(angiogenesis) within dermal papillae, along with mild dermal oedema and spongiosis. 
At this time, T-cells and/or neutrophil invasion of the epidermal layer (exocytosis) is 
rare (Albanesi, 2014, Creamer et al., 2002). Lymphatic system remodelling sees their 
increased permeability yet in contrast to capillaries, lymphatics constrict in their 
diameter (Meier et al., 2013) (Moustou et al., 2014). The increased angiogenesis is 
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linked to an increase in vascular endothelial growth factor (VEGF). However, the impact 
of such increase for psoriasis needs further investigation, as it may assist in the 
development of new drugs (Man et al., 2008, Ryan et al., 2013).  
As lesions develop further there is slight psoriasiform (regular) epidermal 
hyperplasia, with greater neutrophil exocytosis and development of parakeratosis 
containing neutrophils. When psoriasis is fully developed, clinical plaques show marked 
epidermal hyperplasia with characteristic features, including regular elongation and 
‘clubbing’ (widening of the deep portion) of epidermal rete. The dermal papillae become 
elongated, containing dilated and twisted capillaries and the epidermis covering these 
papillae becomes progressively thinner. In addition, superficial epidermal layers show 
pallor, while increased keratinocyte proliferation thickens other epidermal areas. This 
reflects increased mitotic activity of basal and suprabasal layers (Murphy et al., 2007). 
Further aggravating this thickening are inflammatory mediators such as IL-15, which 
increase apoptotic resistance of abnormal keratinocytes (Ruckert et al., 2000, Wrone-
Smith et al., 1997). 
At the epidermal layer, presence of both orthokeratosis and horizontally confluent 
parakeratosis suggests fluctuations in epidermal growth of lesions and hyperkeratosis 
is more obvious (Murphy et al., 2007). For lesioned areas, keratinocyte proliferation 
increases substantially, where up to 100% of keratinocytes are in a proliferating state 
and cell cycle time reduces from around 13 days to just 36 hours (Weinstein et al., 
1985). When compared with normal skin, psoriatic lesions are shown to be 27 times 
more mitotically active and have a 12-fold decrease in cell cycle time of basal and 
suprabasal keratinocytes. There is also more than a 7-fold increase in epidermis 
turnover time (∼7 days in psoriatic skin vs. ∼56 days in normal skin) (Murphy et al., 
2007). Such altered growth reflects the complexity of involved immunological pathways, 
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where lesions are characterised by presence of both neutrophilic and mononuclear 
infiltrates, signalling that both acute and chronic inflammatory responses are occurring. 
As a result, psoriasis vulgaris treatments need to target both chronic and acute 
inflammatory cells for optimum effect. The specificity of many psoriasis 
pharmaceuticals could explain why some drugs such as TNF- blockers (thought to be 
active mainly on innate immunity) are only 75% effective, or why response to topical 
corticosteroids can differ within the same psoriatic lesion (chronic inflammatory areas 
respond well and acute areas are more resistant) (Griffin et al., 1988).  
Interestingly, identified as activated in psoriasis, the Th1 pathway is evidenced to 
be triggered by Th1-type immunity drugs, such as IFN-α or imiquimod (a Toll-like 
receptor agonist that triggers production of IFN-α by plasmacytoid dendritic cells), and 
has been shown to exacerbate psoriasis (Toichi et al., 2000, Ketikoglou et al., 2005). 
Furthermore, in vivo blocking of IFN-α or prevention of its production from 
plasmacytoid dendritic cells prevents development of psoriasis (Nestle et al., 2005). 
Theory suggests that plaque presence may correspond with neutrophil and lymphocyte 
levels, where decreasing neutrophil levels subsequently reduces lesions, and following 
cessation of neutrophil-specific treatment lesions return as the neutrophil level raises 
(Toichi et al., 2000). 
Despite obvious aspects of hyper-immune system function in psoriasis, research 
indicates that psoriasis-affected people have impaired immune reactivity to common 
bacterial and viral infections (Henseler and Christophers, 1995). The cause of such 
immune dysfunction is contentious. Research suggests it is associated with an 
imbalance in the numbers of Th1 and Th2 cells. However, therapies have targeted Th 
cells, raising Th2 type cell levels in an attempt to recalibrate ratios of Th1 to Th2 cells 
without obvious psoriasis effect (Nickoloff and Nestle, 2004). DNA has also been 
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implicated in immune dysfunction, yet investigation into cytokine gene polymorphism 
indicates local inflammatory factors and antigen presence are more likely to be relevant 
than genotype (Craven et al., 2001, Romagnani, 1997).  
As they normally provide an important role in inflammatory response, the potent 
ability of Th17 line cytokines to induce tissue inflammation has implicated them as key 
in development of autoimmune diseases and inflammatory conditions such as psoriasis 
(Korn et al., 2009). Produced by multiple lineages of leukocytes and stromal cells, the 
regulatory cytokine TGF-β has been identified as a fundamental precursor for the 
development of naïve T-cells into Th17 cells (Korn et al., 2009). Interestingly, dendritic 
cells are believed to have an essential role in raising the level of TGF-β (transforming 
growth factor beta) in the affected area and contributing to the psoriasis inflammatory 
loop (Travis et al., 2007). 
Continued Th17 cell response after initial induction requires continued presence 
of IL-23. Limiting the availability of IL-23 subsequently impairs Th17 immune and 
inflammatory responses (Veldhoen et al., 2006). Discovery of the beneficial effects of 
limiting IL-23 has seen development of newer biologic drugs such as etanercept. These 
IL-23 target drugs aim to reduce inflammatory dendritic cell products driving Th17 cell 
proliferation and in turn reduce downstream secretion of psoriasis inflammatory cells 
and the chronic psoriasis loop (Zaba et al., 2007). Despite the major role Th17 plays in 
psoriasis, evidence suggests regulation of Th1 cells may also be required for complete 
disease resolution and may explain why even high efficacy biologics are still not 100% 
effective (Zaba et al., 2007). 
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2.2.2 Other potential evidence for pathogenesis of psoriasis 
A study of psoriatic-like mice (triggered by either chemical Aldara or cytokine-induced 
models) identified that deficiency of toll IL-1R8/single Ig IL-1 related receptor 
(TIR8/SIGIRR) leads to development of more severe psoriasis (Russell et al., 2013). The 
TIR8/SIGIRR has been shown to decrease expression of IL-17A and IL-1R1–driven 
proliferation of Th17 (Russell et al., 2013). In mouse models of inflammation triggered 
by IL-23, when toll like receptors (7, 8 and 9) are targeted by antagonists there is 
decreased expression of the IL-17 pathway (Suarez-Farinas et al., 2013). 
Comprehensive research indicates that people with psoriasis have decreased 
melanin production in lesion-affected areas, which is likely related to increased 
production of TNF- and IL-17. After treatment with anti-TNF- and anti-IL-17 
therapies, melanocytes increase, with subsequent basal cell hyperpigmentation and 
elongation of rete ridges. This may explain why psoriasis sufferers have lower incidence 
of skin cancer, but more research is needed (Di Cesare et al., 2015). 
The functional protein caveolin-1 decreases considerably in psoriasis vulgaris 
(Campbell et al., 2002). Caveolin-1 inhibits associated kinase activity of pathways 
involved in cell differentiation and proliferation by modulating signal transduction 
(Zhang et al., 2014c). Further, caveolin-1 likely sensitises cells to apoptosis through 
inhibition of anti-apoptic kinases, suggesting low levels of caveolin-1 may contribute to 
increased proliferation in psoriasis (Liu et al., 2001). 
Oxidation has also been implicated in the development and severity of psoriasis, 
including increased oxidant levels in people with psoriasis (Pujari et al., 2014). Such 
increase in oxidants leads to development of reactive oxygen species ROS, which are 
known to release superoxide anions that mediate dermal tissue damaging interleukins 
such as TNF- (Fuchs et al., 2001). 
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MicroRNAs are small non-coding RNA molecules that modulate gene expression at 
post-transcriptional level. Laser capture micro-dissection followed by next-generation 
sequencing has identified deregulated miRNAs in psoriatic skin (Lovendorf et al., 2014). 
There is evidence that these miRNAs are involved in proliferation and differentiation of 
keratinocytes; however, more research into their specific role in psoriasis is needed 
(Lovendorf et al., 2014). The proliferation of keratinocytes and lack of apoptosis in 
psoriasis also implicates mitogen-activated protein kinases p38 (p38 MAPKs) in its 
development. Understood to be important for the differentiation of cells p38 MAPKs, an 
increase in cell differentiation activity has been found in psoriatic compared with 
unaffected skin (Mavropoulos et al., 2013). 
Natural killer cells regulate immune cells and cause secretion of cytokines, thus 
they have also been implicated in the development of psoriasis. A unique function of NK 
cells is their ability to kill T-cells and antigen-presenting cells, subsequently down-
regulating the inflammatory response and the psoriasis inflammatory cascade. Likely 
due to competitive binding by another receptor cell (NKG2A), the NK receptor cell 
NKG2C is reduced in people with psoriasis. The subsequent imbalance reduces 
activation of NK cells, allowing T-cells to propagate uncontrolled. Similarly, another 
theory suggests that when NKG2A is bound to HLA-E it competes with HLA-Cw* 0602, 
subsequently protecting against psoriasis. With a decrease in NKG2A there is less bound 
to HLA-E, and development of psoriasis increases (Patel et al., 2013). 
2.2.3 Known contributing factors to psoriasis pathogenesis 
In an attempt to explain why and how psoriasis is initiated and sustained, extensive 
research into the biological mechanisms of psoriasis continues. Although active 
pathways for psoriasis sufferers are identified, the initiating and/or triggering factors 
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vary considerably. Preventable lifestyle factors such as cigarette smoking, alcohol 
consumption and stress have been linked with psoriasis development. Genetics have 
also been linked to increased psoriasis risk. For some people, use of various 
pharmaceuticals also increases the risk of psoriasis. The variety of triggers and their 
inconsistency in psoriasis development contributes to difficulty understanding the 
precise pathogenesis of psoriasis. This section discusses the main known external and 
internal triggers or aggravators known to induce and/or exacerbate psoriasis.  
Pharmaceutical drug psoriasis inducement and/or aggravation 
Some pharmaceutical drugs have been reported to trigger or exacerbate psoriasis in 
both the genetically susceptible and those without a family history of psoriasis. Drugs 
have been implicated with psoriasis in four ways: (1) precipitating psoriasis de novo in 
predisposed and non-predisposed individuals; (2) exacerbating pre-existing psoriatic 
lesions; (3) inducing lesions in clinically normal skin areas of patients with psoriasis; 
and (4) developing treatment-resistant psoriasis (Tsankov et al., 2000). It is likely that 
biological mechanisms of implicated drugs trigger or induce psoriasis, or in psoriasis 
sufferers aggravates the psoriatic inflammatory cascade, amplifying symptoms (Dika et 
al., 2006). Drugs commonly administered for non-psoriasis related conditions that have 
been implicated for psoriasis include lithium, beta-adrenergic receptor blocking agents 
(β-blockers) and antimalarials. This section discusses these known drugs and their 
potential psoriatic biological activity. 
β–blockers 
Used predominantly for cardiovascular conditions, β–blockers such as practolol have 
been known to trigger psoriasis. As a result of this and other side effects, practolol has 
since been withdrawn (Basavaraj et al., 2010). The psoriasis-activating pathway is likely 
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to be from the presence of β-adrenergic receptors in the skin, with β-blockers 
preventing binding to β–agonists. Such binding is necessary for increases in secondary 
messenger, cellular cyclic adenosine monophosphate (cAMP), which stimulates skin cell 
differentiation and inhibits their proliferation. For some, this lack of binding results in 
keratinocyte proliferation and skin appearance symptoms the same as psoriasis 
(Basavaraj et al., 2010, Tsankov et al., 2000). Such lesion development usually appears 
1–18 months after β-blocker use (Heng and Heng, 1988). 
Lithium salts  
Prescribed for psychological and urology management, a common unwanted side effect 
of lithium salts is the triggering or exacerbation of psoriasis (Albert et al., 2014). The 
prevalence of cutaneous skin disorders including psoriasis may be as high as 45% in 
lithium users (Yeung and Chan, 2004). Interestingly, psoriasis sufferers without a 
history of lithium use have greater serum lithium concentration than people without 
psoriasis (Hanada et al., 1987). The precise mechanism through which lithium induces 
psoriasis is unknown; however, evidence suggests lithium affects cAMP levels, 
inhibiting inositol-I-phosphate and by subsequently lowering the intracellular levels of 
calcium, alters cellular transduction signals (DiGiovanna et al., 1981, Skoven and 
Thormann, 1979). This leads to reduced keratinocyte differentiation and increased 
proliferation, while chemotaxis and phagocytic activity of polymorphonuclear 
leukocytes is enhanced (Bloomfield and Young, 1983). In psoriatic patients, levels of 
inositol are typically low following lithium treatment and supplementation has shown 
reduction of psoriatic symptoms and overall severity (Allan et al., 2004). Studies also 
report increased IL-2 and TNF-α production following lithium therapy. This increase 
may assist development of psoriasis supported by the efficacy of TNF-α inhibitors such 
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as etanercept in lithium-triggered psoriasis (Fry and Baker, 2007) (Wachter et al., 2007). 
Psoriasis typically subsides when lithium therapy stops and returns when it is 
recommenced (Skoven and Thormann, 1979). 
Synthetic antimalarial drugs 
In approximately 18% of psoriasis sufferers, synthetic antimalarial drugs such as 
chloroquine, hydroxychloroquine, primaquine and meflo-quine have been found to 
exacerbate psoriasis symptoms (Gravani et al., 2013). Synthetic antimalarial drugs are 
not thought to induce psoriasis in previously unaffected people, yet in the susceptible, 
psoriasis retrigger is common and reported to occur quicker than with other drugs 
(Namazi, 2008). Psoriasis symptoms subside after the drug is ceased in only 30% of 
cases. The mechanism is not well understood, however, theory suggests keratinocytes 
inhibit transglutaminase activity and/or cholesterol biosynthesis, causing breaks in 
epidermis barrier function so the epidermis responds to repair and restore the break 
(Namazi, 2008, Basavaraj et al., 2010, Wolf and Lo Schiavo, 1997). 
Antibiotics 
There is limited evidence that antibiotics induce psoriasis, although the relationship is 
uncertain and it is possible the underlying infection the antibiotics were administered 
to treat is actually the psoriatic trigger. Among antibiotics, tetracyclines are most likely 
to cause or exacerbate psoriasis due to their ability to cause photosensitisation and 
reduction in cAMP (Wright and Colver, 1988, Kim and Del Rosso, 2010). 
Non-steroidal anti-inflammatory drugs 
Limited evidence indicates non-steroidal anti-inflammatory drugs can both induce and 
exacerbate psoriasis (Basavaraj et al., 2010). Indomethacin has been implicated, 
although incidence of psoriasis from its use is relatively low (Lazarova et al., 1989). 
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Non-steroidal anti-inflammatory drugs inhibit metabolism of arachidonic acid via the 
cyclooxygenase pathway, leading to accumulation of leukotrienes known to aggravate 
psoriasis (Lammers and van de Kerkhof, 1987). 
Biological drugs 
New-onset psoriatic lesions and exacerbation have been described after treatment with 
biologics for multiple sclerosis, mainly interferon-beta (INF-β) or natalizumab 
(Gkalpakiotis et al., 2014). Similarly, psoriasis has been induced after treatment with an 
antibody targeting CD20, rituximab, for immunological diseases such as rheumatoid 
arthritis. The CD20 antigen is found on mature B-cells (Ozen et al., 2013, Fiorillo et al., 
2014). Due to action on the Th1 pathway, interferon has been implicated in psoriasis 
activation in a hepatitis C patient (Nestle and Gilliet, 2005, Kim et al., 2013b). Imatinib is 
a first line therapy for newly diagnosed chronic myeloid leukaemia patients, and 
patients with no previous history of psoriasis have also been reported to develop 
psoriasis after its administration (Atalay et al., 2013). Contrary to their common 
administration as treatments for psoriasis, biologics ustekinumab and adalimumab as 
well as other TNF- blocking biologics also risk onset and/or exacerbation of psoriasis 
(Borras-Blasco et al., 2008, Ko et al., 2009, Sanso Sureda et al.). 
Interferon-β 
A drug utilised for multiple sclerosis, interferon-β may aggravate or induce psoriasis. It 
is unclear whether imunomechanisms of multiple sclerosis and psoriasis are similar 
although, interestingly, both multiple sclerosis and psoriasis respond to treatment with 
fumaric acid esters (Fellner et al., 2014) (Zecca et al., 2014). 
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Thalidomide 
Possibly related to its effects on TNF-, immunomodulator thalidomide was reported to 
trigger psoriasis in a person without previous psoriatic history (Ferrazzi et al., 2014). 
Granulocyte-macrophage colony-stimulating factors 
Used for treatment of myelodysplasias and after chemotherapy, there is clinical 
evidence suggesting granulocyte-macrophage colony-stimulating factors can exacerbate 
psoriasis symptoms, though more research is needed to clarify a direct link (Kelly et al., 
1993). 
Angiotensin-converting enzyme inhibitor 
Utilised for hypertensive patients, angiotensin-converting enzyme (ACE) inhibitor use 
in people with familial history of psoriasis and specific ACE genotype exhibiting low 
enzyme activity are more susceptible to developing psoriasis (Chang et al., 2007).  
Other 
Drugs with limited evidence for exacerbation or development of psoriasis include 
interferon, gemfibrozil, iodine, digoxin and chlonidine (Milavec-Puretic et al., 2011). 
There are also reports of incidents in which vaccinations, such as the H1N1 vaccine, 
trigger psoriasis. Although the risk is typically low it is interesting to note that the 
majority who develop psoriasis from vaccinations tend to present a mixture of vulgaris 
and guttate types (Sbidian et al., 2014). As mentioned previously, guttate psoriasis 
typically develops after infection (Henley, 2012). A clinical case study reports psoriasis 
onset after administration of a purified protein derivative, which was part of a negative 
Mantoux test for tuberculin (Khanna et al., 2014). 
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Although psoriasis may be an unwanted side effect of some drug treatments, there 
are also some drugs in development designed to trigger psoriasis. Such psoriasis-
inducing drugs are intended to assist laboratory exploration of psoriasis pathogenesis, 
help understand its development and aid drug development for future treatments 
(Vinter et al., 2014).  
Genetics and psoriasis 
Research has long indicated a genetic psoriatic predisposition and significant evidence 
now indicates genetics as one of the strongest factors determining psoriasis 
development in a person, and its age of onset (Elder et al., 2001). If either parent suffers 
from psoriasis, the incidence in their children is increased by 14%. If both parents are 
afflicted with psoriasis, then the reported incidence rises to 41% in their children 
(Andressen and Henseler, 1982). More recent studies have confirmed such parental 
‘transmission’ of disease with 59% of psoriasis-affected people reporting at least one 
relative with psoriasis (Di Lernia et al., 2014). 
A genetic basis of psoriasis is also supported by studies of monozygotic (identical) 
twins, with similarity in age of onset, distribution of disease and severity (Duffy et al., 
1993). Early studies of twins with psoriasis revealed higher concordance in 
monozygotic twins than dizygotic (non-identical) twins (Farber et al., 1974, Duffy et al., 
1993). 
Susceptibility to psoriasis has been linked to specific genetic markers known to 
increase the probability of psoriasis development in carriers. However, not all people 
with the psoriasis-promoting gene markers will develop the disease, and others without 
positive genetic markers may still develop psoriasis (Barker, 2001). Thus, genetics is 
not considered to be the sole determining factor in psoriasis development, and research 
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indicates environmental factors also play a significant role (Szczerkowska-Dobosz, 
2005).  
Despite their varied role, genetic markers may still assist researchers in future 
drug development. One promoter region highly likely to be related to psoriasis is an 
increased production of IL-22, which increases the risk of psoriasis in children (Nikamo 
et al., 2014). As discussed previously, TNF- production is key to psoriasis development 
and progression. Produced by keratinocytes, dermal dendrocytes, macrophages, mast 
cells and activated T-cells the production of TNF- is then further increased by 
subsequent intervention of other cytokines (Bonifati and Ameglio, 1999). There is 
plausible research indicating that increased TNF- gene promoter polymorphism 
confers higher risk of early-onset psoriasis (Zhuang et al., 2013). A recent review 
evaluated the two most evidenced TNF- gene polymorphisms implicated in 
development of psoriasis, with both polymorphisms at guanine-adenine (G-A) 
transitions, one at position 308 and the other at position 238. Interestingly, people with 
the TNF-α308 G-A polymorphism have a decreased risk of psoriasis, while those with 
TNF-α 238 G-A have an increased risk of psoriasis (Zhuang et al., 2013). 
Genome-wide linkage scans have identified 20 possible susceptible loci on 15 
different chromosomes. These loci have been designated as PSORS 1 to PSORS 6 with 
others also identified (PSORS 7 and PSORS 9). Active genome sequences likely impact 
on the IL-23 and Th17 pathways, significant pathways in the susceptibility of people to 
psoriasis development (Yin et al., 2014).  
A mapped genetic region known as PSORS1, has been associated with presence of 
psoriasis in 60–65% of psoriasis sufferers. (Barker, 2001, Jordan et al., 2012, Bowcock, 
2004, Duffin and Krueger, 2009). It consists of a region on the 6p chromosome 
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containing the major histocompatibility complex and is the location of genes for human 
leucocyte antigens (Barker, 2001).  
Several human leukocyte antigens (HLA), classes I and II, associated with psoriasis 
vulgaris have been investigated. Presence of antigens produced in this region such as 
the HLA-Cw6 antigenic peptide have been linked to both earlier onset of psoriasis (<40 
years) and positive family history (Tiilikainen et al., 1980). Around 66% of people with 
psoriasis have the HLA-Cw6 allele and are identified as type I (Gudjonsson et al., 2004, 
Cassia et al., 2007). Those positive to HLA-Cw6 have more severe psoriasis, more 
extensive plaques and higher incidence of Koebner’s phenomenon (skin lesions 
appearing along lines of trauma)(Gudjonsson et al., 2002). On the other hand, type II 
psoriasis is associated with HLA-Cw2 and HLA-B27, which is correlated with later 
psoriasis onset (>40 years) and a negative family history (Lebwohl, 2007, Bahcetepe et 
al., 2013). Atypical cases that fit neither type I nor type II led to further classification of 
types Ia, Ib, IIa and IIb where ‘a’ types are associated with HLA-Cw6 and ‘b’ types are 
not (Fry et al., 2006). 
Despite extensive research it is possible there is linkage disequilibrium between 
HLA-Cw6 and other genes also affecting the development of psoriasis. The mechanism is 
likely to be an antigen bound to either HLA class I or HLA class II, which interacts with 
T-cell receptors via peripheral tissue dendritic cells, which migrate, mature and activate 
T-cells (Cassia et al., 2007). The triggering antigen remains unknown, however 
excessive production of non-antigen specific, innate antimicrobial peptides and proteins 
(AMPs or alarmins) are characteristic of psoriasis.  
The absence or presence of some single nucleotide polymorphisms (SNPs) has 
been associated with psoriasis. Specifically, absence of HLA-Cw6 and presence of IL12B 
SNP and IL6 SNP decreases psoriasis risk by 96% (Boca et al., 2013). Although 
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substantial research indicates Cw6 is related to development of psoriasis, Cw6 is not 
present in all people with psoriasis (Fry et al., 2006). 
Difference in genetic susceptibility is also evidenced among different races. 
Chinese psoriatic populations with SNPs of the IL-15 gene have been associated with 
psoriasis, but Caucasian populations from the UK, Germany and the US do not show the 
same association (Smith et al., 2008). Research in Han Chinese of other polymorphisms 
such as those that regulate epidermal growth factor receptors implicates further SNPs 
in the development of psoriasis (Zhang et al., 2014d). Further, in the Han Chinese 
polymorphisms such as rs610604 have been implicated in increasing psoriasis severity 
(Zhang et al., 2014a). On the other hand, European populations with primary SNPs IL-
23R and IL-17 show association with psoriasis, yet they are polymorphic in the Chinese 
(Li et al., 2014, Ellinghaus et al., 2010). In a Spanish population, genetic variation in 
IL12B, IL23R and IL23A increased risk of psoriasis development and severity, and also 
increased risk of developing the metabolic disorder type II diabetes (Eiris et al., 2014).  
Although genetics likely play a substantial role, it should be highlighted that ethnic 
differences exist in the location of such susceptible genes, and further difference is likely 
between genders of the same ethnicity (Haase et al., 2014, Mabuchi et al., 2014). Such 
genome location variation has implications for biological drug efficacy and adverse 
events as they target specific genes for psoriasis treatment. Prior to market release, it 
could be argued that, to ensure sufficient safety of biologic drugs, each biologic should 
be tested in a wide range of ethnicities prior to therapeutic approval by governing 
bodies.  
Thanks to genome-wide association studies, upwards of 36 genes have been 
linked to psoriasis and researchers have developed a complex model of psoriasis 
pathogenesis. This complex model consists of theory involving irregular skin barrier 
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function, innate immunity and adaptive immunity (Tsoi et al., 2012, Mahil et al., 2015). 
The only well-recognised protective allele against psoriasis is present in less than 3% of 
the population: IL23R SNP impairs the IL-23-induced Th17 effector response (Di Meglio 
et al., 2011). An area of the major histocompatibility complex, with glutamine at 
position 45 has recently been identified as likely linked to susceptibility of more severe 
arthritic phenotypes of psoriasis (Eder et al., 2015).  
Future of genetics research for psoriasis  
Numerous genetic factors may be involved in psoriasis, and understanding how each of 
these factors relates to its development is becoming more and more complex. 
Considering such complexity, researchers are developing new technology allowing 
correlation of multiple genetic factors with psoriasis. Such technology may in the future 
lead to specific clinical testing to evaluate susceptibility to psoriasis and could 
eventually lead to development of personalised psoriasis drug treatments (Climer et al., 
2014). Further genetic research is needed to determine how genotype differences 
impact on development of the various psoriasis phenotypes and should further explore 
differences in molecular pathways between psoriasis phenotypes (Ryan et al., 2013). 
Lifestyle and other external factors in psoriasis 
A number of lifestyle and non-genetic factors have been implicated in development and 
exacerbation of psoriasis. This section discusses such factors, reviewing the evidence for 
pregnancy and hormonal change, cigarette smoking, sunlight, and bacterial or viral 
infection. 
Pregnancy and hormonal change 
Research has revealed links between hormonal changes, such as that evidenced in 
stress, and improvement or worsening of psoriasis symptoms. Commonly people with 
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psoriasis indicate worsening (flare-up) of their symptoms during stressful events (Xhaja 
et al., 2014). It has been theorised that altered hypothalamic-pituitary-adrenal response 
from higher circulating levels of hormones, such as corticotrophin-releasing hormone, 
may be associated with these flares; however, more research is needed (O'Kane et al., 
2006, Richards et al., 2005). Conversely, in pregnant psoriatic women, higher levels of 
oestrogen correlate with improvement in psoriasis symptoms (Murase et al., 2005). 
Anti-psoriatic action may be due to the ability of oestrogen to inhibit key psoriasis 
cytokine TNF-α (Ceovic et al., 2013). As oestrogen and progesterone levels fall in 
women during puberty, post-partum or menopausal stages, the opposite often ensues 
and psoriasis symptoms increase. 
Cigarette smoking 
Found to be an independent risk factor for psoriasis in men and women, cigarette 
smoking correlates with increased incidence of psoriasis. As smoking duration 
increases so does the risk to psoriasis development; for instance, risk is highest among 
smokers of 65 or more cigarette packs per year for 30 or more years. In turn, psoriasis 
risk reduces with time since smoking cessation (Li et al., 2012c, Setty et al., 2007). The 
interaction between cigarette smoking and psoriasis is most likely due to the immune-
suppressing effects of the chemical constituents of cigarettes, as well as the increase in 
oxidative stress (Sopori, 2002, Attwa and Swelam, 2011). In addition to acting as a 
trigger, smoking can also exacerbate psoriasis symptoms, perhaps owing to higher level 
of circulating Th17 in smokers, a pathway well evidenced in the inflammatory loop of 
psoriasis (Torii et al., 2011). 
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Sunlight 
Evidence indicates that sunlight exposure can improve psoriatic plaque symptoms. 
Conversely, lack of sunlight is known to aggravate psoriasis plaques. The therapeutic 
relationship between sunlight and psoriasis is related to the beneficial production of 
vitamin D, where ultraviolet radiation (UV) is necessary for basal epidermal vitamin D 
synthesis (Ryan and Menter, 2012) (Holick, 1981). Promoting keratinocyte 
differentiation, the action of vitamin D on psoriasis is likely related to its ability to act as 
an anti-inflammatory and anti-angiogenic (Oikawa et al., 1990). Vitamin D level 
concentration in psoriatic people tends to be lower than in healthy controls (El-Moaty 
Zaher et al., 2013). Therapies such as UVB phototherapy aim to enhance vitamin D 
production to reduce psoriasis plaque severity. Vitamin D analogues are commonly 
used topically (e.g. calcipotriol) and are understood to emulate vitamin D by reducing 
Th17 pathways and other key chemo-attractants. Without regulation these would 
otherwise signal cytokine production by keratinocytes, amplifying the psoriasis immune 
response (Hegyi et al., 2012). 
Bacterial or viral infection 
Psoriasis development has been linked to bacterial and viral infection, with reports 
indicating they may trigger and/or exacerbate psoriasis symptoms (Travers et al., 1999). 
Most likely, bacterial and viral impacts on psoriasis pathogenesis are due to previous 
antigen presentation in pathogenic tissues (e.g. throat) and subsequent production of 
pathogenic T-cells. These T-cells migrate to the skin dermis and are presented to 
antigen-presenting cells (APCs), triggering or contributing to epidermal and dermal 
inflammation (Valdimarsson et al., 2009). Staphylococcal exotoxin is commonly found 
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on the surface of psoriasis-affected skin, although its part, if any, in psoriasis 
pathogenesis is unclear (Leung et al., 1993).  
Likely related to lymphatic function and formation of antigens, reports identify 
higher prevalence of psoriasis (most typically guttate type) after throat infection by b-
haemolytic streptococci (tonsillitis), and it is known these infections exacerbate 
psoriasis symptoms (Whyte and Baughman, 1964, Telfer et al., 1992, Fry et al., 2006, 
Horiuchi et al., 1998, Gudjonsson et al., 2003, Wardrop et al., 1998). Controversial yet 
significant evidence suggests that tonsillectomy after streptococcal infection is an 
effective treatment for psoriasis (Wu et al., 2013). However, evidence should be 
evaluated with caution, more long-term controlled studies are needed to evaluate true 
risks and benefits of tonsillectomy intervention (Rachakonda et al., 2014).  
Viral diseases such as herpes zoster, hepatitis C virus and chickenpox have also 
been implicated with the development and/or exacerbation of psoriasis (Blanco 
Gonzalez et al., 2000, Failla et al., 2012, Veraldi et al., 2009, Gabr et al., 2014). Indeed, 
people with hepatitis C typically have more severe psoriasis than those without (Taha et 
al., 2014). The human immunodeficiency virus (HIV) has also been connected with 
psoriasis, likely due to an immunodeficiency drop in CD4+ lymphocyte (Montazeri et al., 
1996).  
Helicobacter pylori bacterial infection has been implicated with increased severity 
of psoriasis (higher PASI than non-H. pylori psoriatic cases). There is also a subsequent 
greater improvement in symptoms when such cases are concurrently treated for H. 
pylori and psoriasis rather than anti-psoriatic alone (Onsun et al., 2012). The precise 
involvement of H. pylori in psoriasis, however, is still unknown  
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Other factors 
The Koebner phenomenon, in which lesions appear along a site of injury, can ensue in 
people with psoriasis following localised trauma such as from tattoos, burns, animal and 
insect bites, skin grafts, and surgical incision, but is less frequent in those without 
previous psoriasis (Zitelli and Lucky, 2013). 
2.2.4 Summary of aetiology and pathogenesis for psoriasis 
Various triggers and aggravators of psoriasis have been identified, and it is likely that 
many others remain undiscovered. Evidence suggests psoriasis pathogenesis and 
aetiology have genetic components that may be complicated or exacerbated by external 
factors. In the future, treating physicians may need to identify psoriasis triggers for each 
patient to decide which therapy should be administered. While it is possible to reduce 
known risk factors that trigger or exacerbate psoriasis, future immunising drug 
therapies may be developed to protect high-risk patients against development of 
psoriasis. New research techniques with the ability to screen for psoriasis indicators at 
the genome level may provide such immunisation opportunities and lead to 
development of a range of pharmaceuticals that target known psoriasis sequences. It is 
clear that understanding the pathogenesis and aetiology of psoriasis is paramount for 
the eventual discovery of a cure for psoriasis. 
2.2.5 Exploring potential biological marker targets for psoriasis  
Part of the hunt for a psoriasis cure involves identification of psoriasis-related biological 
markers. Such markers may also aid in the diagnosis and/or monitoring of psoriasis and 
its treatment. Recently, promising research has emerged indicating that such psoriasis-
specific markers do exist, such as neutrophil to lymphocyte ratios (Ataseven et al., 
2014). Although as yet no single determinant marker has been identified, many 
 44 
cytokines are recognised to be involved in psoriasis pathogenesis, and changes in their 
concentrations can assist with diagnosis, evaluate the efficacy of treatment or correlate 
directly with psoriasis severity (Bonifati and Ameglio, 1999). Unfortunately, despite 
identification of such cytokines none have yet proven to be reliable and consistent 
markers for such symptom clearance and subsequently are insufficient on their own to 
evaluate the clinical benefit of a given therapy or indicate when it should be changed or 
ceased (Griffiths and Barker, 2007).  
To further explore therapeutic impacts on biological concentrations of various cell 
types, the current pilot study collected plasma samples of participants at various time 
points to evaluate changes in a number of inflammatory factors. For further details on 
the inflammatory factors that have been implicated in psoriasis see Chapter 7 
(Development of a pilot randomised, placebo-controlled parallel design study). 
2.2.6 Research gaps of psoriasis aetiology and pathogenesis  
Despite available evidence for psoriasis pathogenesis and key identification of many key 
cytokines in psoriasis, researchers have identified a number of knowledge gaps. While 
some biological markers may help evaluate treatment response, such markers are not 
specific to psoriasis. Discovery of a new subset of CD4+ cells known as follicular helper 
T-cells provides promise that psoriasis-specific markers may be identified in the future 
(DaErme et al., 2014, Niu et al., 2015). Encouragingly, recent research has also identified 
entire pathways that are more active in severe than mild psoriasis (Nikamo et al., 2015). 
There is a push from research experts for further large, broad, longitudinal studies 
investigating further in areas such as: the natural history of psoriasis; genetic factors 
that influence clinical phenotypes; severity trends in incidence over time; prevalence of 
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associated co-morbidities; and the spontaneous remission of psoriasis (Ryan et al., 
2013). Such research will assist in progression towards a cure for psoriasis. 
2.3 The epidemiology and socioeconomic burden of psoriasis 
Psoriasis is distributed relatively equally between males and females, with mean age of 
psoriasis development calculated to be 33 years of age. For the majority of psoriasis 
cases onset occurs between 11 and 20 years old, with 75% of cases developing before 
age 46 (Nevitt and Hutchinson, 1996). Research generally suggests increasing psoriasis 
incidence with increasing age. Adolescents tend to have a low prevalence (0.5–2%), 
however, as is found in other age groups they most commonly present with the vulgaris 
phenotype (74%). Interestingly, children with childhood asthma have increased risk of 
developing psoriasis (Parisi et al., 2013, Tollefson et al., 2010).  
With figures varying among population demographics, ethnicity has been clearly 
indicated as a factor that determines incidence of psoriasis. Higher psoriasis incidence 
is reported in Caucasians than Asians or people of African descent (Boehncke et al., 
2010). There has been no reported incidence of psoriasis in the Australian Indigenous 
population, suggesting they are not genetically susceptible to its development (Green, 
1984). Australia’s psoriasis prevalence has been estimated to be between 3.5 and 6.6%, 
but no health cost has yet been applied to this figure (Plunkett et al., 1999, Kilkenny et 
al., 1998). Considering many psoriatic therapies are subsidised in Australia through 
Medicare (e.g. acitretin 25mg pack of 100 reduced from $334.55 to $36.90 for the 
consumer), new interventions that provide substantial savings would be welcome 
(Australian Government - Department of Health, 2014).  
Globally, the prevalence of psoriasis varies considerably. A large telephone survey 
involving both the US and a number of European countries estimated global prevalence 
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to be between 1.4% and 3.3% (Lebwohl et al., 2014). In the US, prevalence is between 
1.2% and 5.1% (Lima et al., 2012, Stern et al., 2004, Kurd and Gelfand, 2009). In 
Malaysia, psoriasis incidence was calculated at 9.5%, however, the study was conducted 
in a dermatological outpatient clinic so results would be expected to be higher than in 
the general population (Sinniah et al., 2010). Studies conducted in the UK report 
psoriasis prevalence of between 1.3% and 1.9% (O'Neill and Kelly, 1996) (Seminara et 
al., 2011). In Europe, there is substantial variation in reported incidence of psoriasis, 
including: Croatia 1.5% (Barisic-Drusko et al., 1989); Denmark 2.5% for women and 3.2% 
for men (Brandrup and Green, 1981); France 5.2% (Wolkenstein et al., 2009); and 
Norway between 4.8% and 8.5% (Bo et al., 2008, Kavli et al., 1985). More research is 
needed to examine the incidence disparities between age and race groups, and may 
provide further insight into psoriasis aetiology and pathogenesis (Ryan et al., 2013). 
In the United States of America in 2011, annual healthcare costs related to 
psoriasis were estimated at US$11.3 billion and by 2013 this had risen to $11.8 billion 
(Staidle et al., 2011, Vanderpuye-Orgle et al., 2015). Related losses in productivity are 
more difficult to estimate, but estimates tend to be well over $10 billion (Mustonen et al., 
2015, Brezinski et al., 2015). Given the increasing cost of psoriatic treatments, as new 
drugs such as biologics enter the market, this figure will continue to rise (Schmitt and 
Ford, 2006). 
Further research into employment and income availability of sufferers would help 
evaluate the socioeconomic impacts of the disease (Ryan et al., 2013). Introduction of 
new expensive psoriasis drugs, such as biologics, require both direct and indirect cost 
evaluation along with clinical efficacy assessment to assist clinicians and governments 
develop cost-effective treatment guidelines (Ryan et al., 2013). Further, comparative 
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studies between different drugs may help determine intervention superiority relative to 
their efficacy and cost (Conway and Clancy, 2009).  
2.4 Disease differentiation of psoriasis vulgaris  
Currently, no specific diagnostic tests for psoriasis exist; however, tests (e.g. biopsy and 
microscopic examination) can be performed to differentiate psoriasis from diseases that 
are visually similar (such as seborrheic dermatitis, lichen planus and sub-acute 
cutaneous lupus erythematous) (World Health Organization (WHO), 2013). A lack of 
diagnostic tests requires clinicians to visually diagnose psoriasis, using presentation of 
key characteristic features and clinical progression. This requires the physician to 
inspect the affected skin area, review the patient’s medical history and evaluate possible 
precipitating causes (Callen et al., 2003).  
The lesioned areas of typical psoriasis vulgaris present silver (grey) or white 
flaking, which may be thicker than unaffected skin, with lesions individual or merged 
into larger plaque areas (Dermatology Expert Group, 2004). As a result of blood 
profusion from increased angiogenesis, affected areas may present with erythema 
(redness) and can be accompanied by pruritus (itching) (Figure 2.1: Psoriasis vulgaris 
lesion)(Burden et al., 2010). A key feature of psoriatic skin, often diagnostic, has long 
been the Auspitz sign, where slight abrasion (e.g. scratch) to an affected skin area leads 
to pinpoint bleeding. Unfortunately, the Auspitz sign alone is not sufficient to diagnose 
psoriasis, as is not specific to psoriasis and is not present in all psoriasis cases 
(Bernhard, 1990). In some psoriasis cases fingernail changes such as pitting, onchylosis 
(detachment of the nail) and/or subungual hyperkeratosis (excessive nail proliferation) 
may help diagnose psoriasis (Figure 2.9)(Cohen et al., 2012). 
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Figure 2.9: Characteristic pitting, onchylosis and subungual hyperkeratosis of psoriatic 
nails (DermNet New Zealand Trust, 2014) 
 
As diagnosis requires a reasonable degree of physician experience and 
judgement, psoriasis may be mistaken for other dermatological conditions, such as 
eczema, fungal infection or skin cancer. Patients presenting to general practitioners 
(GPs) may be referred to a dermatologist for definitive diagnosis, or a skin biopsy may 
be taken to be viewed under a microscope to detect key histological characteristics. 
Under dermoscopy, for instance, psoriatic scales are typically white whereas those of 
eczema are more commonly yellow (Xu et al., 2014). Compared with normal skin 
(Figure 2.10), psoriatic skin has marked histological difference, with obvious 
inflammatory signs such as lymphocyte and neutrophil infiltration, thickening of dermal 
(acanthosis) and epidermal (keratosis) layers, increased vascularity and, due to 
incomplete cell differentiation, keratinocyte cells show presence of nuclei 
(parakeratosis) (Figure 2.11) (Menter et al., 2008). Increased vascularity is likely due to 
increased levels of vascular endothelial growth factor (VEGF) receptors on 
keratinocytes (Man et al., 2008).  
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Figure 2.10: Histologically normal skin appearance (DermNet New Zealand Trust, 2014) 
 
 
Figure 2.11: Histologically psoriatic appearance skin (Adapted from: (DermNet New 
Zealand Trust, 2014)) 
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More recently, the dermoscopy techniques reflectance confocal microscopy and 
confocal laser scanning microscopy have shown possible usefulness in diagnosis and 
monitoring progression of psoriasis plaques (Hui and Ai, 2013). Such advanced 
dermoscopy techniques can reveal micro-morphological aspects such as epidermal 
spongiosis not evident in histopathological examination (Caruntu et al., 2014). 
Following successful treatment and macro-improvement of psoriasis lesions, skin 
samples show histopathological evidence of decreased parakeratosis, Munro’s micro 
abscesses, acanthosis, pustules of Kogoj, lymphocyte and neutrophil infiltration, 
granular layer reduction, spongiosis and angiogenesis (Ozkanli et al., 2014). With 
further research and validation, more non-invasive techniques may be employed in the 
future to diagnose and assess progression of psoriasis (Lacarrubba et al., 2015).  
2.5 Measuring psoriasis severity  
Clinically, psoriasis severity is typically determined via visual assessment of skin lesions 
and evaluation of the size of the surface area involved. While many different methods 
have been proposed for severity measurement, the most well-known measure is the 
psoriasis area severity index (PASI)(Cabrera et al., 2015). Despite common global usage, 
since its inception, variation in classifying severity has persisted, due largely to the 
subjective decision-making required by assessors (Finlay, 2005). Typically, psoriasis is 
divided into three classifications: mild, moderate or severe. However, determining 
where PASI scores for each rating should start and finish has also been contentious. As a 
result of this inconsistency, a European consensus was developed by a group of 
specialists to standardise classifications for severity of psoriasis and provide guidelines 
for measuring improvement (Mrowietz et al., 2011). 
 51 
Even after development of these guidelines, researchers and clinicians continue to 
search for new instruments that are effective, suitable for all degrees of psoriasis, 
simple to conduct and reflect both psoriasis severity and QoL (Gottlieb et al., 2014). 
International health bodies now recognise that psoriasis severity measures should not 
only be based on symptom severity, but also should consider QoL measures, both 
physical and psychological. This adds another level of complexity to discussion 
surrounding suitability of psoriasis severity measurement instruments (Kimball et al., 
2005) (Magin et al., 2011). Researchers have attempted to reduce confusion by 
developing protocols and guidelines aimed to simplify severity assessment, such as the 
rule of tens, which proposes psoriasis is classified ‘severe’ if body surface area (BSA) 
coverage is >10%, psoriasis area severity index (PASI) score >10 or dermatology life 
quality index (DLQI) score >10, although uptake of such protocols by clinicians has not 
been consistent (Finlay, 2005). This section describes available severity instruments 
and QoL measures for psoriasis and discusses their strengths and weaknesses. 
2.5.1 Common psoriasis severity measures 
Body surface area  
Rarely utilised alone to assess severity, body surface area (BSA) only measures surface 
area coverage of psoriatic lesions. Instead, BSA is typically combined with specific 
psoriasis symptoms such as erythema and scaling in order to get a clinically meaningful 
measure of severity. Considered a beneficial measure for treatment selection and 
monitoring treatment change, BSA change or lack of change can signal whether therapy 
should be altered or continued (i.e. when a treatment has substantially reduced 
erythema and induration, yet BSA has not changed, a different type of therapy may be 
substituted to enhance effect)(Van Voorhees and Fried, 2009). 
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Psoriasis area and severity index (PASI)  
In use for over 30 years, the PASI is the most well-known psoriasis-specific instrument 
and its reliability and validity has been well evaluated (Mrowietz et al., 2011, Spuls et al., 
2010, Fredriksson and Pettersson, 1978, Cabrera et al., 2015). Calculated using a 
somewhat complex formula, the PASI first involves estimation of the affected skin 
surface area, dividing the body into four regions and assigning a percentage BSA to each: 
head (10%), upper extremities (20%), trunk (30%) and lower extremities (40%). The 
lesion area for each division is then allocated a score between 1 and 6 (where 1 is <10% 
BSA affected, 2 is 10–29% BSA, 3 is 30–49% BSA, 4 is 50–69% BSA, 5 is 70–89% BSA 
and 6 is 90–100% BSA). After surface involvement evaluation, the degree of erythema 
(redness), desquamation (scaling) and induration (thickness) of the psoriatic plaques is 
assessed. For each symptom a score of 0–4 is given: 0=none, 1=mild, 2=moderate, 
3=severe and 4=very severe. The figures are then applied to a mathematical formula 
and a total score result is produced ranging from 0 to 72, with higher scores 
representing greater severity of disease (Table 2.1). 
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Table 2.1: Psoriasis area severity index (PASI) score calculation  
Plaque 
characteristic 
Rating 
Body region 
Head Upper limbs Trunk Lower limbs 
Erythema 0=none 
1=slight 
2=moderate 
3=severe 
4=very severe 
    
Thickness     
Scaling     
Add each of the three scores together for each body region giving four separate subtotals 
Sub totals A1= A2= A3= A4= 
Multiply each subtotal by amount of body surface area represented by that region i.e. A10.1 for 
head, A20.2 for upper limbs, A30.3 for trunk, A40.4 for lower limbs 
 A10.1=B1 A20.2=B2 A30.3=B3 A40.4=B4 
B1=  B2= B3=  B4= 
Degree of 
involvement of 
each body region 
affected (0–6) 
0=none 
1=1–9% 
2=10–29% 
3=30–49% 
4=50–69% 
5=70–89% 
6=90–100% 
    
For each body region multiply B1, B2, B3 and B4 by the % body region affected (0–6) to give 
subtotals for each body region 
 B1score=C
1 
B2score=C
2 
B3score=C
3 
B4score=C
4 
C1= C2= C3= C4= 
Final PASI score=sum of C1+C2+C3+C4 PASI (0–72)=  
(Adapted from severe chronic plaque psoriasis initial PBS authority application, 
Australian Government, Department of Health & Ageing, Medicare Australia, 2005) 
 
Using the PASI for severity assessment helps ensure psoriasis severity 
measurement is similar between cases. Combining lesion size, location and appearance 
of lesions calculates severity with a relative weighting applied to key symptoms of 
psoriasis. Therefore, temporary, inconsequential environmental reactions affecting one 
aspect of the PASI, for example, erythema will have an effect on the final score.  
Often reported by clinical trials as overall mean percentage PASI improvement, 
trials may also add a responder analysis, with responders being defined as those 
 54 
patients who have reached a predetermined percentage PASI improvement, for example, 
PASI 50 (the percentage of patients who have reached a level of 50% PASI reduction 
from baseline). Responder analyses permit intention-to-treat analysis of the percentage 
of patients who achieve a predetermined level to be considered treatment success 
(Weisman et al., 2003). The highest typically reported responder outcome for psoriasis 
is PASI 90, well above most guideline recommendations for evaluating effectiveness of a 
therapy (commonly PASI 50 or 75), it is most commonly utilised for strong action 
pharmaceutical trials such as those investigating the use of biologics for psoriasis (Reich 
et al., 2012, The Australian Government, 2004, Food & Drug Administration, 1998).  
It should be noted that following treatment, if BSA of lesions does not change, but 
erythema, induration and scaling do then PASI 75 is not achievable. Similarly, PASI 75 
cannot be reached if there is dramatic reduction in BSA, but no change to erythema, 
induration and scaling of remaining plaques. Thus, guidelines sometimes consider PASI 
50 a suitable outcome measure when assessing clinical efficacy of an intervention 
(Carlin et al., 2004).  
Despite its popularity, the PASI still has limitations. It has been argued that the 
PASI is not comprehensive enough, ignoring symptoms such as itching (pruritus) and 
pain, which can play significant roles in the personal experience of psoriasis severity 
(Nast and Schmitt, 2013). The PASI has also been criticised for a lack of sensitivity in 
milder conditions, although researchers have recently modified the PASI to improve its 
sensitivity (Kolios et al., 2015). As the PASI requires subjective estimation based on 
visual appearance, assessor variation may affect its accuracy and consistency. 
Furthermore, the possible variation in induration, scaling and erythema over a single 
plaque makes standardisation of PASI measurement more difficult. 
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Self-administered PASI  
The self-administered PASI has been developed to utilise the patient’s own observations 
of disease severity. The instrument is designed for the patient to give an objective score, 
independent of their subjective impression of their ‘overall’ disease severity. This 
method is more suitable to large epidemiological studies where the PASI may not be 
feasible to collect in person. A silhouette of the body is given to participants to shade in 
the affected areas and a visual scale to rate and record the erythema, induration, and 
scaling of an average lesion. Test–retest reliability of the self-administered PASI is quite 
good, with variability of less than 2%; validity has been also been demonstrated 
(Weisman et al., 2003). 
2.5.2 Other psoriasis severity measures 
Ongoing research to improve specificity and relevance of available psoriasis symptom 
measure instruments continues, as does research developing entirely new enhanced 
instruments. Over 50 different psoriasis measurement instruments have been identified, 
each with its own inherent strengths and weaknesses, and none yet has been proven to 
be without fault (Spuls et al., 2010). Subsequently, further instruments have been 
developed to meet specific needs of researchers or clinicians and as such many are not 
intended for universal use for psoriasis. Research instrument selection should consider 
the outcome researchers seek and should reflect some degree of clinical relevance if 
assessing treatment (Gottlieb and Armstrong, 2013). This section briefly discusses some 
of the less commonly used severity measures for psoriasis. 
Physician’s global assessment and physician’s static global assessment  
The physician’s global assessment (PGA), otherwise known as the investigator’s global 
assessment, is often considered the next best alternative to the PASI, and some have 
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suggested it should be utilised more in clinical trials in collaboration with the PASI (Nast 
and Schmitt, 2013). The PGA and PASI are evidenced to closely correlate in clinical trials 
investigating moderate to severe psoriasis, although the PGA is not as well validated as 
the PASI (Robinson et al., 2012). The PGA was primarily designed to show improvement 
compared with baseline disease severity, quantified on a scale (for example, from 1 to 
6). Selection of scales for PGA varies considerably, from 2-point scales up to 11-point 
scales, however the 6-point scale is the most commonly utilised (Langley et al., 2013). 
However, this approach is limited to the investigator’s ability to remember the disease 
severity observed at the previous visit, with photographs often used to assist 
recollection. A strength of the PGA is its relevance to clinical practice but the degree of 
assessor subjectivity is a weakness (Weisman et al., 2003). 
More recently, the PGA has been further developed so assessment is a 
measurement made at a single moment in time, without need for comparison with 
previous results, known as the physician’s static global assessment (or physician’s static 
global response). This method uses, for example, 0=all clear, 1=nearly clear, 2=mild, 
3=moderate or 4=severe.  
Lattice system physician’s global assessment  
Based on the PGA, the lattice system physician’s global assessment allows quantitative 
measurement of disease severity by integrating involved BSA range (%) and overall 
plaque morphology using a 4-point scale (none to marked)(Langley and Ellis, 2004). 
One benefit of the lattice system PGA is that rather than apply equal weighting to key 
psoriasis symptoms it applies more weight to plaque elevation than to scale or 
erythema. It does this because the degree of scale typically varies with hydration or 
emollients, as can the degree of erythema. Plaque elevation is also related to both 
characteristic psoriasis processes of inflammation and proliferation (Langley and Ellis, 
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2004). The same level of experience needed to ensure consistent reproducible PASI 
scores is not necessary for the lattice system PGA, which appears to be far more reliable 
and with reduced inter-rater variation (Langley and Ellis, 2004). Results are entered 
into a computerised lattice algorithm, hence its name, where clinically meaningful 
improvement is more clear than that of PASI (Chow et al., 2015). It has proven to have 
greater construct validity and correlation, with DLQI than the physician’s static global 
assessment (Simpson et al., 2015). 
Psoriasis disability index  
First developed around 30 years ago, the psoriasis disability index has since been 
improved and now consists of 15 questions, scored along either a visual analogue scale 
(1–7) where scores range from 15 to 105, or via tick box selection (0–3), with a final 
score between 0 and 45 (Finlay and Kelly, 1987). Regardless of scale type, an increase in 
score signals increasing disability, or severity. An advantage of the psoriasis disability 
index is that it is based on actual psoriasis patient feedback, and so might be a more 
acceptable measure for psoriasis sufferers (Lewis and Finlay, 2005). However, 
differences in scale options makes pooling of results between studies difficult and can 
create confusion between clinicians. Thus, to ensure consistency between studies and 
simplify clinical assessment, recent recommendation is to use only the tick box scale. 
Another benefit of the psoriasis disability index is its assessment of psoriasis symptoms 
as well as QoL impacts. However, it assesses neither exceptionally well, for instance, it 
does not include questions on emotions, which are deemed to be an important aspect 
for assessing QoL (Lewis and Finlay, 2005). 
Psoriasis symptom inventory  
A relatively new developed instrument, the psoriasis symptom inventory is an eight-
item patient-reported outcome measure for assessing psoriasis symptom severity 
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(Bushnell et al., 2013). Developed in conjunction with the US Food and Drug 
Administration (FDA), and designed to fulfil insufficiencies of other instruments, it was 
intended to provide information centred on patient-reported outcomes. Unfortunately, 
the psoriasis symptom inventory is currently only rated as highly acceptable for 
psoriasis vulgaris. However, it does provide more outcome detail than the PASI, making 
it potentially useful for clinical trials (Bushnell et al., 2012).  
National psoriasis foundation psoriasis score  
The national psoriasis foundation score is another instrument intending to encompass 
both QoL as well as symptom severity in order to calculate a simplified assessment of 
severity for psoriasis. The national psoriasis foundation score was originally designed 
by dermatologists to measure disease severity endpoints, which were relevant to 
clinically significant improvement in psoriasis (Gottlieb et al., 2003). Its scoring system 
combines five primary endpoints: (1) assessment of induration of two target lesions, 
rated from 0 (clear) to 5 (severe); (2) change in BSA coverage of disease relative to 
baseline, expressed as a percentage from 0%=0 (clear) to 100%=5 (no change or worse); 
(3) physician’s static global assessment, from 0 to 5; (4) patient’s global assessment, 
from 0 (clear) to 5 (worst the psoriasis has ever been); and (5) itching graded 
numerically from 0 (clear) to 5 (severe). The score can be reported as a total from 0 to 
30 or as individual scores (Weisman et al., 2003). Despite its apparent appropriateness 
as a measure and its correlation with the PASI and PGA, uptake of its use has been low, 
with most published trials using the PASI, PGA or other instrument outcome measures. 
Reflective evaluation of psoriasis efficacy of treatment and severity  
A more recently developed instrument, the reflective evaluation of psoriasis efficacy of 
treatment and severity has the potential to fill deficiencies of other instruments. 
Consisting of 29 categorised items related to either psoriasis severity or treatment 
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efficacy, the reflective evaluation of psoriasis efficacy of treatment and severity was 
designed to measure perceived disease severity and treatment efficacy. Within the 
severity category three sub-dimensions exist: disease course, symptoms and the impact 
of psoriasis. Each item is scored from 0 to 100, with higher scores indicating greater 
severity or more effective treatment. Internal reliability and validity of the instrument 
are good, as is the response to change. Furthermore, it measures joint pain in arthritis 
sufferers, which the PASI does not. Although a promising instrument, it was initially 
validated in a French population so future translation and validation is still needed in 
other populations (Gilet et al., 2014). 
2.5.3 Quality of life measures commonly utilised for psoriasis 
As mentioned previously, early treatment goals centred solely on improving the 
symptomatic appearance of psoriatic lesions, however as psoriasis research has 
expanded, the importance of QoL impacts has gained significant weight. Considerable 
research highlights the importance of emotions and the psychological wellbeing of 
people with psoriasis (Dalgard et al., 2014). Such aspects impact on the daily life of 
many sufferers and in turn affect their routine activities or in some cases may prevent 
activity entirely (Dubertret et al., 2006). A survey by the national psoriasis foundation 
reported psoriasis has a negative effect on the life of around 79% of sufferers (Krueger 
et al., 2001). Recently, international treatment guidelines have placed QoL measures on 
equal or almost equal footing as symptom measures when evaluating psoriasis severity 
and/or selecting treatment. Improvements in QoL are hence viewed as an important 
measure for treatment outcomes. As such, counselling or other psychological therapies 
are often advised in conjunction with psoriasis-specific therapy (World Health 
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Organization (WHO), 2013). This push by governing bodies has also generated an 
increased emphasis on monitoring QoL in clinical trials (Basra and Hussain, 2012).  
Dermatology life quality index  
First developed in the 1990s for daily clinical practice, the dermatology life quality 
index is generated by a compact questionnaire and has gained prominent use in clinical 
trials. Reliability and validity have been established, with greater severity of disease 
positively associated with higher scores (Weisman et al., 2003). The questionnaire 
consists of 10 questions, each with four or five tick box response options: ‘very much’, ‘a 
lot’, ‘a little’, ‘not at all’, and for questions 3–10 ‘not relevant’. Each selection 
corresponds to a score from 0 (not at all or not relevant) to 3 (very much). In addition, 
question 7 asks if work or study was prevented due to disease, where the value of ‘yes’ 
is 3. The highest potential total score of 30 indicates most severe QoL impact (Finlay 
and Khan, 1994). The dermatology life quality index has been translated into over 20 
languages and has a separate instrument for children (Lewis and Finlay, 2004). It is still 
not without fault, some suggesting it requires improvement, as some items are ill fitting. 
The instrument has also been accused of not being sensitive enough to measure mild 
illness change (Twiss et al., 2012). In addition, while providing good insight into QoL for 
sufferers, the dermatology life quality index is insufficient for calculation of treatment 
cost effectiveness, requiring it to be combined with further generic QoL measures, such 
as the EuroQol 5D, to provide more clinically relevant results (Norlin et al., 2012). 
Skindex 
Some researchers for its reduced floor effect favour the Skindex instrument, that is, it 
has a greater reliability and sensitivity to lower limit data compared with other QoL 
measures, such as the dermatology life quality index. Another advantage of the Skindex 
is its high cross-cultural validity, beneficial for use in large international studies 
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(Bronsard et al., 2010).Designed to compare QoL differences between different 
dermatological diseases and provide data on their change over time, the Skindex is also 
sensitive to severity change in milder conditions (Fernandez-Penas et al., 2012). 
Originally containing 61 items, to improve ease of administration and construct validity 
it has since been refined to 17-item and 29-item Skindexes (Chren et al., 1996, Chren et 
al., 1997, Chren et al., 2001).  
Each item in the Skindex has five response options – ‘never’, ‘rarely’, ‘sometimes’, 
‘often’ or ‘always’ – which correspond to scores from 1 (never) to 5 (always). These 
scores are then transferred to a linear scale between 0 and 100 (0=never, rarely=25, 
sometimes=50, often=75 and always=100)(Chren, 2012). Instrument items can then be 
further classified (grouped) into scores for different domains: degree of symptoms, 
psychosocial functioning or emotional status. This unique strategy allows an overall 
mean score to be calculated, as well as separate construct group scoring, which provides 
opportunity for comparison between domain groups.  
2.5.4 Other psoriasis quality of life measures 
Numerous other QoL instruments exist, some specific to dermatology, providing more 
comprehensive assessment than generic QoL instruments, but many are not suitable for 
psoriasis. For instrument selection, it is important for researchers to consider the 
nature of the data being collected and intended statistical analyses techniques. For 
instance, the QoL instrument selected should be sensitive enough for the targeted 
psoriasis severity population, or if socioeconomic impacts such as productivity are 
central to study outcomes, then an instrument that enables such calculation should be 
utilised. Generic instruments, although often less sensitive, can provide beneficial data 
to compare psoriasis to other diseases, which can be useful for informing health policy 
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(Weiss et al., 2002). Such research need has seen development of QoL mixed measure 
instruments, consisting of both specific and generic items (Bhosle et al., 2006). This 
section discusses other QoL instrument measures utilised for evaluating psoriasis QoL 
change. 
Dermatology quality of life scale  
Derived from real patients, the dermatology QoL scale assesses the psychological and 
daily activity impacts of dermatological disease. Although when initially developed and 
validated it was not psoriasis-specific, the majority of original test participants were 
suffering from psoriasis. Consisting of 29 questions relating to psychosocial state (n=17) 
and daily activities (n=12), each is rated on a 5-point Likert scale (‘very slightly or not at 
all’, ‘a little’, ‘moderately’, ‘quite a bit’ or ‘extremely’). It further groups items into 
subscales similar to the Skindex, but is more specific: ‘psychosocial’ despair, 
irritableness and distress; and summer, social and sexual ‘activities’ (Morgan et al., 
1997). With good construct validity, the instrument has had greater uptake in clinical 
trials than in general practice (Bronsard et al., 2010).  
Psoriasis index of quality of life  
While being psoriasis-specific for QoL, unlike other QoL measures, the psoriasis index of 
quality of life bases assessment around a needs model for the impact psoriasis has on 
QoL. Again, an instrument derived from patient response, the psoriasis index of quality 
of life was created under the premise that QoL is reduced when needs are not met. 
Consisting of 25 items validly developed using Rasch modelling, the maximum score of 
25 indicates greatest possible life impairment (McKenna et al., 2003). Despite the 
psoriasis index of quality of life focusing on the needs of people with psoriasis it has 
experienced low uptake in clinical trials (Bronsard et al., 2010). 
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EuroQol 5D  
A generic instrument, the EuroQol 5D was designed for use in large population health 
surveys. The first of three components assesses health state over five criteria: mobility, 
self-care, usual activities, pain or discomfort, and anxiety or depression. Each criterion 
has three response options: ‘no problem’, ‘some problem’ or ‘extreme problem’. The 
second component classifies each person into one of 243 distinct health statuses. The 
third component uses a visual analogue scale to self-rate health status (0 equals ‘worst 
imaginable health state’ and 100 equals ‘best imaginable health state’)(EuroQol Group, 
1990). While not being specific for psoriasis, it has often been utilised for psoriasis as it 
provides data that are helpful for cost–benefit analysis (Norlin et al., 2012). 
Short form health survey (SF-36) 
Another generic instrument, the short form health survey (SF-36) is one of the most 
widely used generic instruments for assessing health and life quality in disease. With 36 
items it covers eight different domains: physical activities, social activities, usual 
physical role activities, bodily pain, general mental health, usual emotional role 
activities, vitality, and general health perception. Unlike other instruments it uses a 
mixture of different rating scales where a higher score indicates improved QoL (Ware 
and Sherbourne, 1992). The SF-36 has successfully shown the significance of psoriasis 
disease, where its impact has been rated similar to that of severe community diseases 
(e.g. cancer, chronic lung disease or depression) (Rapp et al., 1999).  
Psoriasis life stress inventory 
Designed to assess stress in people with psoriasis, the psoriasis life stress inventory was 
developed based on clinical experience and then tested in a psoriasis population. The 
psoriasis life stress inventory is a very specific scale and so is not widely used in trials. 
Consisting of 15 items rated on a four-point scale of frequency of experience (0=‘not at 
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all’ to 3=‘a great deal’), the total score can be between 0 and 45 (Gupta and Gupta, 1995). 
The psoriasis life stress inventory asks for each item to be rated over the previous four 
weeks, so it may not be sensitive to acute exacerbations as short-term reassessment in 
follow-up sessions i.e. weekly or fortnightly becomes redundant. Such deficiencies 
contribute to a lack of flexibility for use, hence in most cases where general QoL 
measures are needed other instruments provide a better option, however it is worth 
considering for stress-specific impacts (Fortune et al., 1997). 
Health assessment questionnaire  
Assessing health quality across five domains – disability, pain, medication effects, costs 
of care and mortality – the health assessment questionnaire can also be administered in 
a shorter two-page version that only measures disability and pain (Bruce and Fries, 
2005). If subjects lack significant pain or disability, the domains have limited 
applicability to psoriasis; however, it may be a useful instrument for psoriasis 
complicated by arthritis. The constructs have more focus on severe conditions and 
would probably not be sensitive enough for mild conditions of psoriasis. 
Koo–Menter psoriasis instrument  
Specifically designed for measuring QoL prior to determining if systemic treatment is 
warranted, the Koo–Menter psoriasis instrument is more an aid to physicians than a 
viable instrument for clinical trial use. The instrument combines QoL questions with 
psoriasis severity assessment and records BSA. The outcome of the instrument 
determines whether a patient is a suitable candidate for systemic therapy (Feldman et 
al., 2005).  
Impact of psoriasis questionnaire  
The impact of psoriasis questionnaire was originally developed as part of a study 
investigating a cohort of psoriasis patients receiving psoralen plus ultraviolet light 
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therapy. The questionnaire originally consisted of 16 items based on questions used in 
another instrument, the medical outcomes study short form general health survey. 
Items are rated on a 5-point ordinal scale (1=‘none’, 2=‘some’, 3=‘moderately’, 4=‘quite 
a bit’ and 5=‘extreme’), further grouped as either physical, psychological or social with a 
final score ranging from 0 to 64 (McKenna and Stern, 1997). Since inception it has 
undergone further refinement using Rasch analysis and the number of items has 
reduced to 11 (Nijsten et al., 2006). Since refinement there has been little uptake in 
psoriasis trials despite evidence it has reasonably good reproducibility and acceptability 
(Bronsard et al., 2010). 
Psoriasis family index  
A novel psoriasis-specific QoL instrument, the psoriasis family index, measures QoL of 
family members and partners of psoriasis patients. Item were created based on 
interviews at a dermatology outpatient clinic, with validation into a 20-item instrument 
(Eghlileb et al., 2009). Further testing of the instrument to assess its reliability is needed 
and as yet the instrument has not had significant uptake. 
Salford psoriasis index  
Assisting clinicians to manage the care of psoriasis patients, the Salford psoriasis index 
is a 3-component system consisting of current psoriatic extent score (based on PASI 
banding and valued from 0 to 10), psychosocial impact score and a severity score for 
historical disease. For the psychosocial section patients mark on a visual analogue scale 
the extent that psoriasis impacts on their everyday life (0=‘not at all affected’ and 
10=‘completely affected’). The historical severity score is based on treatment history of 
the patient. Each score is reported separately (e.g. 5:5:0) so clinicians can quickly assess 
patients and choose appropriate treatments. A benefit of the Salford psoriasis index is 
that it combines comprehensive physician and patient input, as well as an objective 
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view of disease history, to give insight into difficulties of psoriasis treatment (Weisman 
et al., 2003, Kirby et al., 2000). Recently, the Salford psoriasis index has been modified 
further into two versions with strong reliability: a professional version designed for 
completion by health professionals and a patient self-assessment version 
(Chularojanamontri et al., 2013). The relevance and design of the Salford psoriasis index 
is more suited to clinical settings than research trials.  
2.5.5 Summary of assessment measures 
With a variety of available instruments and conjecture about their use for psoriasis, 
determining which instrument to use in clinical studies requires consideration of 
psoriasis type, target population, required degree of sensitivity to change and ease of 
use (Ryan et al., 2013). For research, it is advised to use common validated instruments 
with proven reliability. The PASI and various forms of the PGA are most commonly 
utilised for psoriasis severity and should continue to be utilised until more suitable 
methods are developed.  For QoL a number of instruments have been validated in a 
psoriatic population and researchers should consider the population type and intended 
outcomes when choosing an instrument. The DLQI is most often utilised however due to 
lack of sensitivity in mild cases the SKINDEX can supplement QoL data.  
Selecting these instruments enables data from previous and future studies to be 
statistically pooled and/or compared. Many available instrument measures are not ideal 
for psoriasis, lacking key factors known to be significant for sufferers. Newer 
instruments aim to address deficiencies, but as yet none have had significant uptake. 
Unfortunately, as yet there is no worldwide consensus on a severity measure for 
psoriasis; however, the World Health Organization (WHO) suggests that further 
clinician education and support may lead to eventual development of universal severity 
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guidelines appropriate for all aspects of psoriasis (World Health Organization (WHO), 
2013). Researchers are encouraged to include, where possible, newer psoriasis 
instruments in their research design along with more traditional measures, so newer 
instrument data can be further compared and further improvements made. 
2.5.6 Chinese medicine theory for psoriasis measurement 
While validated and reliable conventional instruments exist for measurement of 
psoriasis symptoms and QoL, there is yet no widely accepted instrument that considers 
Chinese medicine theory in psoriasis assessment. While lesion changes are an important 
aspect for management and treatment of psoriasis, Chinese medicine assesses psoriasis 
beyond the appearance of the disease when determining cause and progress of disease. 
In Chinese medicine, features of the tongue and pulse assist in differentiation of 
syndrome type and guide selection of treatment (Mei, 2011).  
Unlike conventional therapy, Chinese medicine treatment prescription is not 
determined predominantly by severity and location of lesions, but instead considers 
Chinese medicine concepts such as yin, yang and meridians. Thus, two people with 
identical conventionally diagnosed psoriasis may be considered to have two very 
different syndromes in Chinese medicine (Lu et al., 2014a). Differentiation uses 
inspection, assessment and Chinese medicine enquiry techniques. Once diagnosed, 
Chinese medicine therapy consists of treatments such as acupuncture and/or CHM, 
among other options. Syndrome differentiation instruments have been designed for 
Chinese medicine with some level of validation and reliability for some health 
conditions, but there is no known specific instrument for psoriasis (Grant et al., 2013, 
Schnyer et al., 2005). Given this, a unique instrument was developed for the current 
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study based on Chinese recommended guidelines for psoriasis to classify study 
participants (China Academy of Chinese Medicine, 2011) (Appendix 1) 
2.6 Co-morbidities associated with psoriasis 
Evidence indicates an increased likelihood of various co-morbidities in psoriasis 
sufferers. Likely as result of such co-morbidity risk, the life expectancy of people with 
psoriasis is around 3–4 years lower than people without the disease (Gelfand et al., 
2007). Metabolic disorders are the most frequent co-morbidities reported and pose risk 
to liver and/or kidney disease (Svedbom et al., 2015). Other significant diseases have 
been associated with psoriasis including hypertension, obesity, restless legs syndrome, 
bowel disease, lymphoma, depression, diabetes, cancer, Crohn’s disease, liver disease, 
infections, dyslipidaemia, osteoporosis and lymphoma (Schell et al., 2015, Gelfand et al., 
2003) (Gottlieb et al., 2008b, Bernstein et al., 2005, Schmitt and Ford, 2007, Zanni, 
2012).  
Available evidence for these potential co-morbidities varies, with some such as 
metabolic disorders attracting far more interest than others. It has been proposed that 
rather than psoriasis leading to these co-morbidities, in fact there is a genetic 
predisposition in people with psoriasis that leads to co-morbidity development (Koch et 
al., 2015). Indeed, paediatric research supports such a genetic link, in which risk of 
developing hyperlipidaemia, obesity, hypertension, diabetes mellitus, rheumatoid 
arthritis and Crohn's disease is increased around 2-fold for children diagnosed with 
psoriasis (Augustin et al., 2010). 
This section discusses the most commonly reported co-morbidities associated 
with psoriasis, detailing their prevalence and reviewing evidence of their relationship to 
psoriasis. 
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2.6.1 Cardiovascular disease 
Mortality from cardiovascular disease is increased by 57% in people with psoriasis, 
although there is conjecture surrounding the precise mechanistic relationship between 
the two. Genetic polymorphisms in psoriatic people is a growing area of research, where 
data are emerging from genome-wide association studies indicating existence of 
common genetic variants predisposing people to increased risk of dyslipidaemia, 
hypertension and coronary artery disease (Lu et al., 2013). However, recent research 
identifies no increased risk of cardiovascular events following adjustment for 
cardiovascular disease risk factors (Aldeen and Basra, 2011) (Parisi et al., 2015).  
A key inflammatory mediator in the development and progression of psoriasis, 
TNF- is also understood to be important in cardiovascular disease. Despite TNF- 
polymorphisms being found to increase incidence of psoriasis, research suggests these 
same polymorphisms have no impact on development of coronary artery calcification 
(Zhuang et al., 2013) (Torres et al., 2014). With TNF- unlikely to be the genetic cause 
of cardiovascular disease development, research has focused on other elevated 
inflammatory factors of both conditions, such as vascular endothelial growth factor, IL-
12, monocyte chemotactic protein-1 (MCP-1) and circulating IL-17A, among others 
(Wang et al., 2012e). 
Of these, IL-17A shows the most promising evidence for involvement (Golden et al., 
2013). Found in blood, plasma C-reactive protein is typically high in inflammatory 
disease and has been implicated in both cardiovascular disease and psoriasis. For 
people with moderate and/or severe psoriasis, greater levels of C-reactive protein have 
been reported than for milder conditions (Beygi et al., 2013). An overall increase in the 
prevalence of metabolic syndromes in people with psoriasis is likely to be the key 
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precursor to development of cardiovascular disease in this population, and with 
suitable preventive therapy this risk may be reduced (Voiculescu et al., 2014). 
2.6.2 Diabetes 
Similar to cardiovascular disease, genetic indicators found in people with psoriasis are 
also known to increase risk of diabetes (Koch et al., 2015). For people with psoriasis 
who develop diabetes, there is an increase in micro-vascular and macro-vascular 
complications compared with non-psoriatic diabetics (Armstrong et al., 2015). 
Incidence of insulin resistance is also higher in psoriatic people, providing some insight 
into how diabetes may develop (Gyldenlove et al., 2015). Similarly, risk of diabetes is 
likely related to a coinciding increased incidence of obesity in psoriatic people (Tobin et 
al., 2014). 
Research indicates decreasing obesity of sufferers correlates with reduced 
psoriasis severity, although again the mechanism is unclear. Indeed, paediatric research 
confirms concomitant obesity in children is common with psoriasis, supporting a 
possible genetic link (Solomon, 2014, Mahe et al., 2014). Obesity also affects metabolism 
and the effectiveness of treatments; for instance, obesity may reduce the success of drug 
treatment for psoriasis (Carrascosa et al., 2013). Despite apparent metabolic risk and an 
increased risk of diabetes, dispute remains among researchers – no direct link was 
detected in a US population, while a Dutch study concluded there was a link 
(Casagrande et al., 2014, Khalid et al., 2013). Clearly more research is needed to 
evaluate if there are indeed any links between diabetes and psoriasis. 
2.6.3 Psychological impacts of psoriasis 
The degree to which psychological state impacts on psoriasis symptoms is arguable. 
Regardless, the statistics are alarming, indicating 20% of people with psoriasis may 
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experience suicidal ideation (Dermatology Expert Group, 2004) (Bhosle et al., 2006). 
Such research does highlight the importance of psychological effects on people with 
psoriasis, likely owing to the physical appearance of lesions, often amplified by their 
location. Lesions on exposed areas of the body, such as the face, can cause significant 
reductions in QoL (Heydendael et al., 2004), triggering shame, anger and worry, further 
contributing to difficulties undertaking daily activities and impacting on social life. 
Sufferers also feel stigmatised by the common misconception that psoriasis is 
contagious (Donigan et al., 2015), leading to an increase in stress, poor self-image and 
embarrassment (Kimball et al., 2005). These emotions can lead to depression and/or 
anxiety disorders (Sampogna et al., 2012). If combined, such factors can diminish QoL 
so substantially that people with psoriasis have reported reduced QoL comparable to 
people with severe diseases such as cancer, ischaemic heart disease, diabetes and 
chronic obstructive pulmonary disease (Rapp et al., 1999). 
Going beyond the psychological and emotional impacts of psoriasis, many patients 
(both male and female) can go on to manifest physical dysfunction, such as sexual 
impairment (Sampogna et al., 2007, Turel Ermertcan et al., 2006, Goulding et al., 2011). 
Erectile dysfunction is a common manifestation in psoriatic men, with high disease 
severity correlated with increasing dysfunction. Such sexual dysfunction is 
predominantly reported as a psychological disorder, however evidence suggests it may 
also be physiological, with reductions in testosterone levels and increases in estradiol 
shown in psoriatic men (Cemil et al., 2015). Depression can also have physiologically 
implications, increasing risk of atrial fibrillation and stroke in psoriasis sufferers 
(Egeberg et al., 2015). 
With greater importance placed on improving QoL as well as psoriasis symptoms, 
during treatment the provision of psychological support and therapy is as important as 
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addressing psoriasis symptoms. This is especially important in cases where anxiety and 
fear of relapse continue even after psoriasis lesions have cleared (Rapp et al., 1999). 
Unfortunately, identification of psychological disorder in people with psoriasis is low 
(Richards et al., 2004). Left untreated, psychological distress can impair treatment; for 
instance, clearance rates of treatments such as psoralen plus ultraviolet light therapy 
and photochemotherapy are reduced in patients with psychological distress (Fortune et 
al., 2003). 
2.6.4 Other potential psoriasis-related co-morbidities 
Another co-morbidity associated with psoriasis is sarcoidosis, an inflammatory disease 
that affects multiple organs in the body, but predominantly the lungs and lymph glands. 
In particular it has been related to pulmonary sarcoidosis, possibly linked via the Th17 
pathway (Wanat et al., 2013). Psoriasis has also been implicated in an increased 
likelihood of other autoimmune diseases (Wu et al., 2012). Although unclear why, 
coeliac disease has shown more positive IgA antigliadin antibodies in psoriasis sufferers 
than healthy controls (Bhatia et al., 2014). Evidence also suggests that psoriasis may 
increase risk of complications during pregnancy (Ben-David et al., 2008). 
2.6.5 Co-morbidities summary 
Psoriasis imparts a significant burden on a sufferers’ health. A survey of psoriasis 
sufferers found 46% of respondents felt it would be better or the same to have diabetes 
instead of psoriasis, and 99% of respondents said they would be prepared to spend two 
or three hours each day on therapy, if it might result in normal skin for the rest of the 
day (Palotai et al., 2010).  
A health-related QoL study describes reduction in physical and mental function of 
psoriatic people as comparable to that seen in cancer, arthritis, hypertension, heart 
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disease, diabetes and depression (Rapp et al., 1999). Growing co-morbidity evidence 
has led to a push from clinicians to assess and appropriately treat co-morbidity risks, 
such as cardiovascular disease and diabetes (Ryan and Kirby, 2015). The impact of 
psoriasis is now understood to be far greater than just the affected skin’s appearence, 
with links to systemic disease patterns increasing mortality and psychological disorder 
risk. Researchers investigating psoriasis treatment should, where possible, also 
investigate changes in related co-morbidity risk through suitable testing such as blood 
glucose and blood lipid levels. 
2.7 Conventional treatments for psoriasis 
The degree of psoriasis severity has important implications in treatment selection. 
Appropriate selection of therapy maximises therapeutic outcomes while minimising 
unwanted effects for patients. Approximately 80% of all psoriasis cases are considered 
as mild to moderate in severity (Menter et al., 2009). Guidelines typically recommend 
milder therapies (e.g. topical steroid creams) for lower severity psoriasis, while 
increasingly stronger therapies (e.g. biological drugs) are administered as psoriasis 
severity increases.  
Historically, with little known about their precise therapeutic mechanism, 
psoriasis treatments were discovered largely via trial and error. As psoriasis research 
techniques have improved so too has the biological understanding of psoriasis. When 
excessive proliferation of keratinocytes was scientifically recognised in psoriasis, a 
significant period of drug development followed. Since cyclosporine A first successfully 
showed anti-psoriatic effects, irregular immune function has been considered central to 
understanding psoriasis. Subsequent drug development has endeavoured to produce 
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new immune-based drug therapies that are less toxic than cyclosporine A (Micali et al., 
2014, Van Joost et al., 1988). 
Current drug development research, such as into targeted biologics, 
predominantly focuses on specific immune pathway activity, reducing likelihood of 
unwanted widespread systemic effects (Nickoloff and Nestle, 2004). Unfortunately, 
many effective modern drugs, including biologics, still have drawbacks, such as high 
retail costs and the risk of potentially severe side effects (Ryan and Menter, 2012). 
Recent drug development has primarily targeted severe and/or unresponsive psoriasis 
cases, so for the majority of milder psoriasis cases available therapies remain quite 
limited. Psoriasis sufferers with mild disease are commonly directed towards less 
effective and inconvenient therapies, such as topical creams, which show low adherence 
(Storm et al., 2008) (Zschocke et al., 2014, Reich and Dauden, 2014). 
In accordance with treatment guideline recommendations, this section reviews 
conventional treatment options for psoriasis (Dermatology Expert Group, 2004, 
Mrowietz et al., 2011, Excellence, 2012, Menter et al., 2008). Therapies are each 
reviewed to explain their potential biological mechanisms relevant to psoriasis and 
their safety. 
2.7.1 Background of therapeutic guideline treatment recommendations 
Documented therapeutic guidelines for psoriasis differ around the world regarding 
measure of severity and selection of treatment. Most well-known and referred 
guidelines are from the United States of America (Menter et al., 2008), United Kingdom 
(Excellence, 2012) and Europe (Pathirana et al., 2009, Nast et al., 2015a). Australia has 
developed its own guidelines based on those internationally available (Dermatology 
Expert Group, 2004). Guidelines aim to ensure patients are consistently managed and 
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cost–benefit typically strongly influences local therapeutic guidelines. Unfortunately, 
global variation in guidelines limits analyses of pooled data. To assist data pooling, 
consistent use of outcome measures and therapies needs to be reported. Global data 
pooling may assist in development of international standardised guidelines to support 
global treatment outcome optimisation.  
The potential benefits of standardisation have led to recent discussion, 
cooperation and consensus between various chief health bodies, and the gradual 
development of wider region guidelines (Mrowietz et al., 2011). Such international co-
operation recently culminated in development of a resolution for psoriasis, put forward 
by the WHO, which resulted in subsequent release of key actions to improve care of 
people with psoriasis (World Health Organization (WHO), 2013). A published WHO 
report describes psoriasis as a “chronic, non-communicable, painful, disfiguring, and 
disabling disease for which there is no cure”. Furthermore, the psychological impacts of 
psoriasis have been acknowledged and the elevated risk of serious co-morbidities, such 
as cardiovascular disease, diabetes and metabolic syndrome, has been recognised 
(World Health Organization (WHO), 2013).  
When assessing psoriasis to determine suitable treatment prescription (drug and 
dosage selection), it is now widely accepted that both psoriasis symptoms and QoL 
should be evaluated (Samarasekera and Smith, 2014). Guidelines commonly divide 
treatment into first, second and third line therapies. First line therapies are targeted at 
milder or newly presenting moderate cases of psoriasis. Typically, first line therapy 
consists of mild-action topical drugs, such as vitamin D analogues. Second line therapies 
typically consist of stronger topical drug such as moderate- to high-strength 
corticosteroids, phototherapy and non-biological systemic treatments such as 
methotrexate and cyclosporine A. Second line therapies are recommended for moderate 
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to severe disease or mild psoriasis cases unresponsive to first line therapy 
(Samarasekera et al., 2012). Third line therapies are typically prescribed when first and 
second line therapies are unsuccessful, or in cases of very severe psoriasis requiring 
immediate and drastic symptom reduction. Third line therapy consists predominantly 
of biologics such as TNF antagonists (e.g. adalimumab and etanercept) or IL-17 
inhibitors (e.g. Brodalumab) (Samarasekera and Smith, 2014). 
Guidelines also recommend addition of concomitant therapies such as emollients 
for people experiencing pruritus (itching) (Excellence, 2012, Menter et al., 2009). 
Interestingly, no one treatment has proven to have superior efficacy for pruritus in 
controlled trials (Reich and Szepietowski, 2014). 
This section discusses the various treatment options available. Conventional 
therapies are grouped with other therapies with similar indicated use and/or 
mechanism in psoriasis: topical therapies, systemic drugs, other conventional therapies, 
novel and emerging therapies. The known mechanisms of these drugs are reviewed 
then associated risks and limitations discussed. 
2.7.2 Conventional topical therapies for psoriasis 
Given the majority of psoriasis cases (80%) are mild to moderate in severity, topical 
drugs are the most commonly prescribed therapy (Menter et al., 2009). 
Topical steroidals  
Understood to inhibit synthesis of some regulatory proteins while inducing synthesis of 
others, the corticosteroids known as glucocorticoids are shown to inhibit psoriasis pro-
inflammatory cell TNF- (Bos and Spuls, 2008). As glucocorticoids act on multiple 
pathways, physicians commonly prescribe them for psoriasis. It has been shown that 
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glucocorticoids have anti-inflammatory, anti-proliferative, anti-pruritic and 
vasoconstrictive activity (Humbert and Guichard, 2015).  
Corticosteroids are rated as mild, moderate, potent or very potent, with increasing 
potency providing greater efficacy, but also increasing risk of side effects. Regardless of 
origin, treatment guidelines tend to advocate and encourage the use of topical steroidals 
as a first line therapy in psoriasis. The benefits of topical steroidals for psoriasis are 
clear, however with the development of newer drugs with far greater efficacy, 
glucocorticoid use is starting to be questioned (Samarasekera et al., 2013). 
Despite the common use of topicals, adherence is typically low. Patients prefer 
gels to ointments yet ointments show greater effect (Bewley and Page, 2011). 
Furthermore, extensive or persistent use of glucocorticoids should be avoided due to 
risk of tachyphylaxis (severe flare-up when steroid is stopped plus poor response when 
restarted), skin atrophy, Cushing’s and risk of suppression of the hypothalamic-
pituitary-adrenal axis (Clarke, 2011, Humbert and Guichard, 2015).  
Vitamin D analogues 
Vitamin D analogues decrease proliferation, induce differentiation and induce apoptosis 
of psoriatic keratinocytes (Tiberio et al., 2009). They reduce expression and/or protein 
levels of inflammatory factors IL-2, IL-6, IL-8, IFN-γ and GM-CSF, which are likely 
involved in the proliferation of T-cells in psoriasis (Nagpal et al., 2001). Thoroughly 
investigated for its involvement in psoriasis, the Th-17 inflammatory pathway is 
reduced by vitamin D analogues (Hegyi et al., 2012). With reduced risk of side effects, 
yet similar efficacy, vitamin D analogues may in fact be superior to corticosteroids as 
topical anti-psoriatics (Soleymani et al., 2015).  
Early animal studies of Vitamin D analogues showed they reduced angiogenesis 
however can be calcemic (Oikawa et al., 1990). Calipotriol however has shown to be as 
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effective as other vitamin D analgues without being as calcemic. Left/right comparative 
study indicates calcipotriol (50gm) to be effective and safe for psoriasis vulgaris when 
compared to vehicle (p<0.001)(Dubertret et al., 1992).  
Other 
Another topical is tar, which despite widespread usage increases risk of spontaneous 
abortion in pregnant women (Bae et al., 2012). Tacrolimus is a topical 
immunosuppressive drug that also carries some risk for pregnant women, with 
potential for lower birth weight, premature birth and substantial levels found in breast 
milk, posing further risk to the infant (Jain et al., 2003). Keratolytics such as salicylic 
acid, lactic acid and urea are used typically as adjunct therapies, to remove thick scaling, 
and are not typically prescribed as a sole treatment (Tollefson, 2014). 
2.7.3 Conventional systemic therapies for psoriasis 
Systemic corticosteroids 
Having similar action to topical corticosteroids systemic forms are orally ingested and 
metabolised through the GI tract, as such GI related side effects can ensue. Oral forms 
also carry greater risk to pregnant women, with low foetal weight and a reported 
increase in the incidence of cleft pallet (Chi et al., 2011, Edwards et al., 2003). 
Methotrexate  
An immunosuppressant, methotrexate is a folic acid antagonist, acting by competitively 
inhibiting the enzyme dihydrofolate reductase, which is needed in the synthesis of 
folate and subsequent DNA, RNA and protein synthesis (Ho et al., 2009). Its therapeutic 
mechanism is also a potential risk for people with folic acid deficiency, and can lead to 
adverse effects requiring folic acid supplementation to relieve them (Whittle and 
Hughes, 2004). The dosage of such supplementation requires further research, as too 
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high a dosage has been shown to reduce methotrexate efficacy, thus requiring a careful 
balance (Baran et al., 2014). Use of methotrexate is further limited by other potential 
side effects including increased risk of pulmonary complications, myelosuppression, 
hepatotoxicity and haematological toxicities (Barrera et al., 1994). Consequently, to 
monitor hepatic and haematological parameters, strict laboratory monitoring, including 
a liver biopsy is essential after administering a total cumulative dose of 1.5g of 
methotrexate (Kovesdy and Kalantar-Zadeh, 2012, Staidle et al., 2011).  
Considering the increased prevalence of alcohol use and co-morbidities such as 
obesity and diabetes in people with psoriasis, the risk of liver fibrosis is also greater, 
and as such restricts use of methotrexate in some cases (Montaudie et al., 2011). 
Methotrexate can also cause severe teratogenicity such as mental retardation and 
craniofacial defects in pregnant women so use should be avoided in women considering 
pregnancy. Emerging evidence suggests low dose methotrexate use may reduce risk of 
cardiovascular disease events, although the mechanism behind this is still unclear (De 
Vecchis et al., 2015). 
Acitretin  
Shown to decrease the expression of chemokines in peripheral blood of people with 
psoriasis, acitretin is an oral retinoid that acts by binding to nuclear transcription 
factors (Dai et al., 2014a). Binding induces keratinocyte differentiation and reduces 
epidermal hyperplasia, however at higher doses side effects can arise, including itchy 
dry skin, dry mucus membranes and joint pain. Another concern of oral retinoids is 
their highly teratogenic nature, so it should be avoided in women of childbearing age 
(Bae et al., 2012). Reports suggest avoiding pregnancy for at least two years following 
the cessation of oral retinoid use (Staidle et al., 2011). Acitretin is a useful option for 
psoriasis patients in which immunosuppression is contraindicated.  
 80 
Calcineurin inhibitors  
Derived from soil fungi, cyclosporine A is the most well-known calcineurin inhibitor for 
psoriasis vulgaris. Calcineurin is a key molecule in inducing transcription factors of 
potential cytokines. When administered, cyclosporine A reduces numbers of epidermal 
and dermal T-cells and inhibits mast cell activity (Boyman et al., 2007, Oran et al., 1997). 
Evidenced to reduce production of TNF- and IL-2 it is also understood to reduce helper 
T-cells, regulatory T-cells, NK cells and block the activation of monocytes, all assisting to 
reduce inflammation of psoriasis (Akcali et al., 2014). Although cyclosporine A can 
supress psoriasis symptoms, resolved plaques still often show regenerative 
keratinocytes, indicating its actions do not reverse psoriasis inflammatory pathways 
(Guttman-Yassky and Krueger, 2007).  
Long-term use of cyclosporine A is associated with nephrotoxicity, thus 
monitoring of renal function and blood pressure is recommended. As such, cyclosporine 
A is best avoided in the elderly and is typically only prescribed in short courses for 
acute flare-ups (Grossman et al., 1996). Following remission or control, cyclosporine A 
therapy should cease and patients changed to other forms of systemic therapy safer for 
long-term maintenance (e.g. acitretin) (Staidle et al., 2011). As cyclosporine A is 
understood to cross the foetal blood barrier, it should be avoided in pregnant patients 
(Lamarque et al., 1997). Similar calcineurin inhibitors have also been developed include 
sirolimus, pimecrolimus and racrolimus, with the latter being 50–100 times more 
potent than cyclosporine A (Reitamo et al., 2001, Rappersberger et al., 2002, Reynolds 
and Al-Daraji, 2002). 
Tumour necrosis factor alpha inhibitors 
Anti-tumour necrosis factor therapies work against psoriasis by decreasing Th17 
pathway cells (Zaba et al., 2007). While effective, they are not without risks, including 
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subsequent development of serious infections and malignancy (Staidle et al., 2011). 
Further risk of spontaneous abortion is linked to administration of TNF- inhibitors 
before and after conception in women (Verstappen et al., 2011). Although TNF- 
inhibitor drugs show strong efficacy in psoriasis, due to progressive formation of 
antibodies against them, subsequent immunogenicity can considerably reduce long-
term efficacy (Baert et al., 2003). In contrast to its therapeutic use for psoriasis, anti-
TNF- drug use in people without psoriasis may actually trigger psoriasis lesions 
(Pugliese et al., 2015). A few of the more common anti-TNF- drugs are now discussed 
in more depth. 
Etanercept 
Known to suppress Th17 pathway cytokines that inhibit psoriasis-related pathways, 
etanercept prevents excess TNF from binding and interacting with cell-bound receptors 
by competitively inhibiting TNF-mediated activity (Wang et al., 2012b). Significant 
adverse effects noted with etanercept therapy include temporary injection site 
reactions, exacerbation of congestive heart failure (although rare) and bone marrow 
suppression during therapy. Users are also at increased risk of antinuclear antibody 
development, but only in rare cases do patients develop any clinical manifestations. 
There are extremely rare yet severe reports of central nervous system demyelinating 
disease associated with etanercept, and a small number of lymphoma cases reported 
following induction of etanercept (Staidle et al., 2011). 
Adalimumab 
A fully human monoclonal antibody, adalimumab binds to TNF-, blocking its 
interaction with TNF cell-surface receptors. Common side effects associated with 
adalimumab include upper respiratory infections and nasopharyngitis. Disseminated 
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and extra pulmonary infections have also been reported, most commonly in patients 
treated with doses of adalimumab higher than recommended. Like other TNF- 
inhibitors, the main concerns associated with adalimumab therapy, aside from infection, 
are malignancy and development of antinuclear antibody positivity (Staidle et al., 2011). 
Infliximab 
A chimeric monoclonal antibody, infliximab binds specifically to soluble and membrane-
bound TNF-. Administered by intravenous (IV) infusion, the most common adverse 
events are infusion reactions, headache, itching and myalgia. Rare incidents of latent 
tuberculosis reactivation have occurred with infliximab as well as T-cell lymphoma 
(Staidle et al., 2011). 
Alefacept 
A CD2-binding fusion protein combining a portion of human IgG and binding site of 
lymphocyte function associated antigen-3 (LFA-3), alefacept reduces infiltrating T-cells, 
activated dendritic cells and inflammatory genes of psoriasis. Given intramuscularly, 
symptom reduction has been proposed to be via depletion of T-cell surface CD2 , 
thereby inhibiting memory T-cell activation and proliferation (e.g. lesional T-cells and 
dendritic cells) (Boyman et al., 2007, Chamian et al., 2005). Risk of lymphopenia, 
malignancy and serious infections due to T-cell reduction has led the US FDA to 
recommend monitoring CD4+ and CD8+ T-cell counts on a weekly basis (Staidle et al., 
2011). 
Interleukin-12 and interleukin-23 inhibitors 
Efalizumab 
A human monoclonal antibody, efalizumab is directed against LFA-1 adhesion to 
endothelial cells, blocking interaction in infiltrated T-cells and the intercellular adhesion 
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molecule-1 (ICAM-1) on dendritic cells, which consequently reduces dendritic cell 
numbers (Boyman et al., 2007, Ghoreschi et al., 2007). Efalizumab is known to prevent 
movement of T-cells from circulation to psoriasis plaques through blockage of LFA-1, 
however usage is restricted and it was removed from the US market by the US FDA in 
2009 (Jullien et al., 2004). 
Ustekinumab 
A fully human monoclonal antibody, ustekinumab seems to be the most favourable 
biologic in terms of cost per PASI 75 response in psoriasis treatment (Terranova et al., 
2014). Ustekinumab acts by binding to the p40 subunit shared by pro-inflammatory 
cytokines IL-12 and IL-23, thereby neutralising their activity and blocking interactions 
with related receptors and associated T-cells producing IL-17 (Croxtall, 2011). The most 
commonly reported adverse events include nasopharyngitis, upper respiratory tract 
infection and increased incidence of malignancy, although long-term safety data are 
unknown (Staidle et al., 2011).  
Tazarotene  
With similar action to other retinoids, tazarotene also has potential teratogenic effects, 
causing post-implantation loss in animal studies, and so is usually avoided in pregnant 
women (Bae et al., 2012). 
2.7.4 Other conventional therapies for psoriasis 
Psoralen and ultraviolet A  
Psoralen is often utilised along with ultraviolet treatment (320nm–400nm) to decrease 
numbers of lesional dendritic cells and epidermal T-cells (Boyman et al., 2007). When 
psoralen is exposed to UVA it enters an excited state, cross-linking with DNA and 
inhibiting DNA replication. Treatment risk includes those associated with significant 
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exposure to UV such as melanoma and non-melanoma skin cancer. Ultraviolet A 
patients may also experience acute phototoxicity, which is considered more severe than 
the risk in ultraviolet B therapy (UVB) (Staidle et al., 2011). 
Narrow-band ultraviolet B phototherapy 
Applied in broadband (280nm–315nm) or narrow-band (311 nm) form, UVB acts as an 
immunomodulator to cause cytopathic and delayed immunosuppressive effects. 
Narrow-band UVB appears to be more effective than broadband UVB despite the 
broader safety profile of broadband UVB. Risks associated with use of UVB include acute 
skin reactions, similar to sunburn, and a small increased risk of skin cancer with long-
term use (Staidle et al., 2011). Therapy response is often quick, although after a number 
of weeks or months relapse often ensues, likely due to UVB’s lack of sensitivity in 
keratinocytes. Following this treatment there is likely gradual dendritic cell 
replenishment to the area by blood, only epidermal CD8+ T-cells are evidenced to be 
reduced long term (Gudjonsson et al., 2004). The relatively low risk of UVB combined 
with significant efficacy and reasonable cost has established it as the most cost-effective 
psoriasis therapy available (Miller and Feldman, 2006). 
2.7.5 Novel and emerging therapeutics for psoriasis 
Significant effort is currently going into development of biologic and small molecule 
drug treatments, such as promising janus kinase (JAK) inhibitors for psoriasis (Kwatra 
et al., 2012). Growth in the biologic sector of the psoriasis pharmaceutical industry is 
due to clearer identification of immunological activities and pathophysiological 
pathways involved in psoriasis (Krueger, 2002, Krueger and Bowcock, 2005). The use of 
biologics has not only improved psoriasis symptoms, but also enhanced QoL, for 
example, seen in decreasing DLQI scores (Basra and Hussain, 2012). 
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Despite their strong efficacy, biologics are disconcerting to some psoriasis 
sufferers, as typically they require IV injection. To increase usage and allow oral 
administration there has been recent development of small molecule medicines with 
trial results indicating lesion clearance rates approaching those of IV biologics. However, 
ingestible versions do carry risks, typically of gastrointestinal side effects, so small 
molecule drugs are being further refined into topical forms (Han, 2014). 
The benefits of target-action pharmaceuticals and growing evidence of genetic 
alleles has seen gradual increase in development of pharmacogenomics, in which 
markers predicting response to treatment are being investigated (Menter and Griffiths, 
2015). Commonly known as personalised or stratified medicine, such research has 
potential to target people with specific alleles with corresponding biologics known to 
benefit that group (Foulkes and Warren, 2015). Already, evidence has emerged in 
identification of polymorphisms, which influence outcomes of anti-TNF- treatment 
(Julia et al., 2013). Assisting this progress is research analysing clinical transcriptomics 
data set to further identify novel drug targets, not just psoriasis-specific transcriptomics 
(Qu et al., 2014). Current evidence suggests that biologics are more effective than 
traditional systemic treatments, although their recent introduction limits prediction of 
their long-term safety profile (Sandoval et al., 2014). 
Interleukin-17 (IL-17) 
Treatments targeting IL-17 have been shown to suppress expression of psoriasis-
related genes, and a number of newer drugs now target this pathway (Russell et al., 
2014) (Chiricozzi and Krueger, 2013). For example, secukinumab is a fully human 
monoclonal antibody that binds and neutralises IL-17A, and in a phase II trial proved to 
be superior in achieving PASI 75 and PASI 100 compared with placebo (Rich et al., 2013, 
Leonardi et al., 2012, Edson-Heredia et al., 2015). While secukinumab neutralises IL-17, 
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brodalumab, a human monoclonal antibody that antagonises IL-17RA receptors, 
decreases downstream effects of IL-17. Subsequently, brodalumab inhibits binding of 
IL-17 subtypes (IL-17A, IL-17F and IL-17E) to their receptor (Gisondi et al., 2014) 
(Coimbra et al., 2014). In clinical trials a decent proportion of participants using 
brodalumab achieved clearance of PASI 90 and PASI 100 (Papp et al., 2012b). 
Of the experimental drugs targeting IL-17 and undergoing phase III trials for 
psoriasis, phase II results show brodalumab has the greatest potential efficacy, which 
suggests blocking of IL-17RA receptors is superior to neutralising IL-17. Interestingly, 
there is evidence these drugs may also reduce associated cardiovascular plaque 
formation, likely owing to reduction of IL-17 and the subsequent inflammatory 
pathways that lead to plaque formation. Adverse events caused by drugs targeting IL-17 
include nasopharyngitis, upper respiratory infections, injection site reactions and, less 
frequent but more concerning, reduction in neutrophils with potential neutropenia 
(Brown et al., 2014). 
Interleukin-23 (IL-23)  
Geuselkumab and tildrakizumab are human monoclonal antibodies that target and 
neutralise IL-23 and prevent downstream production of cytokine IL-17. It is unclear if it 
is safest and most efficacious to targeting IL-23 or its downstream cytokine IL-17 and 
further comparison research is needed (Yiu and Warren, 2015). Recent research does, 
though, show strong efficacy of tildrakizumab with promise in moderate to severe 
psoriasis (Kopp et al., 2015). 
MicroRNA (miRNA) 
Although not yet established in human studies, locked nucleic acid-modified anti-
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miRNA-21 compounds have shown to be effective treatments in mouse models of 
psoriatic disease (Guinea-Viniegra et al., 2014). 
Tumour necrosis factor alpha (TNF-) 
In phase II studies, a new anti-TNF- agent, certolizumab pego, has caused 
improvement in psoriasis following 12 weeks of treatment (Reich et al., 2012). 
Janus kinase (JAK) 
Of the JAK targets, JAK1/3 has proven to be the most effective, with late phase trials 
continuing (Kaffenberger et al., 2014, Papp et al., 2015). Small molecule tofacitinib 
inhibits JAK1/3, leading to down-regulation of systemic levels of IL17, IL-22, IL-23 and 
TNF- (Chang et al., 2009, Papp et al., 2012c, Mamolo et al., 2013). Baricitinib and 
ruxolitnib are also JAK inhibitors undergoing further research for psoriasis. Ruxolitnib 
has been developed into a topical drug with improvements seen in erythema, induration 
and scaling of psoriatic lesions (Punwani et al., 2012).  
Cyclic adenosine monophosphate (cAMP) 
Preventing activation of transcription factors, apremilast is understood to decrease 
production of pro-inflammatory cytokines through blocking of phosphodiesterase-4 
and degradation of cAMP (Conti et al., 2003). A low dose (10mg) efficacy study indicated 
no difference to placebo, but PASI 75 has been achieved in 40% of users when dose is 
increased to 30mg (Papp et al., 2012a). 
Kv1.3 
Applied topically in psoriasis, the protein Kv1.3 targets voltage-gated potassium 
channels, preventing Ca2+ influx in T-cells. In vitro it appears to target memory T-cells 
while not affecting immune-affected conditions with naïve T-cells (Kundu-
Raychaudhuri et al., 2014).  
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Vascular endothelial growth factor (VEGF) 
As mentioned previously, increased levels of VEGF are found in psoriasis sufferers. 
Research into VEGF therapies is limited; however, there is some evidence of anti-VEGF 
treatment being effective for psoriasis, such as inflammatory skin conditions in in vitro 
mice study (Halin et al., 2008). A human case has also been reported in which the anti-
VEGF bevacizumab was utilised in colon cancer with subsequent remission in coexisting 
psoriasis (Akman et al., 2009). 
2.7.6 Combined therapies for psoriasis 
Research indicates that combining therapies for psoriasis increases efficacy of common 
monotherapies such as corticosteroids, vitamin D analogues and UV therapy (Bailey et 
al., 2012). Calcipotriol plus betamethasone dipropionate has been commercially 
developed due to proven increased efficacy in clinical trials compared with each utilised 
alone (Stein Gold, 2014). Application options for betamethasone dipropionate now 
range from creams, ointments and gels to, more recently, aerosols, which improve ease 
of application and provide greater efficacy (Queille-Roussel et al., 2015). It should be 
noted that although efficacy may increase with combined therapy, there is also 
increased risk of side effects, for instance, polypharmacy use of biologics and 
methotrexate can increase risk of the herpes simplex virus (Shalom et al., 2015). 
2.7.7 Limitation of conventional therapies 
Risks vary depending on treatment type; typically, mild–moderate action therapies 
carry low risk of side effects and those of stronger action, including many newer drugs, 
tend to have greater risk of side effects. Unfortunately for biologic users it has recently 
been evidenced they lose efficacy over time with continued use (Levin et al., 2014). This 
commonly results in dosage escalation over time, and physicians switching between 
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biologics in search of efficacy (Feldman et al., 2015). To minimise risk of infection after 
surgery, people with psoriasis are advised to stop taking biologics between two and 
twelve weeks prior and recommence following recovery (Smith et al., 2009, Ledingham 
and Deighton, 2005). In some people biologics cause a tendency to weight gain, 
increasing risk of cardiovascular disease in a population already at increased risk (Ross 
et al., 2015). There is well-documented evidence of anti-TNF- therapy increasing risk 
of tuberculosis in people with latent psoriasis (Ergun et al., 2015). 
2.7.8 Summary of conventional therapy for psoriasis 
Most commonly prescribed psoriasis medications have side effects and some degree of 
risk associated with them. In some instances side effects of therapies can be more 
severe than the condition itself, which can limit psoriasis treatment options and 
frustrate both treating physicians and sufferers. A survey in Europe reported 53% of 
dermatologists were dissatisfied with their patients’ treatments (Palotai et al., 2010). In 
almost all of these patients, physicians considered changing treatments. Indeed, on 
average, people change treatment once a year (Palotai et al., 2010, Anderson and 
Feldman, 2015). An earlier study in Europe found over 70% of people with psoriasis 
rated available therapies as having moderate to low effect, indicating general 
dissatisfaction with the treatment options available (Dubertret et al., 2006). In a survey 
of psoriasis patients receiving oral or biologic therapy, 57% and 45%, respectively 
discontinued therapy, most often for safety or tolerability reasons, and lack or loss of 
efficacy (Lebwohl et al., 2014). For patients receiving topical therapies, 51% are 
reported to change therapies, and although reasons for a switch are unclear it is likely 
that lack of efficacy is a factor (Neri et al., 2014). 
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Biologic research studies are still on the increase, which provides good news for 
moderate to severe psoriasis sufferers, but provides little hope for people with milder 
conditions or for groups in which biologic use is contraindicated (Manalo et al., 2015). 
Despite new psoriasis drug successes, treatment options in vulnerable populations such 
as children, pregnant women and the elderly are unfortunately still limited. Risks and 
side effects are reported in even mild action drugs such as corticosteroids (Fotiadou et 
al., 2014, Edwards et al., 2003, Chi et al., 2011). These issues indicate a need for further 
discovery and development of safe and effective treatments for use in wider 
populations. Such a need has seen interest in non-drug interventions such as the WHITE 
Holographic Bioresonance method, although research into this approach is still limited 
(Del Giudice et al., 2015).  
Efficacy of therapeutic intervention varies, perhaps reflecting variation in 
pathogenic stage and inflammatory activity at the time of administration (Albanesi, 
2014). For instance, TNF- blockers are thought to be active mainly on innate immunity, 
which may explain why they are effective in only 75% of cases. In addition, new 
research has found greater efficacy in patients with the Cw6-positive polymorphism 
than those without (Batalla et al., 2015). Such differences may explain why response to 
topical corticosteroids can differ within the same psoriatic lesion, with chronic areas 
responding well to therapy while areas characterised by acute inflammation are more 
resistant. 
The complex pathogenic pathways and biological activity involved makes 
psoriasis a difficult disease to decipher. While genetic factors are likely involved they 
are yet inconclusive. Much of the psoriasis pathogenic pathway knowledge has come 
from previous demonstrated biological action from efficacious drug exploration 
(Christophers, 1996). Even without treatment, plaque symptoms can mysteriously 
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disappear (such spontaneous remission occurs in around 25% of psoriasis sufferers), 
but can resurface again years later (Griffiths and Barker, 2007, Nevitt and Hutchinson, 
1996). The complex pathogenic pathways that contribute to psoriasis, along with 
psoriasis-specific symptoms, co-morbidities and psychosocial impacts, make 
management and treatment of the condition difficult (Martin et al., 2011). Such disease 
complexity has led clinical experts to develop more multi-disciplinary approaches for 
psoriasis management (Prignano et al., 2015). 
Physicians are aware of conventional treatment limitations and there has been 
discussion that an individualised approach may help improve adherence, outcomes and 
QoL for patients with psoriasis. This is the fundamental philosophy behind CHM 
treatment and may be one reason why patients turn to it for treatment (Bewley and 
Page, 2011). 
2.8 Complementary and alternative medicine therapies for psoriasis 
As societal interest in ‘wellness’, complementary and alternative medicine (CAM) has 
become increasingly mainstream, use has increased substantially in recent years 
(Steinberg, 2007, Frass et al., 2012, Xue et al., 2007a). Widespread interest in CAM may, 
in part, be due to the offer of holistic nonsurgical treatments for conditions that may 
otherwise involve invasive medical procedures or administration of pharmaceuticals 
with potential side effects (Wardle et al., 2012, Astin, 1998, McLaughlin et al., 2012). In a 
UK hospital survey, 81% of respondents indicated their main problem had improved 
since commencing CAM and 61% of those surveyed who were taking prescription 
medication had reduced or stopped medication use since commencing CAM (Sharples et 
al., 2003). While this raises concerns over patient safety around ceasing prescribed 
pharmaceuticals it also indicates the confidence patients have in CAM. 
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This growing popularity in CAM and its perceived benefits has encouraged 
Australian private health insurance companies to increase their cover and access to 
therapies including CAM. In the June 2015 quarter, over $12 million was charged in 
acupuncture and natural therapy fees through private health and, of this, only 
$87,128,018 was covered by their entitled benefits (Australian Prudential Regulation 
Authority (APRA), August 2015). Reimbursements for private health cover members 
who use CAM reduces out of pocket expenses for patients which may also contribute to 
the growing popularity of CAM. In 1995, 31% of the population had general private 
health cover, which had risen to over half the population by 2015 (56%)(Australian 
Prudential Regulation Authority (APRA), June 2015). Cost does not appear to be a great 
concern for psoriasis patients when seeking treatment and a study reported 71% of 
respondents would pay $1500 or more for a cure for their psoriasis (Finlay and Coles, 
1995). This section discusses some of the key herbal and dietary therapies used for 
psoriasis. 
2.8.1 Chinese medicine  
Chinese medicine treatment may consist of a variety of modalities including 
acupuncture, Chinese herbal medicine, tui na (Chinese massage) and gua sha (scraping 
of the skin with an instrument to induce redness), amongst others. Chinese medicine 
usage in Australia increased significantly from 1993 to 2000 (MacLennan et al., 2002). 
In 2004, an Australian survey indicated of those surveyed who had used a form of 
complementary and alternative medicine, 7% had visited a CHM practitioner in the 
previous 12 months (Xue et al., 2007b). Of surveyed Australian GPs, 50% rated CHM as 
effective; however, 66% also consider CHM to be potentially harmful (Cohen et al., 
2005). (MacLennan et al., 2002, Fuhrmann et al., 2010) 
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With the inclusion of Chinese medicine in the Australian Health Practitioner 
Regulation Agency’s regulated professions in 2012, use of CHM is likely to increase 
further. Improvements in regulation to ensure safety of patients could also increase 
consumer confidence. Specific risks to people with psoriasis include the usual risks 
associated with acupuncture and cupping, in addition to an increased risk of further 
induction of lesions (Koebner phenomenon)(Vender and Vender, 2015). To inform 
healthcare professionals and policymakers, CHM clinical research monitoring Chinese 
medicine and concomitant drug therapy, reporting on population patterns of Chinese 
medicine use and any significant harms or risks is needed. 
Herbal medicine has a long historical usage for psoriasis, predating scientific 
investigative procedures. Key texts recommend numerous herbs for psoriasis based on 
past usage; however, scientific evidence for use of herbs in psoriasis is relatively low. 
However, treatment guidelines available from China recommend various herbal 
medicine therapies based on the presenting patient’s symptoms (discussed further in 
Chapter 5)(China Academy of Chinese Medicine, 2011). 
To develop a CHM formula for psoriasis vulgaris, historic CHM use should be 
considered, as well as modern research techniques and available treatment guidelines. 
Investigation into CHM formulations should consider clinical evidence, scientific 
evidence, relevant guideline recommendations and specialist opinion. Chinese herbal 
medicine formulations should be evaluated using the gold standard for testing, that is, 
via double blind, randomised placebo controlled trial. Chapters’ three to seven describe 
the process of developing and investigating a CHM formulation for psoriasis.  
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2.8.2 Diet therapy for psoriasis 
Nutritional supplementation may provide a viable treatment alternative for patients 
with psoriasis. There have been positive effects of vitamin B12, selenium, retinoic acid 
metabolism-blocking agents, and a gluten-free diet on psoriasis (Ricketts et al., 2010). 
As discussed previously, obesity can exacerbate psoriasis, so dietary changes along with 
exercise that reduce obesity can consequently improve psoriasis (Jensen et al., 2013, 
Naldi et al., 2013). Fasting periods, low-energy diets, vegetarian diets and diets rich in 
omega-3 polyunsaturated fatty acids from fish oil have improved psoriasis symptoms 
(Wolters, 2005). For psoriasis sufferers with coeliac disease, a gluten-free diet can 
reduce IgA anti-gliadin antibody values as well as PASI score (Bhatia et al., 2014). 
2.8.3 Other herbal therapies for psoriasis 
A herbal-marine origin drug, HESA-A (Osveh Drug Co.), has reported positive results for 
psoriasis; however, all trials were carried out by the same research group, which raises 
potential bias concerns (Ahmadi et al., 2008). Furthermore, HESA-A has been indicated 
for macular degeneration and metastasis in breast cancer, raising query around the 
specificity of the product (Ahmadi et al., 2009, Ahmadi et al., 2005). Aloe vera appears to 
be largely safe, with drying of the skin the most common side effect; however, efficacy in 
psoriasis is uncertain and more high-quality studies are needed (Miroddi et al., 2015, 
Paulsen et al., 2005). 
2.9 Summary of psoriasis disease and its treatment 
Psoriasis vulgaris is the most common psoriasis phenotype and the aetiology and 
pathogenesis of its development is multi-factorial. Genetic factors are the most likely 
determinant of psoriasis development, but limiting external risk factors, such as 
cigarettes, are also recommended for susceptible people (Di Lernia et al., 2014, Ryan et 
 95 
al., 2013). Psoriasis does not appear to discriminate between age and sex; however, 
there do appear to be geographical areas with higher prevalence of psoriasis, which is 
likely due to genetic factors. 
Psoriasis severity varies considerably; lesions can be small and indiscriminate or 
large and widespread across multiple surfaces of the body. Those with mild conditions 
can still experience reduced QoL depending on the location of the lesion and their 
emotional and psychological perspective of the disease. It is important that QoL 
instruments are utilised along with symptom measures when evaluating severity of 
psoriasis and monitoring response to treatment. The severity of psoriasis determines 
therapy selection and helps physicians calculate dosage as well as decide when to 
change therapies. 
It is clear there is link between psoriasis and a number of serious co-morbidities, 
yet it is still unclear how direct the relationships are and what specific biological 
pathways link them. More research is needed to investigate the biological relationship 
between psoriasis and co-morbidities, and evaluate the potential of current psoriasis 
therapy for reducing co-morbidity risk. Further research of co-morbidities may lead to 
the development of new or novel therapies for psoriasis based on newly identified 
common pathway activity. 
Psoriasis therapies generally aim to reduce inflammation and decrease irregular 
skin cell proliferation (Mrowietz et al., 2011). Available therapies range from topical 
and oral drugs to light therapy. There is general consensus about the complex 
inflammatory pathways involved in psoriasis, which has led to development of new 
therapies such as biologics; however, these are expensive and their long-term safety 
profile is still unclear. Traditional oral therapies also carry risks, such as liver damage, 
so some drugs need to be avoided by immune-compromised sufferers. Furthermore, 
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rebound, relapse, tolerance and resistance are all potential limitations to 
pharmaceutical therapies for psoriasis (Gottlieb et al., 2008a). For mild–moderate 
severity psoriasis there is currently a lack of low cost and safe oral therapeutic options.  
Complementary and alternative therapy for psoriasis is increasing in popularity, 
but there is little data available for their efficacy and safety. Historical evidence suggests 
CHM has potential for treating psoriasis, however scientific evidence is relatively low. 
As such, treatment guidelines do not yet recommend CAM therapies for psoriasis and 
more research is needed. Textbooks and published data, however, do indicate likely 
efficacy of some CAM therapies such as CHM. Considerably more research into the 
safety and efficacy of CHM for psoriasis is needed.  
The next chapter presents systematic review of RCT evidence for efficacy and 
safety of oral CHM compared with placebo and evaluates potential mechanisms of 
common phytochemicals found in utilised CHM. 
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Chapter 3 – The efficacy and safety of oral Chinese herbal medicine 
compared with placebo for psoriasis vulgaris: A systematic review  
This chapter presents systematic review data of RCTs of oral CHM for psoriasis vulgaris 
compared to placebo. It evaluates published efficacy and safety evidence for oral CHM 
and assesses the quality of published RCTs to date based on Cochrane risk of bias. 
Characteristics of the studies are compared and the CHM intervention ingredients are 
reviewed to identify the most common utilised herbs and potential psoriatic biological 
activity of their phytochemicals.  
3.1 Background, rationale and objectives 
Review of psoriasis aetiology, pathogenesis and treatment indicates psoriasis vulgaris is 
common and mild-moderate disease is often poorly managed. Traditional Chinese 
medicine has a long history of treating psoriasis, with previous reviews identifying 174 
different herbs that have been used for psoriasis (Huang et al., 2012, Zhang et al., 2014b, 
Yu et al., 2013b). Comprehensive evaluation of oral CHM for psoriasis has not been 
published so recommendation for its use cannot be confidently given. Evaluation of 
clinical evidence from RCTs is recognised as the most rigorous method to evaluate an 
intervention.  
This chapter consists of a systematic review of databases for RCTs of human 
subjects with psoriasis vulgaris receiving oral CHM compared with placebo groups. The 
systematic review aims to evaluate the efficacy and safety of oral CHM for psoriasis and 
recommend future trial improvements. Most common CHM utilised in RCTs are also 
detailed along with available evidence for their biological activity in psoriasis. Trial 
designs are compared to assist development potential for further CHM RCTs 
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3.2 Methods 
The review method was based on the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins J, 2011). Outcome measure data for symptom severity were 
extracted from identified studies. Study data for QoL, syndromes and adverse events 
were also extracted to evaluate potential future use of oral CHM for psoriasis. 
Ingredients of CHM of each included study were investigated for frequency of use and 
constituent compounds with anti-psoriasis activity. 
3.2.1 Search strategy  
To identify relevant studies both Chinese and English databases were searched. The 
English databases searched were the Cochrane Central Register of Controlled Trials 
(CENTRAL), Embase and PubMed, which were pre-assessed as the most likely to have 
inclusions that fit the eligibility criteria. CINAHL was also searched using the option 
‘exclude Medline results’, as PubMed covers Medline; however, none of the 136 title 
results in CINAHL matched the inclusion criteria, and so were not included in the review. 
Four Chinese databases were searched, Wanfang, Chinese Biomedical Literature (CBM), 
China National Knowledge Infrastructure (CNKI) and Chongqing VIP Information Co. 
(CQVIP), which were pre-assessed as the most extensive and applicable to our criteria. 
The chosen databases were searched from their inception to June 2015. Search 
terms were grouped into three search blocks: condition (psoriasis vulgaris), CHM 
intervention and study design (RCT), and synonyms of each (see below). Selection of 
search terms was individualised for each database. For ‘condition’ and ‘study type’ 
previously published Cochrane review protocols were screened to ensure a 
comprehensive list of search terms. These terms were then combined with medical 
subject headings (MeSH) terms as well as source and map terms for each criterion of the 
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databases. The list of search terms was then modified specific to the search functions of 
each database. 
Cochrane search term development 
Since the focus of the Cochrane Library is clinical trials and systematic reviews of 
clinical trials the group of search terms for ‘study type’ was not used for this search. The 
two groups and subgroups of terms are listed below. These were entered into the 
advanced search bar and the ‘all text’ search option was selected. 
Condition 
Psoriasis or psoriases or psoriasiform or parapsoriasis or psoriatic or skin diseases, 
papulosquamous or palmoplantar pustulosis or "pustular psoriasis of palms and soles 
or pustulosis palmaris et plantaris. 
Intervention 
(a) Chinese medicine, traditional or medicine, Chinese traditional or Chinese traditional 
medicine or traditional Chinese medicine or medicine, traditional or medicine, oriental 
traditional or medicine, Chinese traditional or tcm or t.c.m. or medicine, Tibetan 
traditional or medicine, Mongolian traditional or medicine, east asian traditional or 
alternative medicine or complementary medicine or complementary therapies or 
medicine, ayurvedic. 
(b) Chinese drugs, plant or drugs, Chinese herbal or Chinese herbal drugs or 
ethnopharmacology or ethnomedicine or ethnobotany or medicine, kampo or kampo or 
phytotherapy or medicine, herbal or herbology or plants, medicinal or plant 
preparations or plant extracts or materia medica or single prescription or herbs or 
herbal medicine. 
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The subgroups of group 2 were combined with ‘OR’ then groups 1 and 2 were 
combined with ‘AND’. The sub-databases for ‘clinical trials’ and ‘Cochrane reviews’ were 
searched and the results were downloaded to a dedicated EndNote library. 
Embase search term development 
The ‘multi field search’ tab option was selected and each of the three criteria was 
entered into separate fields selecting ‘all fields’ as a search method. 
Condition 
(a) Psoriasis or psoriasiform or psoriatic or psoriases or erythematous squamous skin 
disease or parapsoriasis. 
(b) Palmoplantar pustulosis or pustulosis palmaris et plantaris or acrodermatitis 
continua or impetigo herpetiformis or pustulosis palmaris et plantaris or 
palmoplantaris pustulosis. 
(c) Pustulosis of palms and soles. 
(d) Pustular psoriasis of palms and soles. 
Intervention 
(a) Medicine, traditional or oriental traditional medicine or traditional medicine or 
medicine, Chinese traditional or tcm or t.c.m. or medicine, ayurvedic or alternative 
medicine or complementary medicine or complementary therapies. 
(b) Ethnopharmacology or ethnomedicine or ethnobotany or medicine, kampo or 
kampo or phytotherapy or medicine, herbal or herbology or plants, medicine or drugs, 
Chinese herbal or materia medica or single prescription or herbal medicine or herbs or 
Chinese medicine herb. 
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Study type 
Clinical trial or clinical study or controlled trial or controlled study or random! control! 
trial or random! control! study or multicentre study or meta-analysis or random 
allocation or double-blind or single-blind or comparative study or evaluation study or 
follow-up study or prospective study or research design or control group or placebo 
control or dummy control or blinding or clinical research or medical trial or in vivo 
study or case control study or case study or intervention study or longitudinal study. 
The results of the search were downloaded to a dedicated EndNote library using 
the ‘export citation(s)’ function and the ‘complete reference’ option. 
PubMed search term development 
Search terms were mapped to MeSH headings. Using the ‘advanced’ search option each 
of the developed criteria was entered into the ‘builder’ in separate fields and 
‘title/abstract’ selected. 
Condition 
Psoriasis or psoriases or psoriasiform or parapsoriasis or psoriatic psoriasis 
arthropathica or psoriasis, arthritic or skin diseases, papulosquamous or palmoplantar 
pustulosis or pustular psoriasis of palms and soles or pustulosis palmaris et plantaris or 
pustulosis of palms and soles or acrodermatitis continua or impetigo herpetiformis. 
Intervention 
Traditional Chinese medicine or Chinese traditional medicine or Chinese herbal drugs 
or Chinese drugs, plant or medicine, traditional or ethnopharmacology or 
ethnomedicine or ethnobotany or medicine, kampo or kampo or tcm or t.c.m. or 
medicine, ayurvedic or alternative medicine or complementary medicine or 
phytotherapy or herbology or plants, medicinal or plant preparations or plant extracts 
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or plants, medicine or materia medica or single prescription or acupuncture or 
meridians or electroacupuncture or moxibustion or auriculotherapy or catgut 
embedding or herbs or Chinese medicine herb or herbal medicine. 
Study type 
Clinical trial or clinical study or biomedical research or controlled trial or controlled 
study or random* control* trial or random* control* study or multicentre study or 
meta-analysis or random allocation or double-blind or single-blind or comparative 
study or evaluation study or follow-up study or prospective study or research design or 
control group or placebo control or dummy control or blinding or clinical research or 
medical trial or in vivo study or case control study or case study or intervention study or 
longitudinal study. 
The three main groups were combined with ‘AND’ and the results downloaded to a 
dedicated EndNote library. 
Chinese database search 
Due to language restrictions, Chinese database searching was conducted by a colleague. 
The method for the development of search terms and conditions of the search is 
detailed and described in Chinese in appendix 2. 
3.2.2 Study screening and data extraction  
Trial selection was based on the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins J, 2011). The results of each of the three databases were 
exported to separate EndNote files, which were then combined to form a 
comprehensive library. Duplicates were removed using the ‘remove duplicates’ function. 
The researchers then visually scanned the remaining list and excluded obvious 
duplicates. The remaining records were then screened via title and or/abstract to 
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exclude articles that did not meet all three initial search criteria. Thus, the exclusion 
criteria were: 
1. Duplication 
2. Condition –not specifically investigating psoriasis 
3. Intervention –not CHM oral form 
4. Study type – not RCT 
5. Publication language – not English or Chinese 
6. Subjects – not human 
7. RCT – not for investigating the efficacy of oral CHM 
8. RCT – not CHM and conventional medicine administered together compared to 
conventional medicine alone 
Randomised controlled trials in which oral CHM was the intervention were 
included. Condition was limited to psoriasis vulgaris type of any stage, severity or 
duration. Only trials published in English or Chinese were included with no limitations 
on age or gender. Journal articles, conference proceedings and theses were eligible for 
inclusion. Multiple arm studies were considered if one of the control arms was placebo. 
Studies investigating psoriasis type other than vulgaris or utilising CHM in a form other 
than orally were excluded. Any RCTs involving use of a conventional therapy along with 
CHM were also considered, providing the control group (placebo) received the same 
conventional therapy and the therapy was recommended by international guidelines.  
Data were extracted from included studies to an Excel spread sheet, including: 
author, year, country, trial design, number of participants, treatment duration, 
intervention, methodological quality, outcome measures, study results and adverse 
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events. In situations of missing data, attempts were made to contact authors to attain 
the information.  
3.2.3 Risk of bias assessment  
Risk of bias was assessed according to the Cochrane Collaboration’s tool for items of: 
sequence generation, allocation concealment, blinding of participants and practitioner, 
blinding of outcome assessors, incomplete data, selective outcome reporting and other 
bias (if any) (Higgins J, 2011). For each domain two reviewers assessed bias risk as low, 
high or unclear. Where two different judgements were made, the two researchers 
discussed the case and continued disagreement was resolved by a third reviewer. 
Where information was not sufficient to make judgement, attempt was made to contact 
authors for further information and an unclear rating was judged for that domain. 
3.2.4 Meta-analyses 
Data for primary outcomes were entered into RevMan 5.2 for analysis. If there were 
more than two clinically homogeneous studies, such as multiple studies reporting PASI 
outcome, they were pooled together for meta-analysis. The variation in oral CHM 
intervention did not affect how data were pooled and specific formulation data were 
sufficient to perform any subgroup analysis based on heterogeneous intervention. For 
dichotomous data, relative risk (RR) and 95% confidence interval (CI) were reported, 
while mean difference (MD) and 95% CI was reported for continuous data. Statistical 
heterogeneity was explored through sensitivity and subgroup analyses where the I2 
statistic was >50%. Where I2 remained >50% a random effects model was employed. 
3.3 Results  
The initial database search identified 16,020 records. After removal of duplicates and 
screening titles and abstracts, 1014 full-text articles were screened for inclusion. Seven studies 
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from eight publications were included in the final review (Figure 3.1), two articles referred to 
data from the same study (Chen, 2005, Wang, 2003) and one study was excluded from meta 
analyses as it did not use PASI as an outcome measure (Tan, 2008).
 
Figure 3.1: PRISMA flowchart detailing study selection for analysis 
CHM, Chinese herbal medicine; PRISMA, preferred reporting items for systematic 
reviews and meta-analyses; PT, pharmacotherapy; RCT, randomised controlled trial 
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3.3.1 Description of the included studies  
Out of the seven included studies, six were conducted on hospital outpatients and the 
seventh did not state location (Dai et al., 2014b). Five studies were published in Chinese 
and undertaken in China and the other two were published in English, one conducted in 
China (Dai et al., 2014b) and the other in Hong Kong (Ho et al., 2009). The earliest study 
was published in 1999 (Zhang et al., 1999) and the most recent in 2012 (Zhou et al., 
2012a). Two studies had a third arm (control other than placebo), but these arms of 
data were not included in this review (Ho et al., 2009, Tan, 2008). One study stratified 
participants into one of three groups based on Chinese medicine syndrome type, but all 
groups received the same treatment (Table 3.1)(Dai et al., 2014b). 
3.3.2 Participants 
The total number of included participants in the seven studies was 569, but 31 were 
reported as either dropouts or lost to follow-up, so the remaining 538 were included in 
assessed data (Table 3.1). In four studies the participants had progressive stage 
psoriasis and the remaining studies did not state stage (Dai et al., 2014b) (Ho et al., 
2009, Tan, 2008). For baseline severity, one study described participants as mild, 
moderate or severe (Su et al., 2010b), another included participants with body surface 
area (BSA) greater than 20% (Ho et al., 2009), while the remaining five did not state 
initial severity. Mean psoriasis duration ranged from 3.3 (Wang, 2003) to 8.9 (Dai et al., 
2014b) years in the intervention group and 3.3 (Wang, 2003) to 6.45 (Dai et al., 2014b) 
years in control groups (Table 3.1), but was not reported by Ho (2009).  
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Table 3.1: Characteristics of included trials (oral CHM vs. placebo) 
First 
author; 
publication 
year; 
country; 
setting 
Study 
design; 
blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Stage; 
severity and 
duration of 
condition 
No. of participants 
randomised/assessed; 
dropouts 
Age (mean 
(SD) or 
range); 
gender (M/F) 
Intervention Control 1 Control 2 
Dai; 2014 RCT; NS; 
4 
8w I1:NS, NS, 
9.62(5.33)y 
I1: 30/30; 0 I1: 38.7(11.8); 
12/18 
Yinxieling 
decoction and 
cod liver oil 
ointment 
 
Placebo 
decoction 
(0.5g 
caramel) 
and cod 
liver oil 
ointment 
N/A 
I2: NS, NS, 
8.51(7.69)y 
I2: 30/30; 0 I2: 
36.48(12.34); 
11/19 
I3: NS, NS, 
8.59(5.4)y 
I3: 30/30; 0 I3: 36.3(12.7); 
13/17 
C: NS, NS, 
6.45(8.15)y 
C: 30/30; 0 C: 37.39 
(13.04); 
14/16 
Ho; 2009; 
Hong Kong; 
hospital 
outpatient 
RCT; S-B; 
3  
6m; 0 I: NS; 
>20%BSA; NS 
I: 21/14; 7 I: 48.5; 14/7 Wen tong hua 
yu fang 
Placebo 
capsule 
Methotrexat
e and folic 
acid C1: NS; 
>20%BSA; NS 
C1: 20/17; 3 C1: 43.5; 18/2 
C2: NS; 
>20%BSA; NS 
C2: 20/19; 1 C2: 38. 5; 
18/2 
Su; 2010; 
China; 
hospital 
outpatient 
RCT; NS; 
2 
12w; 0 I: progressive 
stage; mild; 
moderate and 
severe; 11.7 
(3.5)y 
I: 35/35; 0 I: 48.8 (18.1); 
28/7 
Ke yin he ji Placebo 
(Starch 
pill);  
N/A 
C: progressive 
stage; mild; 
moderate and 
severe; 11.4 
(4.0)y 
C: 35/35; 0 C: 52.2 (16.1); 
26/9 
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First 
author; 
publication 
year; 
country; 
setting 
Study 
design; 
blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Stage; 
severity and 
duration of 
condition 
No. of participants 
randomised/assessed; 
dropouts 
Age (mean 
(SD) or 
range); 
gender (M/F) 
Intervention Control 1 Control 2 
Tan; 2008; 
China; 
hospital 
outpatient 
RCT; S-B; 
3 
NS; 0 I: NS; NS; 6.3 
(3.4)y 
I: 49/49; 0 I: 30.3 (7.23); 
31/18 
CHM 
(unnamed 
formula) 
Placebo Diyin tablet 
C1: NS; NS; 7.8 
(4.7)y 
C1: 40/40; 0 C1: 31.6 (7.3); 
27/13 
C2: NS; NS; 7.3 
(3.8)y 
C2: 47/47; 0 C2: 33.3 (6.4); 
31/16 
Wang; 2003; 
China; 
hospital 
outpatient 
RCT; D-B; 
2 
4w; 0 I: progressive 
stage; NS; 56.7 
(40)m 
I: 27/25; 2 I: 26.7 (12.3); 
16/9 
Fu fang qing 
dai jiao nang 
Placebo N/A 
C: progressive 
stage; NS; 61.2 
(40)m 
C: 32/27; 5 C: 28.6 (14.2); 
20/7 
Zhang; 
1999; China; 
hospital 
outpatient 
RCT; D-B; 
2  
4w; 0 I: progressive 
stage; NS; 56.7 
(40.1)m 
I: 29/25; 4 I: 26.7 (12.3); 
16/9 
Lei gong teng 
jiao nang 
Placebo 
capsule 
N/A 
C: progressive 
stage; NS; 61.2 
(39.6)m 
C: 32/27; 5 C: 28.6 (14.3); 
20/7 
Zhou; 2012; 
China; 
hospital 
outpatient 
RCT; D-B; 
2  
8w; 0 I: progressive; 
NS; 4.0 (5.9)y 
I: 35/33; 2 I: 34.1 (9.2); 
16/19 
Liang xue huo 
xue fu fang 
Placebo 
decoction 
N/A 
C: progressive; 
NS; 3.7 (5.8)y 
C: 27/25; 2 C: 31.0 (7.9); 
11/16 
AE, adverse event; BSA, body surface area; CHM, Chinese herbal medicine; C, control; D-B, double blind; F, female I, intervention; m, 
months; M, male; S-B, single blind, SD, standard deviation; NS, not stated; N/A, not applicable; RCT, randomised control trial; w, weeks; y, 
years 
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3.3.3 Interventions 
Six studies investigated multi-ingredient formulations, while one utilised a single CHM, 
Tripterygium wilfordii (Lei gong teng) (Zhang et al., 1999). Four of the studies 
administered treatments in decoction form (liquid prepared from cooking herbs) (Su et 
al., 2010b, Dai et al., 2014b, Tan, 2008, Zhou et al., 2012a), while the remaining three 
administered treatment in capsule form (Ho et al., 2009) (Wang, 2003) (Zhang et al., 
1999). All studies utilised different CHM formulations, with a total of 47 different CHM 
ingredients used; however, some formulation ingredients were common between 
multiple trials. Rehmannia glutinosa was used in all multi-ingredient studies (n=6), 
although it was processed in two different ways. Two studies used it in raw form, 
known as ‘di huang’ (Tan, 2008, Zhou et al., 2012a), and in three studies it was cooked 
with wine, referred to as ‘shu di’ (Ho et al., 2009, Su et al., 2010b, Tan, 2008). Although 
Dai (2014) also included Rehmannia glutinosa, they did not report whether the 
processed or non-processed form was administered.  
Salvia miltiorrhiza was used in all multi-ingredient CHM studies except Dai (2014). 
Angelica sinensis was used in four studies (Su et al., 2010b, Dai et al., 2014b, Tan, 2008, 
Zhou et al., 2012a). Four studies did not detail the quantity of ingredients used (Dai et 
al., 2014b, Zhang et al., 1999) (Su et al., 2010b) (Wang, 2003), and three did not detail 
all ingredients in the formulations (Table 3.1)(Ho et al., 2009, Zhou et al., 2012a, Tan, 
2008).  
Chinese medicine syndrome was utilised by four studies (Dai et al., 2014b, Zhou et 
al., 2012a, Tan, 2008, Su et al., 2010b), while the remaining studies did not state 
whether syndrome was considered. After syndrome differentiation, intervention type 
remained the same for participants in each study except Tan (2008), in which one of 
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four different formulations was administered based on syndrome type (blood heat, 
blood dryness, blood deficiency or blood stasis). 
All studies utilised placebo as a control arm, administered on its own in all studies 
except Dai (2014), which combined the placebo and CHM arms with cod liver oil. 
Placebo was administered in capsule form in three studies (Ho et al., 2009, Zhang et al., 
1999, Wang, 2003), starch pills in one (Su et al., 2010b) and as decoction in two studies 
(Dai et al., 2014b, Zhou et al., 2012a). One study did not provide sufficient detail to 
identify the placebo form, nor did it detail dosage or administration (Tan, 2008). Su 
(2010) administered the placebo in a different form (pill) from its CHM (decoction). 
This study used the same frequency of administration for both arms, however the 
dosages differed. The remaining studies used the same dosage and administration 
procedures in both arms (Dai et al., 2014b, Ho et al., 2009, Wang, 2003, Zhang et al., 
1999, Zhou et al., 2012a)(Table 3.2). 
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Table 3.2: Intervention/comparators of included RCTs (oral CHM vs. placebo) 
First 
author, 
public
ation 
year 
Syndrome 
differenti
ation  
CM principle 
of treatment 
Chinese herbal medicine formula and ingredients 
Preparati
on type 
and 
dosage 
Pharmaco
therapy 
(specify) 
Dosage and 
administrati
on 
Dai, 
2014 
Wind heat; 
Blood 
stasis; 
Blood 
dryness 
Remove heat to 
cool blood, 
promote blood 
circulation 
remove blood 
stasis, and 
nourish yin and 
blood.  
Radix rehmanniae recen (shu di), angelica sinensis (dang 
gui), radix paeoniae rubra (chi shao), ligusticum wallichii 
(chuan xiong), radices lithospermi (zi cao), curcuma zedoary 
(e zhu), chloranthus spicatus (zhong jie feng), rhizome 
smilacis glabrae (tu fu ling), smoked plum (wu mei), liquorice 
(gan cao) etc. 
Decoction 
100mL po, 
bid 
Placebo 
decoction 
(.5g 
caramel) 
100mL po, 
bid 
Ho, 
2009 
NS NS 
Wen tong hua yu fang: ephedra sinica (ma huang) 6g, radix 
aconiti lateralis praeparata (fu zi)10g, semen brassicae (bai 
jie zi)10g, cortex cinnamomi (rou gui) 3g, rhizoma zingiberis 
(gan jiang) 3g, cornu cervi degelatinatum (lu jiao 
shuang)15g, radix rehmanniae preparata (shu di) 10g, 
rhizoma smilacis glabrae (tu fu ling) 60g, cortex dictamn (bai 
xian pi) 30g, rhizoma imperatae (bai mao gen) 30g, salvia 
miltiorrhiza (dan shen) 15g, caulis spatholobi (ji xue teng) 
30g, radix lithospermi (zi zao) 30g, flos sophorae immaturus 
(huai hua mi) 30g, radix glycyrrhizae (gan cao) 6g, indigo 
naturalis (qing dai) 6g 
Capsule, 
NS 
C1: 
Placebo 
capsule; 
C2: 
Methotrex
ate and 
folic acid 
C1: Po, NS; 
C2: 
Methotrexate 
po, 2.5mg 
then increase, 
no more than 
30mg per 
week; folic 
acid 5mg per 
day 
Su, 
2010 
Blood 
stasis 
Nourish Blood 
and clear 
dryness, 
invigorate 
Blood and 
remove stasis 
Ke yin he ji: angelica sinensis (dang gui), radix rehmanniae 
preparata (shu di), radix paeoniae rubra (chi shao), semen 
persicae (tao ren), radix sophorae flavescentis (ku shen), flos 
carthami (hong hua), herba taraxaci (pu gong ying), radix 
salviae miltiorrhizae (dan shen), etc. 
Decoction, 
150ml, po, 
bid 
Placebo 
(Starch 
pill) 
3.75g/(kg.d), 
po, bid 
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First 
author, 
public
ation 
year 
Syndrome 
differenti
ation  
CM principle 
of treatment 
Chinese herbal medicine formula and ingredients 
Preparati
on type 
and 
dosage 
Pharmaco
therapy 
(specify) 
Dosage and 
administrati
on 
Tan, 
2008 
4 types: 
Blood 
heat; 
Blood 
dryness; 
Blood 
deficiency; 
Blood 
stasis 
Blood heat 
type: clear heat 
and cool Blood 
Blood dryness 
type: nourish 
Yin 
Blood 
deficiency type: 
tonify Blood 
Blood stasis 
type: remove 
stasis 
For blood heat type: flos sophorae immaturus (huai hua mi) 
30g, radix lithospermi (zi cao) 15g, radix paeoniae rubra (chi 
shao) 15g, rhizoma imperatae (bai mao gen) 30g, radix 
rehmanniae (di huang) 30g, radix salviae miltiorrhizae (dan 
shen) 15g, radix scutellaria baicalensis (huang qin) 15g, 
gypsum fibrosum (shi gao) 30g; 
For blood dryness type: radix rehmanniae preparata (shu 
di) 30g, angelica sinensis (dang gui) 30g, radix astragali 
(huang qi) 30g, radix polygoni multiflori (he shou wu) 30g, 
radix salviae miltiorrhizae (dan shen) 30g, semen cannabis 
(huo ma ren) 15g, cortex paeonia suffruticosa andr (mu dan 
pi) 15g, radix ophiopogonis (mai dong) 15g, radix asparagi 
(tian men dong) 15g, fructus tribuli (bai ji li) 15g, radix 
glycyrrhizae (gan cao) 10g; 
For blood deficiency type: rhizoma atractylodis 
macrocephalae (bai zhu) 30g, radix rehmanniae preparata 
(shu di) 30g, angelica sinensis (gang gui) 30g, radix paeoniae 
alba (bai shao) 30g, scierotium poriae cocos (fu ling) 30g, 
radix astragali (huang qi) 15g, caulis spatholobi (ji xue teng) 
15g, fructus tribuli (bai ji li) 10g, radix glycyrrhizae (gan cao) 
10g; 
blood stasis type: radix astragali (huang qi) 30g, angelica 
sinensis (dang gui) 30g, radix paeoniae rubra (chi shao) 30g, 
rhizoma chuanxiong (chuan xiong) 30g, semen persicae (tao 
ren) 15g, cortex dictamni (bai xian pi) 15g, pericarpium citri 
reticulatae (chen pi) 15g, flos carthami (hong hua) 10g, radix 
glycyrrhizae (gan cao) 10g 
Decoction, 
one pack 
per day 
Placebo NS 
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First 
author, 
public
ation 
year 
Syndrome 
differenti
ation  
CM principle 
of treatment 
Chinese herbal medicine formula and ingredients 
Preparati
on type 
and 
dosage 
Pharmaco
therapy 
(specify) 
Dosage and 
administrati
on 
Wang, 
2003 
NS NS 
Fu fang qing dai jiao nang: indigo naturalis (qing dai), radix 
angelicae dahuricae (bai zhi), radix lithospermi (zi cao), 
radix salviae miltiorrhizae (dan shen), etc. 
Capsule, 
12 po, qd 
Placebo 
Capsule, 12 
po, qd 
Zhang, 
1999 
NS NS Lei gong teng jiao nang: tripterygium wilfordii (lei gong teng) 
Capsule, 6 
(18g)/d, 
po 
Placebo 
capsule, 6 
(18g)/d, 
po 
6 capsules 
(18g)/d, po 
Zhou, 
2012 
Wind heat 
and blood 
dryness 
Cool Blood and 
invigorate 
Blood 
Liang xue huo xue fu fang: folium isatis tinctoria (da qing ye) 
15g, radix rehmanniae (di huang) 30g, radix scutellaria 
baicalensis (huang qin) 12g, radix lithospermi (zi cao) 9g, 
radix salviae miltiorrhizae (dan shen) 12g, radix paeoniae 
rubra (chi shao) 6g, cortex paeonia suffruticosa andr (mu dan 
pi) 9g, angelica sinensis (dang gui) 12g, rhizoma smilacis 
glabrae (tu fu ling) 30g, cortex dictamni (bai xian pi) 9g, 
herba schizonepetae (jing jie) 6g, flos lonicerae (jin yin hua) 
20g 
Decoction, 
one pack a 
day 
Placebo 
decoction 
One pack a 
day 
bid, twice per day; CM, Chinese medicine; g, grams; po, oral administration; NS, not stated 
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3.3.4 Treatment duration and follow-up 
Treatment duration of studies ranged from four weeks (Wang, 2003, Zhang et al., 1999) 
to six months (Ho et al., 2009). Only one study did not state treatment duration (Tan, 
2008). Treatment durations of four weeks (n=2) (Wang, 2003, Zhang et al., 1999) or 
eight weeks (n=2) (Dai et al., 2014b, Zhou et al., 2012a) were most common. None of the 
studies presented follow-up data after treatment (Table 3.1). 
3.3.5 Outcome measures 
Total effective rate (TER) was the primary outcome measure used for all included 
studies except Dai (2014), which only utilised PASI score. Rates were all based on 
percentage change to PASI score except Tan (2008), which based primary outcome on 
percentage of lesion reduction (95% and 50%). The endpoint for PASI score change 
varied for each study. Four studies indicated a PASI 90 endpoint as the greatest degree 
of improvement (Su et al., 2010b, Wang, 2003, Zhang et al., 1999, Zhou et al., 2012a), 
with PASI 70 considered mid-level improvement (Wang, 2003, Zhang et al., 1999) or 
PASI 60 (Su et al., 2010b). Zhou (2012) reported the greatest PASI reduction outcome of 
95% and Ho (2009) had the lowest PASI reduction outcome with 75% (Table 3.3). 
Variation also existed in the lowest level improvement, with two studies reporting PASI 
50 (Wang, 2003, Zhang et al., 1999), one PASI 25 (Su et al., 2010b) and one PASI 20 
(Zhou et al., 2012a). 
 115 
Table 3.3: Outcome measures of included RCTs (oral CHM vs. placebo) 
First 
author, 
publication 
year 
Definition of 
effectiveness 
Psoriasis lesions Quality of life 
Biological 
markers 
Relapse 
rate 
Adverse 
events PASI score 
reduction 
Lesion 
reduction 
PASI score DLQI Other QoL 
assessment 
Dai, 2014 PASI change - - Yes - - Yes - - 
Ho, 2009 PASI 75, 50 Yes - Yes - PDI - - Yes 
Su, 2010 PASI 90, 60, 25 Yes - - - - Yes - Yes 
Tan, 2008 Lesion reduction 
(%) 95, 50 
- Yes - - - - - - 
Wang, 2003 PASI 90, 70, 50 Yes - Yes - - - - Yes 
Zhang, 1999 PASI 90, 70, 50 Yes - Yes - - - - Yes 
Zhou, 2012 PASI 95, 60, 20 Yes - Yes Yes SF-36 - - Yes 
DLQI, dermatology life quality index; QoL, quality of life; PASI, psoriasis area severity index; PDI, psoriasis disability index
Four of the studies specifically reported PASI assessment data (Dai et al., 2014b) (Ho et 
al., 2009) (Zhou et al., 2012a, Wang, 2003), while the remaining studies only reporting 
effective rates. Two studies presented QoL data, but only one utilised the most 
recognised QoL outcome for psoriasis, the dermatology life quality index (Finlay and 
Khan, 1994) as well as a non-dermatology specific QoL instrument, the SF-36 (Zhou et 
al., 2012a). Ho (2009) utilised the psoriasis disability index, a measure of QoL specific to 
psoriasis but not commonly used (Bhosle et al., 2006). Potential biological marker 
changes were reported in two studies (Dai et al., 2014b, Ho et al., 2009), with no data on 
relapse rates provided by any of the studies (Table 3.1).  
3.3.6 Dropouts 
Four of the seven studies reported dropouts, with Ho (2009) reporting the highest 
dropout rate (11/61) including seven from the intervention group (n=21). Zhang (1999) 
reported nine dropouts (n=61) with five from the control group (n=32). Wang (2003) 
reported seven dropouts (n=59), five from the control group (n=32). And Zhou (2012) 
reported two dropouts from the intervention group (n=35) and two from the control 
group (n=27) (Table 3.1).  
3.3.7 Risk of bias assessment 
Two studies were assessed as ‘low risk’ for sequence generation, as they reported 
techniques that were fully randomised with low potential risk in the method (Tan, 2008, 
Zhou et al., 2012a). The remaining studies were assessed as unclear because the method 
for sequence generation was not described in sufficient detail (Dai et al., 2014b, Ho et al., 
2009, Su et al., 2010b, Wang, 2003, Zhang et al., 1999). Allocation concealment was 
reported satisfactorily in Wang (2003) and Zhou (2012), and so was assessed as low 
risk; however, for all other studies the reporting was insufficient to make clear 
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judgment on bias risk so were rated unclear (Dai et al., 2014b, Ho et al., 2009, Su et al., 
2010b, Tan, 2008, Zhang et al., 1999). 
Risk of bias assessments for blinding of participants and blinding of personnel 
were assessed as high risk for Ho (2009) and Su (2010) as they did not employ 
participant or personnel blinding to treatment allocation. Su (2010) administered the 
intervention in decoction form, yet the placebo was employed in pill form, indicating 
high risk of bias for inadequate blinding. Dai (2014) was assessed as unclear for 
personnel blinding and the remaining four studies were rated low risk for both 
categories (Tan, 2008, Wang, 2003, Zhang et al., 1999, Zhou et al., 2012a). 
For blinding of outcome assessors all studies were rated unclear, as published 
details were insufficient to make a judgment. For incomplete outcome, only three 
studies were assessed as low risk (Su et al., 2010b, Tan, 2008, Dai et al., 2014b), 
considering none reported dropouts, final data were assumed to be complete. The other 
four studies were rated as high risk, as they did not include dropout data in their final 
analysis. There was no evidence to suggest bias so selective outcome reporting was 
considered low risk for all studies. Without available published protocols for each study, 
data could not be completely evaluated for selective outcome reporting, and as a result 
it could be argued this criterion should be assessed as unclear (Table 3.4)
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Table 3.4: Risk of bias assessment of included trials (oral CHM vs. placebo) 
First author, 
publication 
year 
Sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
Blinding of 
personnel 
Blinding of 
outcome 
assessors 
Incomplete 
outcome data 
Selective 
outcome 
reporting 
Dai, 2014 Unclear Unclear Low Unclear Unclear Low Low 
Ho, 2009 Unclear Unclear High High Unclear High Low 
Su, 2010 Unclear Unclear High High Unclear Low Low 
Tan, 2008 Low Low Low Low Unclear Low Low 
Wang, 2003 Unclear Unclear Low Low Unclear High Low 
Zhang, 1999 Unclear Unclear Low Low Unclear High Low 
Zhou, 2012 Low Low Low Low Unclear High Low 
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3.3.8 Efficacy 
For outcome measure evaluation, Chinese guidelines recommend minimum PASI 60 for 
treatment to be considered successful. Internationally recognised clinical guidelines 
commonly consider treatment success as PASI 75 and below PASI 50 as treatment 
failure (Gordon and Ruderman, 2005). As reported in a similar systematic review, a 
PASI reduction of at least 60% was selected as the outcome criterion for meta-analysis 
and pooling of data (Zhang et al., 2014b).  
Of those studies evaluating multi-ingredient CHM compared with placebo, four 
(n=215) used an outcome of PASI 60 or above (Ho et al., 2009, Zhang et al., 1999, Zhou 
et al., 2012a, Su et al., 2010b). These showed no significant effect for CHM intervention 
(RR: 2.74 [0.92, 8.21] I2=65%) (Figure 3.2). 
 
Figure 3.2: Meta-analysis forest plot (PASI 60 and above) 
 
For PASI score change, five studies (Dai et al., 2014b, Zhang et al., 1999, Zhou et al., 
2012a, Ho et al., 2009, Wang, 2003) (n=141) showed effect in favour of CHM compared 
with placebo (MD –7.00 [–10.74, –3.27]); however, heterogeneity of the studies was 
quite high (I2=98%) (Figure 3.3).  
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Figure 3.3: Meta-analysis forest plot (PASI score) 
 
Although not utilising PASI as an outcome, Tan (2008) study data (n=89) also showed 
superiority of CHM compared with placebo, where CHM reduced lesions by at least 50% 
(RR: 4.49 [2.40, 8.40]). For QoL via the dermatology life quality index only one study 
reported sufficient data (Zhou et al., 2012a), in which CHM showed improvement in 
health-related QoL of subjects (n=58) (MD: –4.08 [–7.56, –0.60]).  
Known as a key inflammatory factor, tumour necrosis factor alpha (TNF-) is 
often targeted by conventional drugs for psoriasis (Tobin and Kirby, 2005) The TNF-α 
biomarker was the only biomarker with results available in more than one study and 
able to be assessed using meta-analysis. Dai (2014) separated participants into four 
groups: three groups received different CHM (groups A, B and C) and one group placebo 
only (group D). As A, B and C all received oral CHM, subgroup classification was not 
important so subgroup data were combined. Sample size was added together for the 
CHM groups A, B and C (n=90), then mean was calculated using the formula:
E.g. M1, group one mean; N1, group one sample size 
  
and standard deviation (SD) was calculated using the formula: 
(Higgins J, 2011).  
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Results were entered into a meta-analysis along with placebo data to be evaluated 
along with Ho’s (2009) data. Results showed CHM overall had an effect on TNF-α 
reduction (MD: –4.92 [–5.31, –4.53] I2=0%) (Figure 3.4).  
 
 
Figure 3.4: Meta-analysis forest plot (TNF-α) 
 
3.3.9 Safety 
Adverse events data were presented in all but three studies (Su et al., 2010b, Dai et al., 
2014b, Tan, 2008). Gastrointestinal symptoms were the most commonly reported 
adverse events, reported in three studies in the CHM arm (Ho et al., 2009) (Wang, 2003, 
Zhang et al., 1999). Wang (2003) reported seven gastrointestinal events, five mild and 
two moderate, while Zhang (1999) reported four events. Ho (2009) did not report the 
number of gastrointestinal events. Diarrhoea or loose stools were the next most 
commonly reported adverse events, four in the CHM group in Zhang (1999), and six in 
the CHM group and one in the placebo group of Zhou (2012), all considered mild. Other 
reported adverse events included menstrual disorder (Zhang et al., 1999), infection and 
abnormal liver function in the treatment group, and infection and increased liver 
enzymes in the placebo group (numbers of events not reported)(Ho et al., 2009). 
Regardless of similarity of adverse events between the control and intervention arms of 
Ho (2009), the authors gauged the tolerability of CHM as moderate (Table 3.5)
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Table 3.5: Adverse events of included studies 
Study Adverse events (number of events) Author’s conclusion 
Dai, 2014 Not reported N/A 
Ho, 2009 
I: infections and gastrointestinal symptoms, abnormal liver function 
C1 (placebo): infections and increased liver enzymes 
C2 (methotrexate): nausea, vomiting, increased liver enzyme 
The tolerability of both methotrexate and CHM was 
moderate 
Su, 2010 Not reported  N/A 
Tan, 2008 Not reported N/A 
Wang, 2003 
I: moderate gastrointestinal upset (2), mild gastrointestinal upset (5) 
C (placebo): no AEs  
CHM is safe for psoriasis management 
Zhang, 1999 
I: gastrointestinal upset (4), diarrhoea (4), menstrual disorder (1) 
C (placebo): no AEs.  
AEs caused by CHM are mild and were relieved by 
reducing dosage 
Zhou, 2012 
I: loose stool (6) 
C (placebo): loose stool (1)  
All AEs were mild 
AE, adverse event; CHM, Chinese herbal medicine; C, control; I, intervention; N/A, not applicable
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3.4 Discussion  
3.4.1 Efficacy of oral CM vs. placebo 
Although the systematic review found CHM significantly affects PASI change, CHM did 
not reduce PASI score by at least 60% compared with placebo. It is noted only four 
studies were eligible for PASI 60 assessment with a total of 215 participants so it is 
possible the sample size was not sufficient in power to detect significance as no studies 
reported a priori power. A post hoc power analysis was not performed in this review 
due to variation in the intervention types and unknown effect sizes. To ensure sufficient 
examination of future studies, a priori power analyses should be conducted using 
results from pilot studies on experimental CHM interventions providing effect size 
estimates for the population. 
Oral CHM does not appear to have as potent effects as common oral systemic 
therapies that achieve PASI 75, such as infliximab (RR: 13.07, [8.60–19.87]), etanercept 
(8.39, [6.74–10.45]) and apremilast (5.83, [2.58–13.1]) (Nast et al., 2015b). 
Methotrexate has been reported to have less effect than the aforementioned systemic 
drugs (Schmitt et al., 2014). Ho’s (2009) comparison between oral CHM and 
methotrexate and placebo found both methotrexate and placebo to be superior to CHM. 
However, more sensitive analysis (after removal of Ho’s intervention data) may show 
that oral CHM effects approach that of systemic drugs for PASI 60 or above.  
From previous systematic reviews, efficacy of topical therapies, vitamin D 
analogues (SMD: –0.58 [–0.71, –0.45]) and corticosteroid (SMD: –0.97 [–1.31, –0.62]), as 
well as their combined use (SMD: –1.24 [–1.53, –0.95]), are indicated to have less effect 
than oral CHM (MD: –7.00(–10.74, –3.27)(Mason et al., 2013). 
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With previous clinical and pre-clinical evidence suggesting its potential in immune 
disease, Zhang (1999) investigated use of a single ingredient oral CHM, Tripterygium 
wilfordii, for psoriasis (Lv et al., 2015) (Tao et al., 2001) (Ma et al., 2007). Despite 
achieving the greatest effect on PASI 60, no other reviewed studies included it in their 
formulations. The botanical has been indicated for use in rheumatoid arthritis, where it 
reduces immune response inflammation and T-cell proliferation, key aspects of 
psoriasis pathogenesis, which might explain its efficacy (Canter et al., 2006, Chan et al., 
1999).  
3.4.2 Safety 
All studies that reported adverse events for oral CHM described them as relatively mild 
or at most moderate. Although Tripterygium wilfordii (from leaves, flowers and the skin 
of the roots (National Center for Complementary and Integrative Health (NCCIH) 
Clearinghouse, 2007)) is considered toxic, Zhang (1999) reported only mild 
gastrointestinal disturbances, which were relieved by reduction in dosage. Preparation 
and processing of Tripterygium wilfordii is important for reducing its toxicity (Tao et al., 
2001). In addition, to further reduce toxic effects on the gastrointestinal tract, 
researchers and clinicians should consider the addition of Glycyrrhizae radix, which is 
often added to formulations to reduce toxic effects of other ingredients (Hempen and 
Fischer, 2009b). Of the included studies, only two reported inclusion of Glycyrrhizae 
radix in their intervention formulations (Ho et al., 2009, Tan, 2008). Tan (2008) used it 
in three out of the four formulations it administered to different groups and did not 
report any adverse events.  
Ho (2009) utilised two CHM ingredients well known for their toxicity, Ephedra 
sinica and Radix aconiti lateralis praeparata; the latter’s toxicity can be reduced by 
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special processing (Flanagan et al., 2010) (Singhuber et al., 2009). It is unclear if 
Glycyrrhizae radix inclusion reduced the toxic effects of these herbs and further study 
would be needed to evaluate effects of the same formulations without its inclusion.  
It is difficult to individually evaluate the safety of ingredients in each formulation, 
as numerous interactions are likely occurring between constituent compounds of 
ingredients. Such interaction would likely see synergism of some compound effects and 
neutralisation of others. However, the current review indicates that oral CHM forms of 
the utilised formulations are relatively safe with, at most, moderate side effects. This is 
similar to the risk profile of commonly utilised pharmaceutical therapy methotrexate. 
Other studies that reported adverse events evaluated CHM as safe overall (Wang, 2003), 
or with only mild risk (Zhang et al., 1999, Zhou et al., 2012a).  
Further research is needed to investigate the safety of combined use of oral CHM 
and conventional therapy. Polypharmacy has proven to be an important issue for 
physicians with increasing numbers of products also increasing the risk of drug–drug 
interaction (Marengoni and Onder, 2015). As with any drug, CHM should be prescribed 
with caution, and where available toxicity evidence between herbal ingredients and 
conventional drugs should be considered to evaluate risk. For instance, common herbal 
supplement Hypericum perforatum (St John’s wort) should not be used with 
immunosuppressant cyclosporine A, which is sometimes prescribed for psoriasis (Mai 
et al., 2000). To reduce likelihood of severe adverse effects, patients with reduced liver 
or kidney function should be monitored while taking oral CHM. Similarly, for psoriasis 
sufferers with multiple co-morbidities, physicians should consider other co-morbidity 
medications along with psoriasis medications for potential herb–drug interactions 
(Scottish Government Model of Care Polypharmacy Working Group, 2015).  
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3.4.3 Methodological quality of included studies 
Two of the four studies for PASI 60 outcome had no blinding of participants or 
personnel (Ho et al., 2009, Su et al., 2010b). Such insufficiency in design may have 
resulted in outcome bias and contributed to effect size. Similarly, blinding of 
participants was absent for one of five studies for PASI score outcomes (Ho et al., 2009). 
Only one study (Ho et al., 2009) utilised the recommended treatment efficacy 
outcome PASI 75, making it difficult to pool or compare results with other international 
clinical trials. No included trials included all consolidated standards of reporting trials 
(CONSORT) items (Schulz et al., 2010). Such reporting would provide more detail on 
accuracy and specificity of each intervention for its target population. Furthermore, four 
studies had incomplete data reporting, raising concern over the quality and accuracy of 
reporting (Ho et al., 2009, Wang, 2003, Zhang et al., 1999, Zhou et al., 2012a). It was 
noted that the final assessment data for Wang (2003) and Zhang (2009) had identical 
outcomes despite differences in initial sample size and reported interventions. Age, 
duration of disease and gender descriptors was also identical for both studies, raising 
concern among reviewers of legitimacy. No other bias or conflict of interest was 
identified in the studies. Future trials need to improve the quality and content of their 
reporting. Publishing of study protocols would ensure consistency between investigated 
and reported outcomes.  
3.4.4 Potential therapeutic actions of Chinese herbal medicine for psoriasis vulgaris 
Despite formulation variation between studies, some CHM ingredients were common. 
The Chinese medicine actions and biological pathways of their constituents may help 
explain their repeated selection for clinical trials of psoriasis. Due to the large variety of 
CHM utilised in the studies it is not feasible to review the phytochemical activity of all 
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herbs. A brief review of the three most commonly used CHM in the reviewed studies 
was undertaken to present both theoretical anti-psoriatic Chinese medicine action and 
biological mechanisms. 
Salvia miltiorrhiza (dan shen) 
The Chinese medicine syndrome blood stagnation is commonly attributed to psoriasis 
and it is likely Salvia miltiorrhiza’s Chinese medicine functions of moving blood and 
breaking up blood stasis is why it was the most commonly utilised CHM in the reviewed 
studies (five studies) (Ho et al., 2009, Su et al., 2010b, Tan, 2008, Wang, 2003, Zhou et al., 
2012a) (Hempen and Fischer, 2009b).  Salvia miltiorrhiza is considered to possess anti-
inflammatory, antioxidant and anti-proliferative effects, as well as protective effects on 
the liver and cardiovascular system (Wang et al., 2007). Biologically, Salvia miltiorrhiza 
constituents have been evidenced to suppress inflammatory mediators such as IFN-γ 
and IL-12, and it may also reduce mast cell degranulation and inhibit the aggregation of 
platelets (Bartosińska et al., 2011).  
Proliferation of keratinocytes is a key feature of psoriatic skin and in vitro study 
of mouse keratinocytes indicated tanshinone IIA, a constituent of S. miltiorrhiza root, 
inhibited keratinocyte proliferation in a dose- and time-dependent manner by inducing 
apoptosis via the caspase pathway (Li et al., 2012a, Ma et al., 2013). Another possible 
mechanism of action for tanshinone IIA in keratinocytes is via inhibiting dimerization of 
the activator protein 1 transcription factor resulting in reduced interferon sensitivity, 
which in turn could lead to a reduced inflammatory response (Pedersen et al., 2012). 
Angelica sinensis (dang gui) 
Angelica sinensis (used in four studies) is thought to possess Chinese medicine functions 
of tonifying blood, moving blood and draining wind-dampness (Su et al., 2010b, Dai et 
al., 2014b, Tan, 2008, Zhou et al., 2012a), and so may reduce psoriasis by reducing the 
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dryness of skin (Hempen and Fischer, 2009b). Ferulic acid is one of its major 
constituents, which contains constituents evidenced to prolong prothrombin time and 
inhibit platelet aggregation (Chinese Pharmacopoeia Commission, 2005). Furthermore, 
it has both antimicrobial and hepato-protective effects. Other biological actions that 
may have some effect on psoriasis include its antioxidative actions and potential as a 
weak analgesic. There is also evidence it can reduce inflammation and inhibit cell 
proliferation of tumours (Hempen and Fischer, 2009b). 
Rehmannia glutinosa (shu di/di huang) 
In di huang (raw) form, the Chinese medicine functions of Rehmannia glutinosa (used in 
two studies) (Tan, 2008, Zhou et al., 2012a) are generally to cool heat, cool blood, stop 
bleeding and tonify yin, all functions that may reduce symptoms such as Auspitz sign 
(pinpoint bleeding from angiogenesis) (Hempen and Fischer, 2009b). When further 
processed by mixing with wine and steaming, the Chinese medicine functions of shu di 
(used in three studies) (Ho et al., 2009) (Su et al., 2010b, Tan, 2008) become less cooling 
and more tonifying. 
Rehmannia glutinosa has been evidenced to be anti-inflammatory, inhibiting 
histamine release and production of TNF-, both of which are known to be significant 
contributors to inflammation. An in vitro study reported that an aqueous extract of fresh 
R. glutinosa root inhibited the release of histamine and the production of TNF- in mast 
cells (Kim et al., 1998). Study reports R. glutinosa aqueous extracts promote free radical 
scavenging activity due to suppression of pro-inflammatory gene expression, including 
TNF-, monocyte chemotactic protein-1, interferon inducible protein-10, 
cyclooxygenase-2 and inducible nitric oxide synthase (Baek et al., 2012). There is 
further evidence that R. glutinosa may reduce production of cytokine IL-1, but how 
specific this is to psoriasis is unclear (Kim et al., 1999). 
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Catalpol, a compound of R. glutinosa, also shows anti-inflammatory action, 
reducing production of pro-inflammatory mediators such as inducible nitric oxide 
synthase, monocyte chemotactic protein-1, TNF- and the receptor for advanced 
glycation end-products, as well as reducing the transcriptional activation of nuclear 
factor-jB (Wang et al., 1997, Astaf'eva et al., 2002, Chinese Pharmacopoeia Commission, 
2005, Choi et al., 2013, Zhang et al., 2013b). Although not focused on psoriasis, several 
studies have indicated that extracts of R. glutinosa and its constituent catalpol have anti-
inflammatory effects. 
These are just the common CHM ingredients highlighted in this review that may 
have psoriasis-related mechanistic actions. More experimental research is needed to 
evaluate which are the most potent as anti-psoriatic therapies and to assess any toxicity. 
Those constituents with anti-inflammatory and/or anti-proliferative effects hold most 
promise for psoriasis treatment, as current conventional therapies target these 
pathways.  
3.4.5 Limitations of the review 
Due to variation in the primary outcomes for efficacy in the studies, only the outcomes 
PASI 60 or above and general PASI change had enough data to be pooled and evaluated 
using meta-analysis. Commonly, global treatment guidelines consider PASI 75 
treatment effect to be effective; however, as the majority of studies did not state this 
outcome measure, oral CHM effectiveness for PASI 75 cannot be evaluated (The 
Australian Government, 2004). This makes it difficult to compare the effect size of CHM 
with results of other psoriasis therapies. Application of any significant weight to 
conclusions should first consider the relatively low sample sizes and risk of bias of each 
study. Three studies did not detail all the ingredients used in their interventions (Su et 
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al., 2010b, Dai et al., 2014b, Wang, 2003) so some CHM ingredients are missing from 
this review.  
The review did not evaluate the potential phytochemical activity of all CHM 
ingredients, only the three most frequently used, and most likely to have anti-psoriatic 
activity, CHM ingredients. Further review is needed to evaluate the large number of 
phytochemicals of CHM utilised for psoriasis. Such research may provide data on 
common phytochemicals found in CHM that warrant further in vitro and in vivo study 
for development of potential new anti-psoriatic drugs. 
The included studies provided little justification for how or why they selected 
their formulation and ingredients. This limits the conclusions that can be drawn from 
the frequency of herbs used as there may actually be herbs which are better indicated 
for psoriasis which were not utilised. As per CONSORT herbal extension 
recommendations for rationale(Gagnier et al., 2006a).  
3.4.6 Clinical and future research implication of review findings 
The sheer variety of CHM formulations and diverse ingredient selection makes it 
difficult to determine which are of greatest benefit for psoriasis. However, this review 
does indicate that various forms of administration type (decoction, capsule or pill) of 
CHM can benefit psoriasis, although the degree of effect for each is unclear. Dai (2014) 
used the decoction form and reported the greatest effect on PASI change (–13.09[–13.91, 
–12.27]); however, Zhou (2012) also used CHM in decoction form with less effect (–
3.10[–4.23, –1.97]) than two studies utilising capsule form of CHM, Zhang (1999) and 
Wang (2003) (–7.52[–8.45, –6.59]).  
Each study used different combinations of herbs, so future research should 
compare effects between different forms (i.e. capsules vs. decoction) of the same herbal 
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ingredients to investigate the impact on outcomes. In this review, the multiple-
ingredient interventions administered by Dai (2014) had the greatest effect on PASI 
change (–13.09 [–13.91, –12.27]), and single-ingredient CHM Tripterygium wilfordii (lei 
gong teng) administered in Zhang (1999) had the greatest effect, achieving PASI 60 
(46.31[2.95, 726.24]). As the CHM formulation of each study was unique, it was difficult 
to distinguish which ingredients had the greatest and least psoriatic therapeutic 
response. To better compare effects, future studies might consider additional arms 
consisting of different CHM formulations. More pre-clinical evidence such as in vitro and 
in vivo research may provide data for researchers to construct an optimised psoriasis-
specific CHM formulation that could be further explored in clinical trials (May et al., 
2012). 
While reviewed studies reported psoriasis symptoms according to international 
treatment guideline recommendations, they did not consistently report on QoL effects. 
Future clinical trials should include reliable QoL instruments validated for psoriatic 
populations. Only one study (Zhou et al., 2012a) utilised the commonly recommended 
QoL outcome the dermatology life quality index, which found CHM had greater effect 
than placebo. To evaluate oral CHM for QoL, more data are clearly needed.  
The common CHM ingredients highlighted in this review show potential anti-
psoriatic activity such as anti-inflammation and anti-proliferation (Man et al., 2008, Tse 
et al., 2007); however, more research is needed to evaluate such effects. For Chinese 
medicine disease treatment, CHM selection varies according to syndrome classification 
based on physiological characteristics and symptoms of the sufferer along with 
inspection of the pulse and tongue. Chinese clinical guidelines identify three main 
Chinese medicine syndromes: blood heat, blood dryness and blood stasis (China 
Academy of Chinese Medicine, 2011). Clinicians and researchers should consider both 
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conventional biological activity potential of CHM and Chinese medicine theoretical basis 
when selecting formulation ingredients for prescription.  
Formulations of CHM in this review appear safe for use in people with psoriasis, 
although populations were predominantly Asian; so safety is less clear for other 
ethnicity groups. Sample sizes were relatively low and so had insufficient power to 
detect statistical significance of outcomes. Future studies should conduct a priori power 
analysis to ensure sufficient sample sizes, minimise design bias and publish study 
details that follow the CONSORT and its extension for herbal interventions (Schulz et al., 
2010, Gagnier et al., 2006b).  
3.5 Conclusion  
This systematic review compared seven RCT studies of oral CHM, identifying use of 47 
different CHM. Following systematic review of oral CHM for psoriasis, data indicate 
CHM is relatively safe and has some efficacy for psoriasis. However, evaluation of oral 
CHM effect was only possible for PASI change and PASI 60.The effects of CHM compared 
with placebo were not significant for PASI 60 or above, however CHM was superior to 
placebo for overall PASI score change. The effect size of oral CHM was relatively modest 
compared with oral systemic treatments, and more likely reflects efficacy of 
conventional topical treatments. Limited data indicated CHM had greater improvement 
in QoL. Risk of adverse events from CHM was mild, however long-term safety is 
unknown.  
The review process was limited by inconsistent reporting of intervention details 
and outcome measures, as well as low participant numbers. Chinese herbal medicine 
appeared to have some effect on psoriasis symptoms; however results are insufficient to 
draw sound conclusions on efficacy and safety. More high-quality studies are needed 
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that utilise targeted interventions, have psoriasis-specific outcome measures, utilise 
validated QoL instruments and report long-term follow-up periods. Given the growth of 
CAM therapy and increasing likelihood that CAM therapies may be utilised alongside 
conventional therapies, a second review of RCTs combining oral CHM with conventional 
therapy was proposed to evaluate efficacy and safety compared with conventional 
therapy alone.   
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Chapter 4 – The efficacy and safety of integrating oral Chinese herbal 
medicine and conventional medicine for psoriasis vulgaris: A 
systematic review  
This chapter presents the methodology and results of a systematic review of RCTs of 
oral CHM combined with conventional medicine for psoriasis vulgaris. It evaluates 
published efficacy and safety evidence of their combined therapy and assesses the 
quality of published RCTs to date based on Cochrane risk of bias. Characteristics of the 
studies are compared and both CHM and conventional medicine interventions are 
presented.  The most common CHM are also reviewed for phytochemicals, which have 
potential psoriatic biological activity. 
4.1 Background, rationale and objectives  
Having determined from review one (see Chapter 3), CHM has benefit for psoriasis and 
is relatively safe, which is also supported by previously conducted reviews, further 
investigation was needed to evaluate its use alongside conventional therapies (May et 
al., 2012, Wang and Liu, 2004). Conventional therapies are effective for psoriasis 
symptoms yet do not cure the disease and can cause unwanted side effects, particularly 
with long-term use (Nast et al., 2012, Menter et al., 2008). While integrated therapy 
using CHM and conventional therapy is common in China, such practice in westernised 
regions is relatively new (Xu and Chen, 2008). Individual limitations of conventional 
therapy and CHM have been discussed (see Chapter 2); however, the effects of their 
combined use for psoriasis are relatively unknown. 
In order to advise clinicians, patients, policymakers and researchers on the safety 
and efficacy of such combined treatment further evaluation are needed. This review 
analyses data from published RCTs to investigate the efficacy and safety of oral CHM 
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combined with various forms of conventional pharmacotherapy for psoriasis vulgaris. 
This review also identifies the most common CHM ingredients administered in psoriasis 
RCTs and discusses their potential biological activity in psoriasis. The review aims to 
evaluate the feasibility of a clinical study on combined CHM and conventional therapy 
for psoriasis vulgaris. It also aims to determine the optimal population characteristics, 
intervention ingredients (both CHM and conventional), outcome measures, study 
duration and design for a subsequent clinical study. The systematic review evaluates 
data from RCTs involving CHM combined with conventional therapy, compared with 
conventional therapy alone and, where possible, meta-analyses of the data are 
presented. The results of this review have already been published (Zhang et al., 2014b), 
an updated search was conducted in May 2014 and new studies that were not included 
in the original search results are discussed in the supplementary search section 4.5. 
4.2 Methods 
4.2.1 Search strategy 
The Cochrane Library, PubMed, Embase, CINAHL, CNKI and CQVIP were searched from 
their inception to November 2012. Three groups of search terms were used: condition 
(psoriasis vulgaris and synonyms); intervention type (oral CHM and synonyms); and 
study type (RCT and synonyms). These groups of terms were combined and the results 
downloaded to a dedicated file. The same search strategy was used as the previous 
review (Chinese medicine vs. Placebo See 3.2.1 for English database strategies and 
appendix 2 for Chinese database strategies); however, study selection differed as the 
current review focuses on RCTs of combined CHM and conventional therapy compared 
with conventional therapy alone, rather than compared with placebo.  
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4.2.2 Study selection and data extraction 
Included studies were RCTs published in English or Chinese that compared oral CHM 
plus pharmacotherapy with pharmacotherapy alone. Participants were limited to 
people with psoriasis vulgaris, but no limits were placed on stage or severity of disease 
or participant age or gender. Journal articles, conference proceedings, and these were 
considered. If the RCT consisted of more than two arms, only the data for the CHM plus 
pharmacotherapy arm and the pharmacotherapy arm were included. Studies that used 
non-oral CHM or phototherapy, or treated other types of psoriasis were excluded. 
Studies with a third arm consisting of CHM alone were eligible for inclusion in the 
review; however, data from the CHM alone arm was excluded from analysis.  
One reviewer screened the Chinese titles and abstracts, and another screened 
the English search results. Full-text articles were obtained for further assessment of 
eligibility. Any uncertainty was resolved through discussion with a third reviewer. 
Reasons for exclusion were recorded. Data were extracted from the remaining RCTs to 
an Excel spread sheet and crosschecked by two reviewers. When information was found 
to be unclear, attempts were made to contact the authors. In the event there was no 
reply, a judgment was made through discussion between all three reviewers. 
4.2.3 Risk of bias assessment 
Risk of bias was assessed by two reviewers using the Cochrane Collaboration tool 
(Higgins J, 2011) for the following items: sequence generation, allocation concealment, 
blinding of participants and practitioner, blinding of outcome assessors, incomplete 
outcome data, selective outcome reporting, and other bias (defined as funding resource). 
As per the review in Chapter 3, two reviewers assessed each domain and disagreement 
was resolved through discussion with a third reviewer. Where published information 
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was not sufficient to make a judgment on a domain the authors were contacted to 
provide further information and if data were still insufficient the domain was judged as 
unclear. 
4.2.4 Meta-analysis 
Meta-analysis was carried out using Review Manager (the Cochrane Collaboration) 5.1. 
Studies were grouped according to the pharmacotherapy type used and the outcome 
measure. Dichotomous data were expressed as risk ratio (RR), and continuous data 
were presented as mean difference (MD), both with 95% confidence intervals (CI). A 
fixed-effect or random effect model was used according to heterogeneity. Any dropouts 
were included in the meta-analysis as ineffective following an intention-to-treat (ITT) 
approach. 
4.3 Results 
In total, 1883 records were obtained through database searches, and 198 potentially 
relevant articles were identified after screening titles and abstracts. Among them, 19 
met the inclusion criteria for the review. Thirteen studies were included in meta-
analyses for primary outcomes, of those six excluded from meta-analysis one study 
utilised different outcome measures to other studies (Yu and Pan, 2007), two studies 
did not define their outcome measure calculation (Kong, 2007a, Chen, 2010) one had 
outcome below required minimum improvement (Xie, 2006), one study reported 
incorrect data (Wan, 2012) and the last excluded study did not provide effect size data 
(Tan and Li, 2010) (Figure 4.1). 
4.3.1 Description of studies 
All included trials were conducted in hospitals in China and published in Chinese within 
the last 11 years. Three studies had a third arm for CHM alone (Huang, 2010, Wan, 2012, 
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Xie, 2006), but as indicated in the methods section this data was not included in the 
review. 
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Figure 4.1: Flow chart of study selection according to PRISMA guidelines 
CHM, Chinese herbal medicine; PRISMA, preferred reporting items for systematic 
reviews and meta-analyses; PT, pharmacotherapy; RCT, randomised controlled trial 
Records excluded  
(n=1685) 
E1: laboratory studies (n=52) 
E2: non RCT (n=1003) 
E3: non psoriasis (n=217) 
E4: non CHM studies (n=215) 
Records excluded 
(n=179) 
E2: non RCT (n=10) 
E5: non psoriasis vulgaris (n=1) 
E6: non oral CHM + WM vs. 
WM/WM+CHM placebo (n=146) 
E7: duplications (n=15) 
E8: conference abstract (n=3) 
E9: non-human subjects (n=2) 
E10: non English or Chinese (n=2) 
E11: no description of WM (n=1) 
  
  
Full-text articles reasons for 
exclusion from meta-analysis  
(n=6) 
E12: RCTs using different outcome 
measures (n=1) 
E13: RCTs no outcome measure 
definition or below minimum 
required outcome (n=3) 
E14: reported wrong data (n=1) 
Records identified through 
Chinese database searching  
(n=1417) 
Records after duplications removed  
(n=1883) 
Titles and abstracts screened  
(n=1883) 
Full-text articles assessed for eligibility  
(n=198) 
Studies included in qualitative synthesis  
(n=19) 
Studies included in meta-analysis 
(n=13) 
Records identified through 
English database searching  
(n=594) 
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Participants 
The total number of participants included in the two arms of the 19 RCTs was 1691, 
with 915 in the CHM plus pharmacotherapy groups and 776 in the pharmacotherapy-
only groups. There were inconsistencies in the number of participants reported in two 
studies, the text and results tables differing (Huang, 2010, Wan, 2012). Attempts were 
made to contact the authors but these were unsuccessful, so the numbers of 
participants in the results tables were used. Participants’ ages ranged from 13 to 70 
years (Lin and Jin, 2012) and there were 571 males and 406 females. Two studies 
(Huang, 2010) (Luo, 2010) did not provide information on participant gender, and this 
information in Wan, although reported, was unclear (Wan, 2012).  
All included RCTs recruited people with psoriasis vulgaris, with duration since 
initial onset varying from two weeks (Mao and Mao, 2007) to 11 years (Jin et al., 2009). 
Four studies reported a baseline psoriasis area severity index (PASI score) (all >10) (Jin 
et al., 2009, Tian, 2011, Wu et al., 2009a, Zheng, 2011). The other studies did not 
provide information on baseline disease severity, although baseline balance was 
reported in all studies. One study (Liu, 2005a) only included patients with stationary 
stage psoriasis vulgaris, while six other RCTs recruited patients known to be in 
progressive or stationary stages (Lin and Jin, 2012, Xie, 2006, Mao and Mao, 2007, Wu et 
al., 2009a, Yang et al., 2005, Zhang, 2012), and the remaining studies did not provide 
this information (Table 4.1) (Huang, 2010]{Jin, 2009 #2525, Kong, 2007a, Wan, 2012, 
Yu and Pan, 2007, Chen and Tan, 2004, Tan, 2008, Chen, 2010, Luo, 2010, Zheng, 2011, 
Tian, 2011, Shen and Zhao, 2005) (Jin et al., 2009) (Huang, 2010).
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Table 4.1: Characteristics of included RCTs 
Author, 
year, 
setting, 
country 
Sample size 
(T/C); 
Average or 
range of 
age (T/C) 
Treatment 
interventions 
Control 
interventions 
Treatment 
and follow-
up duration 
Outcome 
measures 
Results 
Participants who 
reported AE (n=); 
SAE 
Mao 2007,  
Hospital, 
China 
62 (31/31); 
Age:  
T: 45.48,  
C: 43.45 
CHM decoction bid; 
Acitretin capsules, 10mg 
bid; compound Amino-
polypeptide tablets, 5 
tablets bid. 
Acitretin capsules, 
10mg bid; 
compound amino-
polypeptide tablets, 
5 tablets bid. 
8 weeks; 
3 months  
TER based on 4 
levels (PASI 90, 
60, 30, 0); 
blood tests of 
liver and 
kidney function 
Reported T>C for TER; 
effect size of PASI 60: RR 
1.09 [0.81, 1.46]. 
Mild AEs of skin 
dryness, pruritus, 
T/C: (1/3); 
No SAE 
Jin 2009, 
Hospital, 
China 
60 (30/30);  
Age:  
T: 37±16.1, 
C: 36±17.2 
CHM decoction bid; 
Topically use 
Calcipotriol, bid. 
 
Topically used 
Calcipotriol bid. 
12 weeks; 
No follow-
up 
TER based on 4 
levels (PASI 90, 
60, 20, 0), PASI 
score. 
 
Reported T>C for TER 
and PASI score; effect 
size of PASI 60: RR 1.27 
[1.01, 1.61]; effect size 
of PASI score: MD 1.63, 
[0.58, 2.68]. 
5 participants from 
two groups 
reported mild skin 
redness, caused by 
WM. 
Kong 
2007,  
Hospital, 
China 
86 (45/41); 
Age:  
T: 
32.7±8.21, 
C: 33.1±7.98 
CHM decoction bid; 
Compound Amino-
polypeptide tablets: 3-4 
tablets bid, IV 10% 
gluconate calcium, 40ml 
qd. 
Compound Amino-
polypeptide tablets: 
3-4 tablets bid, IV 
10% gluconate 
calcium, 40ml qd. 
6 weeks; 
No follow-
up 
TER based on 3 
levels of lesion 
reduction, no 
scoring 
method. 
Reported T>C for TER, 
no definition for 
effectiveness, no effect 
size analysis. 
No information for 
AE or SAE. 
 Wan 
2012, 
Hospital, 
China 
64 (32/32); 
Age:  
T: 13 to 66,  
C: 15 to 65. 
CHM decoction bid; 
Compound Amino-
polypeptide tablets: 5 
tablets, bid. 
Compound Amino-
polypeptide tablets: 
5 tablets, bid. 
1 month; 
6 months 
TER based on 4 
levels (lesion 
reduction 95, 
75, 30, 0).  
Reported T>C for TER, 
significant errors in data 
reporting, no effect size 
analysis. 
Reported no AE. 
Yu 2007, 
Hospital, 
China 
58 (30/28); 
Age:  
Total: 45.85 
CHM powder: bid, 
topically use emollient; 
Compound Amino-
polypeptide tablets: 5 
tablets, bid. 
Topically use 
emollient; 
Compound Amino-
polypeptide tablets: 
5 tablets, bid. 
2 months; 
No follow-
up 
TER based on 4 
levels of the 
combined 
score of PASI 
and DLQI 
Reported T>C for TER, 
no definition for 
effectiveness, no effect 
size analysis. 
No information for 
AE or SAE. 
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Author, 
year, 
setting, 
country 
Sample size 
(T/C); 
Average or 
range of 
age (T/C) 
Treatment 
interventions 
Control 
interventions 
Treatment 
and follow-
up duration 
Outcome 
measures 
Results 
Participants who 
reported AE (n=); 
SAE 
Liu 2005,  
Hospital, 
China 
60 (40/20); 
Age: 
T: 33.63,  
C: 32.7 
CHM decoction bid; 
Compound Amino-
polypeptide tablets: 5 
tablets, bid. 
Compound Amino-
polypeptide tablets: 
5 tablets, bid. 
No 
information  
TER based on 4 
levels of (PASI 
95, 70, 30, 0) 
Reported T>C for TER; 
effect size of PASI 70: RR 
1.93 [1.02, 3.64]. 
Mild AEs: dry 
mouth, dry skin, 
scaly skin, skin 
itchiness, p<0.05 
between T/C 
groups; No SAE 
Yang 
2005, 
Hospital, 
China 
60 (30/30); 
Age: 
T: 
38.42±10.78
,C: 
35.79±9.18 
CHM pill: 18g, bid; 
Compound Amino-
polypeptide tablets: 5 
tablets, bid.  
Compound Amino-
polypeptide tablets: 
5 tablets, bid. 
1 month; 
No follow-
up 
TER based on 4 
levels (PASI 90, 
60, 30, 0) 
Reported T>C for TER 
and PASI score; 
effect size of PASI 60: RR 
1.38 [0.92, 2.05]; effect 
size of PASI score: MD -
0.44, [-2.54, 1.66]. 
Mild AEs of skin 
dryness, pruritus, 
T/C: (2/10); 
No SAE 
Chen 
2004, 
Hospital, 
China 
56 (30/26); 
Age: 
T: 32.4 (16 
to 65); C: 
33.2 (17 to 
63) 
CHM decoction bid; 
Compound Amino-
polypeptide tablets: 5 
tablets, bid. 
Compound Amino-
polypeptide tablets: 
5 tablets, bid. 
6 weeks; 
No follow-
up 
TER based on 5 
levels (lesions 
reduction 100, 
90, 60, 30, 0); 
blood tests of 
liver and 
kidney function 
Reported T>C for TER; 
effect size of lesion 
measurement reduction 
60%: RR 1.14 [0.86, 
1.51]. 
Mild AEs: dry 
mouth, dry lips, dry 
skin, scaly skin, skin 
itchiness, p<0.05 
between T/C 
groups;  
No SAE 
Tan 2010, 
Hospital, 
China 
90 (50/40); 
Age:  
Total: 
33.24±11.32 
CHM decoction, bid; IV 
compound glycyrrhizin, 
40ml qd; Topically use 
Tacalcitol, bid. 
IV compound 
glycyrrhizin, 40ml 
qd;  
Topically used 
Tacalcitol, bid. 
8 weeks; 
No follow-
up 
TER based on 4 
levels (PASI 90, 
60, 20, 0); 
blood tests of 
liver and 
kidney function 
Reported T>C, no data 
for effect size analysis. 
3 mild AEs of skin 
irritation, caused by 
WM. 
No SAE 
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Author, 
year, 
setting, 
country 
Sample size 
(T/C); 
Average or 
range of 
age (T/C) 
Treatment 
interventions 
Control 
interventions 
Treatment 
and follow-
up duration 
Outcome 
measures 
Results 
Participants who 
reported AE (n=); 
SAE 
Zhang 
2012, 
Hospital, 
China 
 112 
(56/56); 
Age:  
Total: 
35.8±3.9 
CHM decoction, tid; 
Acitretin capsules: 10mg 
tid. 
Acitretin capsules: 
10mg tid. 
4 weeks; 
No follow-
up 
TER based on 4 
levels (lesions 
reduction 95, 
75, 30, 0). 
Reported T>C for TER; 
effect size of lesion 
measurement reduction 
75%: RR 1.64, [1.23, 
2.19]. 
No information for 
AE or SAE. 
Huang 
2010, 
Hospital, 
China 
70 (40/30); 
Age: no 
information 
Xiaoyin formula 
powder: 3.5g tid; 
Acitretin Capsules: 
20mg/qd.  
Acitretin Capsules: 
20mg qd. 
No 
information 
TER based on 4 
levels (lesions 
reduction 100, 
60, 30, 0). 
Reported T>C for TER; 
effect size of lesion 
measurement reduction 
60%: RR 1.31, [0.87, 
1.96]. 
Mild AEs in both 
groups: dry mouth, 
dry lips, dry skin, 
scaly skin, caused 
by WM 
No SAE. 
Chen 
2010, 
Hospital, 
China 
200 
(150/50); 
Age:  
T: 42.3, C: 
43 
CHM decoction, bid; 
Acitretin capsules: 30mg 
tid, then 20mg tid. 
Acitretin capsules: 
30mg tid, then 
20mg tid. 
60 days, No 
follow-up 
TER based on 3 
levels of lesions 
reduction 
without 
scoring; change 
of blood IL-6, 
IL-8 level 
Reported T>C for TER, 
no definition for 
effectiveness, no effect 
size analysis. 
No information for 
AE or SAE. 
Luo 2010, 
Hospital, 
China 
174 
(74/100); 
Age: 
T: 38.0±3.1, 
C: 34.5±5.1 
CHM decoction, bid; 
Acitretin capsules: 
0.5mg/kg/d; IV 
compound glycyrrhizin, 
30ml qd; topically use 
Calcipotriol, bid. 
Acitretin capsules: 
0.5mg/kg/d; IV 
compound 
glycyrrhizin, 30ml 
qd; topically use 
Calcipotriol, bid. 
 
6 weeks, No 
follow-up 
TER based on 4 
levels (PASI 95, 
60, 30, 0) 
Reported T>C for TER; 
effect size of PASI 60: RR 
1.71 [1.30, 2.24]. 
Mild AEs in C group 
only, caused by 
WM; 
No SAE 
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Author, 
year, 
setting, 
country 
Sample size 
(T/C); 
Average or 
range of 
age (T/C) 
Treatment 
interventions 
Control 
interventions 
Treatment 
and follow-
up duration 
Outcome 
measures 
Results 
Participants who 
reported AE (n=); 
SAE 
Wu 2009, 
Hospital, 
China 
158 
(79/79); 
Age: 
T: 
37.5±13.2, 
C: 37.7±14.4 
CHM decoction, qd; 
Acitretin capsules: 
0.5mg/kg/d; boric acid 
ointment, bid. 
Acitretin capsules: 
0.5mg/kg/d; boric 
acid ointment, bid. 
12 weeks, 
No follow-
up 
TER based on 4 
levels (PASI 90, 
60, 30, 0); PASI 
score; blood 
tests liver and 
kidney 
function. 
Reported T>C for TER 
and PASI score; effect 
size of PASI 60: RR 1.29 
[1.10, 1.51]; effect size 
of PASI score: MD -4.03, 
[-4.97, -3.09]. 
Mild AEs in both 
groups, dry and 
scaly skin, caused 
by WM, p<0.05 
between T/C 
groups;No SAE 
Xie 2006, 
Hospital, 
China 
52 (32/20); 
Age: 
T: 32.5, 
C: 35 
CHM decoction, bid; 
Acitretin capsules: 10mg 
tid for 30 days, then 
10mg bid for 60 days. 
Acitretin capsules: 
10mg tid for 30 
days, then10mg bid 
for 60 days. 
3 months; 
No follow-
up 
TER based on 3 
levels (lesions 
reduction 95, 
50, 0). 
Reported T>C for TER, 
effect size of lesion 
measurement reduction 
50%: RR:13.00 (0.63, 
266.29) 
Mild AEs: dry 
mouth, dry skin, 
scaly skin, skin 
itchiness, in C group 
only, no SAE. 
Zheng 
2011, 
Hospital,  
China 
120 
(60/60); 
Age:  
T: 
42.1±14.6, 
C: 42.3±15.4 
CHM decoction, bid; 
Acitretin capsules: 
started from 20mg/day, 
then increase to 30-
40mg/day, then 
decrease to 10-
20mg/day. 
Acitretin capsules: 
started from 
20mg/day, then 
increase to 30-
40mg/day, then 
decrease to 10-
20mg/day. 
8 weeks; 
No follow-
up 
TER based on 4 
levels (PASI 95, 
60, 30, 0); PASI 
score. 
Reported T>C for TER 
and PASI score; effect 
size of PASI 60: RR 2.00, 
[1.21, 3.32]; effect size 
of PASI score: MD -2.45, 
[-3.60, -1.30]. 
Mild AEs in both 
groups: 
gastrointestinal 
reaction in both 
groups; leukocyte 
decrease in C group 
only;No SAE 
Tian 2011, 
Hospital,  
China 
60 (30/30); 
Age:  
T: 36.2±9.8, 
C: 34.5±10.2 
CHM decoction; 
Antihistamine, Vitamin 
C, B6, IV gluconate 
calcium.  
Antihistamine, 
Vitamin C, B6, IV 
gluconate calcium. 
60 days; 
No follow-
up  
TER based on 4 
levels (PASI 90, 
60, 20, 0); PASI 
score. 
Reported T>C for TER 
and PASI score; effect 
size of PASI 60: RR 2.27, 
[1.38, 3.74]; effect size 
of PASI score: MD -5.48, 
[-6.98, -3.98]. 
No information for 
AE or SAE. 
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Author, 
year, 
setting, 
country 
Sample size 
(T/C); 
Average or 
range of 
age (T/C) 
Treatment 
interventions 
Control 
interventions 
Treatment 
and follow-
up duration 
Outcome 
measures 
Results 
Participants who 
reported AE (n=); 
SAE 
Lin 2012, 
Hospital,  
China 
89 (46/43); 
Age:  
T:13 to 76, 
C:14 to 73 
Progressive stage: CHM 
decoction bid; stable 
stage and progressive 
stage: compound 
Danshen tablets, 2 
tablets tid; Compound 
Amino-polypeptide 
tablets: 5 tablets tid; 
topical use Tazarotene 
and emollient  
Compound Amino-
polypeptide tablets: 
5 tablets tid; 
topically use 
Tazarotene and 
emollient 
alternatively. 
2-3 months;  
1 year  
TER based on 3 
levels (lesions 
reduction 90, 
70, ?); 
Reported T>C for TER; 
effect size of lesion 
measurement reduction 
70%: RR 2.12 [1.36, 
3.30] 
No information for 
AE or SAE. 
Shen 
2005, 
Hospital, 
China 
60 (30/30); 
Age: total 
average 37 
CHM decoction, bid; 
Compound Amino-
polypeptide tablets: 5 
tablets bid; topically use 
clobetasol propionate 
ointment. 
Compound Amino-
polypeptide tablets: 
5 tablets bid; topical 
use clobetasol 
propionate 
ointment. 
8 weeks; 
No follow-
up 
TER based on 4 
levels (PASI 90, 
60, 30, 0) 
Reported T>C for TER; 
effect size of PASI 60: RR 
1.38 [0.92, 2.05]. 
Mild AEs in both 
groups: dry month, 
scaly skin, p<0.05 
between T/C 
groups;  
No SAE. 
AE, adverse events; bid, twice a day; C, control; CHM, Chinese herbal medicine; DLQI, dermatology life quality index; ES, effect size; IV, intravenous drip; 
MD, mean difference; PASI, psoriasis area and severity index; qd, once a day; RR, risk ratio; SAE, severe adverse events; T>C, treatment group is 
significantly greater to control group; T, treatment; tid, three times a day; TER, total effective rate. 
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4.4.1 Supplementary search results 
The previous review data has since been published (Zhang et al., 2014b) however an 
updated search was conducted in May 2013. These results are briefly presented here 
however were not included in systematic analyses as the studies were not considered 
prior to protocol development 
Supplementary search study characteristics 
A further nine eligible studies were identified with treatment periods ranging from 4 
weeks (Xie, 2012) to 12 weeks (Ma SY, 2012, Jiang et al., 2012a, Huang, 2012) with the 
most utilizing either 8 weeks (n=3) (Han and Yu, 2012, Liu et al., 2012a, Zhu XP, 2012) 
or 12 weeks (n=3) (Huang, 2012, Jiang et al., 2012a, Ma SY, 2012) treatment period. 
Only one study reported dropouts in both the intervention arm (n=3) and the control 
arm (n=5) (Ma SY, 2012). Of the intervention arms the most utilized conventional 
therapy was acitretin (n=5) (Zhai XF, 2012, Xie, 2012, Ma SY, 2012, Liu et al., 2012a, 
Jiang et al., 2012a). The most common utilized topical conventional therapy was 
calcipotriol (n=2) (Zhai XF, 2012, Liu et al., 2012a) (Table 4.4) 
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Table 4.2 Characteristics of supplementary RCTs (oral CHM plus pharmacotherapy vs. pharmacotherapy for psoriasis vulgaris) 
First author; 
publication 
year; 
country; 
setting 
Study 
design; 
blinding; 
number of 
arms 
Treatme
nt 
duration; 
follow-up 
duration 
Stage; severity and duration of 
psoriasis 
No. of 
participants 
randomised/a
ssessed; 
dropouts 
Age: mean 
(SD) (or 
range); 
gender M/F 
Intervention Control 
Han, 2012 
(Han and Yu 
2012), China; 
hospital 
outpatients 
RCT; NS; 2  8w; 0 
I: progressive stage and 
stationary stage; psoriasis lesion 
area>20% BSA; 25 (6.7)m 
I: 66/66; 0 
I: 32.2 (7.3); 
35/31 
Liang xue jie du 
yang yin tang, 
acitretin, 
compound 
flumetasone 
ointment 
Acitretin, 
Compound 
flumetasone 
ointment 
C: progressive stage and 
stationary stage; psoriasis lesion 
area< 20% BSA; 24 (6.5)m 
C: 60/60; 0 
C: 32.4 (7.4); 
31/29 
Huang, 2012 
(Huang 
2012), China; 
hospital 
outpatients 
RCT; NS; 2  12w; 0 
I: NS; NS; 4.5 (0.3)y I: 58/58; 0 
I: 38.8 (0.6); 
32/26 
Tripterygium 
glycosides single 
herb, 
tacalcitol 
ointment, 
tazarotene gel  
Tacalcitol 
ointment 
tazarotene 
gel C: NS; NS; 4.5 (0.3)y C: 58/58; 0 
C: 38.8 (0.6); 
30/28 
Jiang, 2012 
(Jiang, Chen 
et al. 2012), 
China; 
hospital 
out/inpatient 
RCT; S-B; 2  3m; 3m 
I: NS; NS; 4.2 (2.8)y I: 30/30; 0 
I: 33.4 (4.3); 
16/14 
Shen di ke li, 
acitretin 
Acitretin 
C: NS; NS; 4 (2)y C: 30/30; 0 
C: 34.7 (5); 
17/13 
Liu, 2012 
(Liu, Liu et al. 
2012), China; 
hospital 
outpatients 
RCT; NS; 2  8w; 0 
Total: progressive stage; 
psoriasis lesion area <30% BSA; 
NS 
I: 42/42; 0 
I: 40 (10.3); 
24/18 
Run zao zhi yang 
jiao nang, 
acitretin, 
calcipotriol 
ointment 
Acitretin, 
calcipotriol 
ointment C: 42/42; 0 
C: 39 (10.5); 
23/19 
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C, control; D-B, double blind; F, female I, intervention; m, months; M, male; S-B, single blind, SD, standard deviation; ST, subtotal; T, total; 
NS, not stated; N/A, not applicable; RCT, randomised control trial; w, weeks; y, years 
First author; 
publication 
year; 
country; 
setting 
Study 
design; 
blinding; 
number of 
arms 
Treatme
nt 
duration; 
follow-up 
duration 
Stage; severity and duration of 
psoriasis 
No. of 
participants 
randomised/a
ssessed; 
dropouts 
Age: mean 
(SD) (or 
range); 
gender M/F 
Intervention Control 
Ma, 2012, 
China; 
hospital 
outpatients 
RCT; S-B; 2 12w; 12m 
I: stationary stage; NS; 7.3 (0.9) I: 79/76; 3 
I: 37.5 (13.2); 
48/31 
Da huang zhe 
chong wan, 
acitretin 
Acitretin 
C: stationary stage; NS; 7.5 (1.2) C: 79/74; 5 
C: 37.7 (14.4); 
50/29 
Xie, 2012 (Xie 
2012), China; 
hospital 
outpatients 
RCT; NS; 2  4w; 0 Total: NS; NS; 8.5y 
I: 50/50; 0 
Total: 35.5 
(3.2); 49/45 
Run zao zhi yang 
jiao nang, 
acitretin, 
clobetasol 
propionate 
ointment  
Acitretin, 
clobetasol 
propionate 
ointment C: 44/44; 0 
Zhai, 2012, 
China; 
hospital 
outpatients 
RCT; NS; 2 7w; 0 
I: NS ; psoriasis lesion area>30% 
BSA; 12.1 (3.2)y 
I: 85/85; 0 I: 30.7 (4.1); NS Unnamed 
formula, 
aritretin, 
calcipotriol 
Aritretin, 
calcipotriol C: NS ; psoriasis lesion area>30% 
BSA; 10.2 (2.5)y 
C: 100/100; 0 
C: 33.4 (4.3); 
NS 
 C: 56/56; 0  
Zhu, 2012 
(Zhu, Deng et 
al. 2012), 
China; 
hospital 
outpatients 
RCT; NS; 2  6w; 0 
I: NS; NS; 37.9m I: 50/50; 0 I: 41.2; 34/16 Er dong huo xue 
tang,  
Methotrexate  
Methotrexat
e 
C: NS; NS; 39.2m C: 26/26; 0 C: 40.7; 11/15 
Zhu XP 2012, 
China; 
hospital 
RCT; NS; 2 8w; 0 
I: NS; NS; NS I: 90/90, 0 I: 34.6, 7/83 CHM formula 
(no name), 
routine care 
Routine 
care C: NS; NS; NS C: 196/ 196, 0 C: 35.7, 25/171 
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Interventions 
All studies investigated multi-ingredient CHM formulas. Of these, 15 studies 
administered CHM in decoctions (Wan, 2012, Xie, 2006, Luo, 2010, Chen and Tan, 2004, 
Jin et al., 2009, Tian, 2011, Wu et al., 2009a, Zheng, 2011, Liu, 2005a, Zhang, 2012, Chen, 
2010, Kong, 2007a, Shen and Zhao, 2005, Tan and Li, 2010, Yu and Pan, 2007), two used 
granulated powders (Huang, 2010, Mao and Mao, 2007), one used patent pills (Yang et 
al., 2005) and one did not state the form of the CHM (Kong, 2007a). Each study 
employed a different formula. The names of the formulas are listed in Table 4.2 Twelve 
studies applied a standardised CHM formula (Huang, 2010, Wan, 2012, Luo, 2010, Chen 
and Tan, 2004, Jin et al., 2009, Zheng, 2011, Zhang, 2012, Chen, 2010, Shen and Zhao, 
2005, Yu and Pan, 2007, Yang et al., 2005) (Lin and Jin, 2012), whereas the other seven 
studies modified the CHM according to the stage of psoriasis vulgaris (Mao and Mao, 
2007), the Chinese medicine syndrome (Kong, 2007a) or individual symptoms (Xie, 
2006) (Tian, 2011) (Wu et al., 2009a) (Liu, 2005a) (Kong, 2007a) (Tan and Li, 2010).  
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Table 4.3: Chinese herbal medicine formulas and ingredients used in included RCTs 
Author, 
Year 
CHM 
formula 
CHM form CHM ingredients 
Mao 
2007 
No name Granule 
powder 
For progressing stage: Radix rehmanniae (di huang) 30g, rhizoma smilacis glabrae (tu fu ling) 30g, sophorae 
immaturus (sheng huai hua) 15g, rhizoma imperatae (bai bao gen) 30g, radix lithospermi (zi cao gen) 15g, radix 
paeoniae rubra (chi shao) 15g, radix salviae miltiorrhizae (dan shen) 15g, gentiana scabra (long dan cao) 10g, 
radix scutellaria baicalensis (huang qin) 10g, radix glycyrrhizae (gan cao) 10g;  
For stable stage: radix rehmanniae (di huang) 30g, rhizoma smilacis glabrae (tu fu ling) 30g, angelica sinensis 
(dang gui) 10g, rhizoma chuanxiong (chuan xiong) 10g, rhizoma sparganii (san leng) 10g, zedoary rhizome (e zhu) 
10g, semen persicae (tao ren) 10g, fructus aurantii (zhi ke) 10g, herba artemisiae scopariae (yin chen) 20g, radix 
glycyrrhizae (gan cao) 10g. 
Wan 
2012 
Er Dong 
Huo Xue 
Tang 
Decoction Radix ophiopogonis (mai dong) 15g, radix asparagi (tian dong) 15g, xue shen 15g, angelica sinensis (dang gui) 
15g, radix rehmanniae (di huang) 30g, caulis spatholobi (ji xue teng) 30g, radix salviae miltiorrhizae (dan shen) 
30g, rhizoma smilacis glabrae (tu fu ling) 30g, semen persicae (tao ren) 30g, cortex dictamni (bai xian pi) 30g, 
indigo naturalis (qing dai) 30g. 
Liu 
2005 
Jian Pi yi 
Shen 
Tang 
Decoction Scierotium poriae cocos (fu ling) 10-20g, radix codonopsis (dang shen) 10g, atractylodes macrocephala (chao bai 
zhu) 10-30g, semen dolichoris lablab (bai bian dou) 10g, rhizoma dioscoreae (shan yao) 10-20g, herba epimedii 
(xian ling pi ) 10-30g, radix astragali (zhi huang qi) 15-30g, rhizoma smilacis glabrae (tu fu ling) 15-30g, herba 
hedyotidis diffusae (bai hua she she cao) 15-30g. 
Yang 
2005 
Pi Fu 
Bing Xue 
Du Wan 
Patent pill Angelica sinensis (dang gui), Radix Paeoniae Rubra (chis shao), fructus forsythiae (lian qiao), flos lonicerae (jin yin 
hua), periostracum cicadae (chan tui), lithospermum erythrorhizon root (zi cao), etc., in total 39 herbs. 
Chen 
2004 
No name Decoction Lithospermum erythrorhizon root (zi cao) 15g, polygonum cuspidatum (hu zhang) 15g, flos lonicerae (jin yin hua) 
15g, salvia miltiorrhiza (dan shen) 15g, rehmannia glutinosa (di huang) 12g, platycodon grandiflorum (jie geng) 
12g, folium isatis tinctoria (da qing ye) 12g, cortex Paeonia suffruticosa andr (dan pi) 12g, radix paeoniae rubra 
(chi shao) 12g, sophorae immaturus (huai hua) 12g, angelica sinensis (dang gui) 12g, caulis spatholobi (ji xue 
teng) 25g. 
Zhang 
2012 
Qing Ying 
Tang 
Decoction Cornu bubali (shui niu jiao) 30g, rehmannia glutinosa (di huang) 15g, radix scrophulariae (xuan shen) 9g, 
lophatherum (zhu ye xin) 3g, radix ophiopogonis (mai dong) 9g, salvia miltiorrhizae radix (dan shen) 6g, coptis 
rhizome (huang lian) 5g, flos lonicerae (jin yin hua) 9g, fructus forsythiae (lian qiao) 6g. 
Huang  
2010 
Xiao Yi ke 
Li 
Granule 
powder 
Rehmannia glutinosa (di huang) 3.5g, cortex paeonia suffruticosa andr (mu dan pi) 3.5g, angelica sinensis (dang 
gui) 3.5g, sophorae flavescentis (ku shen) 3.5g, flos lonicerae (jin yin hua) 3.5g, radix scrophulariae (xuan shen) 
3.5g, flos carthami (hong hua) 3.5g, cortex dictamn (bai xian pi) 3.5g, etc. 
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Author, 
Year 
CHM 
formula 
CHM form CHM ingredients 
Chen 
2010 
Ke Yin Yi 
Hao 
Decoction Radix lithospermi (zi cao) 5g, cornu bubali (shui niu jiao) 20g, rehmannia glutinosa (di huang) 15g, mu cortex 
paeonia suffruticosa andr (dan pi) 15g, radix paeoniae rubra (chi shao) 17g, sargentodoxa cuneata (hong teng) 
20g, scolopendra (wu gong) 2, buthus martensi (quan xie) 9g, flos carthami (hong hua) 15g, angelica sinensis 
(dang gui) 20g, radix scutellaria baicalensis (huang qin) 15g, fructus forsythiae (lian qiao) 20g. 
Xie 
2006 
Tui Yin 
Tang 
Decoction Rehmannia glutinosa (di huang) 30g, rhizoma smilacis glabrae (tu fu ling) 30g, angelica sinensis (dang gui) 15g, 
radix polygoni multiflori (he shou wu) 15g, ligustrum lucidum (nu zhen zi) 15g, rhizoma polygonati (huang jing) 
15g, fructus tribuli (bai ji li) 15g, radix ophiopogonis (mai dong) 10g, zaocys (wu shao she) 2, flos lonicerae (jin yin 
hua) 10g, cortex paeonia suffruticosa andr (mu dan pi) 10g, radix glycyrrhizae (gan cao) 6g.  
For blood stasis, add semen persicae (tao ren) 10g, flos carthami (hong hua) 10g;  
For red skin gypsum fibrosum (sheng shi gao) 30g. 
Jin 
2009 
No name Decoction Rhizoma sparganii (san leng), zedoary rhizome (er zhu), semen persicae (tao ren), flos carthami (hong hua), caulis 
spatholobi (ji xue teng), lignum euonymi suberalati (gui jian yu), semen coicis (sheng yi yi ren), spica prunellae (xia 
ku cao), pericarpium citri reticulatae (chen pi), no dosage information. 
Kong 
2008 
No name No 
informatio
n 
Blood heat type: rehmannia glutinosa (di huang) 30g, radix paeoniae rubra (chi shao) 9g, radix lithospermi (zi 
cao) 9g, cornu bubali (shui niu jiao) 30g, folium isatis tinctoria (da qing ye) 30g, herba hedyotidis diffusae (bai hua 
she she cao) 30g, salvia miltiorrhizae radix (dan shen) 30g, semen persicae (tao ren) 29g, radix glycyrrhizae (gan 
cao) 3g;  
Blood deficiency type: rehmannia glutinosa (di huang) 30g, radix rehmanniae recen (shu di) 30g, angelica 
sinensis (dang gui) 15g, caulis spatholobi (ji xue teng) 30g, salvia miltiorrhizae radix (dan shen) 15g, radix 
scrophulariae (xuan shen) 15g, semen cannabis (huo ma ren) 10g, folium isatis tinctoria (da qing ye) 15g, radix 
sophorae tonkinensis (shan dou gen) 10g, cortex dictamn (bai xian pi) 15g, polygonum bistorta rhizome (cao he 
che) 15g, fructus forsythiae (lian qiao) 15g;  
Blood dryness type: caulis spatholobi (ji xue teng) 30g, rhizoma smilacis glabrae (tu fu ling) 30g, angelica 
sinensis (dang gui) 15g, rehmannia glutinosa (di huang) 15g, radix clematidis (wei ling xian) 15g, rhizoma 
dioscoreae (shan yao) 15g, lu feng gang (honeycomb) 15g;  
Blood stasis type: semen persicae (tao ren) 10g, flos carthami (hong hua) 10g, rhizoma sparganii (san leng) 10g, 
zedoary rhizome (e zhu) 10g, angelica sinensis (dang gui) 10g, zaocys (wu shao she) 10g, jia xue teng 30g, rhizoma 
smilacis glabrae (tu fu ling) 30g, herba hedyotidis diffusae (bai hua she she cao) 30g, cortex dictamn (bai xian pi) 
15g, radix paeoniae rubra (chi shao) 15g, salvia miltiorrhizae radix (dan shen) 20g, radix glycyrrhizae (gan cao) 6g 
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Author, 
Year 
CHM 
formula 
CHM form CHM ingredients 
Tan 
2010 
Liang 
Xue Xiao 
Yin Tang 
Decoction Rehmannia glutinosa (di huang) 30g, sheng huai hua 30g, rhizoma smilacis glabrae (tu fu ling) 20g, rhizoma 
imperatae (bai mao gen) 15g, ban lan gen 15g, radix lithospermi (zi cao) 15g, radix paeoniae rubra (chi shao) 10g, 
cortex paeonia suffruticosa andr (mu dan pi) 10g, radix scrophulariae (xuan shen) 10g, flos lonicerae (jin yin hua) 
10g, fructus forsythiae (lian qiao) 10g, cao he che 10g, radix glycyrrhizae (sheng gan cao) 10g.  
For lesions on upper body: rhizoma chuanxiong (chuan xiong);  
For lesions on lower body: fructus chaenomelis (mu gua), radix achyranthis bidentatae (chuan niu xi);  
For sore throat: fructus arctii (niu bang zi), radix sophorae tonkinensis (shan dou gen);  
For stomach discomfort: atractylodes macrocephala (sheng bai zhu), pericarpium citri reticulatae (chen pi), 
semen coicis (yi yi ren);  
For itchiness: sophorae flavescentis (ku shen), cortex dictamn (bai xian pi) 
Wu 
2009 
Yin Xie 
Kang 
Decoction Radix astragali (huang qi), rehmannia glutinosa (di huang), radix lithospermi (zi cao), salvia miltiorrhizae radix 
(dan shen), angelica sinensis (dang gui), radix asparagi (tian dong), radix ophiopogonis (mai dong), rhizoma 
smilacis glabrae (tu fu ling), herba hedyotidis diffusae (bai hua she she cao), no dosage information 
Luo 
2010 
No name Decoction Angelica sinensis (dang gui) 12g, rehmannia glutinosa (di huang) 30g, radix scrophulariae (xuan shen) 15g, radix 
lithospermi (zi cao) 9g, (chi shao) 6g, cortex paeonia suffruticosa andr (mu dan pi) 9g, semen persicae (tao ren) 
10g, salvia miltiorrhizae radix (dan shen) 30g, folium isatis tinctoria (da qing ye) 15g, cortex phellodendri (huang 
bai) 15g, periostracum cicadae (chan tui) 10g, radix saposhnikoviae (fang feng) 10g, sophorae flavescentis (ku 
shen) 10g, radix glycyrrhizae (gan cao) 10g 
Zheng 
2011 
Xiao Yin 
Ke Bi 
Tang 
Decoction Cornu bubali (shui niu jiao) 20g, rehmannia glutinosa (di huang) 10g, cortex paeonia suffruticosa andr (mu dan pi) 
10g, radix paeoniae rubra (chi shao) 15g, rhizoma smilacis glabrae (tu fu ling) 30g, sophorae flavescentis (ku shen) 
12g, cortex dictamn (bai xian pi) 12g, fructus kochiae (di fu zi) 12g, radix lithospermi (zi cao) 15g, periostracum 
cicadae (chan tui) 10g, radix scutellaria baicalensis (huang qin) 12g, radix saposhnikoviae (fang feng) 10g, 
rhizoma imperatae (bai mao gen) 30g, rhizoma atractylodis (cang zhu) 10g 
Tian  
2011 
Qing Fei 
Liang 
Xue Tang 
Decoction Cornu bubali (shui niu jiao) 30g, rehmannia glutinosa (di huang) 15g, radix paeoniae rubra (chi shao) 15g, cortex 
paeonia suffruticosa andr (dan pi) 10g, angelica sinensis (dang gui) 10g, cortex dictamn (bai xian pi) 10g, caulis 
spatholobi (ji xue teng) 20g, rhizoma smilacis glabrae (tu fu ling) 25g, radix lithospermi (zi cao) 20g, flos lonicerae 
(jin yin hua) 15g, radix scutellariae barbatae (ban zhi lian) 10g, herba hedyotidis diffusae (bai hua she she cao) 
20g, zaocys (wu shao she) 10g, salvia miltiorrhizae radix (dan shen) 20g, radix glycyrrhizae (gan cao) 10g 
Yu 
2007 
Qing Re 
Huo Xue 
Decoction Sheng huai hua, flos carthami (hong hua), rehmannia glutinosa (di huang), radix scrophulariae (xuan shen), caulis 
spatholobi (ji xue teng), angelica sinensis (dang gui), rhizoma chuanxiong (chuan xiong), rhizoma sparganii (san 
leng), zedoary rhizome (er zhu), rhizoma smilacis glabrae (tu fu ling), herba solani lyrati (shu yang quan), no 
dosage detail 
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Author, 
Year 
CHM 
formula 
CHM form CHM ingredients 
Lin  
2012 
No name Decoction Sophorae flavescentis (ku shen) 15g, angelica sinensis (dang gui) 15g, rhizoma menispermi (bei dou gen) 10g, 
anemarrhena rhizome (zhi mu) 10g, radix scutellariae barbatae (ban zhi lian) 20g, rhizoma smilacis glabrae (tu fu 
ling) 30g, bai mao gen30g, rehmannia glutinosa (di huang) 30g 
Shen 
2005 
Xiao Yin 
Fang 
Decoction Radix astragali (huang qi) 30g, angelica sinensis (dang gui) 15g, rehmannia glutinosa (di huang) 15g, rhizoma 
chuanxiong (chuan xiong) 12g, radix paeoniae rubra (chi shao) 12g, radix scrophulariae (xuan shen) 12g, cortex 
paeonia suffruticosa andr (mu dan pi) 12g, salvia miltiorrhizae radix (dan shen) 12g, semen persicae (tao ren) 9g, 
flos carthami (hong hua) 9g, radix curcumae (yu jin) 9g, cortex dictamn (bai xian pi) 15g, rhizoma dioscoreae 
hypoglaucae (bi xie) 15g, rhizoma smilacis glabrae (tu fu ling) 15g, fructus gardeniae (zhi zi) 9g, flos lonicerae (jin 
yin hua) 9g 
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In total, 70 different herbs were included in the studies. The most frequently used 
herbs were Rehmannia glutinosa root (di huang) (n=15 studies), Angelica sinensis root 
(dang gui) (n=12), Smilax glabra root (tu fu ling) (n=11), Paeonia veitchii root (chi shao) 
(n=9), Salvia miltiorrhiza root (dan shen) (n=9) and Lithospermum erythrorhizon root (zi 
cao) (n=9). Eleven studies used a single conventional pharmacotherapy drug as a 
comparator (Huang, 2010, Wan, 2012, Xie, 2006, Chen and Tan, 2004, Jin et al., 2009) 
(Zheng, 2011, Liu, 2005a, Zhang, 2012, Chen, 2010, Yu and Pan, 2007, Shen and Zhao, 
2005), six studies used two (Wu et al., 2009a, Kong, 2007b, Yu and Pan, 2007, Tan, 2008, 
Lin and Jin, 2012, Shen and Zhao, 2005) and two studies combined three drugs (Luo, 
2010, Tian, 2011). In total, 10 different drugs were used, including topical vitamin D3 
analogues, calcipotriol (Luo, 2010, Jin et al., 2009) and tacalcitol (Tan and Li, 2010) as 
ointments (n=3), corticosteroid clobetasol propionate ointment (n=1)(Shen and Zhao, 
2005) and a combination of retinoid tazarotene with emollient (n=1)(Lin and Jin, 2012). 
The oral retinoid acitretin was used in eight studies (Huang, 2010, Xie, 2006, Luo, 2010, 
Mao and Mao, 2007, Wu et al., 2009a, Zheng, 2011, Zhang, 2012, Chen, 2010). 
In addition, pharmacotherapies that are used in China for psoriasis management 
were employed, such as oral Diyin tablets (n=9)(Wan, 2012, Mao and Mao, 2007, Chen 
and Tan, 2004, Liu, 2005a, Kong, 2007a, Shen and Zhao, 2005, Yu and Pan, 2007, Yang et 
al., 2005, Lin and Jin, 2012), which contain multiple amino acids and peptides, 
aminophylline and chlorpheniramine maleate, and aim to regulate immune response, 
improve microcirculation, benefit metabolism, provide microelements, and reduce the 
keratinocyte proliferation present in psoriasis (Song et al., 2013, Yang, 2011). 
Compound glycyrrhizin solution via IV drip was also used (n=2)(Luo, 2010, Tan and Li, 
2010), which contains glycyrrhizin, cysteine hydrochloride and glycine, and is said to 
produce an effect similar to a glucocorticoid, including reduced inflammation (Zhu and 
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Hu, 2011). Intravenous drip containing 10% calcium gluconate solution was also used 
(n=2), which aims to reduce itching in various dermatological conditions (Zhao, 2009, 
Tian, 2011, Kong, 2007a). It should be noted that these pharmacotherapies are not 
recommended by international psoriasis treatment guidelines. 
Supplementary search interventions of studies 
As found in RCTs of the main review, no study utilized same CHM, with a variety of 
different herbal formulation ingredients administered. Only one study used a single 
herb (Huang, 2012) as treatment the rest of the studies used multiple ingredients as 
their CHM intervention. Three studies administered the CHM intervention in decoction 
form (Han and Yu, 2012), two in granule form (Jiang et al., 2012a, Zhai XF, 2012), two in 
capsule form and one each in tablet (Huang, 2012) and pill form (Ma SY, 2012). Only 
two of the nine studies stated using syndrome differentiation to determine treatment 
(Zhai XF, 2012, Zhu XP, 2012) (Table 4.5). 
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Table 4.4: Supplementary search intervention/comparators of included RCTs (oral CHM plus pharmacotherapy vs. pharmacotherapy 
for psoriasis vulgaris) 
bid, twice per day; CM, Chinese medicine; po, oral administration; qn, nightly; NS, not stated; tid, three times a day 
First author, 
publication 
year 
Syndrome 
differentiation 
CM principle 
of treatment 
Chinese herbal medicine formula and 
ingredients 
Preparation 
type and 
dosage 
Pharmacoth
erapy 
Dosage and 
administration 
Han, 2012 NS 
Cool blood, 
remove toxin, 
nourish Yin 
Liang xue jie du yang yin tang:  rehmannia 
glutinosa (di huang) 30g, paeonia suffruticosa 
(mu dan pi) 15g, paeoniae radix Rubra (chi 
shao) 15g, arnebia euchroma (zi cao) 15g, 
rubiae radix et rhizoma (qian cao) l5g, smilacis 
glabrae rhizoma (tu fu ling)30g, isatidis radix 
(ban lan gen) 30g,  hedyotis diffusae herba (bai 
hua she she cao) 30g,  sophorae tonkinensis 
radix et rhizoma (shan dou gen) l0g,  lehniae 
radix (bei sha shen) 10g, ophiopogonis radix 
(mai dong) 10g. Individual modification 
according to symptoms 
Decoction, 
one pack a 
day 
Acitretin and 
Compound 
flumetasone 
ointment 
Acitretin, 20-60mg, 
qd-bid, po; topical 
Compound 
flumetasone 
ointment, qd 
Huang, 2012 NS NS Tripterygium glycosides single herb 
Tablet, 30mg 
tid  
Tacalcitol 
ointment and 
Tazarotene 
gel 
Topical apply 
tacalcitol ointment 
bid, tazarotene gel qn 
Jiang, 2012 NS 
Clear heat, 
cool blood, 
remove toxin, 
clear lesions, 
nourish Yin 
and produce 
body fluid 
Shen di ke li: scrophulariae radix (xuan shen), 
rehmannia glutinosa (di huang), paeonia 
suffruticosa (mu dan pi), paeoniae radix rubra 
(chi shao), chrysanthemi indici flos (ye ju hua),  
taraxaci herba (pu gong ying), isatidis radix 
(ban lan gen), violae herba (zi hua di ding), 
gardeniae fructus (zhi zi), smilacis glabrae 
rhizoma (tu fu ling), fritillariae cirrhosae 
bulbus (bei mu),  trichosanthis radix (tian hua 
fen), platycodonis radix (jie geng), glycyrrhizae 
radix et rhizoma (gan cao) 
 
Granule, one 
pack a day 
Acitretin 
Initial dosage 10mg 
qd, then 20mg qd, 
then 10mg qd, po 
 157 
First author, 
publication 
year 
Syndrome 
differentiation 
CM principle 
of treatment 
Chinese herbal medicine formula and 
ingredients 
Preparation 
type and 
dosage 
Pharmacoth
erapy 
Dosage and 
administration 
Liu, 2012 NS 
 
Nourish blood 
and Yin, clear 
wind, stop 
itching, 
nourish 
intestines, 
promote 
bowel motion 
 
Run zao zhi yang jiao nang: polygoni 
multiflori radix (he shou wu), polygoni 
multiflori radix Praeparata (zhi he shou wu), 
rehmannia glutinosa (di huang), mori folium 
(sang ye),  sophorae flavescentis radix (ku 
shen), cannabis sativa (hong huo ma) 
Capsule, 4 tid 
Acitretin and 
calcipotriol 
ointment 
Acitretin, 30mg qd 
po, topical 
calcipotriol ointment 
bid 
Ma, 2012 NS 
Nourish blood 
and Yin, clear 
dryness, 
invigorate 
blood, 
remove stasis 
Da huang zhe chong wan: rhei radix et 
rhizoma (da huang), eupolyphaga steleophaga 
(tu bie chong), hirudo (shui zhi),  tabanidae 
(mang chong),  holotrichia (qi cao),  
armeniacae semen amarum (xing ren),  
persicae Semen (tao hua),  scutellariae radix 
(huang qin),  rehmannia glutinosa  (di huang),  
paeoniae radix alba (bai shao) 
 
Pill, 3g tid po Acitretin 20mg qd po 
Xie, 2012 NS 
 
Nourish blood 
and Yin, clear 
wind, stop 
itching, 
nourish 
intestines, 
promote 
bowel motion 
 
 
 
Run zao zhi yang jiao nang:  polygoni 
multiflori radix (he shou wu), polygoni 
multiflori radix praeparata (zhi he shou wu), 
rehmannia glutinosa (di huang),  mori folium 
(sang ye), sophorae flavescentis Radix (ku 
shen), cannabis sativa (hong huo ma) 
 
 
Capsule 2.0g 
tid po 
Acitretin and 
Clobetasol 
propionate 
ointment 
Acitretin 20mg qd po, 
topical clobetasol 
propionate ointment 
bid 
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First author, 
publication 
year 
Syndrome 
differentiation 
CM principle 
of treatment 
Chinese herbal medicine formula and 
ingredients 
Preparation 
type and 
dosage 
Pharmacoth
erapy 
Dosage and 
administration 
Zhai, 2012 
Yes (Blood heat 
type) 
Clear heat, 
cool blood, 
clear toxin 
and wind 
 
Unnamed formula: rehmannia glutinosa  (di 
huang) 30g, scrophulariae radix (xuan shen) 
15g, paeoniae radix alba (bai shao) 12g, 
gypsum fibrosum (sheng shi gao) 30g, 
anemarrhenae rhizoma (zhi mu) 9g, imperatae 
rhizoma (bai mao gen) 30g, arctii fructus (niu 
bang zi) 9g, schizonepetae Herba (jing jie) 9g,  
glycyrrhizae radix et rhizoma (gan cao) 6g, 
lonicerae Japonicae Flos (jin yin hua) 15g, 
cimicifugae rhizoma (sheng ma) 3g,  
ophiopogonis radix (mai dong) 9g,  moutan 
cortex (mu dan pi) 9g,  scutellariae radix 
(huang qin) 15g,  smilacis glabrae rhizoma (tu 
fu ling) 30g 
 
Granule, no 
information 
of dosage 
Acitretin and 
calcipotriol 
ointment 
Acitretin: 10mg tid, 
po 
Calcipotriol: topical 
bid  
Zhu, 2012 NS 
Clear heat, 
remove toxin, 
clear dryness 
and 
dampness, 
invigorate 
blood and 
remove stasis 
 
Er dong huo xue tang:  asparagi radix (tian 
men dong) 15g, ophiopogonis radix (mai dong) 
15g, angelicae sinensis radix (dang gui) 15g, 
scrophulariae radix (xuan shen) 15g, smilacis 
glabrae rhizoma (tu fu ling) 30g, rehmannia 
glutinosa (di huang) 30g, salviae miltiorrhizae 
radix et rhizoma (dan shen) 30g, spatholobi 
caulis (ji xue teng) 30g, indigo naturalis (qing 
dai) 10g, dictamni cortex (bai xian pi) 10g, 
persicae semen (tao ren) 10g 
 
 
 
 
Decoction, 
one pack a 
day 
Methotrexate 
Methotrexate 2.5-
5mg tid po 
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First author, 
publication 
year 
Syndrome 
differentiation 
CM principle 
of treatment 
Chinese herbal medicine formula and 
ingredients 
Preparation 
type and 
dosage 
Pharmacoth
erapy 
Dosage and 
administration 
Zhu XP 2012 
Yes (Blood heat 
type and blood 
stasis type) 
For blood 
heat type : 
clear heat, 
cool blood, 
remove toxin;  
For blood 
stasis type: 
nourish blood 
and remove 
blood stasis 
 
For blood heat type: bubali cornu (shui niu 
jiao) 30g, rehmannia glutinosa (di huang)  30g, 
paeoniae radix rubra (chi shao) 15g, moutan 
cortex (mu dan pi) 15g, lonicerae japonicae flos 
(jin yin hua) 15g, dictamni cortex (bai xian pi) 
30g, sophorae flavescentis radix (ku shen) 10g, 
smilacis glabrae rhizoma (tu fu ling) 20g, 
coptidis rhizoma (huang lian) 10g, forsythiae 
fructus (lian qiao) 10g 
For blood stasis type: rehmannia glutinosa (di 
huang) 15g, rehmanniae radix praeparata (shu 
di huang)15g, asparagi radix (tian men 
dong)10g, ophiopogonis radix (mai dong)10g, 
scrophulariae radix (xuan shen) 15g, angelicae 
sinensis radix (dang gui) 12g, paeoniae radix 
rubra (chi shao)15g, salviae miltiorrhizae radix 
et rhizoma (dan shen) 30g, curcumae rhizoma 
(e zhu)10g, bombyx batryticatus (jiang can) 
10g, sophorae flavescentis radix (ku shen) 10g, 
dictamni cortex (bai xian pi) 20g 
 
Decoction, 
one pack a 
day 
Routine care NS 
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Treatment duration and follow-up 
The shortest treatment duration was one month (Wan, 2012, Zhang, 2012) (Yang et al., 
2005), while the longest was three months (Xie, 2006, Lin and Jin, 2012). The most 
common treatment duration was eight weeks (Mao and Mao, 2007, Zheng, 2011, Shen 
and Zhao, 2005, Tan and Li, 2010). All studies applied CHM and pharmacotherapy for 
equal durations. One study had a follow-up examination at three months (Mao and Mao, 
2007), one at six months (Wan, 2012) and another at one year (Lin and Jin, 2012). 
Outcome measures 
All studies employed total effective rate (TER) as the primary outcome measure. This 
was calculated based on PASI score reduction in ten studies (Luo, 2010),(Mao and Mao, 
2007, Jin et al., 2009, Tian, 2011, Wu et al., 2009a, Zheng, 2011, Liu, 2005a, Shen and 
Zhao, 2005, Tan and Li, 2010, Yang et al., 2005), lesion score reduction in five studies 
(Huang, 2010, Wan, 2012, Xie, 2006, Chen and Tan, 2004, Zhang, 2012, Lin and Jin, 2012) 
and a combination of PASI and the dermatological life quality index scores in one study 
(Yu and Pan, 2007), although the latter did not provide information on the method of 
score calculation. Two studies did not specify the scoring method used (Chen, 2010, 
Kong, 2007a). 
The TERs were categorised as ‘cured’, ‘remarkably effective’, ‘effective’ and 
‘ineffective’; however, the definition of these categories varied among the studies. For 
example, in four studies PASI score reductions of 90, 60 and 30% (PASI 90, 60, 30) were 
used (Mao and Mao, 2007, Wu et al., 2009a, Shen and Zhao, 2005, Yang et al., 2005), 
another study used 95, 70 and 30% (PASI 95, 70, 30) as the criteria (Liu, 2005a), and 
another employed lesion score reductions of 95, 75 and 30% (Zhang, 2012). 
Furthermore, the symptom scoring methods used in seven studies had not been 
validated (Huang, 2010, Wan, 2012, Xie, 2006, Chen and Tan, 2004, Zhang, 2012, Yu and 
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Pan, 2007, Lin and Jin, 2012). PASI 60 or a lesion score reduction of 60% was the most 
common criterion for ‘remarkably effective’. The actual PASI score was reported in five 
studies (Jin et al., 2009, Tan and Li, 2010, Wu et al., 2009a, Zheng, 2011, Yang et al., 
2005) and one study reported serum IL-6 and IL-8 levels (Chen, 2010).  
Adverse events (AEs) were monitored by all studies, with 10 studies examining 
full blood count, urine tests and blood tests for renal and liver function (Huang, 2010, 
Xie, 2006, Luo, 2010, Mao and Mao, 2007, Chen and Tan, 2004, Jin et al., 2009, Tian, 
2011, Kong, 2007a, Shen and Zhao, 2005, Tan and Li, 2010). 
Supplementary search outcome measures 
Psoriasis severity was most commonly reported using PASI reduction (n=5)(Jiang et al., 
2012a, Liu et al., 2012a, Ma SY, 2012) with the other four studies reporting lesion 
reduction(Han and Yu, 2012, Huang, 2012, Xie, 2012, Zhu et al., 2012) (%). Four of the 
studies reporting PASI score reduction also reported overall PASI score also (Jiang et al., 
2012a, Liu et al., 2012a, Ma SY, 2012, Zhu XP, 2012).  Greatest PASI reduction was 
reported as PASI95 (n=1)(Zhai XF, 2012) with the majority of studies using PASI90 as 
the upper most improvement  (n=4) (Jiang et al., 2012a, Liu et al., 2012a, Ma SY, 2012, 
Zhu XP, 2012). Lowest PASI outcome was PASI 20 (n=1) (Liu et al., 2012a) with most 
reporting lowest improvement as PASI 30 (n=3) (Jiang et al., 2012a, Ma SY, 2012, Zhai 
XF, 2012). No studies reported outcomes for QoL nor did any studies report data for 
psoriasis related biological markers. Only two studies presented data on relapse rates 
(Jiang et al., 2012a, Ma SY, 2012) (Table 4.7). 
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Table 4.5: Outcome measures of included RCTs (oral CHM plus pharmacotherapy vs. pharmacotherapy for psoriasis vulgaris) 
First 
author, 
publicati
on year 
Definition of 
effectiveness 
Psoriasis lesions Quality of life 
Biological 
markers 
Relapse 
rate 
Adverse 
Events PASI score 
reduction 
Lesion 
reduction 
PASI 
score 
DLQI 
Other QoL 
assessment 
Han 2012 
Lesion reduction 
(%) 95, 50 
- Yes - - - - - Yes 
Huang 
2012 
Lesion reduction 
(%) 90, 70, 30 
- Yes - - - - - Yes 
Jiang 
2012 
PASI 90, 60, 30 Yes - Yes - - - Yes Yes 
Liu 2012 PASI 90, 60, 20 Yes - Yes - - - - Yes 
Ma 2012 PASI 90, 60, 30 Yes - Yes - - - Yes Yes 
Xie 2012 
Lesion reduction 
(%) 90, 60, 25 
- Yes - - - - - Yes 
Zhai 2012 PASI 95, 60, 30 Yes - - - - - - Yes 
Zhu 2012 Lesion reduction 
(%) 90, 60, 30 
- Yes - - - - - - 
Zhu XP 
2012 PASI 90, 60, 25 Yes - Yes 
- - - - - 
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Dropouts 
Of the total 19 studies, 17 reported no dropouts or were judged as having no dropouts, 
as they reported equal numbers of participants’ randomised and completed. One study 
did not provide information on dropouts or number completed (Tan and Li, 2010). One 
study reported eight dropouts (three from the treatment group and five from the 
control group) due to minor AEs or loss of contact during follow-up (Wu et al., 2009a). 
Although this study mentioned treating dropouts as ineffective in the data analysis, the 
dropouts were not included in the data table, so the numbers were adjusted for meta-
analysis. 
Use of Chinese medicine syndrome differentiation for psoriasis vulgaris 
According to Evidence-based Guidelines for Clinical Practice in Chinese Medicine (China 
Academy of Chinese Medicine, 2011) the most common syndrome in the progressive 
stage of psoriasis vulgaris is blood heat syndrome, while blood stasis syndrome is 
common in the stationary stage. The guidelines indicate that the CHM prescription 
should be modified according to the syndrome to maximise the efficacy of treatment. 
Among the 19 studies, one study (Mao and Mao, 2007) employed two different CHM 
formulas for the two stages of psoriasis vulgaris, one study used four formulas to treat 
four syndromes (Kong, 2007a), six studies used individual modification according to 
patients’ symptoms (Xie, 2006, Tian, 2011),(Wu et al., 2009a, Liu, 2005a, Kong, 2007a, 
Tan and Li, 2010) and all other studies used one standardised formula (Table 4.1). 
4.3.2 Risk of bias assessment 
One study was assessed as low risk for sequence generation as it used a randomisation 
number table (Tian, 2011); the other 18 studies were assessed as unclear due to lack of 
information. Allocation concealment was not reported by any study so all were assessed 
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as unclear; all studies received high-risk assessments for blinding of participants and 
practitioner as none reported a blinding method or used a placebo for the CHM; all 
studies were judged as unclear for blinding of outcome assessors as no details were 
reported. For incomplete outcome data, 13 studies were assessed as low risk because 
there were no dropouts while Wu (2009) was judged as low risk because the dropout 
numbers were low and balanced across the two groups (X2=0.476, d.f.=1, P=0.49). Tan 
and Li (Tan and Li, 2010) did not report dropouts and was assessed as unclear, while 
two studies were assessed as high risk as the numbers of participants reported in the 
post-treatment section did not match the number of participants being randomised and 
no explanations provided for the differences (Huang, 2010, Wan, 2012) (Table 4.3).  
All studies were assessed as low risk for selective reporting, except Tan (2010), 
which was assessed as unclear; however, none of the studies rated low risk had 
published trial protocols so it could be argued they should be all assessed as unclear. 
For other bias, no conflict of interest from funding sources was detected in any of the 
studies. Wan (2012) was excluded from efficacy meta-analyses due to inconsistency in 
the results tables and consequent high risk of bias in the results. Following sensitivity 
analysis it was decided data would still be included for the subgroup analysis of studies 
for effect with CHM modification, where its impact was minor due to the large number 
of included studies (Figure 4.7). 
 
 
 165 
Table 4.6: Risk of bias assessment of included RCTs (oral CHM plus pharmacotherapy vs. pharmacotherapy for psoriasis 
vulgaris) 
 
First author, 
publication 
year 
Sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and personnel 
Blinding of 
outcome 
assessors 
Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other Bias 
Chen, 2004  Unclear Unclear High Unclear Low Low Low 
Chen, 2010 Unclear Unclear High Unclear Low Low Low 
Huang, 2010 Unclear Unclear High Unclear High Low Low 
Jin, 2009 Unclear Unclear High Unclear Low Low Low 
Kong, 2007 Unclear Unclear High Unclear Low Low Low 
Lin, 2012 Unclear Unclear High Unclear Low Low Low 
Liu, 2005 Unclear Unclear High Unclear Low Low Low 
Luo, 2010 Unclear Unclear High Unclear Low Low Low 
Mao, 2007 Unclear Unclear High Unclear Low Low Low 
Shen, 2005 Unclear Unclear High Unclear Low Low Low 
Tan, 2010 Unclear Unclear High Unclear Unclear Low Low 
Tian, 2011 Low Unclear High Unclear Low Low Low 
Wan, 2012 Unclear Unclear High Unclear High Low Low 
Wu, 2009 Unclear Unclear High Unclear High Low Low 
Xie, 2006 Unclear Unclear High Unclear Low Low Low 
Yang, 2005 Unclear Unclear High Unclear Low Low Low 
Yu, 2007 Unclear Unclear High Unclear Low Low Low 
Zhang, 2012 Unclear Unclear High Unclear Low Low Low 
Zheng, 2011 Unclear Unclear High Unclear Low Low Low 
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4.3.3 Supplementary search risk of bias 
All studies were rated high risk for blinding of participants and personnel with a further 
three studies assessed as high risk for allocation concealment (Huang, 2012, Xie, 2012, 
Zhu XP, 2012). Ma 2012 was rated high risk for incomplete data reporting (Table 4.6)
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Table 4.7: Risk of bias assessment of supplementary search RCTs (oral CHM plus pharmacotherapy vs. pharmacotherapy for 
psoriasis vulgaris) 
 
First author, 
publication 
year 
Sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
Blinding of 
personnel 
Blinding of 
outcome 
assessors 
Incomplete 
outcome data 
Selective 
outcome 
reporting 
Han 2012 Unclear Unclear High High Unclear Low Low 
Huang 2012 High High High High Unclear Low Low 
Jiang 2012 Low Unclear High High Unclear Low Low 
Liu 2012 Unclear Unclear High High Unclear Low Low 
Ma 2012 Unclear Unclear High High Unclear High Low 
Xie 2012 High High High High Unclear Low Low 
Zhai 2012 Low Unclear High High Unclear Low Low 
Zhu 2012 Unclear Unclear High High Unclear Low Low 
Zhu XP 2012 High High High High Unclear Low Low 
 168 
4.3.4 Efficacy 
All studies reported superior efficacy for the combination of CHM and pharmacotherapy 
in terms of the TER at the end of treatment, and five studies reported that the 
combination was more effective for PASI score reduction (Jin et al., 2009, Tian, 2011, 
Wu et al., 2009a, Zheng, 2011, Yang et al., 2005). 
Grouping studies for analysis 
Some studies used the PASI score as a basis for TER calculation, while other 
studies used lesion score based on Chinese guidelines. The definition of effectiveness 
also differed between studies. Clinical guidelines suggest the criterion for treatment 
success should be a PASI score reduction of 75% (PASI 75) or greater, and treatment 
failure considered PASI score reduction of 50% (PASI 50) or less (Nast et al., 2012). For 
measuring effectiveness of treatment in China, PASI 60 is considered by Consensus of 
Diagnosis and Treatment of Psoriasis Vulgaris in Integrative Medicine (Chinese Medical 
Association, 2009) as the cut-off level. Ten studies reported the number of participants 
achieving a 60% reduction in PASI or symptom scores, and three studies reported 70 or 
75% reductions, so 60% reduction or more in PASI or symptom score was selected as 
the criterion for meta-analysis of TER. Analysis was based on conventional treatment 
type with the initial meta-analysis including all treatment types, and then subgroup 
analysis was performed including only those recommended by international treatment 
guidelines.  
First analysis: Efficacy of oral CHM and conventional therapies (all types)  
TER based on PASI 60 and above 
For the first meta-analysis, four studies were excluded as they did not report effect size 
(Kong, 2007a, Yu and Pan, 2007, Tan and Li, 2010, Chen, 2010), another was excluded 
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due to significant data errors (Wan, 2012) and one study reported an effect size of only 
50% lesion reduction, which was below the predetermined 60% cut-off (Xie, 2006). 
This left nine studies suitable for pooling for TER based on PASI 60 and above (Jin et al., 
2009, Liu, 2005b, Luo, 2010, Mao and Mao, 2007, Shen and Zhao, 2005, Tian, 2011, Wu 
et al., 2009a, Yang et al., 2005, Zheng, 2011). The overall effect favoured CHM combined 
with conventional medicine compared with conventional therapy alone (RR: 1.44 [1.24, 
1.68]) (Figure 4.2). 
 
 
Figure 4.2: Total effective rate (TER) based on PASI 60 and above 
 
TER based on 60% lesion elimination or more 
Four studies were suitable for meta-analysis as they used outcome TER lesion 
elimination of 60% or greater. Pooled effects showed combined therapy to be superior 
to conventional therapy alone (RR: 1.48 [1.13, 1.93]) (Chen and Tan, 2004, Huang, 2010, 
Lin and Jin, 2012, Zhang, 2012) (Figure 4.3). 
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Figure 4.3: Total effective rate (TER) based on lesion elimination of 60% and above 
 
PASI score change 
Five studies were included based on general PASI score change (Jin et al., 2009, Tian, 
2011, Wu et al., 2009a, Yang et al., 2005, Zheng, 2011), where pooled mean differences 
of studies again showed significantly greater effect in combined treatment than 
conventional therapy alone (MD: –2.17 [–4.76, 0.43]); however, heterogeneity (I2) for 
this meta-analysis was very high at 95% (Jin et al., 2009, Tian, 2011, Wu et al., 2009a, 
Yang et al., 2005, Zheng, 2011). This heterogeneity was likely due to the variation 
between the interventions used in the studies (Figure 4.4). 
 
 
Figure 4.4: Psoriasis area severity index (PASI) score 
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Second analysis: Efficacy of oral CHM and conventional therapy recommended by 
international guidelines 
For the second analysis, six studies were excluded as the pharmacotherapies used were 
not recommended by international guidelines for psoriasis treatment (Wan, 2012, Chen 
and Tan, 2004, Tian, 2011, Liu, 2005a, Kong, 2007a). As these drugs could not be 
considered reliable comparators, only studies that employed well-recognised 
pharmacotherapies were included in the second meta-analysis, such as oral acitretin, 
which was used in eight studies (Huang, 2010, Xie, 2006, Luo, 2010, Mao and Mao, 2007, 
Wu et al., 2009a, Zheng, 2011, Zhang, 2012) (Chen, 2010); four studies used other well-
recognised topical drugs (Luo, 2010) (Jin et al., 2009, Shen and Zhao, 2005, Tan and Li, 
2010). Of the eight studies that used acitretin as a comparator, Huang (Huang, 2010) 
had errors in the results, Chen (Chen, 2010) did not provide information on the criteria 
for effectiveness and Xie (Xie, 2006) used 50% rather than 60% lesion score reduction 
as a criterion, so these three studies were excluded from the meta-analysis pool.  
Efficacy of oral CHM and guideline-recommended conventional therapy for TER 60 and 
above 
Five studies of acitretin provided TER data suitable for pooling in three groups (Luo, 
2010, Mao and Mao, 2007, Wu et al., 2009a, Zhang, 2012, Zheng, 2011). Group 1.1 used 
acitretin alone as the pharmacotherapy with PASI 60 as the criterion and found CHM 
plus acitretin to be superior to acitretin alone (RR: 2.00 [1.21, 3.32])(Zheng, 2011). 
Group 1.2 used acitretin alone as the pharmacotherapy with a 75% symptom reduction 
as the criterion, and found CHM plus acitretin to be superior to acitretin alone (RR: 1.64 
[1.23, 2.19])(Zhang, 2012). The pooled effect for these two studies was RR: 1.77 (1.36, 
2.29), I2=0%. Group 1.3 included three studies that used acitretin plus other drugs as 
pharmacotherapy (Luo, 2010, Mao and Mao, 2007) (Wu et al.). The pool showed a 
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superior effect of the combination of CHM plus pharmacotherapy (RR: 1.40 [1.22, 1.60] 
I2=62%). Of these three studies, two found that adding CHM was more effective than the 
pharmacotherapy alone (Luo, 2010, Mao and Mao, 2007), but one study showed no 
benefit (Wu et al., 2009a). However, sensitivity analysis found the heterogeneity in this 
group was due to Luo (Luo, 2010). After Luo (2010) was removed the heterogeneity 
was reduced to 17% (RR: 1.25 [1.08, 1.46]). The overall effect for these five studies 
showed superiority for the combined groups (RR: 1.50 [1.33, 1.70]) with moderate 
heterogeneity (I2=56%) (Figure 4.5). Sensitivity analysis showed that the removal of 
Mao (2007) and Wu (2009) reduced the heterogeneity to zero (RR: 1.74 [1.44, 2.10]). 
These studies used different co-interventions in addition to acitretin: Mao (2007) used 
Diyin tablets, and Wu (2009) used topical boric acid ointment, which may have 
contributed to the heterogeneity.  
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Figure 4.5: Forest plot total effective rate (TER) on the psoriasis area and severity 
index (PASI) 60 and above  
 
Efficacy of oral CHM and guideline-recommended conventional therapy for PASI score 
The actual PASI score was reported in two of the five included acitretin studies and 
these were combined in meta-analysis (Wu et al., 2009a, Zheng, 2011). Group 2.1 used 
only acitretin as pharmacotherapy and showed superiority to the CHM plus acitretin 
group (MD: –2.45 [–3.85, –1.05]) (Zheng, 2011). Group 2.2 used acitretin combined with 
boric acid ointment as pharmacotherapy and found the combined therapy to be more 
effective in terms of PASI score (MD: –4.03 [–4.97, –3.09]) (Wu et al., 2009a). The 
pooled effect for these two studies showed CHM plus acitretin was more effective than 
acitretin alone (MD: –3.54 [–4.32, –2.76]), but the heterogeneity was high (I2=70%) 
(Figure 4.6). 
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Figure 4.6: Psoriasis area and severity index (PASI) score for guideline recommended 
therapy (acitretin) (CHM, Chinese herbal medicine; IV, inverse variance) 
 
Only single studies were available for other standard pharmacotherapies. Jin et al. 
(2009) used topical calcipotriol and showed a benefit for the combined therapy group 
based on PASI 60 (RR: 1.27 [1.01, 1.61]), but an opposite effect for PASI score (MD: 1.63 
[0.58, 2.68]) (Jin et al., 2009). Shen and Zhao (2005) used topical clobetasol propionate 
combined with oral Diyin tablets and showed benefits for the combined therapy group 
for PASI 60 (RR: 2.27 [1.38, 3.74]) and for PASI score (MD: –5.48 [–6.98, –3.98]) (Shen 
and Zhao, 2005). Recurrence of psoriasis vulgaris was reported at the three-month 
follow-up of one study as 0% in the combined therapy group versus 12.9% in the 
acitretin control (Mao and Mao, 2007), but it was not explained how the recurrence rate 
was determined.  
Third analysis: Efficacy of CHM formulation modification for psoriasis 
The third analysis consisted of all studies except Tan 2010, as it reported no data for 
participants reaching treatment goals. For analysis, studies were grouped according to 
use of modified or standardised CHM for treatment of participants. The pooled studies 
not utilising modified CHM (1.52 [1.32, 1.75] I2=51%) had slightly greater effect than 
studies pooled which did utilise modified CHM (1.46 [1.30, 1.46] I2=12%) (Figure 4.7).  
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Figure 4.7: Subgroup analysis of Chinese herbal medicine (CHM) with or without 
syndrome modification 
 
4.3.4 Safety 
One study (Wan, 2012) reported no AE during the treatment period, while five studies 
did not report information on AEs (Tian, 2011, Chen, 2010, Kong, 2007a, Yu and Pan, 
2007, Lin and Jin, 2012). The other 13 studies reported AEs including: dry mouth, skin 
dryness/scale/itchiness (Huang, 2010, Xie, 2006, Luo, 2010, Mao and Mao, 2007, Chen 
and Tan, 2004, Wu et al., 2009a, Liu, 2005a, Shen and Zhao, 2005, Yang et al., 2005), skin 
irritation (Jin et al., 2009, Tan and Li, 2010), an increase in blood cholesterol level (Luo, 
2010, Wu et al., 2009a), mild gastrointestinal reactions (Zheng, 2011) and decreased 
blood leukocyte count (Zheng, 2011). Among these 13 studies, seven studies reported 
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either that AEs only occurred in the pharmacotherapy group (Xie, 2006, Luo, 2010, 
Zheng, 2011) or the occurrence in the pharmacotherapy group was significantly higher 
than that in the CHM plus pharmacotherapy group (Chen and Tan, 2004, Wu et al., 
2009a, Liu, 2005a, Shen and Zhao, 2005, Yang et al., 2005). Five studies (Huang, 2010, 
Luo, 2010, Jin et al., 2009, Wu et al., 2009a, Tan and Li, 2010) concluded that all the AEs 
were caused by the pharmacotherapies used in the trials. No serious AE was reported in 
any study. 
4.3.5 Supplementary search safety 
Two studies did not report on adverse events (Zhu XP, 2012, Zhu et al., 2012) yet Zhu 
2012 still concluded that adding CHM to MTX treatment reduces the adverse events of 
MTX.  Only Jiang 2012 reported no adverse events were experienced in either the 
intervention or control arms. Zhai 2012 reported no AEs in the intervention group 
however dry skin (n=34) and increased in cholesterol (n=4) were reported in the 
control arm. Xie 2012 reported the same symptoms in their control and intervention 
groups however described all events as mild. Dry skin and itch was reported in both 
control and intervention arms of the remaining studies (Han and Yu, 2012, Huang, 2012, 
Liu et al., 2012a). Two studies concluded adverse events were caused by the 
conventional therapy (Huang, 2012, Ma SY, 2012) whilst four studies concluded CHM 
reduced the adverse events of conventional therapy (Han and Yu, 2012, Liu et al., 2012a, 
Zhai XF, 2012, Zhu XP, 2012). Two studies concluded safety of both CHM and 
conventional therapy for psoriasis vulgaris (Jiang et al., 2012a, Xie, 2012) (Table 4.8). 
 
 
 177 
Table 4.8: Adverse events of included RCTs (oral CHM plus pharmacotherapy vs. pharmacotherapy for psoriasis vulgaris) 
Study Adverse Events Authors’ conclusion 
Han, 2012 
I: dry skin (47), skin itch (5), high ALT (10), high cholesterol (10) 
C: dry skin (60), dry mouth and lips (42), red skin and itch (9), high GPT (11), 
high cholesterol (12) 
Adding CHM could reduce the AEs caused by 
acitretin 
Huang, 
2012 
I: dry skin (2), itch (2), red skin (1), burning sensation (1) 
C: dry skin (2), itch (1), red skin (1), burning sensation (1) 
Mild AEs were caused by the pharmacotherapy 
drugs 
Jiang, 2012 None reported Both treatments safe for psoriasis vulgaris 
Liu, 2012 
I: dry skin (18), dry mouth (5), skin itch (7) 
C: dry skin (32), dry mouth (34), skin itch (32), high cholesterol (2) 
Adding CHM could reduce the AEs caused by 
acitretin 
Ma 2012 
Both groups reported AEs including dry mouth and lips, dry eyes, dry skin, scaly 
skin, 
The AEs were caused by acitretin 
Xie, 2012 
I: dry skin and lips, high cholesterol, all AEs are mild 
C: dry skin and lips, high cholesterol, all AEs are mild 
Both treatments are safe for psoriasis vulgaris 
Zhai 2012 
I: no AEs 
C: dry skin and lips (34), high cholesterol (4) 
Adding CHM could reduce the AEs caused by 
acitretin 
Zhu, 2012 Not reported 
Adding CHM could reduce the AEs caused by 
Methotrexate 
Zhu XP, 
2012 
Not reported NS 
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AE, adverse event; ALT, Alanine aminotransferase; CHM, Chinese herbal medicine; GPT, glutamate pyruvate transaminase; NS, Not 
stated
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4.4 Discussion 
4.4.1 Methodological quality of included studies 
The risk of bias assessments identified deficiencies in sequence generation and 
allocation concealment, and there was no blinding in any of the studies, which may have 
impacted on the results. In one study of oral CHM plus calcipotriol, there was 
contradiction between the result for TER and that for PASI score. The TER showed a 
benefit for the combination group at weeks 8 and 12 of treatment, while the mean PASI 
score showed the opposite result at the same time points, but no explanation was 
provided (Jin et al., 2009). Of the five studies that provided PASI scores, four showed a 
benefit for the combination therapy group (Tian, 2011, Wu et al., 2009a, Zhang, 2012, 
Yang et al., 2005) while one showed a benefit for the control (Jin et al., 2009). One 
reason for the difference between the reported results and those found in this meta-
analysis is likely the adoption of an ITT approach, and another is the statistical analysis 
approach. Using risk ratio, a criterion of 60% improvement or higher removed any 
small improvement events. Considering the diversity of pharmacotherapies used in the 
studies and the differences in outcome measures, results from the first meta-analysis 
(Figures 4.2, 4.3 and 4.4), as well as the pooled data for modification of CHM (Figure 
4.7), should be considered with caution. 
Although some studies used the PASI as an outcome (Jin et al., 2009, Tian, 2011, 
Wu et al., 2009a, Yang et al., 2005, Zheng, 2011), none reported PASI 75, making it 
difficult to directly compare results with international studies of conventional 
treatments, where guidelines recommend PASI 75 a primary outcome measure (Castela 
et al., 2012, The Australian Government, 2004).  
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Only one study mentioned a QoL assessment, but no group data were provided 
(Yu and Pan, 2007). Participant flow diagrams were not provided by any study, none of 
the studies covered all items listed in the CONSORT statement (Moher D, 2001) and ITT 
was not employed in data analysis. These aspects compromise the reliability of the 
results and future trials need to address these issues. Further, a number of studies failed 
to report effect sizes or supplied effect sizes on outcomes that are not typically 
recommended, hence were unable to be pooled. Future studies should employ and 
report common outcome measures as recommended by international guidelines. 
4.4.2 Safety of oral CHM combined with pharmacotherapy 
All of the mild AEs were reported as probably due to the pharmacotherapies, but there 
were no clear justifications for these judgments. Five studies concluded that there were 
significantly fewer AEs in the CHM plus pharmacotherapy groups than in the 
pharmacotherapy groups (Chen and Tan, 2004, Wu et al., 2009a, Liu, 2005a, Shen and 
Zhao, 2005, Yang et al., 2005), suggesting that adding oral CHM may have reduced the 
occurrence of AEs from the pharmacotherapy, such as skin dryness, skin itchiness, and 
dry mouth and lips with Diyin tablets (Chen and Tan, 2004, Liu, 2005a, Shen and Zhao, 
2005, Zhang, 2012) and dry or scaly skin with acitretin (Wu et al., 2009a). It is unclear, 
though, why Diyin tablets had such effects and further study is needed to evaluate 
possible biological mechanisms. 
The approaches used for collecting AE data were not clearly described, and the 
lack of blinding increased the risk of bias in AE data reporting and collection. No serious 
AE was reported, but only 13 studies reported on AEs, and only four studies monitored 
liver and kidney function. Among the five studies included in the meta-analysis of 
acitretin, Zhang did not report on AEs (Zhang, 2012) while the other four reported only 
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mild AEs, as did Xie (Xie, 2006). Two of these studies monitored liver and kidney 
function. Therefore, combination of CHM with acitretin did not appear to result in 
additional AEs, at least with short-term use. 
4.4.3 Efficacy of oral CHM combined with pharmacotherapy for psoriasis vulgaris 
Although all studies in this review concluded that combinations of oral CHM and 
pharmacotherapy were superior to pharmacotherapy alone, at end of the treatment 
phase this was not necessarily confirmed by the effect size analyses. Six studies did not 
provide data suitable for the calculation of the effect size (Huang, 2010, Wan, 2012, 
Chen, 2010, Kong, 2007a, Tan and Li, 2010, Yu and Pan, 2007). Of the remaining 13 
studies, nine showed significant differences in TER in favour of the combined therapy 
groups (Luo, 2010) (Jin et al., 2009, Tan and Li, 2010, Wu et al., 2009a, Zheng, 2011, Liu, 
2005a, Zhang, 2012) (Lin and Jin, 2012) (Yang et al., 2005) and four showed no 
difference (Xie, 2006, Mao and Mao, 2007, Chen and Tan, 2004, Shen and Zhao, 2005). 
The present systematic review indicates greater effect of combined therapy, although 
the true effect size is difficult to predict considering the variation in design between the 
studies.  
For the second meta-analysis, results are likely to be more reliable due to pooling 
of similar studies, where only five of the studies that used oral acitretin as a comparator 
were included. Four of these studies found combination of CHM and acitretin was more 
effective than acitretin alone, but this was only at the end of the treatment period. Only 
three studies provided recurrence rates, one at 3 months (Mao and Mao, 2007), one at 6 
months (Wan, 2012) and the other at 12 months (Lin and Jin, 2012). These favoured 
combined treatment, but there was no definition of how recurrence was determined. 
Consequently, although results indicate that combined therapy provides longer-term 
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benefit than conventional therapy alone, the review cannot provide recommendation on 
how long positive effects may last nor the size of such effects. More studies need to 
report follow-up and use a recognised method to evaluate relapse rate (Pathirana et al., 
2009). 
For previous studies of conventional topical therapy, between 7% and 85% of 
people in the studies achieve PASI 75 (Castela et al., 2012). From results of the current 
review it seems such treatment effect is enhanced when combined with oral CHM. Use 
of oral CHM would likely see a greater percentage of people achieve PASI 60 and PASI 
70 than with conventional therapy alone. More research is needed to evaluate the 
specific effect of oral CHM when it is combined with conventional therapy. 
4.4.4 Potential therapeutic actions of CHM for psoriasis vulgaris 
Although different herbal formulas were used in the studies, certain plants appeared in 
multiple formulas. The herbs used in the nineteen studies included in this review are 
listed in Table 4.2. In these studies, three constituents appear repeatedly: R. glutinosa 
root (di huang) (n=16), S. miltiorrhiza root (dan shen) (n=10) and L. erythrorhizon root 
(zi cao) (n=10). Each of these plants has received recent research attention for activities 
of relevance to psoriasis therapy. 
Rehmannia glutinosa root 
See 3.4.4 Rehmannia glutinosa. 
Salvia miltiorrhiza root 
See 3.4.4 Salvia miltiorrhiza. 
Lithospermum erythrorhizon root 
Shikonin, a bioactive in L. erythrorhizon root, has shown an inhibitory effect on 
angiogenesis (Hisa et al., 1998) and has been investigated for its anti-proliferative 
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effects on a number of cell lines, including liver cancer HepG2 cells (Yingkun et al., 2010) 
and lung cancer A549 cells (Wang et al., 2013). An in vitro study reported inhibitory 
effects of L. erythrorhizon extracts on lipopolysaccharide-stimulated production of 
inflammatory cytokines (Han et al., 2008). In rats, L. erythrorhizon extract inhibited 
release of histamine induced by compound 48/80 and inhibited activation of nuclear 
factor-kappa B and I kappa B-alpha degradation (Kim et al., 2007). In an atopic 
dermatitis model in mice, oral L. erythrorhizon extract reduced scratching behaviour, 
serum IgE, and epidermal hyperproliferation (Kim et al., 2009a). These experiments on 
cell lines or animal models suggest these plants could have anti-inflammatory and/or 
anti-proliferative effects in humans. 
4.6 Conclusion  
This systematic review evaluated administration of oral CHM combined with 
conventional therapy, 19 eligible RCTs had meta-analyses conducted and a further nine 
identified in a follow up search are reported on. There is considerable diversity in both 
the herbal medicines and conventional therapies used. Generally, meta-analysis showed 
combined therapy had a greater effect on psoriasis. When meta-analysis was restricted 
to studies using well-known pharmacotherapy as control interventions with 60% or 
greater clinical improvement in psoriasis as the outcome seven studies remained: five 
that used oral acitretin, one that used topical calcipotriol, and one used topical 
clobetasol propionate. 
At end of treatment, for the pooled result of the five studies the combination of 
CHM plus acitretin provided more benefit than acitretin alone and there were no 
serious AEs reported. Adequate blinding was not implemented in any of the studies so 
results of the meta-analysis must be evaluated with caution. While published data 
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indicate combined treatment may reduce long-term risk of relapse, the number of 
studies reporting follow-up was inadequate and methods for calculating relapse were 
unclear. Thus, no sound conclusions can be made on the long-term benefits or safety of 
combined therapy. 
Research and clinical implications 
In westernised countries, treatment guidelines may recommend combination therapy 
for psoriasis; however, typically this only encompasses conventional therapies such as 
topical corticosteroids or systemic treatments combined with UVB therapy (Armstrong 
et al., 2014). In China, physicians prescribe therapy from CHM and conventional 
medicine, where decisions aim to optimise benefits and reduce drawbacks of both 
treatment types to enhance outcomes for patients (Xu and Chen, 2008). Potential 
advantages of such combined treatment include enhanced efficacy and minimising side 
effects from treatment, which may lead to quicker and safer outcomes for patients. It 
could also see reduction in the cost of conventional treatments, if cheaper conventional 
therapies can be enhanced by addition of CHM. 
From review it appears integrating conventional treatment with CHM treatment 
does in fact enhance treatment effect, with reductions in PASI severity and increased 
elimination of lesions. Given this is yet to be recommended in treatment guidelines and 
is thus likely underutilised, some psoriasis patients may be missing out on an optimised 
approach to treatment.  
It has been suggested that a two-phase combined therapy aimed at suppressing 
both innate and adaptive immune responses would be helpful for treatment of 
inhomogeneous psoriatic plaques, and integrative therapy such as addition of CHM may 
provide such a biological action (Albanesi, 2014). More research, though, is needed into 
 185 
the biological aspects of combined CHM and conventional therapy to ensure it is indeed 
safe for long-term use and to evaluate biologically how the increased effect may occur.  
Both first and second line conventional therapies were utilised alongside CHM, 
with acitretin most common. While there was clearly benefit of combining CHM with 
acitretin, cost to government can be high for long term treatment (Australian 
Government - Department of Health, 2014). Calcipotriol is another first line 
conventional therapy however it is considerably cheaper than acitretin.  Combining it 
with CHM may have increased efficacy in moderate to severe case than first line 
therapies on their own, warranting further research. 
The most common outcome measure provided in the included studies was TER 
based on PASI, and in order to continue to pool future clinical study results with 
previous results clinical trials should also utilise PASI as the primary outcome measure.  
Only a few of the reviewed RCTs included follow-up data, so in order to evaluate 
long-term benefits of combined therapy, such as any reduction on relapse rate, clinical 
studies should include sufficient follow-up data collection periods. Follow-up data may 
also identify any long-term cost benefits of combined therapy, such as reduced health 
resource utilisation, when compared with conventional therapy alone. Clinical study 
should include health resource utilisation to assist health bodies assess the cost benefit 
of combined therapy. 
This systematic review does indicate merit in further investigation of CHM 
combined with conventional therapy for psoriasis. Due to the large variation of CHM 
utilised in the studies, it is unclear which CHM ingredients deserve further investigation. 
Although some ingredients were more frequently used than others, perhaps indicating 
which should be further explored for psoriasis, review results were not sufficient to 
evaluate which CHM were most effective. As such, the systematic review could not 
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clearly establish which CHM should be utilised for the proposed psoriasis vulgaris 
clinical study and further investigation was needed. 
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Chapter 5 – Determining a Chinese herbal formula for further 
psoriasis investigation  
This chapter explains how the clinical trial oral CHM formulation was determined. An 
overview of Chinese medicine syndrome differentiation is presented along with details 
of how therapeutic guidelines; literature review, phytochemical activity and expert 
opinion were incorporated into early development of a concept formulation and guided 
selection of the final formulation. The ingredients of subsequent formulations are 
investigated for relevant Chinese medicine and potential psoriatic biological actions. 
5.1 Background 
Following comprehensive reviews of the relevant literature (see chapters 2, 3 and 4) it 
was concluded that psoriasis vulgaris is the most prevalent phenotype and current 
available conventional therapies may inadequately treat cases that are mild to moderate 
in severity. Typically, conventional treatment guidelines recommend topical creams 
such as corticosteroids for mild to moderate psoriasis (Menter et al., 2009). Previous 
systematic reviews have demonstrated positive therapeutic effects of some topical 
botanicals for psoriasis when compared with placebo, although the quality of the 
evidence supporting it is low (Deng et al., 2013). Review evidence suggests that 
combining therapies, such as topical and oral, may improve treatment outcomes while 
minimising risk of side effects. While various topicals therapies such as creams, 
ointments or gels have been evidenced to be efficacious and their side effects tolerable, 
it has been identified that adherence is often low (Bewley and Page, 2011). Given mild 
efficacy and adherence issues of topical interventions it was determined that 
development of a topical CHM intervention was not ideal.  
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As discussed previously (see 2.7.1 Background of therapeutic guideline treatment 
recommendations), oral systemics and stronger therapies such as biologics are 
recommended only in severe or unresponsive mild–moderate cases of psoriasis due to 
potential side effect and high costs. This identifies a gap in treatment options for people 
with mild–moderate cases, in which, alone, conventional topical therapy is not effective. 
It was recognised that development of an effective oral CHM therapy with low risk of 
side effects may fill such a treatment gap and enhance outcomes for people using 
conventional topicals. From review, oral CHM was shown to be effective for psoriasis 
compared with placebo, and when combined with conventional therapy might further 
enhance effects (see Chapter 4).  
It was concluded that further rigorous clinical controlled study of oral CHM 
combined with topical conventional therapy should be undertaken. The two systematic 
reviews (see Chapter 3 and Chapter 4) identified numerous CHM formulations that have 
been investigated clinically for psoriasis, yet no optimum CHM formulation has been 
recognised. In order to develop an evidence-based CHM oral formulation to be further 
investigated through clinical trial, both Chinese medicine theory such as syndrome 
differentiation and scientific evidence such as biological activity were considered. The 
subsequently developed formulation was then further refined following discussion with 
Chinese medicine dermatology experts. This chapter discusses how the oral CHM 
investigative intervention (PSORI-CM01) was formulated and developed, its ingredients 
and the manufacturing processes required for its production. 
5.2 Overview of Chinese herbal formula development for psoriasis vulgaris  
To assist in the development of an oral CHM formulation a comprehensive review was 
undertaken of published clinical evidence, treatment guidelines and major Chinese 
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medicine textbooks. Treatment guidelines, where available, were first reviewed to 
follow best practice approach to formula development. From these guidelines Chinese 
medicine syndrome types were reviewed as well as the symptomology used to 
differentiate each syndrome type and the recommended formulations. This became the 
starting point for the developed formulation. From available published literature 
reviews and the literature reviews conducted in previous chapters, oral CHM use was 
recorded and their frequency of use analysed to identify potential further key CHM that 
should be considered in the final formulation. To reduce the number of herbs in the 
formulation and ensure the CHM also had biological significance for their inclusion, key 
phytochemical mechanistic pathways for psoriasis were also reviewed for short-listed 
ingredients. 
Following these steps, the initial formulation was reviewed by CHM and psoriasis 
experts to further refine the formulation ingredients. Following expert review, a second 
formulation (PSORI-CM01) was proposed as the intervention to be used in the clinical 
trial. PSORI-CM01 was then further investigated to explore the scientific evidence of the 
constituents based on their possible biological anti-psoriatic activity. The resulting 
formulation, PSORI-CM01, was intended to target mild–moderate psoriasis vulgaris, yet 
be safe and efficacious for people of all Chinese medicine psoriatic ‘syndrome’ types. 
This section describes the process of determining the oral CHM ingredients utilised in 
the clinical trial. 
5.3 Methods 
Development of an optimised CHM formulation for further investigation requires 
understanding the Chinese medicine principals for selection of herbs and the potential 
biological activity of constituents in the herbs. This section details the methods 
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employed to determine ingredients of the investigative CHM formulation.  First Chinese 
medicine syndromes of psoriasis were reviewed, and then available treatment 
guidelines for Chinese medicine were investigated. These guidelines further assisted 
determine the major psoriasis syndrome types and their accompanying symptoms. 
Chinese herbal medicine data from literature reviews of oral CHM for psoriasis (Chapter 
3 and 4) was then considered to identify the most suitable CHM candidates for the 
formulation. Psoriatic like phytochemical activities of chief CHM constituents were then 
reviewed. Lastly the resulting CHM formulation was presented to dermatological and 
CHM experts for further optimization.  
5.3.1 What is Chinese medicine syndrome differentiation? 
While conventional medicine prescribes treatments according to disease (e.g. 
antibiotics for a bacterial infection) or its symptoms (e.g. paracetamol for pain), Chinese 
medicine goes further and differentiates a disease according to its specific Chinese 
medicine pattern or ‘syndrome’ (Mei, 2011). Syndrome differentiation is fundamental to 
Chinese medicine philosophy, ensuring each patient is diagnosed and treated according 
to their syndrome type irrespective of the conventional medical or disease diagnosis. 
Subsequently, conventionally diagnosed diseases are typically identically treated 
according to relevant condition treatment guidelines; however, in Chinese medicine two 
people with identical conventional diagnoses may receive very different treatment 
prescriptions. Syndrome differentiation is determined by the patient’s medical history, 
symptomology, physical appearance, left and right radial pulses and tongue appearance 
(Lu and Chen, 2011). These observations are evaluated using Chinese medicine theory, 
and then treatment is tailored and prescribed for each individual based on the 
syndrome findings.  
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Using such an individualised method to discern treatment ensures prescribed 
treatment targets the most current disease presentation and ensures specificity to the 
patient’s condition with appropriate and safe dosage. Such methods enhance treatment 
effect and reduce risk of side effects. When Chinese medicine syndrome is not 
considered and Chinese medicine prescription is administered solely based on disease 
type, effects may be reduced and risk of adverse events increased.  
Syndrome differentiation by clinicians is largely subjective and although efforts 
have been made to standardise Chinese medicine theory surrounding its use, variation 
remains (Schnyer et al., 2005). In 2007, the WHO standardised some of the terminology 
used in Chinese medicine, which has assisted development of Chinese medicine clinical 
guidelines for many conditions (World Health Organisation (WHO) Regional Office for 
the Western Pacific, 2007) In fact, clinical practice guidelines now exist for common 
diseases accompanied by standardised Chinese medicine syndrome and appropriate 
treatment recommendations (China Academy of Chinese Medicine, 2011) (Shin et al., 
2013).  
Based on objective symptoms as well as a person’s specific responses to set 
questions and/or evaluation of key pulse and tongue features, research tools have been 
developed to clinically assist determination of patient syndrome type (Chen et al., 2012) 
(Schnyer et al., 2005). Such tools provide a more systematic approach to syndrome 
differentiation, by reducing inter-rater variation in research studies and enhancing the 
validity of Chinese medicine clinical trial results (O'Brien et al., 2009). Such 
standardisation has seen further development of guidelines for Chinese medicine and 
related syndromes by the State Administration of Traditional Chinese Medicine, with 
further work underway by the International Organization for Standardization Technical 
Committee (ISO TC/249) to further standardise aspects of Chinese medicine 
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(International Organization for Standardization Technical Committee - 249 Secretariat, 
2014, China Academy of Chinese Medicine, 2011). 
Despite the development of some standardised research tools, there is currently 
no guide for how researchers should incorporate syndrome differentiation into clinical 
trials; however, the use of syndrome differentiation in clinical trials of Chinese medicine 
is still advocated by the Medical Research Council, the National Institute of Health and 
the WHO (O'Brien et al., 2009) (Yan et al., 2009).  
It has been recognised that syndrome differentiation can be utilised at numerous 
time points and potentially on multiple occasions throughout a study (Li et al., 2013). 
For instance, as an inclusion criterion, syndrome differentiation may ensure an 
intervention is appropriate for the sample (Jiang et al., 2012a). When used for 
diagnostic or treatment purposes, the intervention may be tailored for the individual 
according to their syndrome type (Smith et al., 2012). In other instances, syndrome type 
may be ascertained to add further context to results and further statistical analysis may 
be performed on the data, such as evaluating treatment response between syndrome 
types (Hsu et al., 2003). Lu et al (Lu et al., 2009, Lu and Chen, 2011) suggest that 
Chinese medicine syndrome may also have relevance to conventional drug treatment 
response, where it may help determine whether a person is likely to respond to drug 
treatment or not. It has been evidenced that people with similar psoriasis symptoms but 
different Chinese medicine syndrome type may have different concentrations and 
activation of key inflammatory cell components, which impact on their condition (Li et 
al., 1997). 
Despite being an important factor for Chinese medicine disease treatment, 
syndrome differentiation is often overlooked in clinical trial design. In a study 
examining characteristics of Chinese medicine RCTs from 15 international trial 
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registries, Liu et al report for CHM that only 22.4% (65 of 290 studies) included 
syndrome differentiation in trial design, with syndrome differentiation more commonly 
used for recruitment than for treatment (54 trials (18.6%) compared with 11 trials 
(3.8%)) (Liu et al., 2013). 
Fortunately, syndrome reporting in research is improving, which will help future 
researchers improve their study design and develop interventions. Increased syndrome 
reporting would also give experts the opportunity to better evaluate clinical significance 
and implications of trial results. When syndrome differentiation is not stated in trials, 
the validity and conclusions that can be drawn from results are limited. A targeted 
formulation based on syndrome differentiation, for instance, may provide greater 
efficacy than a formulation specific for the disease but not considering syndrome type 
(Bensoussan et al., 1998). Indeed, meta-analysis of RCTs has found syndrome 
differentiation can improve the effect of treatments, although the true effects of utilising 
syndrome differentiation are still unclear (Kou and Chen, 2012) (Yan et al., 2009). 
Despite support for inclusion of syndrome differentiation in CHM clinical studies, a 
systematic review of acupuncture RCTs concluded that syndrome differentiation does 
not influence efficacy (Cao et al., 2012). To date, no such systematic review has 
investigated the influence of syndrome differentiation on the efficacy of CHM in RCTs. 
As part of this thesis I attempted to determine whether the utilisation of syndrome 
differentiation could increase the efficacy of CHM by systematically reviewing CHM 
RCTs similar to the approach by Cao et al (Cao et al., 2012). Unfortunately, due to 
inconsistent and unclear reporting of syndrome differentiation use in publications, the 
screening and data extraction process required significant inferences to be made by the 
reviewers. For instance, commonly studies did not stipulate whether syndrome was 
differentiated, thus it was decided to include such studies if modification of the 
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formulation was made based on the symptoms of subjects. Such reviewer assumptions 
significantly reduce the accuracy of the data and the review was discontinued. For such 
a review to be conducted in the future, studies need to report clearly on: whether or not 
they utilised syndrome differentiation; the theory or evidence that supports their 
syndrome classifications; what relationship syndrome had with the intervention (e.g. 
syndrome type resulted in, increasing or reducing dosage or frequency, adding or 
subtracting ingredients); how syndrome classification was determined (e.g. symptoms, 
severity); and at what stages of the study syndrome was differentiated (e.g. recruitment 
of subjects, allocation to intervention, grouping of data for analysis).  
The addition of such syndrome or pattern differentiation parameters to the 
CONSORT extension for reporting herbal medicines and journal publication 
requirements would ensure more research studies reported it (Gagnier et al., 2006b). 
Such reporting would allow future meta-analysis of CHM studies based on syndrome 
type and assist evaluation of any benefits of syndrome utilisation in clinical studies. The 
development of pre-defined diagnostic tools such as the TEAMSI-TCM would reduce 
inter-rater variation and increase reliability of results (Grant et al., 2013). Research is 
also needed on the effects of syndrome utilisation on the severity and frequency of 
adverse events in clinical trials. 
5.3.2 What are the known Chinese medicine syndromes for psoriasis? 
Given specifying treatment based on syndrome type may enhance outcomes, it was 
considered important to identify the syndrome types associated with psoriasis. As 
discussed in Chapter 1, there are many phenotypes of psoriasis, each with different 
appearance and symptoms. First described over 1600 years ago, Chinese medicine 
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classification of syndrome types for psoriasis varies, which has resulted in some 
conjecture as to how many syndrome types exist (Iliev and Broshtilova, 2003). 
As the intervention being developed for the present study was being investigated in 
vulgaris type psoriasis only, only syndrome types relevant for this phenotype were 
considered. Chinese medicine guidelines for psoriasis (Lu et al., 2012b) recommend 
treatment based on three primary syndrome types, blood stagnation, blood heat and 
blood dryness, of which blood stagnation is reported as the most prevalent type in 
China (52.8%) (Zhang et al., 2009a, Zhang and Qu, 2002, China Academy of Chinese 
Medicine, 2011, He et al., 2011). 
5.3.3 Reviewing treatment guidelines for psoriasis 
Health care physicians rely on published treatment guidelines to inform them of best 
practice and guide their prescriptions. In Australia, conventional psoriasis treatment 
recommendations are published in the dermatology therapeutic guidelines 
(Dermatology Expert Group, 2004). These guidelines are supported by the Australian 
Therapeutic Goods Administration, which regulates pharmaceutical dose prescriptions 
and Medicare, which further guide dosage and authorise pharmaceuticals to be 
subsidised and administered under the Pharmaceutical Benefits Scheme (Australian 
Government - Department of Health and Ageing, 2012). Such guidelines do not inform 
Chinese medicine practitioners on CHM treatment nor are Australian Chinese medicine 
therapeutic guidelines available; instead, Chinese guidelines were reviewed for 
psoriasis treatment for the current study (China Academy of Chinese Medicine, 2011).  
The Chinese guidelines were reviewed and summarised according to the following 
classifications: Chinese medicine syndrome type, the syndromes clinical manifestations, 
accompanying  symptoms, the person’s tongue appearance and their pulse 
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characteristics associated with each syndrome type (China Academy of Chinese 
Medicine, 2011). From these data (Table 5.1), a universal herbal formula was developed 
suitable for all relevant syndrome types (1. wind heat and blood dryness, 2. Blood 
deficiency and wind dryness, 3. Blood stasis). As the prevalence of each syndrome type 
in the Australian population is unknown the formulation needed to be suitable for all 
types. Future epidemiological studies of the Australian population might consider 
exploring the prevalence of syndrome types and evaluating any difference from the 
Chinese population. Such investigation was outside the scope of this project so, instead, 
the assumption was made that syndrome types of Australians are similar to the Chinese 
population. To enhance the likelihood of reaching recruitment targets it was decided 
that syndrome type would not be utilised as an inclusion criteria. Therefore, the 
formulation was developed to be applicable to all syndrome types. 
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Table 5.1: Guidelines on syndrome differentiation for psoriasis (China Academy 
of Chinese Medicine, 2011) 
Syndrome Clinical manifestation 
Accompanying 
symptoms 
Tongue 
appearance 
Pulse on 
palpation 
Wind heat 
and blood 
dryness 
New bright red papules 
or maculopapules of 
varying sizes develop 
continuously, auspitz’s 
sign when the scale is 
removed, Koebner’s 
phenomenon happens 
occasionally. 
Itching, anxiety, 
dry mouth, 
constipation, 
yellow urine 
Red tongue 
with yellow 
or greasy 
coating 
Slippery, 
string taut 
or rapid 
Blood 
deficiency 
and wind 
dryness 
 
Long-term disease, 
lesions manifest as light 
red and patchy, covered 
with plenty of dry 
silvery white scales. 
Parts of lesions have 
disappeared. Dry and 
chapped skin with itch 
or pain. 
Dry mouth, 
constipation 
Red tongue 
body with 
thin white 
coating 
Wiry and 
slow 
Blood stasis The disease duration is 
long and at stable stage. 
Dull red, hard and thick 
plaques are covered by 
thick, dry, silvery-white 
scales, with itch. 
No obvious 
general 
symptoms 
Dark purple 
or red tongue 
body with 
petechial 
spots. 
Pulse is 
uneven, or 
wiry and 
slow 
 
5.3.4 Reviewing published literature of oral CHM for psoriasis 
For the current study, evidence of oral CHM for psoriasis from published studies 
(English only) was also considered for development of the formulation. Oral CHM 
formulations were recorded from publications found during the previous systematic 
reviews (see chapters 3 and 4), including controlled studies, reviews, clinical case 
studies, expert commentaries and in vitro or in vivo experiments. The variety and 
frequency of CHM utilised were then explored as well as any supporting evidence for 
their use by the authors. While not being an exhaustive collection of CHM psoriasis-
related publications, 116 different psoriasis-related CHM ingredients were identified 
(Appendix 3). Chinese herbal medicine ingredients most frequently used for psoriasis 
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and those indicated to most strongly influence psoriasis were then considered for 
inclusion in the formulation for the present investigation. 
5.3.5 Reviewing phytochemical activity of oral CHM for psoriasis 
Although meta-analysis and systematic review have previously identified CHM efficacy 
in clinical trials and identified those CHM most commonly used in research, there is as 
yet no comprehensive evaluation of their individual or combined efficacy (Tse, 2003). 
The short-listed CHM ingredients were further evaluated for key phytochemicals with 
potential anti-psoriatic activity to ensure they had biological significance for psoriasis, 
not just a Chinese medicine basis for their use. PubMed was searched for articles 
detailing the constituent compounds of each CHM and PubChem was further searched 
to evaluate the biological activity of these phytochemicals (Table 5.2). 
5.3.6 Expert opinion and consultation for formulation of oral CHM for psoriasis  
Candidate CHM ingredients for psoriasis were then reviewed by a team of Chinese 
medicine and psoriasis specialists. The specialists evaluated the collected data, giving 
consideration to currently available evidence and recommendations of Chinese 
psoriasis treatment guidelines. Following discussion with specialists, CHM ingredients 
found to be less suitable for the target population (mild–moderate psoriasis vulgaris 
and all three syndrome types) were eliminated. The remaining ingredients constituted 
the final proposed formulation (Table 5.3), and the specialists made recommendations 
on the dosage for each. 
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5.4 Results 
5.4.1 First oral CHM formulation: Primarily developed from Chinese guidelines 
A previously published review identified 174 different herbs that had been used in 
research for psoriasis (Tse, 2003, Tan et al., 2011). As blood stagnation is recognised as 
the most prevalent syndrome type, the first proposed formulation was developed based 
on the formula Xue Fu Zhu Yu Tang (China Academy of Chinese Medicine, 2011). 
Consisting of dang gui (angelica sinensis), di huang (rehmannia glutinosa), tao ren 
(prunus persica), hong hua (carthamus tinctorius), chi shao (paeonia veitchii), chai hu 
(radix bupleuri), gan cao (radix glycyrrhizae), niu xi (achyranthis bidentatae radix), jie 
geng (platycodon grandiflorum), zhi ke (fructus aurantii) and chuan xiong (ligusticum 
chuanxiong). Each of the formulations ingredients has Chinese medicine functions, 
which improve the syndrome of blood stagnation, as well as some evidence of anti-
psoriatic biological activity (Table 5.2). Each herb’s Chinese medicine functions and 
relevant anti-psoriatic biological activity is briefly discussed: 
Angelica sinensis (dang gui) 
Chinese medicine actions and potential psoriasis biological mechanisms are discussed 
in 3.4.4 
Rehmannia glutinosa (di huang) 
Chinese medicine actions and potential psoriasis biological mechanisms are discussed 
in 3.4.4 
Prunus persica (tao ren) 
Prunus persica (tao ren) has Chinese medicine function of moving and breaking up 
blood stasis. Biological mechanism shows it to prolong thrombin time and inhibits 
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platelet aggregation, which is important for clotting of blood (Yang et al., 2011). Such 
action may reduce Auspitz's sign (pinpoint bleeding) a key feature of psoriasis plaques. 
Carthamus tinctorius (hong hua) 
Carthamus tinctorius (hong hua) has Chinese medicine functions of moving and 
breaking up blood stasis as well as relieving pain. It’s ability to inhibit a number of 
different cytokines, including anti-psoriasis key inflammatory target TNF-, as well as 
reduce growth and proliferation of epidermal cells support its biological pathway 
activity in psoriasis (Zhang and Qu, 2002, Tse, 2003). 
Paeonia veitchii (chi shao) 
Chinese medicine actions and potential psoriasis biological mechanisms are discussed 
in Chapter 6 
Radix bupleuri (chai hu) 
Radix bupleuri (chai hu) has Chinese medicine functions to move and regulate qi 
stagnation whilst also raising qi. Biological activity as shown it to have anti-
inflammatory action as well as effects on the immunological lymphocyte response in 
mice, which both have applicability to psoriasis development and progression(Ushio et 
al., 1991, Jiang et al., 2012b). 
Radix glycyrrhizae (gan cao) 
Radix glycyrrhizae (gan cao) is primarily added to Chinese herbal formulations to 
harmonize other herbal ingredients. This reduces the experience of adverse events from 
other herbal ingredients. It also has function to clear fire and tonify spleen and stomach. 
Biological evidence has shown it to suppress some immune activity whilst enhancing 
other activity (Bartosińska et al., 2011). Histamine release inhibition has been reported 
in rats where its action has been likened to that of a corticosteroid (World Health 
Organization, 2010). 
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Achyranthis bidentatae radix (niu xi) 
Achyranthis bidentatae radix (niu xi) is another herb with Chinese medicine function of 
moving and breaking up blood stagnation. Scientific study has shown it enhances 
chondrocyte proliferation through promotion of cell division during cell replication (Yu 
et al., 2013a). Interestingly this evidence of cartilage support is reflected in another 
Chinese medicine function it has, to strengthen sinews and bones. However how this 
might relate to psoriasis is not known. 
Platycodon grandiflorum (jie geng) 
Platycodon grandiflorum (jie geng) has Chinese medicine functions of moving, 
regulating and raising qi. It is another herb which has shown evidence it has anti-
inflammatory activity which may indicate its potential benefit for psoriasis (World 
Health Organization, 1999). 
Fructus aurantii (zhi ke) 
Fructus aurantii (zhi ke) is indicated for Chinese medicine conditions requiring 
movement and raising of qi. Biologically it has been indicated to have both antibacterial 
and anti-inflammatory activity, which may indicate it for both preventing flare-ups of 
psoriasis and controlling its symptoms (Zhou et al., 2011). 
Ligusticum chuanxiong (chuan xiong) 
Ligusticum chuanxiong (chuan xiong) has unique Chinese medicine functions to move 
both blood and qi whilst also expelling wind. The wind component is commonly 
experienced as itch in Chinese medicine, a symptom which can often aggravate psoriasis 
sufferers (Zhang and Qu, 2002). Scientific research has shown ligusticum chuanxiong 
inhibits the growth and proliferation of epidermal cells, which is one of the most 
characteristic histological features of psoriasis contributing to its macroscopic 
appearance see chapter 2.2. 
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Expert opinion further theorised the other two syndrome types (blood heat and 
blood dryness) have underlying blood stagnation as their ‘root’, thus these syndrome 
types were likely to be treated effectively with a modified version of the same formula. 
Chinese guidelines acknowledge people may have a more complex condition consisting 
of multiple syndrome types (e.g. blood heat and blood stagnation, or blood dryness and 
blood stagnation), thus they recommend formulation modification (inclusion or 
exclusion of ingredients) based on the symptoms of the sufferer. Following review of 
the literature, it was determined the addition of dan shen, ku shen and huang qi were the 
optimum additions to the Xue Fu Zhu Yu Tang formula.  
Salvia miltiorrhizae Radix (dan shen)  
Salvia miltiorrhizae Radix (dan shen) is indicated in the guidelines as treatment for 
blood heat type psoriasis through inclusion in the Ke Yin formula 2. Its primary Chinese 
medicine theory related functions for psoriasis are to activate blood circulation 
(enhancing the actions of the other herbs in the formulation), cool blood and reduce 
swelling of sores (e.g. psoriasis lesions) (Chen and Chen, 2004). It is has also shown 
anti-hypertensive, antimicrobial, antipyretic, anti-inflammatory and hepato-protective 
effects. In addition, it may play a role in the treatment of psoriasis through its 
suppression of IFN-c and IL-12 as well as mast cell degranulation (Yuqi, 2005, Tse, 
2003). 
Sophora angustifolia (ku shen)  
Although not recommended for blood stagnation, Sophora angustifolia (ku shen) is 
recommended for both blood heat and blood dryness in the formulation Xiao Yin Ke Li 
(China Academy of Chinese Medicine, 2011). Its primary psoriasis-related Chinese 
medicine functions are to clear damp heat. It is also understood to be an antibiotic, anti-
parasitic, antimycotic (to treat fungal infections of the skin), as well as suppress the 
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growth of keratogenetic cells by way of stimulating TNF-α, with evidence it can 
suppress pathogenic CD4+ T-cell differentiation and the overall immune response (Gao 
et al., 2009b, Tan et al., 2011, Kim and Kim, 2012, Zhang and Qu, 2002). 
Astragalus membranaceus (huang qi)  
Astragalus membranaceus (huang qi) is not mentioned in the Chinese guidelines for 
psoriasis; however, Chinese medicine theory indicates ‘qi deficiency’ can be a possible 
cause of blood stagnation as sufficient qi is required for blood to move (Jingyi Zhao, 
2011, Chen, 2004). While moving blood is an important Chinese medicine treatment 
approach for psoriasis, blood movement is enhanced by strengthening and 
supplementing qi. This may see longer-term relief of psoriasis symptoms than just 
moving blood alone. The primary Chinese medicine function of huang qi is to tonify qi 
(Chinese Pharmacopoeia Commission, 2005). Laboratory research has identified huang 
qi to be a potential 5-lipoxygenase inhibitor in intact leukocytes and platelets, which 
may be valuable for managing skin conditions such as psoriasis (Prieto et al., 2003). 
Published articles also state huang qi enhances T-cells and natural killer cell function 
promoting humeral immunity and potentially reducing psoriasis symptoms (Yuqi, 
2005). Furthermore, in vitro studies in rats have found huang qi can significantly inhibit 
vaginal epithelium mitosis and the expression of proliferating cell nuclear antigen. 
Furthermore, huang qi promotes development of the granular layer and reduces the 
serum level of endothelin (ET)-1 in rats, possibly by blocking multiple pathogenic 
psoriasis linkages (Zhang and Gu, 2007). 
For each ingredient, based on recommendations from the Pharmacopoeia of the 
people’s republic of China and evidenced from available PubChem data, one chief 
constituent (referred to as a marker) was chosen as a primary active constituent for 
each ingredient, and possible mechanisms for therapeutic efficacy in psoriasis were 
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evaluated by reviewing the activity of the constituent compounds (Chinese 
Pharmacopoeia Commission, 2005). 
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Table 5.2 First developed oral CHM formulation ingredients and constituent compound functions 
Chinese 
herb 
name 
Botanical 
herb name 
Adult 
dosage 
raw form 
(g) 
CM 
function 1 
CM 
function 2 
CM 
function 3 
Potential psoriatic biological 
mechanisms 
Chosen biological 
marker 
Dang gui Angelica 
sinensis 
(Apiaceae) 
9 Tonifies 
blood 
Moves 
blood 
Drains 
wind 
dampness 
Prolongs prothrombin time, inhibits 
platelet aggregation, has 
antimicrobial, hepato-protective and 
weak analgesic, antiphogistic, 
tumour-inhibiting and antioxidative 
actions (Hempen and Fischer, 
2009a) 
 
Ferulic acid (Chinese 
Pharmacopoeia 
Commission, 2005) 
Di huang Rehmannia 
glutinosa 
9 Cools heat Cools 
blood 
Cools fire Inhibits the release of histamine and 
production of TNF- and Il-1 (Kim et 
al., 1999) 
Catalpol (Wang et al., 
1997, Astaf'eva et al., 
2002, Chinese 
Pharmacopoeia 
Commission, 2005) 
 
Tao ren Prunus 
persica 
(Rosaceae) 
12 Moves 
blood 
Breaks up 
blood 
stasis 
Unblocks 
the bowels 
Prolongs thrombin time and inhibits 
platelet aggregation (Yang et al., 
2011) 
 
Amygdalin (Liu et al., 
2012b) 
Hong hua Carthamus 
tinctorius 
(Asteraceae) 
9 Moves 
blood 
Breaks up 
blood 
stasis 
Relieves 
pain 
Inhibit the production of TNF-, IL-1 
a, IL-1 b and IL-6 and the growth 
and proliferation of epidermal cells 
(Zhang and Qu, 2002, Tse, 2003) 
Extracts methanol and ethanol; anti-
inflammatory and antimicrobial 
(World Health Organization, 2007) 
 
Kaempferol (Chinese 
Pharmacopoeia 
Commission, 2005)  
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Chinese 
herb 
name 
Botanical 
herb name 
Adult 
dosage 
raw form 
(g) 
CM 
function 1 
CM 
function 2 
CM 
function 3 
Potential psoriatic biological 
mechanisms 
Chosen biological 
marker 
Chi shao Paeonia 
veitchii wild 
(Ranunculac
eae) 
6 Cools heat Cools 
blood 
Moves 
blood 
Inhibits epithelial cell mitosis, 
reduces PCNA expression, promotes 
epidermal cell differentiation (Zhang 
and Gu, 2007)  
Sedative, analgesic, antipyretic, 
anti-inflammatory and vasodilatory 
effects (World Health Organization, 
1999) 
 
Paeoniflorin (World 
Health Organization, 
1999, Chinese 
Pharmacopoeia 
Commission, 2005) 
Chai hu Radix 
Bupleuri 
(Apiaceae) 
3 Releases 
the 
exterior 
Moves and 
regulates 
qi 
Raises qi Anti-inflammatory, immunological 
lymphocyte functions (Ushio et al., 
1991, Jiang et al., 2012b) 
Saikosaponin D  
(World Health 
Organization, 1999, 
Chinese Pharmacopoeia 
Commission, 2005) 
 
Gan cao Radix 
glycyrrhizae 
(Fabaceae) 
3 Harmonise
s and 
tonifies the 
qi 
Harmonise
s and 
tonifies the 
spleen and 
stomach 
Clears fire Immunosuppressive and immuno-
enhancing activities, prevents side 
effects of herbal therapy 
(Bartosińska et al., 2011)  
Inhibits histamine release from rat 
mast cells; corticosteroid-like 
activity (World Health Organization, 
2010) 
 
Glycyrrhizin (glycyrrhi-
zic acid, glycyrrhizinic 
acid) (World Health 
Organization, 2010, 
Chinese Pharmacopoeia 
Commission, 2005) 
 
Chuan 
xiong 
 Ligusticum 
chuangxiong 
Hort.  
(Apiaceae)  
 
4.5 Moves 
blood 
Moves and 
regulates 
qi 
Dispels 
wind 
Inhibits growth and proliferation of 
epidermal cells (Zhang and Qu, 
2002) 
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Chinese 
herb 
name 
Botanical 
herb name 
Adult 
dosage 
raw form 
(g) 
CM 
function 1 
CM 
function 2 
CM 
function 3 
Potential psoriatic biological 
mechanisms 
Chosen biological 
marker 
Ku shen Sophora 
flavescens 
(Fabaceae) 
3-15 Clears 
damp heat 
Dispels 
wind 
Stops 
itching 
Suppresses growth of keratogenetic 
cells, stimulates TNF-α and 
suppresses pathogenic CD4+ T-cell 
differentiation (Tan et al., 2011, Kim 
and Kim, 2012)  
Strong antimicrobial activity against 
mutans streptococci (Kim et al., 
2013a) 
Anticancer (Sun et al., 2012) 
 
Oxymatrine (Sun et al., 
2012, Chinese 
Pharmacopoeia 
Commission, 2005) 
Dan shen Salvia 
miltiorrhiza 
(Lamiaceae) 
6-15 Moves 
blood 
Breaks up 
blood 
stasis 
Cools heat Suppresses IFN-γ and IL-12; 
degranulates mast cell (Bartosińska 
et al., 2011)  
Inhibits platelet aggregation  
 
Tanshinone IIA (Ma et 
al., 2013)  
Huang qi Astragalus 
membranace
us 
(Fabaceae) 
9-30 Harmonise
s and 
tonifies the 
qi 
Raises 
collapsed 
yang 
Stabilises 
the 
exterior 
Inhibits epithelium mitosis and 
expression of PCNA; promotes 
development of granular layer; 
reduces serum level of ET-1 (Zhang 
and Gu, 2007) 
Astragaloside IV 
(Chinese Pharmacopoeia 
Commission, 2005, Zhou 
et al., 2011) 
 
Niu xi Achyranthis 
bidentatae 
radix 
9 Moves 
blood 
Breaks up 
blood 
stasis 
Strengthen
s sinews 
and bones 
Enhances chondrocyte proliferation 
(Yu et al., 2013a) 
Oleanolic acid (Chinese 
Pharmacopoeia 
Commission, 2005) 
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Chinese 
herb 
name 
Botanical 
herb name 
Adult 
dosage 
raw form 
(g) 
CM 
function 1 
CM 
function 2 
CM 
function 3 
Potential psoriatic biological 
mechanisms 
Chosen biological 
marker 
Jie geng Platycodon 
grandifloru
m 
4.5 Moves and 
regulates 
qi 
Stops 
coughing 
Raises the 
qi 
Anti-inflammatory activity (World 
Health Organization, 1999, Zhou et 
al., 2011) 
Platycodins (Platycodin 
A, Platycodin C , 
Platycodin D, Platycodin 
D2, Platycodin 
D3)(World Health 
Organization, 1999, 
Chinese Pharmacopoeia 
Commission, 2005) 
Zhi ke Fructus 
aurantii  
6 Moves and 
regulates 
qi 
Raises the 
yang qi 
Breaks up 
lumps 
Antibacterial and anti-
inflammatory(Zhou et al., 2011)  
 
Naringin (Park et al., 
2005, Zhang et al., 2012, 
Chinese Pharmacopoeia 
Commission, 2005) 
Note: Adult dosage and Chinese medicine function were adapted from (Bensky et al., 1993) and (Zhou et al., 2011) with further expert 
advice. 
Abbreviations: CD, cluster of differentiation; CM, Chinese medicine; ET, endothelin; IFN- γ, interferon gamma; IL, interleukin; T-cell, 
thymus lymphocyte; TNF-, tumour necrosis factor alpha; PCNA, proliferating cell nuclear antigen
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5.4.2 Second CHM formulation (PSORI-CM01): The origin and evidence for its utilisation in 
psoriasis vulgaris 
Following the development of the first formulation, details of the ingredients and 
supporting evidence for their use was sent to dermatologist specialists in China for 
feedback and comment on its suitability for clinical trial investigation. After discussion 
it was determined that the initial formulation, while being theoretically suitable, may 
not be optimal and should be further considered. Instead of further modifying the 
developed formulation, a pre-existing formulation with extensive clinical use was 
chosen for a pilot clinical controlled study in an Australian population with mild to 
moderate psoriasis vulgaris. 
Of the formulations identified through literature review there was one in 
particular (PSORI-CM01), developed and tested by dermatologists in China, which had 
extensive evidence suggesting its efficacy for psoriasis. Originally known as Yinxieling, 
the formulation was developed by well-known CM dermatologist Professor Xuan 
Guowei (Zhong et al., 2004, Wang and Huang, 2009). It was also originally formulated to 
target the most prevalent psoriatic Chinese medicine syndrome type, blood stagnation 
(Lu et al., 2014a) and had been previously investigated by a member of the research 
team (Prof. Chunjian Lu). 
Early human study evaluated Yinxieling fumigation effects on psoriasis related 
protein expression in subjects with psoriasis vulgaris (n=30). For twelve subjects they 
were assessed as cured following treatment with an effective rate of 96.7%. Further 
blood showed T-bet  and GATA3 restored to normal levels following fumigation, both 
correlating with PASI score change(Wei et al., 2008). Early oral administration human 
single blind study (n=84) of Yinxieling decoction with or without auricular acupuncture 
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(8 weeks), in subjects with psoriasis vulgaris found both groups had significant 
reduction in PASI score. This significance was greater in subjects with initial PASI > 10, 
although this group also had greater room for improvement (Lu et al., 2012a). More 
recent oral human study (n=120) of Yinxieling in decoction form found it significantly 
decreased TNF-α and IL-8 as well as reduced PASI significantly for all syndrome types. 
It was noted the control group did not have significant reduction in PASI (Dai et al., 
2014b). 
 Following in vitro, in vivo, high-performance liquid chromatography, electrospray 
ionisation hybrid linear trap quadrupole Orbitrap mass spectrometry (UHPLC-(-) ESI-
MS)  techniques and clinical studies, it has since been optimised to its current form 
(PSORI-CM01) (Gu et al., 2009) (Han Ling, 2011), and was suitable for further clinical 
evaluation under controlled conditions (Lu et al., 2014a, Chen et al., 2015) (Figure 5.1). 
Researchers were already in the early stages of investigating PSORI-CM01 in a Chinese 
population with severe psoriasis, although a protocol of how it would be implemented 
had not yet been developed (Wen et al., 2014). 
  
Figure 5.1: UHPLC-(-) ESI-MS of (A) standards and (B) PSORI-CM01(Chen et al., 
2015) 
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The optimised formula of PSORI-CM01 comprises seven ingredients: Paeonia 
lactiflora root (chi shao), Curcuma wenyujin rhizome (e zhu), Sarcandra glabra (zhong jie 
feng), Glycyrrhiza uralensis root and rhizome (gan cao), Prunus mume fruit (wu mei), 
Arnebiae radix (hong tiao zi cao) and Smilax glabra rhizome (tu fu ling) (Table 5.3). The 
constituent compounds of each ingredient of PSORI-CM01 were reviewed and those 
most likely to have potential therapeutic mechanistic action for psoriasis were 
identified. For each ingredient (prinicipal herb listed first), the most likely biologically 
psoriasis active constituent was considered the main therapeutic marker for that 
ingredient (Table 5.3). These were then later explored using mass spectrometry 
techniques, using various samples to determine the final optimised preparation (Lu et 
al., 2014a). It was found that granulated extract was phytochemically content superior 
to pill and decotion forms of  PSORI-CM01(Chen et al., 2015) (Figure 5.2). 
 
KLJ (1&2), granulated extract method 1 & 2; PJ, Pill formulation 1 & 2; TJ (6,7 & 8), 
decoction form method 1, 2 & 3 
Figure 5.2: Contents of 14 key phytochemicals of  PSORI-CM01 (g/g or 
ug/mL)(Chen et al., 2015)
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Table 5.3: Second developed oral CHM formulation (PSORI-CM01) ingredients and constituent compound functions 
Chinese 
herb 
name 
Botanical 
herb 
name 
CM 
function 1 
CM 
function 2 
CM 
function 3 
Potential psoriatic biological 
mechanisms 
Likely psoriatic 
active contained 
compounds 
Chosen 
biological 
marker 
Chi shao Paeonia 
lactiflora 
root 
Clears heat 
and cools 
blood 
Dispels 
blood 
stasis and 
relieves 
pain 
Reduces 
swelling 
and sores 
Platelet aggregation inhibitor 
(daucosterol, paeoniflorin (Koo et al., 
2010)),  
Inhibits lipolysis; antioxidant 
(eugeniin, paeoniflorin), 
Anti-inflammatory (paeoniflorin, 
paeono) 
Antipyretic (paeoniflorin, paeonol) 
(Chen et al., 2011). 
 
Daucosterol 
eugeniin 
paeoniflorin 
paeonol 
Paeoniflorin 
Tu fu ling Smilax 
glabra 
rhizome 
Eliminates 
toxic heat 
Dispels 
toxic heat 
from the 
skin 
Promotes 
normal 
urination 
Antineoplastic (Astilbin) 
Anti-inflammatory (astilbin, 
dihydroquercetin) (dihydroquercetin 
-γ) 
ICAM-1 protein, as well as miRNA 
expression in human keratinocytes 
Cytotoxic (caffeoylshikimic acid) 
Antibacterial (syringic acid)(Zhou et 
al., 2011) 
Astilbin 
caffeoylshikimic acid 
dihydroquercetin 
isoengelitin 
syringic acid 
 
Syringic acid 
E zhu  Curcuma 
wenyujin 
rhizome 
IBC and 
breaks up 
blood 
stasis 
Activates 
qi 
circulation 
and 
relieves 
pain 
 
 
 
 Antineoplastic (furanodiene, 
curdione, curcumol)(Gao et al., 2009a, 
Sun et al., 2009) 
Curcumol 
curdione 
furanodiene 
Furanodiene 
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Chinese 
herb 
name 
Botanical 
herb 
name 
CM 
function 1 
CM 
function 2 
CM 
function 3 
Potential psoriatic biological 
mechanisms 
Likely psoriatic 
active contained 
compounds 
Chosen 
biological 
marker 
Zhong jie 
feng 
Sarcandra 
glabra 
(Chloranth
us glaber) 
Reduces 
heat in the 
blood  
Activates 
blood to 
remove 
ecchymosi
s  
Dispels 
wind and 
eliminates 
damp  
Increase platelet production (Zhong 
2005)  
Antineoplastic; choleretic; cytotoxic 
(isofraxidin) (Zhou et al., 2011) 
Antibacterial; antineoplastic (fumaric 
acid) (Zhou et al., 2011) 
Antibacterial (Staphylococcus aureus, 
Coccus catarrhal, Bacillus pyocyaneus, 
Bacillus proteus, B. typhosus and 
Bacillus dysenteriae (Succinic 
acid)(Zhou et al., 2011) 
Coumarone 
fumaric acid 
isofraxidin 
succinic acid 
Isofraxidin  
Fumaric acid 
Gan cao Glycyrrhiza 
uralensis 
root and 
rhizome 
Harmonise
s and 
tonifies the 
qi 
Harmonise
s and 
tonifies the 
spleen and 
stomach 
Clears fire Immunosuppressive and immuno-
enhancing activities (Bartosińska et 
al., 2011) 
Anti-inflammation (glycyrrhetinic 
acid, glycyrrhizic acid, isoliquiritin, 
isoquercitrin) 
Antibacterial (formononetin, 
glabrene, glabridin, glabrol, 
glycyrrhetinic acid, hispaglabridin A 
and B, hydroxyglabrol, isoquercitrin, 
licochalcone B, pinocembrin, 
wighteone) 
Antiallergic (glycyrrhetinic acid, 
glycyrrhizic acid, licochalcone B 
antineoplastic (glycyrrhetinic acid, 
isoliquiritigenin 
Cytotoxic (isoliquiritigenin, 
pinocembrin 
Inhibits cell proliferation 
(isoliquiritigenin) 
Formononetin 
glabrene 
glabridin 
glabrol 
glycyrrhetinic acid 
glycyrrhizic acid 
hispaglabridin A and 
B hydroxyglabrol 
isoliquiritigenin 
isoliquiritin 
isoquercitrin 
licochalcone B 
pinocembrin 
wighteone 
Glycyrrhizin 
(glycyrrhi-zic 
acid) 
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Chinese 
herb 
name 
Botanical 
herb 
name 
CM 
function 1 
CM 
function 2 
CM 
function 3 
Potential psoriatic biological 
mechanisms 
Likely psoriatic 
active contained 
compounds 
Chosen 
biological 
marker 
Wu mei Prunus 
mume fruit 
Stops 
sweating 
due to lung 
qi 
deficiency 
Binds the 
intestines 
Generates 
body fluids 
Antibacterial (Staphylococcus aureus, 
Bacillus coli, Bacillus dysenteriae and 
B. typhosus);  
Antineoplastic and cytotoxic (Hou et 
al., 2001) (naringenin) 
Anti-inflammatory (macrophages, 
COX-2 inhibitor, inhibits COX-2 
expression)(Calixto et al., 2003); 
(naringenin); 
 
Amygdalin 
citric acid 
hydrocyanic acid 
malic acid 
naringenin 
picric acid 
Ursolic acid 
Naringenin 
Hong tiao 
zi cao 
Arnebiae 
Radix (or 
Arnebia 
euchroma 
or Radix 
Lithosperm
i seu 
Arnebiae)  
Remove 
heat from 
blood 
Promote 
blood 
circulation 
Reduce 
toxicity 
and 
facilitate 
eruptions 
Anti-inflammatory (acetylalkannin, 
shikonin) 
Antineoplastic (alkannin angelate) 
Antibacterial (Staphylococcus aureus, 
Staphylococcus epidermidis) 
(deoxyshikonin, 
dimethylacrylshikonin, 
dimethylacrylalkannin, shikonin, 
teracrylshikonin) 
Treatment of allergic purpure 
(dimethylacrylalkannin) (Zhou et al., 
2011) 
 
Alkannin (β-
dimethylacryalkanin)  
isolated compounds: 
acetylalkannin 
alkannin angelate 
caffeic acid 
deoxyshikonin 
dimethylacrylalkanni
n (Alkannin) 
dimethylacrylshikoni
nahikonin,  
teracrylshikonin 
Alkannin 
Note: Adult dosage and Chinese medicine function are adapted from Bensky 1993 (Bensky et al., 1993) and (Zhou et al., 2011) COX, 
cyclooxygenase ICAM, intercellular adhesion molecule; IFN- γ, interferon gamma
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5.5 Discussion 
Although the first formulation (Table 5.2) may have premise for efficacy in psoriasis, it 
has no pre-existing clinical evidence reports. There is clinical evidence to support each 
of its ingredients individually; however, the synergistic and/or antagonistic 
consequences of combining them are unknown. The cost and time requirements of an 
RCT necessitate optimal interventions, so the PSORI-CM01 formulation (Table 5.3), 
which has significant prior clinical evidence of its potential efficacy, was chosen for the 
proposed trial. 
Although originally formulated for the syndrome of blood stagnation, PSORI-CM01 
has since been optimised and research results indicate it also has benefit for blood 
dryness and blood heat syndromes (Wang and Huang, 2009, Dai et al., 2014b). Despite 
this evidence, its effect in an Australian mild–moderate severity psoriatic population is 
unknown. As the prevalence of syndrome types is also unknown for the Australian 
population, the RCT was designed to assess syndrome type of participants at several 
time points during the trial.  
As technology for identifying constituents of substances, such as high-
performance liquid chromatography, improves there is likely to be new compounds 
discovered (Bai et al., 2013). In the current study, we endeavoured to outline all known 
compounds in each ingredient in the formulation. Although a primary constituent was 
chosen as a marker for each ingredient, this marker is not necessarily the most 
biologically active for psoriasis. Markers were chosen using the Chinese pharmacopeia, 
and in vitro and in vivo evidence of all the known constituents. Those with the most 
evidence of psoriatic-like bioactivity were shortlisted, and those with the greatest 
concentration in the ingredient were identified. Using this method, the constituent 
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identified was often the same as that recommended by pharmacopeia, however this was 
not always the case. 
It should be noted that selection of a suitable marker should not be based solely on 
its concentration. Consideration needs to be given to the processing the substance will 
undergo to prepare it for therapeutic use, and the disease it is being administered for. 
Some processing methods such as boiling at high temperatures may denature the 
constituent to such a degree it becomes undetectable and subsequently may lose its 
therapeutic activity. For other constituents, although still detectable in large quantities, 
following processing they may be inert. Identification of the constituents and 
understanding their chemical structures can assist in development of manufacturing 
and processing methods to ensure they remain in significant concentrations in the end 
product. Processing and manufacturing methods should provide the optimum yield of 
constituents known to be biologically relevant for the investigated condition. 
5.6 Conclusion 
The first developed formulation was primarily based on review of published oral CHM 
for psoriasis as well as recommendations from available Chinese medicine guidelines. 
While it was developed in a rigorous manner, the clinical efficacy of the formulation is 
yet unknown. Although the first formulation does merit further in vitro, in vivo and 
clinical research investigation, due to the costs and time involved in the conduct of an 
RCT it was decided a formulation with significant previous efficacy would be best 
utilised. 
Of those identified in the reviews, a formulation based on Yinxieling was deemed 
the most suitable (PSORI-CM01). One member of the research team had previous 
clinical and experimental experience with the formulation and it had been optimised 
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significantly since its initial development. The majority of the evidence for its use in 
psoriasis was based on results from animal models or in the Chinese population; 
however, following further evaluation it was determined there was no evidence to 
suggest it would be unsuitable for use in an Australian mild to moderate severity 
psoriatic population. Thus, it was determined the PSORI-CM01 formulation would be 
used in the present Australian RCT.  
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Chapter 6 – Exploring the biological pathway activity of 
phytochemicals in principal herb (chi shao) and investigating their 
potential for psoriasis therapy 
This chapter reviews the biological activity of phytochemicals in chi shao, the principal 
CHM in PSORI-CM01. It compares the phytochemical compositions of the most common 
botanicals sold as chi shao and evaluates their anti-inflammatory, anti-tumour, anti-viral, 
antibacterial, antioxidant/prooxidant and glycaemic activity. 
6.1 Background 
Botanicals have a long history of use in treating diseases or relieving their symptoms, 
where typically they are administered internally or externally in entire form (Balunas 
and Kinghorn, 2005, Wachtel-Galor and Benzie, 2011). The active compounds of plants 
have regularly provided sources for the development of new pharmaceuticals, where their 
chemical structures are analysed to investigate potential therapeutic activity in target 
disease (Jones et al., 2006). These active phytochemicals may then undergo in vitro and 
in vivo experimentation to further elucidate their activity.  
Numerous pharmacological drugs or products originate from botanicals, using 
pharmocogenecy techniques to modify and/or concentrate compounds in order to 
target and enhance their biological activity (Balunas and Kinghorn, 2005, Jones et al., 
2006).  
A thorough review of the evidence for pharmacological action of the principal herb, 
chi shao, in PSORI-CM01, was undertaken (Zaiyou et al., 2013). Chi shao is sourced from 
Paeonia lactiflora or P. veitchii, so the constituent compounds found in both were 
classified according to their chemical group and potential biological therapeutic activity. 
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The aim was to ensure the quality of chi shao product to be utilised in PSORI-CM01 and 
identify suitable compounds to act as biological markers during processing. 
6.1.1 Peony medicinal history 
Plants from the genus Paeonia have a long history of use in medicine. The genus name 
comes from a Greek legend in which a student of medicine known as Paeon healed the 
wound of the god Pluto, who later saved the student from death by turning him into the 
healing plant commonly known as peony. Early medicinal use was for dissolving 
bladder and kidney stones (Pickering, 1989). In recent times, constituent compounds of 
peony have been evidenced to be of medical significance. For example, a group of 
constituents in P. lactiflora known as total glucosides of peony (TGP) exhibit anti-
inflammatory action that has seen them approved by the State Food and Drug 
Administration of China for rheumatoid arthritis (He and Dai, 2011). 
6.1.2 Herbaceous peony species used in China 
Paeonia is the single genus in the family Paeoniaceae, consisting of around 35 species of 
either tree or herbaceous plant, 11 of which are found in China (Zaiyou et al., 2013). 
Herbaceous species grow to around three feet in height and are perennial with flowers, 
often fragrant, which grow to around six inches in diameter (Kamenetski, 2007, 
Cooperative Extension Service Kansas State University, 1993). A number of Chinese 
peonies are used in traditional medicine (Chinese Pharmacopoeia Commission, 2005). 
The roots of herbaceous peony species are commonly utilised medicinally in China. 
In the herbal market, peony roots are distinguished by white or red colour. Radix 
Paeoniae Alba, or ‘white peony root’ (bai shao 白芍), is generally sourced from Paeonia 
lactiflora Pallas (syn. P. albiflora) (shao yao 芍药) (Chinese Pharmacopoeia Commission, 
2005), but can also be produced from Paeonia lactiflora Pallas var. trichocarpa Bunge 
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(mao guo shao yao 毛果芍药), both of which are grown in the north and east of China 
(State Administration of Traditional Chinese Medicine 'Chinese Materia Medica 
Committee' (ed.), 1998). Radix Paeoniae Rubra, ‘red peony root’ (chi shao 赤芍), is 
brownish in appearance and is officially sourced from Paeonia lactiflora Pallas or 
Paeonia veitchii Lynch (aka Paeonia anomala subsp. veitchii (Lynch) D.Y.Hong & K.Y.Pan) 
(chuan chi shao川赤芍), which are from the Sichuan province and other parts of 
northern and western China (Chinese Pharmacopoeia Commission, 2005, Zhu et al., 
2014). In addition, red peony root can be sourced from P. obovata Maxim., P. mairei 
Levl., P. anomola L. and associated varieties (State Administration of Traditional Chinese 
Medicine 'Chinese Materia Medica Committee' (ed.), 1998). 
Of the geographical varieties of P. lactiflora, a rare form farmed from Duolun has 
been identified as the variety most characterising red type (chi shao), however it is also 
considered to be rare (Zhou et al., 2002). As its name suggests, wild P. lactiflora typically 
has white flowers (Figure 6.1), whereas P. veitchii has red flowers; however, modern 
cultivars of P. lactiflora can have red, pink or purple flowers (Figure 6.2)(Halda and 
Waddick, 2010). Consequently, the traditional distinction between white and red peony 
in China based on flower colour has contributed to the current confusion distinguishing 
the two types as medicinals (Mikage and Ono, 2009, Hooper, 1929, Zhang and Dai, 
2012). 
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Figure 6.1: Paeonia lactiflora Pallas (Tatyana, 2015) 
 
 
Figure 6.2: Paeonia veitchii (Smit, 2015) 
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Traditional Chinese Medicine Materia Medica (an encyclopaedia of herb descriptions, 
sources, botanical name and known functions) describe a white peony in which the 
colour of the root when cut is white (Figure 6.3A: Radix Paeoniae Alba) (Zaiyou et al., 
2013), compared with another peony in which the colour of the root when cut is pinkish 
and is known as the red peony (Figure 6.3B: Radix Paeoniae Rubra)(Liang et al., 2014, 
Chinese Pharmacopoeia Commission, 2005). While white peony root is typically 
sourced from Paeonia lactiflora, there is considerable diversity in the sources of red 
peony root in the herbal market, although only P. lactiflora and P. veitchii are considered 
official (Chinese Pharmacopoeia Commission, 2005). The two species have received 
considerable research attention regarding their constituents and pharmacological 
actions (Mikage and Ono, 2009, Hooper, 1929). Due to use of both species as chi shao 
constituent compounds, both herbs were evaluated and significant in vitro and in vivo 
evidence of compound pathway activity was reviewed (Zhang et al., 2013a). 
      
Figure 6.3: A (left) – sections of root of Radix Paeoniae Alba (cms) (Hempen and 
Fischer, 2009b) B (right) – sections of root Radix Paeoniae Rubra (cms) (Hempen and 
Fischer, 2009b) 
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6.1.3 High-performance liquid chromatography of P. lactiflora and P. veitchii 
Chemical classification using high-performance liquid chromatography analysis shows 
that two subspecies of P. lactiflora exist, a northern or southern China species (Zhu et al., 
2014, Wang et al., 2014). As yet there is no consistent consensus on which is 
therapeutically superior. Paeonia lactiflora appears to have greater concentration of the 
principal component paeoniflorin) compared with P. veitchii (Zaiyou et al., 2013), yet 
other research indicates the opposite, paeoniflorin reported to make up 72% of total 
constituent weight (mg/g) of P. veitchii samples, which is greater than 54-65% in P. 
lactiflora samples (Chuang et al., 1996). In P. lactiflora samples, a higher concentration 
of constituent paeoniflorin (65% of total) is reported in decorticated (skin removed) 
samples than corticated (skin remains) samples (54% of total) (Chuang et al., 1996). 
Research also indicates that P. lactiflora samples generally contain a greater 
number of constituents than P. veitchii samples (Chuang et al., 1996). Further, samples 
of decorticated P. lactiflora contain higher concentration of the major constituents than 
corticated samples (Chuang et al., 1996). Similarly, P. veitchii has higher constituent 
content in the root cortex (skin) than the root core, thus it is likely that retention of the 
cortex is therapeutically important for P. veitchii products (Chuang et al., 1996). 
Geographical location of farming may affect constituent concentrations of botanicals 
due to local temperature and rainfall, and even season of harvest can affect 
concentrations of contained phytochemicals (Jian et al., 2010). 
6.1.4 Processing methods 
Production methods allow P. lactiflora to be sold as white (Radix Paeoniae Alba or bai 
shao) or red (Radix Paeoniae Rubra or chi shao) types. Different harvesting and 
processing procedures for P. lactiflora distinguish its type at sale. As bai shao, P. 
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lactiflora is cultivated then the root boiled, peeled and sun-dried (Zhang and Dai, 2012). 
To further preserve the white appearance, the P. lactiflora root it is often fumigated 
with sulphur dioxide (Wang et al., 2006), so monoterpene glycoside sulphonated 
derivatives of many of the constituent compounds are regularly detected in commercial 
samples of P. lactiflora (Wang et al., 2006, Li et al., 2009). Fumigation is not officially 
sanctioned and the therapeutic effects of the resultant sulphonated compounds are 
unknown (Luo et al., 2013). 
6.1.5 Traditional Chinese medicine use of P. lactiflora and P. veitchii 
From a Chinese medicine perspective the two Paeonia colours (chi shao and bai shao) 
are prescribed for different therapeutic purposes. Bai shao is mostly administered for 
conditions involving menstrual disorder (dysmenorrhoea or menorrhagia) or various 
painful conditions such as cholecystitis; however, it is also indicated for dysentery, 
hypertension and spermatorrhoea. Similarly, chi shao is also indicated for painful 
conditions, but is also indicated for infectious conditions that affect the skin, such as 
measles or chickenpox, in which its action is to treat infection (Hempen and Fischer, 
2009b). The therapeutic differences between chi shao and bai shao suggest possible 
variation in the constituent compound content of the two types and this has been 
supported by evidence from high-performance liquid chromatography (Xu et al., 2009). 
6.2 Methods 
A database search was undertaken and key herbal pharmacological encyclopaedia 
reviewed to identify the known constituents of both botanicals (Zhou et al., 2011). 
Publications with high performance liquid chromatography (HPLC) results (or other 
analytic technique) for P. lactiflora and P. veitchii were compared to encyclopaedia 
results to ascertain a comprehensive list of the known phytochemicals in each.  
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Search terms for P. lactiflora and P. veitchii included their full names Paeonia lactiflora 
and Paeonia veitchii. Constituent search terms primarily used the main chemical name 
of each, however in an instance a constituent had more than one main chemical name a 
further publication search was conducted.  
Using PubChem and PubMed each constituent was then reviewed to identify 
evidence of their biological activity and then grouped with other similar activity 
constituents. Where multiple publications were available on the same pathway activity, 
the original publication identifying the constituents activity for that pathway was used 
or publications in which the constituent was originally extracted from a paeonia source. 
Pathway activities of compounds were then grouped under common drug actions which; 
reduce or modulate inflammation pathways (anti-inflammatory/immunomodulation), 
reduce proliferation of cells or increase cell apoptosis (cytoxic/anti-tumour), reduce or 
prevent viral replication in healthy cells (anti-viral), inhibit bacteria or fungal cell 
development and replication (anti-bacterial/anti-fungal), influence blood glucose levels 
(glycaemic), reduce or increase free radical production (anti-oxidant/pro-oxidant) or 
have activity other than the previous mentioned (other). Within each of the above 
categories, phytochemical with the highest concentrations are discussed first. 
6.3 Results 
6.3.1 Main phytochemistry and constituents of P. lactiflora and P. veitchii 
Most constituents of P. lactiflora and P. veitchii are classified as monoterpenoids, 
triterpenoids, flavonoids, phenols or tannins (Wu et al., 2010, Li et al., 2009). High-
performance liquid chromatography shows that paeoniflorin is the most abundant 
phytochemical in both species (54–65% in P. lactiflora and up to 72% in P. veitchii), 
with pentagalloylglucose also found in significant concentrations in both. Albiflorin is 
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another major phytochemical in P. lactiflora, while oxypaeoniflorin is found in 
significant amounts in P. lactiflora (Chuang et al., 1996).  
6.3.2 Biological pathway activity 
Anti-inflammatory or immunmodulatory activities 
A large number of compounds in both Paeonia species have been evaluated as having 
potential anti-inflammatory or immunmodulatory pathway activity (Table 6.1).    
Total glucosides of peony 
Among the most well studied constituents of P. lactiflora is the group known as TGPs. 
Individually P. lactiflora contained monterpene glycosides; paeoniflorigenone, 
paeonianiin E, paeonidanin A, paeonidanin B and paeonidanin C display inhibitory 
effects on NO production, reducing the inflammatory response and preventing NO 
hyper-function tissue damage. When grouped as TGP the anti-inflammatory therapeutic 
mechanism is likely due to modulation of pro-inflammatory mediators, mediation of 
cAMP levels and inhibition of synoviocyte proliferation, which in turn decreases 
production of IL-1, TNF- and prostaglandin (Xu et al., 2007, Wu et al., 2009b, Deng et 
al., 2010).  
Research has indicated TGP may have potential use in diseases of the kidneys 
and liver, where they prevent diabetes-associated renal damage through increased 
expression of nephrin protein and inhibition of diabetic nephropathy progression (Wu 
et al., 2009b, Wang et al., 2012d, Zhang et al., 2009b, Zhang et al., 2014e, Su et al., 
2010a). The anti-inflammatory properties of TGP may also lower blood lipids and 
inhibit the expression of inflammatory cytokines, subsequently reducing the 
development of atherosclerotic disease (Li et al., 2011). Potential TGP therapeutic 
effects include treatment of systemic lupus erythematosus, in which it reduces the use 
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of drugs such as prednisone, as well as provides potential hepato-protective effects 
from drugs such as methotrexate (Zhang et al., 2011a, Chen et al., 2013). Through 
inhibition of T-cell proliferation and reduction in the maturation of DCs, the TGP group 
arrests the DCs antigen-presenting ability subsequently reducing the immune-mediated 
inflammatory response (Zhou et al., 2012b).  
Paeoniflorin 
Paeoniflorin is the constituent with the highest concentration in both species (54-65% 
in P. lactiflora and up to 72% in P. veitchii) and is one of the most well studied 
compounds for potential therapeutic properties (Chuang et al., 1996). It has been shown 
to reduce chemokine secretion in TNF--induced endothelial cells and inhibit TNF- 
induced leukocyte migration. Paeoniflorin pre-treatment may also block 
phosphorylation of IB, which requires degradation of its levels to activate NF-B for 
the subsequent expression and production of inflammatory chemokines (Chen et al., 
2011). Paeoniflorin has been shown to reduce ICAM-1 molecules, which mediate the 
adhesion of leukocytes. Possibly through inhibiting TNF- activation pathways of MAP 
kinases, ERK1/2 and p38, required for the subsequent activation of ICAM-1. 
Paeoniflorin has also been shown to inhibit the TNF- stimulated adhesion of 
monocytes to endothelial cells (Nizamutdinova et al., 2007). 
Albiflorin 
The monoterpene albiflorin (found in both species), has shown minor inhibitory effects 
on cAMP-PDE activity in neutrophils resulting in a rise in intracellular cAMP (Jiang et al., 
2011). (Jiang et al., 2011). This subsequent cAMP rise, increases protein kinase A 
activity, inhibits the activation of NADPH oxidase and reduces neutrophil release of 
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oxygen free radicals. These all reduce the activity of neutrophils in an inflammatory 
response.  
Oxypaeoniflorin and paeoniflorigenone 
The monoterpene glycoside oxypaeoniflorin and the lesser abundant paeoniflorigenone, 
which are found in P. lactiflora, act through nitric oxide (NO) reduction from 
lipopolysaccharide-activated macrophages, whereas for the other phytochemicals, NO 
reduction is via lipopolysaccharide (LPS)-activated N9 microglia (Ding et al., 2012, Duan 
et al., 2009). 
Gallic acid 
Gallic acid has been shown to act on a similar pathway to paeoniflorin, however with 
stronger effect (Jiang et al., 2011). It is also known to interfere with polymorphonuclear 
leukocyte (PMN) functioning, inhibiting the release and activity of myeloperoxidase, 
scavenging superoxide anions and possibly interfering with active NADPH-oxidase 
assembly (Kroes et al., 1992).  
Pentagalloylglucose 
Lesser studied is the hydrolysable tannin, (1,2,3,4,6-) pentagalloylglucose, which is 
considered an ester of gallic acid and found in both P. lactiflora and P. veitchii. It has an 
anti-allergic effect, inhibiting IL-4 signal activation in the IgE production pathway. A 
number of common type-1 hypersensitivity conditions, such as eczema are associated 
with IgE, and IL-4 is considered the most important cytokine regulating its synthesis 
(Corry and Kheradmand, 1999, Kim et al., 2013c). It’s understood that IL-4 induces 
expression of  germline transcript (GT), which goes on to initiate IgE production.  
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Daucosterol andβ-sitosterol 
Acting as an immunorestorative, daucosterol increases human peripheral lymphocyte 
proliferation and enhances secretion of lymphokine IL-2 and gamma interferon, whilst 
also enhancing NK-cell activity of lymphocytes. This action shows potential for assisting 
the inflammatory response of immunodeficient people. Interestingly, by increasing 
TH1-type helper cells, daucosterol appears to act on lymphokines, whereas TH2-type 
helper cells are inhibited or remain unchanged, suggesting it might enhance TH-1 
pathway activity and/or reduce TH-2 pathway activity (Bouic and Lamprecht, 1999, Lee 
et al., 2007). Further anti-inflammatory actions of daucosterol have been evidenced 
through inhibition of both IL-6 and TNF-α (Bouic and Lamprecht, 1999). Acting 
similarly to its glucoside (daucosterol), but with greater potency, β-sitosterol acts in the 
reduction of lipopolysaccharide-induced secretion of IL-6 and TNF-, requiring much 
lower concentration for its effect (Ding et al., 2009). 
Other 
Other phytochemicals found in either botanical but with less significant concentration 
and function include; hydrolysable tannins 1-O-galloyl-beta-D-glucose, casuariin, 
pedunculagin, strictinin, and casuarictin; monoterpene glycoside paeoniflorigenone, 
paeonianiin E, paeonidanin A, paeonidanin B and paeonidanin C; galloyl glucoses 1,2,3-
Tri-O-galloyl-β-D-glucose and 1,2,6-Tri-O-galloyl-β-D-glucose. Their actions are briefly 
described in table 6.1. 
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Table 6.1: Anti-inflammatory or immunomodulatory pathway activity 
Compound 
Chemical structure (src. 
PubChem) 
Chemical group Extended group Pathway activity 
↑ or ↓ 
pathway 
Albiflorin (v, l)  
 
 
Pinnae-type 
monoterpenes 
Monoterpenoid Neutrophil activation via cAMP-
PDE (cyclic adenosine 
monophosphate –
phosphodiesterase) (Jiang et al., 
2011) 
 
↓ 
Daucosterol (beta-
Sitosterol glucoside) 
(v, l) 
 
 
Phytosterols Steroid  
1. Proliferation of T-cells and 
natural killer cell activity (Bouic 
et al., 1996) 
↑ 
 
2. Lymphokines belonging to 
TH1-type (IL-2 and IFN-γ)(Bouic 
and Lamprecht, 1999, Lee et al., 
2007) 
 
↑ 
 
3. Lymphokines TH2-type helper 
cells (IL-4 IL-10)(Bouic and 
Lamprecht, 1999, Lee et al., 2007) 
 
 
 
 
 
↓ 
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Compound 
Chemical structure (src. 
PubChem) 
Chemical group Extended group Pathway activity 
↑ or ↓ 
pathway 
Oxypaeoniflorin (v)  
 
 
Monoterpene 
glycoside 
Monoterpenoid  NO production in 
lipopolysaccharide-activated- 
macrophages (Ding et al., 2012) 
↓ 
Paeoniflorin (v, l)  
 
 
Monoterpene 
glycoside 
Monoterpenoid 1.Chemokine mRNA expression in 
TNF--induced Human dermal 
microvascular endothelial cell -1 
cells (Chen et al., 2011) 
↓ 
2.TNF- induced leukocyte 
migration (Chen et al., 2011) 
↓ 
3.TNF--induced NF-B 
activation (Chen et al., 2011, 
Nizamutdinova et al., 2007) 
↓ 
4.TNF-α-induced phosphorylation 
of p38 and ERK (Nizamutdinova 
et al., 2007) 
↓ 
β-Sitosterol (v, l)  
 
 
Phytosterol Steroid LPS-induced secretion of IL-6, as 
well as TNF- (Ding et al., 2009) 
↓ 
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Compound 
Chemical structure (src. 
PubChem) 
Chemical group Extended group Pathway activity 
↑ or ↓ 
pathway 
Casuariin (l)  
 
 
Hydrolysable 
tannin 
Tannin iNOS and cytokine RNA (Kolodziej 
et al., 2005) 
↑ 
Gallic acid (v, l)  
 
 
Polyphenol Others Superoxide anions (Kroes et al., 
1992) 
 
↓ 
 
Myeloperoxidase release and 
activity (Kroes et al., 1992) 
 
↓ 
   
Neutrophil activation via cAMP-
PDE (cyclic adenosine 
monophosphate –
phosphodiesterase (Jiang et al., 
2011) 
 
 
 
 
 
↓ 
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Compound 
Chemical structure (src. 
PubChem) 
Chemical group Extended group Pathway activity 
↑ or ↓ 
pathway 
1-O-galloyl-beta-D-
glucose (l) 
 
 
 
Hydrolysable 
tannin 
Tannin Aldose reductase and 
lipopolysaccharide (LPS)-induced 
activation of JNK and p38 and 
lowered reactive oxygen species 
levels (Yamamoto and Gaynor, 
2001) 
↓ 
Casuarictin (l)  
 
 
Hydrolysable 
tannin 
Tannin Antigen-induced activation type I 
allergies (Yamada et al., 2012) 
↓ 
Oxypaeoniflorin (l)  
 
 
Monoterpene 
glycoside 
Monoterpenoid NO production in LPS 
macrophages (Ding et al., 2012) 
↓ 
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Compound 
Chemical structure (src. 
PubChem) 
Chemical group Extended group Pathway activity 
↑ or ↓ 
pathway 
Paeonidanin E (l)  
 
 
Monoterpene 
glycoside 
Monoterpenoid NO production in LPS-activated 
N9 microglia (Duan et al., 2009) 
↓ 
Paeonidanin A (l)  
 
 
Monoterpene 
glycoside 
Monoterpenoid NO production in LPS-activated 
N9 microglia (Duan et al., 2009) 
↓ 
paeonidanin B (l) N/A Monoterpene 
glycoside 
Monoterpenoid NO production in LPS-activated 
N9 microglia (Duan et al., 2009) 
↓ 
Paeonidanin C (l)  
 
 
Monoterpene 
glycoside 
Monoterpenoid NO production in LPS-activated 
N9 microglia (Duan et al., 2009) 
↓ 
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Compound 
Chemical structure (src. 
PubChem) 
Chemical group Extended group Pathway activity 
↑ or ↓ 
pathway 
Paeoniflorigenone (l)  
 
 
Monoterpene 
glycoside 
Monoterpenoid NO production from LPS-
activated macrophages (Ding et 
al., 2012) 
↓ 
Palbinone (l)  
 
 
Triterpene Diterpenoid Interleukin-1β (Kadota et al., 
1995) 
↓ 
Pedunculagin (l) 
 
 
Hydrolysable 
tannin 
Tannin Human neutrophil elastase (HNE) 
(Cryan et al., 2013) 
↓ 
Expression of IL-1b mRNA in 
Langerhans cells, and secretion of 
IL-1b (Lee et al., 2010) 
↑ 
NO production (Marzouk et al., 
2007) 
↓ 
Proliferation of T-cells and 
macrophages (Marzouk et al., 
2007) 
↑ 
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Compound 
Chemical structure (src. 
PubChem) 
Chemical group Extended group Pathway activity 
↑ or ↓ 
pathway 
1,2,3,4,6-
Pentagalloylglucose 
(l) 
 
 
 
Hydrolysable 
tannin 
Tannin IL-4 and antigen-specific IgE 
production (Kim et al., 2013c) 
↓ 
Strictinin (l)  
 
 
Hydrolysable 
tannin 
Tannin IgE class switch (IgE heavy chain 
germ transcript) of B-cells 
(Tachibana et al., 2001) 
 
↓ 
Tyrosine phosphorylation of 
STAT6 (IL-4 pathway) (Tachibana 
et al., 2001) 
↓ 
1,2,3-Tri-O-galloyl-β-
D-glucose (l) 
N/A Polyphenol Tannin Advanced glycation end-products, 
activation of nuclear factor-k B 
(Lee et al., 2011) 
 
 
 
 
 
↓ 
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Compound 
Chemical structure (src. 
PubChem) 
Chemical group Extended group Pathway activity 
↑ or ↓ 
pathway 
1,2,6-Tri-O-galloyl-β-
D-glucose (l) 
 
 
 
Polyphenol Tannin Advanced glycation end-products 
and activation of nuclear factor-k 
B (Lee et al., 2011) 
↓ 
V, Paeonia veitchii; l, Paeonia lactiflora; cAMP, Cyclic adenosine monophosphate; ERK, extracellular signal-regulated kinase; IFN- γ, 
interferon gamma; HNE, human neutrophil elastase; IgE, immunoglobulin E; IL, interleukin; iNOS, nitric oxide synthase; LPS, 
lipopolysaccharide; mRNA, messenger ribonucleic acid; JNK, c-Jun N-terminal protein kinase; NK-B, nuclear factor kappaB; NO, nitric 
oxide; PDE, phosphodiesterase; STAT, signal transducer and activator of transcription; TH, T helper; T-Cells, thymus lymphocytes; TNF-
, tumour necrosis factor-alpha.
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Cytotoxic and anti-tumour pathway activity 
Numerous compounds have been evaluated as having potential anti-tumour pathway 
activity (Table 6.2).   
Paeoniflorin 
Paeoniflorin has demonstrated in vitro, that it possesses anti-proliferative action, 
inhibiting HT29 colorectal cancer cell growth by as much as 87.3% (Wang et al., 2012c). 
Such action is understood to be through induction of HT29 cell apoptosis. Paeoniflorin 
activates initiator caspases, which then further activate effector caspases (caspase-3 
and caspase-9), which are important apoptosis moderators (Yamakawa et al., 2000). 
Further, paeoniflorin presence shows a decreased S phase cell population and at 
sufficient concentration can lead to cell arrest at the G1 phase. It is likely that increased 
expression of the pro-apoptotic gene p53 is activated by paeoniflorin and has 
downstream effects on proteins causing arrest of cell cycle during G1 phase (Wang et al., 
2012c). Research on lung cancer A549 cells has shown cell arrest during the same G1 
phase, although interestingly, p53 expression was not increased despite a downstream 
p53 target, p21/WAF1 protein, being enhanced. Also differing is the apoptotic pathway, 
which in A549 cells is likely triggered by the Fas/Fas Ligand (FasL) system and 
activation of caspase 8 (Nagata, 1997, Hung et al., 2008). 
Pentagalloylglucose 
The hydrolysable tannin (1,2,3,4,6-) pentagalloylglucose has been described as a 
potential chemopreventive. Due to overexpression, oncoproteins (e.g., fatty acid 
synthase, clusterin) are abundant in carcinoma and pentagalloylglucose can suppress 
such oncoproteins whilst up-regulating tumour suppressor proteins (e.g., glutathione S-
transferase M) (Zhang et al., 2011b). Further, pentagalloylglucose acts to reduce 
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angiogenesis via inhibition of capillary morphogenesis gene 2a, which is typically up-
regulated in endothelial cells undergoing angiogenesis (Cryan et al., 2013). It also 
reduces proliferation of human prostate cancer cells through inhibition of DNA 
synthesis in S-phase cells (Cryan et al., 2013). 
Daucosterol 
The phytosterol daucosterol is found in both species and acts on the extrinsic cellular 
apoptosis pathway. In human breast cancer (estrogen receptor-positive MCF-7) cells, 
daucosterol increases expression of cell surface death receptor Fas, which leads to 
activation of caspase-8 and eventual apoptosis. It possibly does so by changing the cell 
membrane sterol content, in turn affecting Fas expression (Awad et al., 2007). 
Gallic acid 
Gallic acid’s anti-tumour potential lies in its ability to inhibit transcription factor NFB. 
Products of NFB are important for regulating the expression of several genes and cell 
cycle regulatory components involved in tumour development (Morais et al., 2010). 
Carcinogens such as cigarette smoke are understood to trigger NFB, while blocking it 
with a gallic acid may halt proliferation of tumour cells or sensitise them to anti-tumour 
agents leading to apoptosis (Yamamoto and Gaynor, 2001). Research into gallic acid as 
chemotherapy is extensive for a number of different cancer cell types including prostate, 
lung and colon. A review of potential mechanistic anticancer pathways for gallic acid has 
been previously conducted and identified: activation of ATM kinase; inhibition of 
ribonucleotide reductase; inhibition of cyclooxygenase-2 (COX-2); depletion of the 
antioxidant glutathione; inhibition of UDP-glucose dehydrogenase (UGDH); activation of 
Fas, FasL and p53 proteins; and a number of other pathways surrounding apoptosis 
induction.  
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Another key aspect of tumour growth is angiogenesis, and a number of anti-
angiogenic gallic acid pathways have also been identified. Gallic acid’s potential to 
prevent tumour cell invasion via disturbance of signal transduction pathways indicates 
why there is so much interest in it as a potential chemotherapy (Verma et al., 2013). 
Other 
A number of other phytochemicals have been found in the botanicals in lower 
concentration and likely have weaker cytotoxic actions including hydrolysable tannin 
tellimagrandin II (eugeniin), β-sitosterol, 1,2,3,6-Tetra-O-galloyl-β-D-glucose, 13-methyl 
tetradecanoic acid, peonin, phenol (carbolic acid) and pedunculagin. Their known 
activity is briefly described in table 6.2. 
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Table 6.2: Cytotoxic or anti-tumour pathway activity 
Compound 
Chemical structure (src. 
PubChem) 
Chemical 
group 
Extended group Pathway activity 
↑ or ↓ 
pathway 
Daucosterol (beta-
Sitosterol 
glucoside) (v, l) 
 
 
 
Phytosterols Steroid Fas protein and the activity of caspase-8, 
for apoptosis (Awad et al., 2007) 
↑ 
Eugeniin 
(Tellimagrandin 
II)(v) 
 
 
 
Hydrolysable 
tannin 
Tannin IL-1 beta and tumour cell proliferation 
(Miyamoto et al., 1993) 
↑IL-1beta 
↓ tumour 
cell 
proliferati
on 
Paeoniflorin (v)  
 
 
 
 Monoterpenoid Active caspase-3 and caspase-9 (Wang et 
al., 2012c) 
↑ 
p53 in HT29 cells (Wang et al., 2012a) ↑ 
14-3-3 protein HT29 cells (Wang et al., 
2012a) 
↓ 
mFasL and sFasL (Hung et al., 2008) ↑ 
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Compound 
Chemical structure (src. 
PubChem) 
Chemical 
group 
Extended group Pathway activity 
↑ or ↓ 
pathway 
β-Sitosterol (v, l)
  
 
 
 
Phytosterol Steroid Caspase activity resulting in apoptosis 
(Park et al., 2008) 
↑ 
Anticarcinogenic agent changes cell 
membrane wall fluidity and cell 
transduction pathways (Awad and Fink, 
2000) 
↓ 
DNA polymerase β lyase activity for 
repair of DNA (Chaturvedula et al., 2003) 
↓ 
1,2,3,6-Tetra-O-
galloyl-β-D-glucose 
(Tetragalloylglucos
e) (v, l) 
 
 
 
Polyphenol Tannin Matrix metalloproteinases (Saeki et al., 
1999) 
↓ 
Gallic acid (3,4,5-
trihydroxybenzoic 
acid) (l) 
 
 
 
Polyphenol Others 
 
TNF-α-induced NFκB activation (Morais 
et al., 2010) 
 
↓ 
ATM kinase signalling (Chaturvedula et 
al., 2003) 
↑ 
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Compound 
Chemical structure (src. 
PubChem) 
Chemical 
group 
Extended group Pathway activity 
↑ or ↓ 
pathway 
13-Methyl 
tetradecanoic acid 
[Patent] (l) 
 
 
 
Fatty acid Fatty acid Possibly topoisomerase I (Yang, 1999, 
Lee et al., 1998) 
↓ 
Pedunculagin (l)  
 
 
Hydrolysable 
tannin 
Tannin Cytotoxic activity against cancer cells 
(Marzouk et al., 2007) 
unsure 
1,2,3,4,6-
Pentagalloylglucose 
(l) 
 
 
Hydrolysable 
tannin 
Tannin Tumour suppressor proteins (e.g., 
glutathione S-transferase M (Zhang et al., 
2011b) 
↑ 
Oncoproteins (e.g., fatty acid synthase, 
clusterin)(Zhang et al., 2011b) 
↓ 
DNA synthesis in S-phase (Mizushina et 
al., 2010) 
↓ 
 CMG2 and angiogenesis (Cryan et al., 
2013) 
↓ 
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Compound 
Chemical structure (src. 
PubChem) 
Chemical 
group 
Extended group Pathway activity 
↑ or ↓ 
pathway 
Peonin (peonidin-
3,5-diglucoside) (l) 
 
 
 
Flavonoid Flavonoid Of DNA fragments (sub-G1 fraction)(Shin 
et al., 2009) 
↑ 
Anti-apoptotic proteins (Shin et al., 
2009) 
↓ 
Phenol (Carbolic 
acid) (l) 
 
 
 
Phenol Others Coagulation necrosis (Quint et al., 1998, 
Quint et al., 1996) 
↑ 
Tellimagrandin I (l)  
 
 
Hydrolysable 
tannin 
Tannin Arachidonate-12-lipoxygenase (Zheng et 
al., 2012) 
↓ 
Gap junctional communication (GJIC) and 
Cx43 gene expression at mRNA and 
protein levels (Yi et al., 2006) 
↑ 
Cells in G0/G1 and G2/M phases (Yi et al., 
2006) 
↓ 
Erythroid and megakaryocytic 
differentiation (Yi et al., 2004) 
↓ 
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V, Paeonia veitchii; l, Paeonia lactiflora; cAMP, Cyclic adenosine monophosphate; ATM, ataxia-telangiectasia mutated; CMG2, capillary 
morphogenesis gene 2; DNA, eoxyribonucleic acid; ERK, extracellular signal-regulated kinase; FasL, fas ligand; G, gap; GJIC, Gap 
junctional communication; IFN- γ, interferon gamma; HNE, human neutrophil elastase; HT, Human colon adenocarcinoma cells; IgE, 
immunoglobulin E, IL, interleukin; iNOS, nitric oxide synthase; LPS, lipopolysaccharide; mRNA, messenger ribonucleic acid; JNK, c-Jun N-
terminal protein kinase; NK-B , nuclear factor kappaB; NO, nitric oxide; PDE, phosphodiesterase; S-phase, synthesis phase; STAT, signal 
transducer and activator of transcription; TH, T helper; T-Cells, thymus lymphocytes; TNF-, tumour necrosis factor-alpha.
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Anti-viral pathway activity  
Three compounds (pentagalloylglucose, gallic acid and tellimagrandin II) have been 
evaluated as having potential anti-viral pathway activity (Table 6.3).   
Pentagalloylglucose 
Pentagalloylglucose inhibits NS3 protease, where it shows therapeutic potential against 
influenza-A virus by reducing plasma membrane accumulation of viral nucleoprotein at 
the replication stage. Further, by affecting the surface structure of infected cells, release 
of their virus particles (budding) is reduced (Liu et al., 2011). Strictinin also has 
potential against influenza-A virus, where it has antioxidant and anti-viral activities. 
Evidence indicates inoculation with strictinin can inhibit influenza-A virus replication 
resulting in a reduced number of infected cells. It may also inhibit influenza B virus (IBV) 
and human parainfluenza virus type-1 (hPIV-1) (Saha et al., 2010). 
Gallic acid 
Via disruption of viral glycoproteins and detachment of virus-infected cells, gallic acid 
suppresses expression of viral proteins (ICP27, gC, gD and VP5) in cells infected with 
the herpes simplex virus; however, it has shown no assistance in inoculation to prevent 
initial infection with the virus. Similarly, gallic acid has shown to reduce the degree of 
viral replication of HIV (Kratz et al., 2008). 
Tellimagrandin II 
Found in P. veitchii, tellimagrandin II (eugeniin) inhibits herpes simplex; however, it 
also has preference for inhibition of herpes simplex virus-1 DNA polymerase activity 
over unaffected DNA polymerase activity, leading to an overall reduction in viral DNA 
synthesis (Kurokawa et al., 1998, Kurokawa et al., 2001). Further evidence suggests 
tellimagrandin I may also have anti-viral activity towards viruses such as hepatitis C 
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where tellimagrandin I prevents invasion of hepatitis C into hepatocytes (Tamura et al., 
2010).  
Another constituent with potential action on hepatitis C is 1,2,3,6-Tetra-O-
galloyl-β-D-glucose. Found in both Paeonia species, it targets a common hepatitis C drug 
pathway inhibiting activity of NS3 protease of the virus’s RNA (Duan et al., 2004). 
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Table 6.3: Anti-viral pathway activity 
Compound 
Chemical structure (src. 
PubChem) 
Chemical group Extended group Pathway activity 
↑ or ↓ 
pathway 
Eugeniin 
(Tellimagrandin II) (v) 
 
 
 
Hydrolysable tannin Tannin Herpes simplex virus-1 DNA 
polymerase (Yamakawa et 
al., 2000, Kurokawa et al., 
2001) 
↓ 
Hepatitis C virus invasion 
(Tamura et al., 2010) 
↓ 
1,2,3,6-Tetra-O-galloyl-
β-D-glucose (v,l) 
 
 
 
Polyphenol Tannin Hepatitis C NS3 protease 
(Duan et al., 2004) 
↓ 
Gallic acid (l)  
 
 
Polyphenol Others Viral proteins ICP27, gC, gD 
and VP5 (Kratz et al., 2008) 
 
↓ 
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1,2,3,4,6-
Pentagalloylglucose (l) 
 
 
 
Hydrolysable tannin Tannin Plasma membrane 
accumulation of NP (Liu et 
al., 2011) 
↓ 
Hepatitis C NS3 protease 
(Duan et al., 2004) 
↓ 
Strictinin (l)  
 
 
Hydrolysable tannin Tannin Viral replication (Saha et al., 
2010) 
↓ 
HIV reverse transcriptase 
(Yoshida et al., 1996) 
↓ 
Tellimagrandin I (l)  
 
 
Hydrolysable tannin Tannin Virus envelope proteins E1 
and E2 (Tamura et al., 2010) 
↓ 
V, Paeonia veitchii; l, Paeonia lactiflora; DNA, deoxyribonucleic acid; ERK, extracellular signal-regulated kinase; G, gap; HIV, human 
immunodeficiency virus; HmRNA, messenger ribonucleic acid; NP, nucleoprotein; NS, non-structural protein; S-phase, synthesis phase
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Antibacterial and anti-fungal activities 
Four P. lactiflora compounds (carbolic acid, pyrethrin I, tellimagrandin I and 1,2,3,4,6-
pentagalloylglucose) have been evaluated as having potential antibacterial or anti-
fungal pathway activity (Table 6.4).  
Pentagalloylglucose 
The most abundant compound with antibacterial activity, pentagalloylglucose, inhibits 
FabG reductase, which is important for fatty acid biosynthesis and necessary for 
bacterial growth (Zhang et al., 2008a). 
Carbolic acid 
Carbolic acid (phenol) is used in antiseptics and disinfectants against gram-positive and 
negative bacteria, acting by denaturing proteins and destroying cell permeability 
(Martingdale, 1996, Hugo, 1978). 
Pyrethrin I 
Pyrethrin I has been shown to inhibit the multiple drug-resistant mycobacterium 
tuberculosis, as well as protozoal parasites leading to diseases such as African 
trypanosomiasis, Chagas disease, malaria and leishmaniasis, although the mechanism of 
these pathways is still not fully understood (Rugutt et al., 1999, Hata et al., 2011).  
Tellimagrandin I 
Tellimagrandin I can reduce drug resistance to antibiotic use and enhance antibacterial 
action. It has been evidenced to decrease production of penicillin-binding protein 2 
(PBP2), which results in a reduction in the resistance level of β-lactams in methicillin-
resistant Staphylococcus aureus (Shiota et al., 2004). Further evidence suggests 
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antibacterial activity against H. pylori, possibly via its membrane-damaging activity 
(Funatogawa et al., 2004). 
Benzoic acid 
Found in both P. lactiflora and P. veitchii, Benzoic acid, shows anti-fungal activity, hence 
its common use in juices, food product preservatives and pharmaceuticals. In an acid 
environment benzoic acid permeates the fungal cell wall until equilibrium inside and 
outside of the cell is reached, leading to internal cell acidification, which inhibits 
glycolysis and depletes adenosine triphosphate in the cell, which is necessary for 
growth (Krebs et al., 1983). 
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Table 6.4: Antibacterial and anti-fungal pathway activity 
Compound 
Chemical structure (src. 
PubChem) 
Chemical 
group 
Extended group Pathway activity 
↑ or ↓ 
pathway 
Phenol (Carbolic acid) (l)  
 
 
Phenol  Denaturing proteins and 
destroying cell permeability 
(Quint et al., 1998, 
Martingdale, 1996) 
↑ 
Pyrethrin I (l)  
 
 
Pyrethrin Monoterpenoid Anti-trypanosomal action 
unknown (Hata et al., 2011, 
Rugutt et al., 1999) 
N/A 
Tellimagrandin I (l)  
 
 
Hydrolysable 
tannin 
(polyphenol) 
Tannin Penicillin binding protein 2 
‘(2a)(Shiota et al., 2004) 
↓ 
Membrane-damaging activity 
(Funatogawa et al., 2004) 
↑ 
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Compound 
Chemical structure (src. 
PubChem) 
Chemical 
group 
Extended group Pathway activity 
↑ or ↓ 
pathway 
1,2,3,4,6-
Pentagalloylglucose (l) 
 
 
 
Hydrolysable 
tannin 
Tannin  FabG (beta-oxoacyl-ACP 
reductase) of the fatty-acid-
elongation cycle (Zhang et 
al., 2008b) 
↓ 
Benzoic acid (v, l)  
 
 
Carboxylic acid Others Glycolysis and ATP 
production (Krebs et al., 
1983) 
↓ 
V, Paeonia veitchii; l, Paeonia lactiflora; ATP, adenosine triphosphate.
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Antioxidant or pro-oxidant activities 
Ten compounds, mostly from P. lactiflora, have been evaluated as having potential 
antioxidant or pro-oxidant pathway activity (Table 6.5). 
Albiflorin 
Found more predominantly in the P. lactiflora species, the monoterpene glycoside 
albiflorin, has strong antioxidant activity. Albiflorin inhibits abnormal production of 
mitochondrial superoxide, in turn protecting mitochondria from pro-oxidant reaction 
activity (Suh et al., 2013). 
Benzoic acid 
A constituent of P. veitchii, benzoic acid reduces oxygen radicals, in particular 
scavenging hydroxyl group radicals, which otherwise enhance arichadonic acid pathway 
activity, a key pathway implicated in a number of diseases such as psoriasis (Haseloff et 
al., 1990).  
Gallic acid 
Gallic acid and 2,3-O-(S)-Hexahydroxydiphenoyl-D-glucopyranose are both polyphenol 
compounds in P. lactiflora. Gallic acid has antioxidative activity, which on weight basis is 
rated as having higher antioxidant potential than vitamin C (Kroes et al., 1992, Kim et al., 
2002). Similarly, 2,3-O-(S)-Hexahydroxydiphenoyl-D-glucopyranose shows superoxide-
dismutase-like activity and stronger scavenging than gallic acid of 1,1-diphenyl-2-
picrylhydrazyl (DPPH) (Haseloff et al., 1990). 
Paeonilactone C 
The monoterpene paeonilactone C, found in P. lactiflora, also shows antioxidant activity, 
reducing the highly toxic ROS. Without reduction, these ROS will oxidatively modify 
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nucleic acid, lipids, sugars and proteins, subsequently forming the cellular toxin H2O2. 
The resultant cellular inflammation from this toxin can potentiate many diseases such 
as those of the glial cells in the brain. It is suggested compounds with antioxidant 
activity such as paeonilactone C may be suitable as a preventive for such disease (Kim et 
al., 2009b).  
Other 
Other contained antioxidant or pro-oxidant phytochemicals with likely weaker actions 
include palbinone, pedunculagin, casuarictin and tellimagrandin I. Their potential 
pathway activity is presented in table 6.5. 
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Table 6.5: Antioxidant/pro-oxidant pathway activity 
Compound 
Chemical structure (src. 
PubChem) 
Chemical group Extended group Pathway activity 
↑ or ↓ 
pathway 
Albiflorin (v, l)  
 
 
Monoterpene 
glycoside 
Monoterpenoid Mitochondrial 
superoxide production 
(Suh et al., 2013) 
↓ 
Benzoic acid (v)  
 
 
Carboxylic acid Others Hydroxyl radical 
scavenging (Haseloff et 
al., 1990) 
↑ 
2,3-O-(S)-
Hexahydroxydiphenoyl-
D-glucopyranose (l) 
N/A 
Polyphenol Tannin Superoxide anion radical 
(Fukuda et al., 2003) 
↓ 
Gallic acid (l)  
 
 
Polyphenol Others Oxidation (Kim et al., 
2002) 
↓ 
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Compound 
Chemical structure (src. 
PubChem) 
Chemical group Extended group Pathway activity 
↑ or ↓ 
pathway 
Paeonilactone C (l)  
 
 
Monoterpene 
glycoside 
Monoterpenoid Reactive oxygen species  
(Kim et al., 2009b) 
↓ 
Palbinone (l)  
 
 
Triterpene Diterpenoid Heme oxygenase-1 (Ha et 
al., 2013) 
↑ 
Pedunculagin (l)  
 
 
Hydrolysable tannin Tannin Radical DPPH and 
physiological radicals 
including ROO*, OH*, and 
O2-*(Marzouk et al., 
2007) 
↓ 
 258 
Compound 
Chemical structure (src. 
PubChem) 
Chemical group Extended group Pathway activity 
↑ or ↓ 
pathway 
Strictinin (l)  
 
 
Hydrolysable tannin Tannin Linoleic acid 
peroxidation 
In micelles, peroxidation 
of LDL and oxidative 
haemolysis of red blood 
cells (Zhou et al., 2004) 
↓ 
Tellimagrandin I (l)  
 
 
Hydrolysable tannin Tannin Mediated oxidated DNA 
strand break (Yi et al., 
2009) 
↓ 
Mediated plasmid 
oxidated DNA strand 
break (Yi et al., 2009) 
↓ at low 
concentrati
on 
↑at high 
concentrati
ons 
V, Paeonia veitchii; l, Paeonia lactiflora; DNA, deoxyribonucleic acid; DPPH, 2,2-diphenyl-1-picrylhydrazyl; LDL, low-density lipoproteins; 
O2-, superoxide anion radical; OH, hydroxyl radical; ROO, peroxyl radical.
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Glycemic activity 
Several components of the two Paeonia species affect blood glucose (Table 6.6). 
Through increased expression of nephrin protein in the kidneys of diabetic rats and 
inhibition of diabetic nephropathy progression, TGP may have potential use in 
preventing diabetes-associated renal damage (Wu et al., 2009b, Wang et al., 2012d, 
Zhang et al., 2009b, Zhang et al., 2014e, Su et al., 2010a). 
Tellimagrandin II, 8-debenzoylpaeoniflorin, gallic acid and palbinone all have anti-
glycaemic activity; 8-debenzoylpaeoniflorin lowers blood glucose, most likely via an 
insulin-dependent pathway (Hsu et al., 1997). 
Gallic acid may prove to be an important future therapy as it decreases blood 
glucose and increases insulin in plasma in rats (Punithavathi et al., 2011). This is 
possibly due to the reduction in oxidation products, an increase in enzymatic 
antioxidant activity and the stimulation of pancreatic insulin secretion. These actions 
correlate clinically with a reduction in glycosylated haemoglobin, which when increased 
is commonly associated with diabetes mellitus (Punithavathi et al., 2011). 
Palbinone likely has antiglycemic activity through regulation of gluconeogenesis, 
the process producing glucose from non-carbohydrate sources in the liver. This 
gluconeogenesis regulates the plasma glucose levels and is controlled by the activation 
of AMP-activated protein kinase and stimulation of fatty acid oxidation, and thus 
increases glucose uptake and glycogen synthesis (Ha do et al., 2009). 
Tellimagrandin II inhibits -glucosidases, in turn reducing the absorption and 
metabolism of carbohydrates and subsequently preventing rise in blood glucose (Toda 
et al., 2000).  
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Table 6.6: Glycaemic effects 
Compound 
Chemical structure 
(src. PubChem) 
Action 
Chemical 
group 
Extended group Pathway activity 
↑ or ↓ 
pathway 
8-
debenzoylpaeoniflor
in (v, l) 
 
 
 
Antiglycemic Monoterpene 
glucoside 
Monoterpenoid Blood glucose (Hsu et al., 
1997) 
↓ 
Eugeniin 
(Tellimagrandin II) 
(v) 
 
 
 
Antiglycemic  Hydrolysable 
tannin 
Tannin 1.Type III collagen 
(Tsukiyama et al., 2010) 
↑ 
2. Intestinal -glucosidases 
(maltase)(Toda et al., 2000) 
↓ 
Gallic acid (l)  
 
 
Antiglycemic Polyphenol Others Blood glucose/insulin 
(Punithavathi et al., 2011) 
↓/↑ 
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Compound 
Chemical structure 
(src. PubChem) 
Action 
Chemical 
group 
Extended group Pathway activity 
↑ or ↓ 
pathway 
Palbinone (l)  
 
 
Antiglycemic Triterpene Diterpenoid AMPK, GSK-3b, and ACC 
phosphorylation 
(Mizushina et al., 2010) 
↑ 
Tellimagrandin I (l)  
 
 
Hepatoprotecti
ve 
Hydrolysable 
tannin 
Tannin CCl 4- and d-GalN -induced 
cell damage (Shimoda et al., 
2008) 
↓ 
V, Paeonia veitchii; l, Paeonia lactiflora; ACC, acetyl-CoA carboxylase; AMPK, 5' adenosine monophosphate-activated protein kinase; ATP, 
adenosine triphosphate; CCl 4-, carbon tetrachloride; d-GalN, d-galactosamine; GSK-3b, glycogen synthase kinase 3 beta.gf
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Other phytochemical biological activities 
A number of constituents have activities not within the previous classifications yet still 
warrant further explanation (Table 6.7). For instance by increasing alkaline 
phosphatase activity of MC3T3-E1 cell (an osteoblast-like cell) at concentration, 
albiflorin shows evidence of cytoprotection. The alkaline phosphatase increase is 
understood to be essential to stimulation of mineralisation and subsequent bone 
hardening, which may prove beneficial in conditions such as osteoporosis (Yen et al., 
2007). Furthermore, albiflorin reduces ROS toxicity in cells and apoptosis, reducing 
subsequent lactate dehydrogenase leaking and thus increasing the viability of the cells. 
Overall, albiflorin tends to be able to protect cell mitochondria from oxidative stress and 
generally improves their function (Suh et al., 2013).  
Total glucosides of peony also have protective effects on cells, where in systemic 
lupus erythematosus they can limit liver damage from drugs such as methotrexate, and 
reduce the usage of prednisone (Zhang et al., 2011a, Chen et al., 2013). 
The chemical structure of daucosterol resembles that of cholesterol, differing only 
by an extra ethyl group. It’s activity then follows the reduction in the dietary and biliary 
cholesterol uptake by intestinal cells, subsequently lowering serum total and low-
density lipoprotein cholesterol levels (Salen et al., 1970, Jones and AbuMweis, 2009). 
Found in both species of Paeonia, paeoniflorigenone has potential neuromuscular 
activity. Paeoniflorigenone has shown in vivo evidence it can inhibit acetylcholine 
chloride contraction of muscle, block muscle twitch response and depolarise the resting 
membrane potential (Kimura et al., 1984). Paeoniflorigenone, along with three other 
hydrolysable tannin compounds found in P. lactiflora (5-desgalloylstachyurin, casuariin 
and pedunculagin) also show anticoagulant activity. Paeoniflorigenone is twice as 
strong as well-known platelet inhibitor acetyl salicylic acid in reducing blood 
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coagulation (Koo et al., 2010). 5-Desgalloylstachyurin, casuariin and pedunculagin also 
have in vivo evidence of prolonging blood clotting time, likely inhibiting thrombin from 
catalysing fibrinogen into clots of fibrin. Likely contributing to this anti-coagulant effect 
is the ability of the compounds to inhibit factor Xa, important for thrombin activation 
and a common target of anti-coagulant drugs such as warfarin and heparin (Dong et al., 
1998). 
Already utilised in the drug bismuth subgallate, gallic acid is commonly utilised for 
its astringent and haemostatic properties. Commonly utilised in a paste from for 
surgical operations or conditions such as haemorrhoids, gallic acid activates factor XII 
and thus accelerates coagulation (Council of Europe, 2005) (Hatton, 2000, Thorisdottir 
et al., 1988).  
Phenol (carbolic acid),  has antibacterial activity and is commonly utilised as an 
antiseptic by pharmaceuticals, however at increased concentration it is understood to 
take on an analgesic action where it is sometimes administered for conditions such as a 
sore throat (Martingdale, 1996). 
There is research suggesting tellimagrandin II may increase type III collagen 
production to reduce the effects of skin aging (Tsukiyama et al., 2010). Further, it may 
be hepato-protective, protecting hepatocytes from carbon tetrachloride (CCl4) damage. 
Tellimagrandin I has shown a similar effect, although with weaker action (Shimoda et al., 
2008). 
Pyrethrins have insecticidal qualities, which have been utilised for treatment of 
skin conditions from parasitic infections such as scabies (Martingdale, 1996). Pyrethrin 
I and II, both found in P. lactiflora, are believed to have neurotoxic activity, damaging 
neuron membranes and prolonging sodium channel gate activation (Brown et al., 1995, 
Kueh et al., 1985, Katsuda, 1999).  
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Unknown activity 
A number of constituents are yet to be found in experiment to have any biological 
activity (Table 6.8). 
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Table 6.7: Other constituent pathway activity 
Compound 
Chemical structure (src. 
PubChem) 
Action 
Chemical 
group 
Extended group Pathway activity 
↑ or ↓ 
pathway 
Albiflorin (v, l)  
 
 
Cytoprotecti
on 
Monoterpene 
glycoside 
Monoterpenoid ALP activity and calcium 
deposition in osteoblastic 
MC3T3-E1 cells (Zhang et al., 
2008b)  
↑ 
 
Oxidative stress and ATP 
production in mitochondria 
(Suh et al., 2013) 
↓ 
Daucosterol (beta-
Sitosterol 
glucoside) (v, l) 
 
 
 
Anti-
cholesterol 
Phytosterols Steroid Serum total and LDL-cholesterol 
(Jones and AbuMweis, 2009) 
↓ 
Paeoniflorigenone 
(v, l) 
 
 
 
1.Anti-
coagulant 
2.Neuromus
cular 
blocking 
Monoterpene 
glycoside 
Monoterpenoid Platelet aggregation and blood 
coagulation (Koo et al., 2010) 
↓ 
Acetylcholine induced 
contraction and muscle twitch 
response (Kimura et al., 1984) 
↓ 
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Compound 
Chemical structure (src. 
PubChem) 
Action 
Chemical 
group 
Extended group Pathway activity 
↑ or ↓ 
pathway 
5-
Desgalloylstachyuri
n (l) 
 
 
 
Anticoagula
nt 
Hydrolysable 
tannin 
Tannin Thrombin and Factor Xa (Dong 
et al., 1998) 
↓ 
Casuariin (l)  
 
 
Anticoagula
nt 
Hydrolysable 
tannin 
Tannin Thrombin and Factor Xa (Dong 
et al., 1998) 
↓ 
Pedunculagin (l)  
 
Anticoagula
nt 
Hydrolysable 
tannin 
Tannin Thrombin, fibrinogen and 
Factor Xa (Dong et al., 1998) 
↓ 
 267 
Compound 
Chemical structure (src. 
PubChem) 
Action 
Chemical 
group 
Extended group Pathway activity 
↑ or ↓ 
pathway 
Phenol (Carbolic 
acid) (l) 
 
 
 
Anaesthetic 
(Chlorasepti
c® and 
Carmex®) 
Phenol Others Paralysis of the free nerve 
endings (Martingdale, 1996) 
N/A 
Pyrethrin I (l)  
 
 
Insecticide Pyrethrin Monoterpenoid Voltage-gated sodium channels 
(Wolansky and Tornero-Velez, 
2013, Brown et al., 1995) 
↓ 
Pyrethrin II (l)  
 
Insecticide Pyrethrin Monoterpenoid Voltage-gated sodium channels 
(Wolansky and Tornero-Velez, 
2013, Brown et al., 1995) 
↓ 
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Compound 
Chemical structure (src. 
PubChem) 
Action 
Chemical 
group 
Extended group Pathway activity 
↑ or ↓ 
pathway 
Tellimagrandin I (l)  
 
 
Hepatoprote
ctive 
Hydrolysable 
tannin 
Tannin Carbon tetrachloride (CCl 4-) 
and d-galactosamine (d-GalN)-
induced cell damage (Shimoda 
et al., 2008) 
↓ 
V, Paeonia veitchii; l, Paeonia lactiflora; ALP, alkaline phosphatase; ATP, adenosine triphosphate; CCl 4, carbon tetrachloride; d-GalN, d-
galactosamine; LDL, Low-density lipoprotein
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Table 6.8: Unknown pathway activity constituents 
Compound Chemical structure (src. PubChem) Chemical group Extended group  
Lactiflorin (v) 
 
 
 
 
Monoterpene glycoside Monoterpenoid 
(Z)-(IS,5R)-β-Pinen-10-yl-β-
vicianoside (v) 
 
 
 
Monoterpene glycoside Monoterpenoid 
Albiflorin R1(l) N/A Monoterpene glycoside Monoterpenoid 
Benzoylpaeoniflorin (l)  
 
 
Monoterpene glycoside Monoterpenoid 
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Compound Chemical structure (src. PubChem) Chemical group Extended group  
3-O-Galloylquinic acid (l)  
 
 
Polyphenol Tannin 
4-O-Galloylquinic acid (l)  
 
 
Polyphenol Tannin 
Paeonilactone A (l)  
 
 
 
Monoterpene glycoside Monoterpenoid 
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Compound Chemical structure (src. PubChem) Chemical group Extended group  
Paeonilactone B (l)  
 
 
Monoterpene glycoside Monoterpenoid 
Paeonidanin D (l)  
 
 
Monoterpene glycoside Monoterpenoid 
1,3,6-Trigalloyl-β-D-glucose 
(l) 
 
 
 
Polyphenol Tannin 
V, Paeonia veitchii; l, Paeonia lactiflora; N/A, not available
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6.3.3 Toxicity 
Despite the possible efficacy of herb botanicals, the identified active pathways may also 
provide potential risks of therapy. There are reports of toxicity associated with oral 
herb intake, and any research involving repeated doses are recommended to consider 
appropriate and timely testing of liver and kidney function among others if there is 
known or suspected toxicity (Perharic et al., 1993, Graham-Brown, 1992). 
There is little published toxicity evidence for either of the Paeonia botanicals, with 
major pharmacopoeia identifying only a precaution not to administer either botanical 
with veratrum root or rhizome (rhizome et Radix veratri bot. Veratrum nigrum L.; lilu). 
This incompatibility has been likely known for thousands of years, where Veratrum 
nigrum is documented in major pharmacopoeia as toxic and requires caution for its 
prescription. Research confirms this classical view, with trembling, convulsions and 
spasms developing in mice following intragastric administration of the combined 
solution resulting in death in 5–10 minutes (Zhang et al., 2014f). In this experiment, the 
mortality of female mice decreased as the concentration of P. lactiflora increased; 
however, the pattern was less obvious in male mice. Interestingly, P. lactiflora had a 
neuroprotective effect against the toxicity of Veratrum nigrum (Zhang et al., 2014f). This 
antitoxic activity has been supported in other research where P. lactiflora has shown to 
be hepato-protective, assisting the liver to excrete toxins (Du, 1989, Sun et al., 2008). 
The US National Institute of Health lists peony as well tolerated with occasional 
gastrointestinal upset and allergic skin reactions reported, the latter more common 
when applied topically. As such, dietary supplements do not require extensive pre-
marketing approval from the US Food and Drug Administration (United States National 
Institute of Health (NIH), 2013). Despite little evidence suggesting the entire botanicals 
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to be of any significant toxicity, there is evidence that the constituents individually have 
some potential toxicity. For example, phenol and pyrethrin I dose toxicity in rats has 
shown development of tremors, spasms and eventual death from respiratory failure, 
likely due to nervous tissue voltage-dependent sodium channels having a prolonged 
open state (Industrial Bio-test Laboratories Inc, 1973, Verschoyle and Barnes, 1972, 
Wolansky et al., 2006). In contrast, potential anti-fungal benzoic acid has been 
recognised as safe by the US Food and Drug Administration for use in foods (Nair, 2001).  
6.4 Discussion  
Although there are constituents in common between P. lactiflora and P. veitchii, there 
are also many that are only found in one of the species. Improved scientific analysis 
techniques such as HPLC will continue to fine-tune the identification and concentrations 
of contained phytochemicals, and may also identify new compounds. The phytochemical 
variation between the two species indicates their biological activity likely differs when 
administered in their entire form.  
For rigorous scientific studies, correct identification of botanicals is vital to ensure 
processed extracts contain the correct phytochemicals for the disease being targeted. 
For psoriasis, most disease activity is associated with inflammation and proliferation of 
cells, so botanical constituents with potential activity on these pathways warrant 
further investigation. Both P. lactiflora and P. veitchii constituents contain activity 
relevant to psoriasis. For instance, monoterpenoids, albiflorin and paeoniflorin found in 
both botanicals have anti-inflammatory activity evidenced in psoriasis. Albiflorin has 
the ability to reduce activation of neutrophils, while paeoniflorin acts by reducing 
chemokine expression in endothelial cells, as well as down-regulating numerous TNF- 
inflammatory induction activities. 
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Studies on constituent activity, however, are not necessarily undertaken in 
psoriasis models, and as such much of the activity can only be theorised to have effect 
on psoriasis. Thus, in vitro and in vivo study of constituent activity is needed in 
psoriasis-specific models to investigate how the actual constituent activity impacts 
psoriatic disease. 
It appears the function of constituents in P. lactiflora and P. veitchii match their 
indication by Chinese medicine for psoriasis therapy. For instance, historic usage of 
Paeonia for kidney and liver disorders matches scientific evidence for TGP activity in 
these organs (Pickering, 1989, Wu et al., 2009b, Li et al., 2011). Further investigation of 
constituents from each botanical in PSORI-CM01 may provide further indication of 
correlation between scientific biological disease activities and indicated Chinese 
medicine therapeutic use.  
Bai shao and chi shao products found in the marketplace are manufactured and 
processed from a variety of botanicals and geographic areas. It is therefore difficult for 
consumers to distinguish which botanical variety they are being sold. Usage of incorrect 
product, may not only impact on therapeutic outcomes for consumers, but may also 
increase risk of adverse events caused by a constituent activity not indicted for their 
disease. 
Toxicity of both species in entire form appears to be low; however toxicity of 
individual constituents varies considerably. More research is needed to evaluate the 
toxicity of constituents prior to utilising a compound as an individual therapeutic. 
Further, pharmacogenics research is also needed to understand interactions and any 
potential synergism or antagonism between constituents, which may impact 
therapeutic and/or toxic outcomes. 
 275 
6.5 Conclusion 
It is evident that while some constituents are common between P. veitchii and P. 
lactiflora many also unique to each. Such difference needs to be considered when 
administering either botanical in their whole form, to ensure the intended therapeutic 
effect matches the intended biological activity. Phytochemical variation between the 
species may support traditional medicine theory and recommendations of each 
botanical for different diseases. Anti-inflammatory, anti-tumour and antioxidant agents 
make up the majority of phytochemical actions in both species. 
Scientific research evidence indicates that activity of Paeonia phytochemicals 
match traditional Chinese medicine usage of the botanicals. For instance, historic usage 
of the Paeonia species for kidney and liver disorders matches evidence for TGP in 
diseases of these organs (Pickering, 1989, Wu et al., 2009b, Li et al., 2012b). However, 
some traditional medicine uses for each species are as yet unable to be explained 
molecularly, such as their historic analgesic use. Such function may be explained by the 
large number of phytochemicals with anti-inflammatory activity present in both species, 
however more research is needed.  
Based on the biological activity of each botanical and historical Chinese medicine 
usage of both peony species, chi shao produced from P. veitchii appears to be the most 
appropriate form for the proposed clinical trial formulation. While P. lactiflora contains 
more known constituents, many of these do not appear to be relevant to psoriasis 
disease activity. Paeoniflorin was determined to be the biological marker of choice given 
its relatively high available concentration in P. veitchii and the multiple activity 
pathways it has on TNF-. As discussed, anti TNF- is one of the key targets for many 
psoriatic pharmaceuticals. 
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Chapter 7 – Development of a pilot randomised, placebo-controlled 
parallel design study: Oral Chinese herbal medicine plus topical 
standard conventional care (Calcipotriol cream) vs. oral placebo plus 
standard conventional care (Calcipotriol cream) for mild–moderate 
adult psoriasis vulgaris 
This chapter details development of a protocol for a pilot RCT to investigate oral CHM 
PSORI-CM01 combined with conventional medicine. It explains how the pilot’s design 
was determined and details its aims and methodology. Full details are presented on 
participant recruitment, screening, randomisation and blinding. Intervention/placebo 
administration and dosage are detailed along with the assessment time points and 
investigated outcome measures. Potential psoriasis related blood markers, regulatory 
aspects of the pilot and the safety measures in place for participants are described. 
Lastly handling procedures for participant data and its proposed statistical analysis 
methods are described.  
7.1 Background 
Following literature review of psoriasis phenotypes, their prevalence, aetiology, 
pathogenesis, severity measures and treatments, results were used to establish the 
basis for design of further clinical study of CHM. Further discussion and literature 
review was needed to determine the most suitable methodology for the study. The two 
main approaches to clinical studies are either a pragmatic design in which 
methodological aspects of the protocol are flexible, or an explanatory style in which 
these aspects are more fixed. Both designs were explored to evaluate their pros and 
cons, and aspects from each were utilised to develop a clinical trial protocol that would 
sufficiently investigate the efficacy of PSORI-CM01 for vulgaris type psoriasis. 
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7.2 Methods of clinical trial design 
The design of a study is important as it can assist or hinder analysis of its data, as well as 
influence potential bias of any results and impact on significance any outcomes may 
have for researchers, physicians, policymakers and sufferers. Pragmatic design studies 
tend to more accurately reflect real life scenarios of a condition; however, as data are 
often quite varied and difficult to classify analysis becomes complicated. Explanatory 
design studies provide much clearer data that can be more simply grouped, as they 
provide data that are repeated or similarly grouped, which can then be compared with 
some level of statistical confidence. Unfortunately, the specificity of explanatory data 
generally means results are only transposable to populations with the same 
characteristics as those targeted in the study. Both approaches have their benefits and 
drawbacks, and ideally study designers should consider aspects from both approaches 
to ensure subsequent development of a study protocol is rigorous, has low risk of bias 
and is likely to provide clinically relevant data.  
7.2.1 Explanatory study design  
Very few trials investigating interventions are purely pragmatic or explanatory in 
design with some aspects of an explanatory study often beyond the investigators’ 
control (Thorpe et al., 2009). Commonly considered the gold standard for assessing the 
efficacy of an intervention, the RCT is predominantly explanatory in style. There is, 
however, criticism that RCT results do not provide sufficient clinically relevant data. A 
key contributing aspect of the explanatory nature of RCTs is the screening of 
participants, where inclusion and exclusion criteria are used to determine the 
characteristics of the sample. For example, a study might exclude people with a worse 
prognosis, or include participants with a better prognosis, subsequently limiting the 
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generalizability of the RCT results and reducing their potential clinical value (McKee et 
al., 1999). Randomised controlled trials may have great internal validity for the studied 
population, but external validity of differing race, age, co-morbidities etc. is often 
reduced (Kovesdy and Kalantar-Zadeh, 2012). Due to these limitations, researchers and 
health policymakers have shifted towards pragmatic style studies (Zwarenstein and 
Treweek, 2009, Foster and Little, 2012, Kovesdy and Kalantar-Zadeh, 2012). 
7.2.2 Pragmatic study design  
Pragmatic trials provide a greater level of external validity to the general population, 
and as a result clinical applicability usually reflects more closely the clinical reality of 
the disease population (Black, 1999). A pragmatic design provides greater 
measurement and analysis of the synergistic effects a population may experience if 
exposed to the intervention. While pure pragmatic study would identify and collecting 
sample characteristics such as severity and concomitant drug use, it would not exclude 
people due to such characteristics. A treatment protocol may be provided to guide 
pragmatic style studies; however, a true pragmatic study would allow other treatments 
to be added at the researchers’ or indeed the participants’ discretion. Frustrated 
medical specialists are now campaigning for researchers to follow pragmatic methods 
to investigate interventions (Kovesdy and Kalantar-Zadeh, 2012).  
7.2.3 Explanatory vs. pragmatic for development of CHM studies  
Chinese herbal medicine physicians treating in clinical scenarios are able to individually 
adjust patient treatment strategies based on syndrome differentiation. Typically, the 
more rigid explanatory design of RCTs prevents pragmatic approaches being utilised. As 
a result, CHM RCTs are often too direct in their approach, where a set intervention is 
used in a set population of a set condition type to measure the effect of the intervention 
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on a set outcome. Taking a more pragmatic approach may involve multiple 
interventions in a diverse population with numerous condition types to measure 
different effects of interventions to known and unknown outcomes. Such a pragmatic 
approach may provide data that reflect real life scenarios well; however, obtaining 
enough data to draw statistical and clinical significance requires very large sample sizes. 
Explanatory design studies can dramatically reduce the sample size required to 
evaluate an intervention. 
The scientific model and explanatory nature of a RCT clearly suits evaluation of an 
explanatory style intervention such as a pharmaceutical drug, where there is often a 
known dosage and mechanism of action for a target group. In CHM, however, it is not 
uncommon that the intervention is a formulation consisting of numerous ingredients 
and subsequently containing countless compounds with many biological modes of 
action. Further difficulties in CHM standardisation arise due to the variability in 
constituents of herbal compounds, which vary depending on growing conditions and 
manufacturing process among other factors (Lu et al., 2014b). Review has found 
standardisation of CHM and reporting in RCTs is poor and it has been recommended 
future RCTs should utilise CHM interventions that have been produced according to 
good agricultural and manufacturing practice (Leung et al., 2006). 
Clinically, CHM practitioners have the flexibility to vary their use of CHM based on 
the suitability of the substance for each patient’s syndrome type. Explanatory designed 
studies make intervention flexibility difficult as any change to the intervention would 
create a new dataset group that, if not separately analysed, would add heterogeneity to 
the results and, if separated, would require an increase in the sample size to show 
statistical significance (Nahin and Straus, 2001). 
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For CHM research of a specific condition, achieving the most efficacious results 
using a pure explanatory approach would require the most efficacious CHM be utilised 
for a specific syndrome type (condition). This, theoretically, should provide the greatest 
likelihood of statistically significant treatment effects. Selection of such a CHM, however, 
is not straightforward, nor is defining syndrome type, as the previous literature reviews 
indicated (see Chapters 2 and 3).  
A more pragmatic approach may simplify such selection where aspects such as 
syndrome type, although somewhat restricted, may vary. Data may also be collected at 
various points throughout the trial by independent blinded assessors not associated 
with the care of the patient, as explanatory studies dictate, yet reflect the effects of 
multiple interventions for which pragmatic style studies such as observational studies 
would usually be utilised. 
A pragmatic style study enables flexibility of eligibility criteria and inclusion of a 
wider range of psoriasis types. Such results would assist in assessing the impact of the 
CHM more broadly on psoriasis and help evaluate the feasibility of CHM in a more 
explanatory designed RCT. Such mixed style studies could lead to development of more 
pure explanatory style studies where researchers have greater confidence in the 
intervention for the disease in the targeted sample (Hennekens and Buring, 1993). 
However, there may also be occasions when results from a pragmatic trial are so strong 
and dramatic (positive outcomes, no change or reduced outcomes) that they provide 
enough evidence to validate an intervention and skip RCT explanatory investigation 
altogether (Black, 1999). 
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7.3 Proposed study design 
Initial trial design was developed using a pragmatic approach then following further 
collaboration with study investigators with previous expertise an explanatory design 
was developed. This section details the initial design method and the finalised protocol 
methods. 
7.3.1 Comparing and evaluating explanatory and pragmatic methods using the 
pragmatic–explanatory continuum indicator summary  
An assessment tool known as the pragmatic–explanatory continuum indicator summary 
is able to help evaluate the degree of pragmatic versus explanatory design in a study. It 
is designed to aid researchers in the development of a protocol suitable to the research 
questions it intends to answer (Thorpe et al., 2009). The pragmatic–explanatory 
continuum indicator summary was utilised in the current study to guide the 
development of a protocol investigating PSORI-CM01 for psoriasis vulgaris. We 
determined that the study would be predominantly explanatory in style to maintain the 
rigour of the study results, but would also contain pragmatic aspects to ensure clinical 
relevance of results. Elements of pragmatism would also ensure that the sample 
characteristics would be varied enough to reach sample size targets yet specific enough 
for data to be grouped for analysis. If the sample characteristics varied too much, results 
would show high heterogeneity.  
The pragmatic–explanatory continuum indicator summary covers 10 domains that 
are used to distinguish explanatory style from pragmatic style studies based on four key 
aspects of a clinical study: participants; intervention/s and expertise; follow-up and 
outcomes; participant compliance and adherence; and analysis of results. The domains 
covering theses are: 
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(1) the eligibility criteria for trial participants; 
(2) the flexibility with which the experimental intervention is applied; 
(3) the degree of practitioner expertise in applying and monitoring the experimental 
intervention; 
(4) the flexibility with which the comparison intervention is applied; 
(5) the degree of practitioner expertise in applying and monitoring the comparison 
intervention; 
(6) the intensity of follow-up of trial participants; 
(7) the nature of the trial’s primary outcome; 
(8) the intensity of measuring participants’ compliance with the prescribed 
intervention, and whether compliance-improving strategies are used; 
(9) the intensity of measuring practitioners’ adherence to the study protocol, and 
whether adherence-improving strategies are used; and 
(10) the specification and scope of the analysis of the primary outcome. 
 
For each of these domains the pragmatic and explanatory design was considered 
then the style was determined for the present psoriasis study (Table 7.1). For eligibility 
criteria we decided that the explanatory method was preferred. Restricting the selection 
of participants (vulgaris type only, of mild–moderate severity, without significant health 
risk) would be important to ensure the sample would be appropriate for the 
intervention. Pragmatic style would be utilised for syndrome type, as the prevalence of 
syndrome types unknown for the Australian population. This would also help us reach 
recruitment targets. While syndrome type would not determine eligibility, all 
participants would still be assessed for syndrome type. 
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As the formulation for the current study already had significant evidence of its 
efficacy for psoriasis, the main purpose of the study was to evaluate it under controlled 
conditions, so we decided dosage, administration and formulation would be purely 
explanatory, that is, fixed. We decided that any efficacy of the experimental intervention 
should be able to be easily evaluated with little impact from any related co-founders. It 
was decided records should be kept of each participant’s use of the experimental 
interventions (daily administration recording with reasoning provided for non-
compliance). As the study was designed as a direct comparison between PSORI-CM01 
plus calcipotriol versus placebo plus calcipotriol the same explanatory approach was 
required for the comparison intervention domain. 
In relation to the expertise of the practitioner administering the experimental 
intervention we decided, for the safety of participants and to ensure consistent 
administration of interventions, only registered (Australian Health Practitioner 
Regulation Authority) CHM practitioners would dispense the experimental medication. 
The same explanatory approach was utilised for the practitioner expertise of the 
comparison intervention domain, in this case the calcipotriol plus placebo. The 
researchers were to be blind to participant intervention at all stages and as the placebo 
was to be manufactured as close as possible to match the appearance and taste of the 
CHM intervention it was important the dispenser gave the same instructions and had 
the same qualifications and training as dispensers of the experimental interventions. 
Similarly, as both groups would also be receiving calcipotriol, the dispenser needed to 
follow dosage and administration instructions provided by the manufacturer and 
according to treatment guidelines (Leo Pharmaceutical Products Ltd A/S, 2002, 
Dermatology Expert Group, 2004, Callen et al., 2003). 
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Of the two follow-up and outcome domains the first evaluates the ‘follow-up 
intensity’ where a pragmatic approach does not require direct follow-up with 
participants to evaluate data measures, instead existing datasets are searched for the 
required data to assess outcomes. For the proposed intervention study, participants 
needed regular follow-up to assess their symptoms and monitor adverse events. One of 
the proposed outcomes was evaluation of changes to cytokines, which would also 
require strict follow-up to ensure blood was collected correctly and stored 
appropriately. This degree of follow-up is explanatory, yet the frequency is still 
comparable with that seen clinically so for this domain there was little reason to take a 
pragmatic approach. 
For the domain surrounding the primary trial outcome a pragmatic approach 
would utilise an outcome that is clinically relevant to the participant. For the proposed 
study it was important the outcomes could be compared with those of other studies in 
order to evaluate the effectiveness of PSORI-CM01. Other studies commonly use PASI 
and DLQI and we decided to utilise these same instruments complimented by 
appropriate use of other validated instruments such as the SKINDEX29. Outcome 
measures were selected for assessment of symptom severity and QoL based on 
guideline recommendations (The Australian Government, 2004). We determined 
wherever possible to use validated instruments and scales. The majority of these have 
already shown some level of reliability and are considered to be relevant to psoriasis 
sufferers ensuring that although the study is taking an explanatory approach to this 
domain the outcomes would still have clinical relevance. 
The next two domains cover compliance and adherence, to the intervention and 
the protocol. As the proposed study is a pilot study designed to investigate intervention 
feasibility and the protocol design for a larger study, it makes sense to monitor the 
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compliance of participants. Such monitoring may provide insights into difficulties 
participants had with the intervention. Taking this explanatory approach we decided 
that the intervention should be provided in a form that is easy to administer, in this case 
a granulated extract that can simply be mixed with water and drunk. Providing it in a 
raw formulation would likely reduce compliance due to the preparation involved to 
cook the herbs. Providing formulation in pill form, while likely improving ease of 
administration, would require multiple pills in order to consume the therapeutic dosage 
required. An antihistamine to ease pruritus was also included. All study interventions 
would be measured to evaluate compliance with intervention administration 
instructions through the treatment phase and a daily diary completed by participants 
would detail further reason for lack of compliance to interventions.  
Adherence to the study protocol by practitioners is an important domain to 
consider. For the proposed study it was important any potential bias was limited and 
for the safety of participants the protocol needed to be adhered to carefully. To ensure 
this, a standard operating procedure was proposed. The standard operating procedure 
would ensure all aspects of the study were undertaken according to pre-defined 
instructions and enhance consistency in all aspects of implementation. This approach is 
solely explanatory in design. 
The last domain to consider in the design of the study was the analysis of the data. For 
the proposed study, both pragmatic and explanatory approaches to analysis were 
chosen. This would allow for analysis of the overall results and would also allow for 
subgrouping of data to evaluate other specific interests such as what impacts syndrome 
type may have on outcome measures. While standard outcomes such as the efficacy of 
the intervention had to be evaluated and comparisons between groups, researchers 
could conduct further analyses suiting the final data.
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Table 7.1: Evaluation of the proposed psoriasis study using the pragmatic–explanatory continuum indicator summary  
 Pragmatic style Explanatory style Psoriasis trial 
Participants  
Eligibility 
criteria 
All participants who have the 
condition of interest are enrolled, 
regardless of their anticipated 
risk, responsiveness, co-
morbidities or past compliance 
Stepwise selection criteria are applied that 
(a) restrict study individuals to those 
previously shown to be at highest risk of 
unfavourable outcomes, (b) further 
restrict these high-risk individuals to those 
who are thought likely to be highly 
responsive to the experimental 
intervention and (c) include just those 
high-risk, highly responsive study 
individuals who demonstrate high 
compliance with pre-trial appointment-
keeping and mock intervention 
Participants with the diagnosis 
of mild–moderate psoriasis 
vulgaris but of any CM 
syndrome type 
Assessment– Mainly 
explanatory with Pragmatic 
influence exploring all CM 
syndrome types 
Interventions 
and expertise 
Experimental 
intervention: 
Flexibility 
Instructions on how to apply the 
experimental intervention are 
highly flexible, offering 
practitioners 
Considerable leeway in deciding 
how to formulate and apply it. 
Inflexible experimental intervention, with 
strict instructions for every element 
Intervention is a fixed dosage 
oral CHM and topical 
conventional therapy 
Assessment- Explanatory 
 
Experimental 
intervention: 
Practitioner 
expertise 
The experimental intervention 
typically is applied by the full 
range of practitioners and in the 
full range of clinical settings, 
regardless of their expertise, with 
only 
Ordinary attention to dose setting 
and side effects. 
The experimental intervention is applied 
only by seasoned practitioners previously 
documented to have applied that 
intervention with high rates of success and 
low rates of complications, and in practice 
settings where the care delivery system 
and providers are highly experienced in 
managing the types of patients enrolled in 
the trial. The intervention often is closely 
monitored so that its ‘dose’ can be 
optimised and its side effects treated; co-
interventions against other disorders 
often are applied. 
Registered practitioners of 
CHM, regardless of their level 
of expertise, will administer 
the intervention.  
Assessment- Explanatory 
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Comparison 
intervention: 
Flexibility 
‘Usual practice’ or the best 
alternative management strategy 
available, offering practitioners 
considerable leeway in deciding 
how to apply it 
Restricted flexibility of the comparison 
intervention; may use a placebo rather 
than the best alternative management 
strategy as the comparator. 
Comparison is placebo plus 
conventional therapy 
(calcipotriol) With a standard 
recue therapy for all 
participants (anti-histamine) 
Assessment- Explanatory 
Comparison 
intervention: 
Practitioner 
expertise 
The comparison intervention 
typically is applied by the full 
range of practitioners and in the 
full range of clinical settings, 
regardless of their expertise, with 
only ordinary attention to their 
training, experience and 
performance. 
Practitioner expertise in applying the 
comparison intervention(s) is 
standardized to maximize the chances 
of detecting whatever comparative 
benefits the experimental intervention 
might have. 
The same practitioners at the 
experimental intervention to 
limit potential bias will apply 
comparison. Assessment- 
Explanatory 
Follow-up and 
outcomes 
Follow-up 
intensity 
No formal follow-up visits of 
study individuals. Instead, 
administrative databases (e.g., 
mortality registries) are searched 
for the detection of outcomes. 
Study individuals are followed with many 
more frequent visits and more extensive 
data collection than would occur in routine 
practice, regardless of whether patients 
experienced any events. 
Telephone follow-up and face 
to face assessments at various 
time points where extensive 
symptom measures, quality of 
life measures and blood tests 
will be performed as well as 
health resource utilisation 
collected to assess 
intervention effect and 
monitor safety 
Assessment– explanatory  
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Primary trial 
outcome 
The primary outcome is an 
objectively measured, clinically 
meaningful outcome to the study 
participants. 
The outcome does not rely on 
central adjudication and is one 
that can be assessed under usual 
conditions (e.g. special tests or 
training are not required). 
The outcome is known to be a direct and 
immediate consequence of the 
intervention. The outcome is often 
clinically meaningful but may sometimes 
(e.g., early dose finding trials) be a 
surrogate marker of another downstream 
outcome of interest. It may also require 
specialised training or testing not 
normally used to determine outcome 
status or central adjudication. 
Primary outcome is a clinically 
meaningful outcome with 
reduction in PASI as suggested 
by the Therapeutic Goods 
Association and relevant 
treatment guidelines. 
Outcomes measures require 
training of PASI calculation. 
Assessment–explanatory  
Participant 
compliance 
with 
‘prescribed’ 
intervention 
There is unobtrusive (or no) 
measurement of participant 
compliance. No special strategies 
to maintain or improve 
compliance are used. 
Study participants’ compliance with the 
intervention is monitored closely and may 
be a prerequisite for study entry. Both 
prophylactic strategies (to maintain) and 
‘rescue’ strategies (to regain) high 
compliance are used. 
Compliance will be recorded 
according to measurement of 
remaining study drugs. A recue 
therapy is being utilised to aid 
compliance rates. 
Assessment- explanatory 
Practitioner 
adherence to 
study protocol 
There is unobtrusive (or no) 
measurement of practitioner 
adherence. No special strategies 
to maintain or improve 
adherence are used. 
There is close monitoring of how well the 
participating clinicians and centres are 
adhering to even the minute details in the 
trial protocol and ‘manual of procedures.’ 
All deviations from the 
protocol and standard 
operating procedure will be 
recorded, as well as details of 
distribution of study drugs as 
well as timely follow-up. 
Assessment – explanatory  
 
IMPPS, integrative medicine for psoriasis pilot study
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 Table 7.2 compares characteristics of the two methodological designs that were 
discussed prior to determining the final trial protocol. Initially a pragmatic designed 
study was developed to optimise treatment effects of CHM intervention (Method A). 
Psoriasis of any type, severity and duration was considered. Effect optimisation would 
permit modification of the intervention based on Chinese medicine syndrome type and 
disease characteristics such as severity. Method A consisted of an observation period (3 
months) where treatment was prescribed and administered as per treating physician 
instructions followed by an intervention period (3-6 months) where CHM is 
administered alongside standard care. Treatment would cease and follow up would 
begin when participants achieved complete clearance of psoriasis or following 6 months 
CHM. 
Table 7.2 Comparing pragmatic and explanatory study designs 
Design characteristics Method A 
(primarily pragmatic) 
Method B 
(primarily explanatory) 
Participant target group Psoriasis any phenotype Psoriasis vulgaris only 
 
Psoriasis severity Any severity Set severity range (i.e. based 
on PASI) 
Psoriasis duration No limits on duration At least 12 months history of 
psoriasis 
Investigative intervention 
- Type 
Can be modified with 
addition or subtraction of 
other CHM at any time point 
of the study. 
CM is fixed for the duration of 
the study 
- Placebo No Yes 
 
- Dosage Can be adjusted as disease 
worsens or improves 
Fixed dosage for duration of 
the study 
Control  
- Type 
No control participant can 
use any psoriasis related 
medication 
Control is fixed and identical 
for each participant 
- Dosage Can be adjusted as disease 
worsens or improves 
Adjusted according to 
recommended treatment 
guidelines for severity 
Concomitant medication No restriction of use Cease all psoriasis related 
medication for the duration 
of the study 
Use of CM syndrome 
differentiation 
Used for determination of 
intervention ingredients and 
dosage 
Can be assessed but has no 
impact on intervention 
selection or dosage 
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Study length 3 months of standard care 
(observation period) 
followed by 3 months of 
study drugs (intervention 
period). Those achieving full 
clearance would then 
commence a 3 month follow 
up phase. Participants not 
achieving clearance would 
continue treatment for a 
further 3 months then 
undergo their 3 month follow 
up phase. 
2 week run-in phase followed 
by 3 months treatment and 3 
months follow up. 
Blinding Assessors would be blinded 
to treatment ingredients 
however would know all 
participants are taking CM 
Participants and assessors 
would be blinded to their 
treatment allocation 
throughout the duration of 
the study 
Outcomes Severity change (%PASI), 
relapse rates, syndrome 
change, dosage and 
ingredient change, adverse 
events, inflammatory marker 
change and health resource 
utilization 
PASI 75 rate, severity change 
(%PASI), adverse events, 
inflammatory marker change 
and health resource 
utilization 
CM, Chinese medicine; PASI, psoriasis area severity index 
7.3.2 Discussion on study design 
While the importance of conducting clinically relevant studies is clear, such studies still 
need to be rigorous in their design to ensure results have low bias. For CHM studies to 
be published in high impact journals, taking an explanatory approach to reduce risks of 
bias is needed. With such rigorous design there is no reason why CHM studies could not 
be published alongside conventional pharmacological studies (Sheehan et al., 1992). 
Randomisation of the sample is an important aspect of explanatory designed 
studies reducing risk of bias. Without randomisation, non-treatment or low efficacy 
treatment groups may preference allocation to more efficacious groups leading to poor 
compliance, increased dropouts and/or false reporting of outcomes (Brewin and 
Bradley, 1989). Incorporating the same conventional medicine intervention in both the 
control and intervention arms of the trial and using an apparently identically placebo 
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will provide explanatory design for the study yet allow for efficacy outcomes to be 
measured and maintain blinding to reduce risk of potential bias.  
Participant-specific inclusion criteria can make study results more specific to the 
intervention; however they need to be weighed up against participant availability. 
Choosing too specific a sample reduces eligibility of the population to participate, 
making recruitment sample targets more difficult and increases the time to reach these 
targets. Thus, for the proposed study, inclusion criteria deemed most important to 
evaluate the intervention were selected and after discussion with specialists those 
deemed less important for evaluation of the intervention were disregarded. The 
purpose was to ensure the included sample population accurately reflected the 
population yet had suitable characteristics (mild–moderate psoriasis vulgaris) for the 
proposed interventions.  
7.3.3 Conclusion on study design 
Research suggests transcribing explanatory RCT data is difficult and expensive, and to 
improve clinical best practice observational pragmatic designed study data should 
complement it (1992, Black, 1996). For the proposed study, previous clinical and 
laboratory evidence supporting PSORI-CM01 already exists, however rigorous, low bias 
research is lacking. It was determined by the research team an explanatory style pilot 
trial should be conducted allowing for minor pragmatic aspects such as syndrome 
diagnosis. With an explanatory approach forefront, a protocol was developed to further 
investigate the efficacy of PSORI-CM01. 
7.4 Aims and objectives of the pilot study 
The aim of this study is to evaluate of the efficacy and safety of a CHM formulation 
(PSORI-CM01) combined with standard conventional treatment (calcipotriol) in the 
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management of mild–moderate psoriasis vulgaris via a randomised, double-blinded, 
placebo-controlled clinical trial.  
Using primarily an explanatory approach the following protocol was developed 
according to recommendations from the publication ‘Standard Protocol Items: 
Recommendation for International Trials’ (Chan et al., 2013) to investigate: 
 Whether the combination of oral CHM formula PSORI-CM01 and 
pharmacotherapy (calcipotriol) is more effective than the combination of CHM 
placebo and pharmacotherapy (calcipotriol), in terms of psoriasis vulgaris 
symptom control (assessing the change in PASI score in treatment phase). 
 Whether the combination of oral CHM formula PSORI-CM01 and 
pharmacotherapy (calcipotriol) is more effective than the combination of CHM 
placebo and pharmacotherapy (calcipotriol), in terms of psoriasis vulgaris 
patients’ QoL (assessing the change in dermatology life quality index score and 
Skindex 29 score in treatment phase) (Appendix 4 and 5). 
 Whether the combination of CHM formula PSORI-CM01 and pharmacotherapy 
(calcipotriol) is safe for the treatment of psoriasis vulgaris (monitoring adverse 
events in treatment and follow-up phases). 
 Whether the combination of oral CHM formula PSORI-CM01 and 
pharmacotherapy (calcipotriol) provides significant psoriasis symptom relief 
beyond the treatment phase (assessing change in PASI score, relapse rate in 
follow-up phase). 
 Whether the oral CHM formula PSORI-CM01 is an acceptable form of treatment 
for people with psoriasis vulgaris (assessing the acceptability, willingness to 
repeat ratings in treatment phase). 
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7.5 Pilot RCT methodology 
The study is a randomised, double-blinded, placebo-controlled parallel trial of 
conventional topical treatment (calcipotriol) plus oral CHM (PSORI-CM01) versus 
conventional topical treatment (calcipotriol) plus oral CHM placebo. 
7.5.1 Participants 
Sample size 
The study will be a pilot trial involving 30 participants designed to test the feasibility 
and assist calculation of the sample size required for a large-scale RCT. Post hoc power 
analysis via effect size estimation of the pilot study data will be used to determine 
sample size for the full-scale trial. 
Sample population 
Thirty participants over the age of 18, with at least a 12-month history of psoriasis 
vulgaris (physician-diagnosed), meeting specific inclusion criteria will be recruited. 
Participants are to be sourced from Bundoora, Victoria, Australia and its surrounding 
suburbs. A participant shortfall will see a second China site commence recruitment at 
Guangdong University and Provincial hospital using the same batch of study drug.  
The inclusion criteria are: 
 aged between 18 and 70 years; 
 at least 12 months of psoriasis vulgaris symptoms; 
 patient-informed consent; 
 PASI score ≥7 and ≤12. 
The exclusion criteria are: 
 pregnant or breast-feeding women; 
 type of psoriasis other than vulgaris; 
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 systemic drugs or phototherapy for psoriasis within 4 weeks of screening; 
 topical drugs for psoriasis within 2 weeks of screening; 
 other severe disorders; 
 known disorders of calcium metabolism (high blood calcium levels); 
 known kidney function disorders; 
 taking calcium, vitamin D supplements or vitamin D-like medicines; 
 known sensitivity to Chinese herbs; 
 known sensitivity to calcipotriol; 
 unwilling or unable to cease other topical and systemic psoriasis-related 
medication for the duration of the trial. 
Recruitment 
Recruitment will be via poster advertisements in hospitals, health clinic waiting rooms 
and around university campus. Further recruitment will be through newspaper 
advertisements, email newsletters and Internet advertisements (Appendix 6). Patients 
may also be referred to the trial by their doctor (general practitioner, dermatologist or 
immunologist). 
Informed consent  
Informed consent will be sought from the participants at their initial assessment prior 
to a run-in period and randomisation. Written information (plain language statement) 
and verbal explanation of the study will be provided prior to consent (Appendix 7). 
Questions that arise will all be answered prior to the signing of informed consent. 
Written consent will be required from the participants in the presence of a witness. The 
witness will be someone who is not involved in the clinical trial. The responsible 
investigator will record the date, time and location of the provision of informed consent.  
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Withdrawal of participants 
Participants are permitted to withdraw at any time during the trial, with or without 
reason provided. All withdrawn cases that have received the intervention will be 
contacted eight weeks after withdrawal to obtain information regarding their condition. 
7.5.2 Blinding and randomisation  
Blinding 
Participants, researchers and outcome assessors will all be blinded to group allocation. 
PSORI-CM01 and placebo will be packaged identically and labelled with a code directly 
corresponding to the generated randomisation sequence required for identification of 
the allocation group. Packaging and labelling will be conducted by persons independent 
of the research team and the randomisation sequence sealed and stored in a locked 
filing cabinet separate from any participant data and accessible only to those who 
generated the randomisation sequence. Testing of participant blinding to allocation will 
be done at various timepoints throughout the duration of the trial.  
Randomisation and allocation concealment 
Participants will be randomly allocated to the intervention group (PSORI-CM01 plus 
calcipotriol) or control group (placebo plus calcipotriol) in equal ratio (1:1). The 
randomisation numbers will be generated by computer program into blocks (blinded 
block number). The randomisation numbers will be kept in sealed envelopes and the 
envelopes will be opened sequentially for each participant only after participant details 
are written on the outside of the envelope. A code inside the envelope will correspond 
with a package number that will contain 12 weeks of either PSORI-CM01 or placebo 
granules.  
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7.5.3 Data management 
Data will be collected at initial assessment (–2 weeks), mid-treatment assessment (6 
weeks), post-treatment assessment (12 weeks) and post-follow-up assessment (24 
weeks) (Appendix 8). Assessors and participants will be trained for data recording prior 
to commencement. Personnel blinded to group allocation will enter all data into a pre-
designed, password-protected file. Data entry will be performed continuously 
throughout the study. Double-checking of entered data will be performed to ensure 
accuracy, with any correction or changes of written data in patient files documented 
and dated. Randomisation codes will only be broken after the data validation and 
editing processes are completed, or if a serious adverse event (SAE) occurs. 
7.5.4 Study intervention description 
Conventional treatment 
The topical drug calcipotriol 0.005% (50μg/g) cream (30g tubes) will be administered 
as pharmacotherapy. Calcipotriol is a moderate action first line therapy drug commonly 
used and recommended in treatment guidelines, with little risk of side effects and 
proven efficacy in people with mild to moderate psoriasis symptoms (Pearce et al., 
2006). The drug is listed on the Australian pharmaceutical benefit schedule for psoriasis. 
Calcipotriol is a vitamin D3 derivative that decreases proliferation and induces 
differentiation of keratinocytes, with a strong immunomodulation effect reducing the 
levels of pro-inflammatory cytokines (Tiberio et al., 2009, Fenton and Plosker, 2004). It 
was favoured over the use of corticosteroids in the current study as it does not cause 
atrophy of skin and is less messy than topically applied tars or anthralin (Nagpal et al., 
2001). Rescue therapy will be provided to all participants, at no cost, for intolerable itch 
in the form of an antihistamine (lortadine). 
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Chinese herbal medicine 
The herbal formula has been developed based on pre-clinical research and clinical 
experience (see Chapter 5). The ingredients and ratios of formula PSORI-CM01 are: chi 
shao (1.5), hong tiao zi cao (2.5), gan cao (1), wu mei (2.5), jiu jie cha (2.5), cu e zhu (1.5) 
and tu fu ling (2.5). Details of each herb are listed in Table 5.3. The granules of PSORI-
CM01 and placebo will be produced by a manufacturer that holds a good manufacturing 
practice certificate. For the PSORI-CM01 granule, the manufacture procedure is: 
 combine raw herbs of chi shao 265kg, hong tiao zi cao 441kg, gan cao 177kg, wu 
mei 441kg, jiu jie cha 441kg, cu e zhu 265kg, tu fu ling 441kg and add 10 times 
the amount of water; 
 bring to the boil and cook for 1.5 hours; filter out the liquid; 
 add eight times the amount of fresh water; 
 bring to the boil and cook for 1 hour; filter out the liquid; 
 combine the extracted liquids; 
 pressure spray dry the mixed liquid extraction to form a granulated extract; 
 package granules in small sachets (9.5cm  9.5cm in size) each weighing 5.5g 
(one dose). 
Placebo 
The placebo will be produced by the same manufacturer as the PSORI-CM01 granules 
and will consist of starch with no active ingredients. It will be matched as closely as 
possible to the appearance and taste of the PSORI-CM01 granules. Colour will be made 
identical by adding artificial pigment while taste will be adjusted by adding medicine 
intermediate D-(+)-Cellobiose octaacetate. Dosage and administration instructions for 
the PSORI-CM01 and placebo groups will be identical (Figure 7.2, 7.3 and 7.4). 
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7.5.5 Intervention administration and dosage instructions  
Instructions for drug administration for both participant groups will be identical and 
will include a starting dosage for the calcipotriol cream.  
Treatment group 
The intervention group will receive PSORI-CM01. Dosage of CHM granules will be 5.5g 
per sachet administered twice daily for 12 weeks. The calcipotriol cream will be 
administered daily to affected body surface areas for 12 weeks according to American 
Academy of Dermatology guidelines (1% surface area coverage=0.5 fingertip unit) 
(Table 7.3 and Figure 7.1) or until complete clearance of the lesions. The maximum dose 
should not exceed 100g per week as per consumer medicine information for Daivonex® 
(calcipotriol)(Leo Pharmaceutical Products Ltd A/S, 2002) (Appendix 9). 
 
Table 7.3: American Academy of Dermatology recommendations for topical medication 
use (one fingertip unit=approx. 500 mg) (Menter et al., 2009) 
Area to be treated No. of fingertip units 
Approximate body 
surface area (%) 
Scalp  3 6 
Face and neck 2.5 5 
One hand (front and back) including fingers 1 2 
One entire arm including entire hand 4 8 
Elbows (large plaque) 1 2 
Both soles 1.5 3 
One foot (dorsum and sole), including toes 1.5 3 
One entire leg including entire foot 8 16 
Buttocks 4 8 
Knees (large plaque) 1 2 
Trunk (anterior) 8 16 
Trunk (posterior) 8 16 
Genitalia 0.5 1 
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Figure 7.1: One fingertip unit 
Control group 
The control group will receive placebo granules identical in appearance and as close as 
possible in taste to the PSORI-CM01. In preparation of the placebo people unassociated 
with the research study were approached to compare the taste, smell and appearance of 
each when in solution. The placebo was further adjusted with addition of starch and 
colour until it was indstiguishable from the PSORI-CM01 by taste. Dosage of 5.5g of 
placebo granules (one sachet) will be administered twice daily for 12 weeks, identical to 
the dosage for the PSORI-CM01. The calcipotriol cream of the control group will be 
administered according to the same methods and dosage guidelines as the intervention 
group (Figure 7.2, 7.3 and 7.4). 
 
Figure 7.2: Packaged satchets of PSORI-CM01 and placebo (blind as to A and B 
allocation) 
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Figure 7.3: Granulated PSORI-CM01 and placebo (blind as to A and B allocation) 
 
Figure 7.4: Solution of PSORI-CM01 and placebo (blind as to A and B allocation) 
7.5.6 Adverse events and risk to participants 
Monitoring of adverse effects 
Potential adverse effects of the calcipotriol are considered minor and may consist of 
skin irritation (including peeling or rash), a change in the colour of the skin and/or 
sensitivity to light (Leo Pharmaceutical Products Ltd A/S, 2002). For the PSORI-CM01, 
the herbal constituents are used commonly in clinical practice with no reported risk. Six 
herbs of the PSORI-CM01 formulation are TGA approved in Australia and another herb 
(zhong jie feng) has been proven safe by research (Guo-qing Ying et al., 2007, Sun et al., 
2003). Minor side effects of CHM are possible, such as nausea and or diarrhoea, but 
these are not identified as specific to the investigated herbal substances (MacPherson 
and Liu, 2005). If participants develop any minor side effects as a result of either 
intervention they will be advised to seek medical advice from their GP and cease the 
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interventions if they become intolerable. As there have been previous reports of toxicity 
with use of CHM (e.g. phosphatase and gamma-glutamyltransferase, alanine 
aminotransferase and aspartate aminotransferase, not specific to the herbs investigated 
here), blood tests for liver and kidney function will be collected at weeks 6, 12 and 24, 
and if any results become abnormal during treatment it will be ceased and documented 
as an AE (Graham-Brown, 1992). Liver and kidney function will also be assessed at 
screening (week -2) to identify any pre-existing liver and kidney disorder and if found 
requires physician permission to continue in the study. Central aortic blood pressure as 
well as systolic and diastolic pressure will also be monitored before and during the 
treatment period at weeks –2, 0, 6 and 12 to evaluate any change treatment may have. If 
increased abnormally, treatment will cease and participants will be advised to seek 
medical advice from their doctors as to their safe continuation in the study. 
Risk management 
The clinical trial will consist of a research team with qualifications in Chinese medicine 
herbal prescription, medical dermatology, statistics and clinical trial operation. Only 
Chinese medicine registered practitioners will provide the packaged herbs or placebo to 
the participant. The manufacturing and production of the CHM and placebo capsules 
will be by a GMP-certified company for quality control. 
Early termination of the trial 
All ingredients of PSORI-CM01 are used routinely in Chinese medicine daily practice; if 
SAE become apparent, the trial will be discontinued. Participants in their daily diary will 
record all reactions, including AEs (Appendix 10). Serious adverse events will be judged 
according to TGA criteria (The Australian Government, 2004) and recorded on the SAE 
form as “Any untoward medical occurrence that at any dose: results in death, is life-
threatening, requires inpatient hospitalisation or prolongation of existing 
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hospitalisation, results in persistent or significant disability/incapacity, is a congenital 
anomaly/birth defect, or is a medically important event or reaction” (Appendix 11). See 
‘Potential risks associated with treatments’ for description on what physiological safety 
monitoring measures are in place. A Data Safety Monitoring Board will be established 
consisting of independent specialists in clinical pharmacology, statistics, medical 
dermatology and traditional Chinese medicine dermatology. The Data Safety Monitoring 
Board will periodically review and evaluate the study data for safety and study conduct 
then make recommendations regarding the continuation, modification or termination of 
the study. Any SAEs will be reported to the relevant human research ethics committee 
and the Therapeutic Goods Administration (TGA). Any dropouts will be reported on an 
“end of study form” with reason provided and placed in the relevant case record file 
(Appendix 13). 
Procedures for breaking codes 
Emergency 24-hour access to the participant ID and treatment codes will be made 
available to authorised personnel at the study site. Should the need to unmask the 
treatment code arise, the authorised personnel will have access to the treatment code 
upon request of the principal investigator. The details of AEs and the unmasking of the 
treatment code will be documented by the investigator with endorsement from the 
principal investigator. 
Ethics and trial registration 
The trial protocol was assessed and subsequently approved by the RMIT University 
Human Research Ethics Committee (HREC) in accordance with the Australian 
Government’s National Statement on Ethical Conduct in Human Research (National 
Health and Medical Research Council et al., 2007). The HREC reviewed the risks and 
assessed the strategies proposed to negate them. The proposed research was also 
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reviewed to ensure potential vulnerable participants were protected from harm and 
that the target population was appropriate for the proposed research. The patient 
informed consent form was also reviewed to ensure it contained all relevant study 
details such as time requirements, tests involved and potential risks of participation 
(Appendix 7). 
The HREC also reviewed the storage of results to ensure it protected the privacy of 
individuals and approved dissemination of results for publication and conference 
presentation when available. Methods of specimen collection and their use were also 
reviewed by the HREC, as well as the ingredients of all interventions, to ensure they 
were appropriate for the outcomes being investigated. Lastly, the HREC ensured the 
potential benefits of the study outweighed the potential risks for participants before it 
was ethically approved (Appendix 14). 
The trial was filed with the TGA under the Clinical Trial Notification scheme and 
registered with the Australian and New Zealand Clinical Trials Registry (ANZCTR): 
ACTRN12614000493640 (Appendix 15). 
The trial will be undertaken in accordance with the National Health and Medical 
Research Council’s National Statement of Ethical Conduct in Human Research (National 
Health and Medical Research Council et al., 2007) and the TGA’s guidance in good 
clinical practice (Therapeutic Goods Administration, 2000).  
Financing and insurance 
This clinical trial is part of the project funded by China-Australia International Research 
Centre for Chinese Medicine. The project is covered by RMIT University, Broadform 
Public and Product Liability Insurance. 
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Publication policy 
No individual identifiable information of participants will be reported or published. To 
avoid individual participant identification data will be published in group form and 
presented in such a way that identifiable data is removed. 
7.7.7 Outcome measures 
For the developed study in an Australian population it was most appropriate to use 
instruments and scales suggested by Australian medical and Therapeutic Goods 
Association guidelines (Baker et al., 2013, The Australian Government, 2004). After 
review of guidelines and consideration of other symptom instruments, PASI and BSA 
were selected to measure psoriasis lesion severity. The majority of published clinical 
trials utilise these two primary outcomes and with considerable research existing of 
their reliability and validity, both are recommended widely. 
As discussed, the PASI does still have deficiencies, a major one being no 
consideration of pruritus in calculation of severity, evidenced to be as prevalent as 80% 
of cases (Stinco et al., 2014). For the present study, there was addition of a separate 
scale measuring participant itch.  
To measure QoL for the pilot study, dermatology life quality index and Skindex 29 
were selected. Again, therapeutic guidelines commonly recommend dermatology life 
quality index, hence its selection, whereas Skindex 29 is reported as the most validated 
QoL measure available. Further, Skindex 29 has been reported most sensitive to change 
in milder psoriasis patients, which is important as they are the target population for the 
pilot trial.  
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Primary outcome measures 
Complete clearance of psoriasis symptoms is usually not achievable, so recommended 
treatment success is considered a reduction in PASI score of 75% (PASI 75) or greater. 
Treatment failure is regarded as a reduction in PASI score of 50% (PASI 50) or less. For 
scores falling between 50% and 75% the dermatology life quality index is used to 
determine if the current treatment should continue or be modified (Mrowietz et al., 
2011). The Australian Therapeutic Goods Administration recommends standard 
outcomes PASI 75, PASI 50 and BSA to assess product efficacy for psoriasis (The 
Australian Government, 2004). The primary outcome measure will be PASI change 
(mean) from baseline to mid-treatment (week 6), end of treatment (week 12) and end 
of follow-up (week 24) (see Table 7.6). The scoring method for PASI will be based on 
the training and reference provided at http://www.pasitraining.com. Researchers are 
experienced in psoriasis assessment and assessors are trained in conducting PASI. Only 
registered Chinese medicine practitioners of dermatologists will conduct outcome 
assessments. Initially two researchers will conduct the assessments to ensure 
consistancy in evaluation then one researcher at a time will continue to assess lesions. 
Secondary outcome measures 
 PASI 75 (the proportion (%) of patients achieving a PASI improvement of 75%) 
(week 12);  
 PASI 50 (the proportion (%) of patients achieving a PASI improvement of 50%) 
(week 12); 
 relapse rate (defined as return of the rash to 50% of the area it involved before 
treatment (Rogers et al., 1979)); 
 BSA score change (%) (week 12); 
 dermatology life quality index score change (%) (week 12);  
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 Skindex 29 score change (%) (week 12); 
 questions on acceptability of treatment and willingness to repeat treatment 
(week 12); 
 blood test (full blood test, and kidney and liver function tests, blood glucose and 
lipids); 
 reported AEs and SAEs; 
 Chinese medicine syndrome type change (weeks –2, 0, 6, 12 and 24); 
 Body mass index (BMI) change (%) (week 12);  
 health resource utilisation data (GP visits, hospital visits and use of medication). 
Psoriasis severity 
The psoriasis area severity index 75, 50 and body surface area (BSA) are recommended 
by TGA as standard outcome achievement goals to assess a product’s efficacy for 
psoriasis (The Australian Government, 2004). The dermatology life quality index 
instrument is recommended by both by the TGA and the Australian College of 
Dermatologists to evaluate psoriasis severity and patient QoL. It is a validated and well 
recognised instrument used in psoriasis research. The Skindex 29 has been evidenced 
for psoriasis as the most sensitive scale with the greatest applicability and is the most 
validated QoL instrument for dermatological conditions (Bronsard et al., 2010, 
Fernandez-Penas et al., 2012). Photos of the major lesion area will be taken at weeks 2, 
6, 12 and 24. Photos will be taken in a way that they do not reveal the identity of the 
participant.  
Acceptability of treatment and willingness to repeat 
Acceptability will be measured on an ordinal scale from 0 to 10 where 0 equals very 
dissatisfied and 10 equals very satisfied with the treatment. Willingness to repeat the 
treatment will be measured at each assessment on a Likert scale with a choice of 
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responses. Adverse events will be measured daily by the participant and by blinded 
assessors at each assessment. 
Safety  
Safety will be assessed according to the number and types of adverse events reported 
by participants and assessors’ observations then classified if they are likely related to 
the CHM or pharmacotherapy. Psoriasis related hospitalisation and physician visit data 
will be collected to evaluate any increased risk from study interventions. Blood tests at 
weeks –2, 6, 12 and 24 for full blood count, and liver and kidney function will be 
evaluated for any significant change (Table 7.6).  
Biological markers  
Cytokine concentrations 
Numerous cytokines have been identified as being involved in psoriasis disease 
progression. A sample of serum is to be stored for further investigation of key cytokines 
levels using BioPlex (weeks –2, 12 and 24). Thus, the cytokines in Table 7.4 will be 
analysed using BioPlex for concentration change during the study. 
Table 7.4: Bio-Plex Pro Human cytokine measurements 
 
Eotaxin IL-2 IL-10 MCP-1 (MCAF) 
FGF basic IL-4 IL-12 (p70) MIP-1α 
G-CSF IL-5 IL-13 MIP-1β 
GM-CSF IL-6 IL-15 PDGF-BB 
IFN-γ IL-7 IP-10 RANTES 
IL-1β IL-8 IL-17 and 17A TNF-α 
IL-1ra IL-9 IL-23, VEGF 
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By comparing cytokine concentrations with those of healthy skin, there is greater 
understanding of differences. Surprisingly evidence indicates systemic chemokine levels 
of psoriatic people don’t tend to differ greatly from unaffected people (Lima et al., 2014). 
There is though significant research for a number of key cytokines involved in psoriasis. 
This section reviews these cytokines and provides justification for the selection of the 
final group to be analysed for concentration change during the study. 
IL-1  
Appearing to mainly be a linking cytokine in the immune response, evidence suggests 
IL-1 is raised in psoriasis sufferers, however its specific role in psoriasis is unclear 
(Bebes et al., 2014). 
IL-2  
With the administration of IL-2 in high doses shown to exacerbate or induce psoriasis, 
in vivo and in vitro studies confirm its increased production in psoriatic lesional skin 
(Lee et al., 1988). 
IL-4 
Increased IL-4 receptor expression is evident in psoriasis, likely the body 
physiologically attempts to increase IL-4 production, as IL-4 presence will subsequently 
down-regulate a number of cytokines implicated in aggravation of psoriasis (Hart et al., 
1989). 
IL-6  
Expressed in the transitional epidermis zone of psoriatic lesions, and corresponding 
with expanding regions of plaques, IL-6 is increased in psoriasis. Secreted by 
macrophages, endothelial cells and epithelial cells, IL-6 concentration is shown to 
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decrease following effective treatment. Increased levels are linked to increases in key 
psoriatic inflammatory cytokine IL-23 (Olaniran et al., 1996, Lindroos et al., 2011, 
Paquet and Pierard, 1996). It is understood IL-6 is responsible for promotion of 
keratinocyte hyperplasia and cellular influx of macrophages and T-cells (Grossman et al., 
1989). Psoriatic keratinocytes are reported to be more sensitive to growth-promoting 
effects of IL-6 than healthy keratinocytes. Also implicated with TGF-beta, IL-6 is 
important for the differentiation of naïve T-cells into pathogenic Th17 cells, a prominent 
psoriasis pathway (Bettelli et al., 2006). Also key to regulating the levels of C-reactive 
protein, IL-6 may be a factor linking psoriasis with co-morbidities in which C-reactive 
protein is pathogenically implicated such as obesity, diabetes and cardiovascular 
disease. 
IL-7 
Produced by keratinocytes and monocytes, IL-7 synergises with IL-12 to induce T-cell 
proliferation, increase IFN-γ production and stimulate cytotoxic activity, all relevant 
activity to psoriasis (Borger et al., 1996). Higher IL-7 levels have been observed in 
lesional samples compared with non-lesional skin and serum of healthy samples 
(Bonifati et al., 1997). 
IL-8 
Research indicates neutrophils and upper layer keratinocytes of lesional epidermis are 
the main producers of IL-8 (Gillitzer et al., 1991, Gillitzer et al., 1996). Enhancing 
angiogenesis, IL-8 is evidenced to be a potent chemo-attractant for neutrophils and T-
cells, as well as a promoting factor for keratinocyte proliferation. Elevated levels are 
found in psoriatic skin (Nickoloff et al., 1994, Barker et al., 1991, Tuschil et al., 1992). 
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Likely IL-8 contributes to the epidermal hyperplasia phenomenon observed in psoriasis 
(Kemeny et al., 1994). 
IL-11 
Predominately inhibiting production of IL-12 from monocytes and macrophages, IL-11 
has shown to also inhibit production of TNF-, IL-6 and IL-1beta, which may have effect 
on psoriasis (Leng and Elias, 1997).  
IL-12  
Found in lipopolysaccharide-stimulated macrophages, IL-12 has increased synthesis in 
psoriatic skin possibly following physiological attempt of the body to reduce the 
inflammatory cascade of psoriasis (Leng and Elias, 1997). Also likely secreted by 
dendritic cells, IL-12 enhances production of Th1 line cells, further producing TNF- 
and INF-γ and continuing further activation of keratinocytes with subsequent 
progression of psoriasis inflammatory loop pathways (Nwe et al., 2013). Efficiency of 
ustekinumab (see 2.7.3 Interleukin-12 and interleukin-23 inhibitors) in psoriasis in a 
phase III clinical trial is believed to target the gene p40, producing IL-23 and IL-12 
which may explain its efficacy (Papp et al., 2008). 
IL-15 
Produced by monocytes, macrophages, dendritic cells and T-cells, IL-15 can induce 
angiogenesis, immune cell recruitment and activation of keratinocytes (McInnes and 
Gracie, 2004). Further, highly expressed in psoriatic skin, in vitro study has shown IL-15 
inhibits apoptosis of keratinocytes, which may associate it with the increased 
proliferation of skin cells seen in psoriasis (Ruckert et al., 2000). 
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IL-17  
A pro-inflammatory cytokine, IL-17 acts on keratinocytes increasing expression of 
chemokines and attracting neutrophils, Th17 cells and dendritic cells to the 
inflammatory site (Girolomoni et al., 2012). Levels of IL-17 are significantly increased in 
lesional compared with non-lesional skin and recent drug development has centred on 
targeting it (Frleta et al., 2014, Gisondi et al., 2014). Being down-regulated by IL-23 and 
subsequent TH17 pathway activation, IL-17 is now considered one of several central 
cytokines in psoriasis pathogenesis and it is recognised as an important target due to it 
inducing inflammation genes known to contribute to psoriasis (Malakouti et al., 2014, 
Chiricozzi and Krueger, 2013). Evidence suggests neutrophils and mast cells are also 
further sources of IL-17, which may indicate why biologics targeting IL-17 have such 
dramatic efficacy for psoriasis (Schon, 2014). 
IL-18 
Inducing production of IFN-γ, increased IL-18 plasma concentrations common to 
psoriatic people are correlated with increasing psoriasis severity. Subsequent psoriasis 
treatments see IL-18 concentrations reduce with coinciding reduction in symptom 
severity. This indicates the likely involvement of IL-18 in the pathogenesis of psoriasis 
(Rasmy et al., 2011). Research suggests links between genetic variation in components 
of the intracellular protein complex NLRP1 inflammasome and increasing IL-18. The 
NLRP1 inflammasome is likely initially activated in individuals by pathogens and 
subsequent cell death (Ekman et al., 2014). 
IL-21 
Cytokine expression of IL-21 is increased in psoriasis plaques and serum, where its 
presence is understood to aggravate presence of hyperplasia and inflammation in 
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psoriasis (He et al., 2012). In a mouse model, blockade of IL-21 with an antibody has 
seen subsequent improvement in hyperplasia and reduction in expression of Th1 and 
Th17 inflammatory pathways (Botti et al., 2012). 
IL-22 
Promoting proliferation of keratinocytes, IL-22 is active in skin inflammation of 
psoriasis (Sa et al., 2007) (Ma et al., 2008). With increased levels of IL-22 found in 
psoriatic sufferers, transcription of IL-22 appears to be triggered by IL-23 as well as 
expressed by mast cells of skin (Benham et al., 2013, Mashiko et al., 2015). Interestingly, 
a study determined IL-22 is not central to psoriasis and that, in mice at least, its absence 
might still see psoriasis develop via the IL-23 pathway (Takaishi et al., 2013). 
IL-23 
Overproduced by keratinocytes and dendritic cells in psoriatic skin lesions, IL-23 when 
injected has been shown to induce hyperkeratosis (Piskin et al., 2006). Presence of IL-
23 stimulates increased proliferation of Th-17 cells, which has an important psoriatic 
downstream role producing IL-17 (see above). A key pathway recognised as involved in 
psoriatic inflammation. As a result of its significance, many newer developed biologics 
now target this pathway (Sonnenreich, 2013). Targeting IL-23 is theorised as one of the 
more sensitive, selective and effective mechanisms for treating psoriasis (Chiricozzi et 
al., 2014). The IL23R R381Q gene variant has shown to be protective of psoriasis 
development, likely due to reduction in IL-23’s ability to produce IL-17A (Di Meglio et 
al., 2011). Research has investigated blocking thymic stromal lymphopoietin, to 
suppress IL-23 production from dendritic cells (Volpe et al., 2014). 
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IL-33 
Understood to be expressed in psoriatic skin by presence of TNF-α, IL-33 is dependent 
on a stimulus invoking it. It acts primarily by alarming or activating either the Th1 or 
Th2 inflammatory pathways. Interestingly, it appears to be expressed more in psoriasis 
(predominantly more Th1 type disease) than in Th2 acting diseases such as atopic 
dermatitis (Balato et al., 2014). 
Growth factors 
In psoriasis, several studies have indicated deregulation of keratinocyte epidermal 
growth factor (EGF) receptor-ligand system and increased expression of EGF receptor, 
as well as ligands TGF-α and amphiregulin in lesional epidermis (King et al., 1990). 
Endothelin-1 (ET-1) 
Different studies have indicated that molecule ET-1 levels are increased in patients with 
psoriasis, with increasing serum levels correlating with increasing PASI scores 
(Trevisan et al., 1994, Cecchi et al., 1994, Bonifati et al., 1998). Its action on psoriasis 
may be due to monogenic and neutrophil chemo-attractant properties associated with 
participation in inflammation and keratinocyte hyper-proliferation. It may also 
counterbalance the vasodilatory action of raised reactive nitrogen intermediates from 
vasoconstrictive activity (Wright et al., 1994). 
TNF- 
Inducing maturation of Langerhans cells and up-regulating T-Cell production, TNF- 
has also shown it stimulates synthesis of prostaglandin and leukotrienes (Terajima et al., 
1998). Langerhans cells have been shown in vivo to be anti-inflammatory and 
immunosuppressive of psoriatic lesions (Glitzner et al., 2014). The TNF- induces 
keratinocyte proliferation and vascular endothelial growth factor (Kimber et al., 2000). 
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Further, TNF- induces synthesis of other pro-inflammatory cytokines including IL-1, 
IL-6, IL-8, transforming growth factor-α, granulocyte macrophage-colony stimulating 
factor and leukaemia inhibitory factor (Wakefield et al., 1991). It may also increase 
plasminogen activator inhibitor type 2 (PAI-2), which is key to inhibition of apoptosis 
absent in psoriasis and further aggravating the proliferation of keratinocytes (Wang and 
Jensen, 1998). 
NF-κB 
Thought to be a key pathway mediator in psoriasis pathogenesis, genetic studies have 
associated a number of genes with activation of transcription factor NF-κB, leading it to 
translocate and bind with DNA (Gupta et al., 2014). Many treatments aimed at cytokines 
also impact on NF-κB signalling, having an effect of up-regulating or down-regulating 
key cytokine production pathways such as IL-17 and TNF-α. NF-κB concentration levels 
have shown to decrease significantly following successful psoriasis treatment, yet some 
drugs increase its levels, suggesting the pathways are quite complex (Goldminz et al., 
2013).  
Prolactin 
Increased serum levels of prolactin have been observed in psoriatic patients, with 
increase also associated with greater psoriasis severity (Keen and Hassan, 2014). The 
precise mechanism of prolactin’s involvement is not yet clear, however research 
theorises it may inhibit T-cell suppression, increase keratinocyte proliferation as well as 
T-cell IFN-γ production, and promote angiogenesis (Lowes et al., 2007). 
Chinese medicine syndrome 
Given the present study was designed not to provide individualised Chinese medicine 
treatments, a syndrome differentiation instrument was developed to provide data that 
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can be utilised for subgroup analysis of Chinese medicine syndrome groups in the 
sample (see Chapter 4). One instrument that showed potential was the traditional East 
Asian medicine structured interview, traditional Chinese medicine version (Schnyer et 
al., 2005). The uniqueness and appeal of the instrument is it can be adjusted to suit any 
health condition; however,  after further discussion with the creator its suitability was 
deemed low for the present study. Limitations for use in our study included the 
considerable time requirements to complete, modify and validate the instrument, and 
potential restrictions due to intellectual property rights.  
Without a suitable syndrome differentiation instrument available for psoriasis, a 
short instrument was developed for the trial following translation of Chinese guidelines 
for psoriasis which list three syndromes for psoriasis (blood heat, blood stasis and 
blood deficiency) and detail the physiological, emotional, tongue and pulse features of 
each syndrome (China Academy of Chinese Medicine, 2011). From this, a simple tick box 
questionnaire was developed with the three syndromes grouped into their key features 
(Appendix 1). 
Other secondary outcomes 
Although the current study is just a pilot to evaluate the feasibility of a large-scale study 
it will collect health resource utilisation such as non-trial related pharmacotherapy use 
(psoriasis related only) and the number of GP and hospital visits. Data will also be 
collected on body mass index to evaluate any change with treatment as psoriasis and 
obesity have a strong correlation (Tobin et al., 2014). To explore co-morbidities such as 
cardiovascular disease and diabetes, blood tests at weeks 0, 12 and 24 will analyse 
blood glucose and lipid level change.  
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7.5.8 Study procedures 
Participants will undergo an initial screening, followed by pre-treatment assessment, a 
two week run-in phase, baseline assessment, randomisation to treatment, six weeks 
treatment, fortnightly compliance and safety assessments, mid treatment assessment, a 
further six weeks treatment period, end of treatment assessment, twelve week follow 
up period and a final end of follow-up period assessment (Figure 7.2). All face to face 
data will be recorded in the participant’s case record forms (CRFs) (Appendix 7).This 
section outlines the study procedures in full. 
 
Figure 7.5: Flowchart of study procedure 
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Screening and pre-assessment (week –2) 
The initial assessment will consist of screening for inclusion and exclusion criteria (see 
6.4.2), informed consent and assessment measures including psoriasis area severity 
index (PASI) and body surface area (BSA), which is calculated based on lesion skin 
surface coverage (Menter et al., 2009), dermatology life quality index (Appendix 4), 
Skindex 29 (Appendix 5) and Chinese medicine syndrome differentiation diagnosis 
(Appendix 3). 
Run-in period (week -2 to week 0) 
Following screening, participants will undergo a two-week run-in period. During this 
period all psoriasis-related medications and herbal supplements will be restricted from 
use. Participants will be provided with sorbolene cream during this period, which they 
may apply as required to assist symptom discomfort until the treatment period 
commences. Sorbolene or QV cream was recommended by specialists for use as a 
moisturiser due their unlikeliness to have any therapeutic action on the psoriasis. Of 
these, Sorbolene was selected for use in the study as it contains the least ingredients of 
the two, thus further reducing the chance of any therapeutic effect (Table 7.5). 
 
Table 7.5: Ingredients of QV cream and Sorbolene 
QV (14 ingredients) Sorbolene (8 ingredients) 
Aqua (water) Butylparaben  
Paraffinum liquidum Cetearyl Alcohol  
Glycerin Cetheareth-20  
Petrolatum Glycerin   
Cetearyl alcohol Methylparaben   
Squalane Mineral Oil   
Dimethicone Petrolatum   
Ceteth-20 Propylparaben 
Glyceryl stearate SE  
Stearic acid  
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Laureth-3  
Glyceryl stearate  
Methylparaben  
Dichlorobenzyl alcohol  
 
Baseline assessment 
After the run-in period, participants will undergo baseline assessments (week 0: Table 
7.6 – PASI, BSA, dermatology life quality index, Skindex 29, and Chinese medicine 
syndrome diagnosis) as well as full blood count, and kidney and liver function tests. 
Photos of the lesion areas will be taken, coded and placed in the patient’s case record 
file.  
Twelve-week treatment phase week 1 to week 12) 
After baseline assessments participants will be randomly allocated to the intervention 
of placebo group. The first six weeks’ worth of medication will be dispensed to 
participants along with administration instruction (Appendix 9). During this period, 
psoriasis symptoms will be recorded in participants’ daily diary using self-administered 
assessments (Appendix 10). A consultation will be scheduled during the treatment 
phase at weeks 6 and 12, at which data will be collected to measure symptom severity, 
safety, dosage used and repeat the physiological tests done at baseline (Table 7.6). 
Phone calls will be made to participants at weeks 2, 4, 8 and 10 to check adherence to 
the dosage guidelines. At week 6 assessments the second 6 weeks’ worth of dosage of 
trial medications or placebo will be allocated to participants. 
Administration of calcipotriol will continue until the end of the treatment period. 
Calcipotriol dosage can be reduced from the initial dosage at the participant’s discretion 
as the symptoms reduce. Participants in their daily diary will record any reduction in 
dosage with reasoning. Participants will be instructed to recommence prescribed dose 
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of calcipotriol if their symptoms return at any stage during the follow-up period. The 
CHM therapy and CHM placebo initial dosages will be continued to the end of the 12-
week course regardless of complete psoriasis rash clearance. Any unused trial 
medications will be collected at the end of treatment assessment. Participant lesion 
areas will be photographed and coded with the participant’s identity masked. 
Twelve-week follow-up phase (week 13 to week 24) 
For the remaining 12-week post-treatment phase participants will continue to record 
symptoms in their daily/weekly diaries as well as utilisation of any health resources 
(including drug therapy use). At the end of this 12-week follow-up period (week 24) 
participants will attend the trial clinic for the end of follow-up assessment (fifth visit). 
Final photos of the lesion areas will be taken, coded and added to the patient’s case 
record file. The end of study form will be completed at this time and the participant’s 
involvement in the study will end.  
7.5.9 Data analysis and security 
Data analysis 
All data will be processed and analysed by an independent statistician. The Statistical 
Package for the Social Sciences (SPSS) software version 21.0 for Windows (SPSS Inc., 
Armonk, New York, USA) will be used for data analysis. Baseline demographic 
characteristics on categorical variables such as gender will be assessed for balance 
between the two treatment groups via the chi-square test. Continuous or interval 
variables (e.g. age) will be assessed for equivalence between the treatment groups by t-
test. Intention-to-treat analysis will be applied to outcome data to minimise bias due to 
withdrawals, all missing data will be replaced using the last observation carried 
forward. Continuous data will be presented as means and standard deviation (SD), or 95% 
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confidence interval (CI). All dichotomous data such as the percentage of participants 
achieving PASI 75 will be presented as risk ratio (RR) and 95% CI. Other outcomes (e.g. 
severity and QoL) will be assessed for equivalence in the two groups. Effects with P-
values <0.05 will be considered statistically significant. 
Reporting of results will be in accordance of the recommendations provided by 
the Consolidated Standards of Reporting Trials (CONSORT)(Schulz et al., 2010) and 
extensions of the CONSORT for both herbal interventions (Gagnier et al., 2006a) and 
pragmatic trials (Zwarenstein et al., 2008). 
Data security 
Information of the participants, including the administration of PSORI-CM01, 
instrument measures, AEs, laboratory reports and other relevant data will be 
documented in or attached to the case record form (CRF) and stored in the participant’s 
file in a locked filing cabinet. The filing cabinet will be accessible only to the researchers 
involved in the study. All corrections made to the CRF must be personally signed and 
dated by the person responsible. On all documents participants will be identified only 
by their study ID code. An end of study form will be completed for all participants in the 
study when they finish their final assessment or withdraw from the trial for any reason. 
Data from the participant files will be entered into a database on a password-protected 
computer accessible only to the researchers involved in the trial. Upon request of a 
regulatory authority or RMIT University HREC, the investigator will make available 
direct access to the source data and other trial-related records.
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Table 7.6: Assessment measures and time points 
 PASI BSA DLQI 
Skindex 
29 
CM 
syndrome 
diagnosis 
Medication 
and Health 
utilisation 
Blood 
tests 
Compliance 
AEs of CHM 
and 
calcipotriol 
Pre assessment (Visit 1/Week 
0) 
X X X X      
Baseline assessment (Visit 
2/Week 1) 
X X X X X  X   
Compliance assessment phone 
call (Week 2 and 4) 
       X X 
Daily/weekly self-assessment 
during eight weeks treatment 
(Weeks 1-12) 
     X X  X 
Mid-treatment assessment 
(Visit 3/Week 6) 
X X X X    X X 
Compliance assessment phone 
call (Week 8 and 10) 
       X X 
End of treatment assessment 
(Visit 4/Week 12) 
X X X X X X X X X 
Daily/weekly self-assessment 
during eight weeks follow-up 
     X   X 
End of follow-up assessment 
(Visit 5/Week 24) 
X X X X X X X X X 
PASI, psoriasis area and severity index; BSA, body surface area; DLQI, dermatology life quality index; CM, Chinese medicine; AEs, 
adverse events.
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7.5.10 Blood samples 
The collection of blood samples from participants will occur at screening (–2 weeks), 
mid-treatment (6 weeks), post-intervention phase (12 weeks) and at the end of the 
follow-up period (24 weeks). Blood samples will undergo full blood count analysis, lipid 
levels, glucose levels as well as kidney and liver function. From the blood collected a 
sample will have the plasma separated and will be frozen for future assay measure of 
relevant cytokines showing possible involvement in psoriasis pathogenesis (see 
7.6.8)(Michalak-Stoma et al., 2013). The sample results in the treatment group will be 
compared for each participant for each time point for any significant changes to 
concentrations. Similarly, the control group samples for each participant will be 
compared for any concentration changes between the three time points. Assay will be 
conducted using Bio-Plex® multi assay plexed kits and analysis will use Bio-Plex Data 
Pro™ software. Assays will be performed according to recommended protocols supplied 
by Bio-Plex®.  
7.5.11 Clinical trial compliance 
The clinical trial will be conducted according to the following guidelines: 
• CPMP/ICH, Note for Guidance on Good Clinical Practice – Annotated with 
Therapeutic Goods Administration (TGA) comments (CPMP/ICH/135/95); 
• CPMP/ICH, General Considerations for Clinical Trial (CPMP/ICH/291/95); 
• CPMP/ICH, Statistical Principles for Clinical trial (CPMP/ICH/363/96); 
• National Health and Medical Research Council, National Statement on Ethical 
Conduct in Research Involving Humans; 
• National Health and Medical Research Council, Guidelines Under Section 95 of 
the Privacy Act 1988, March 2000. 
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The clinical trial will be registered with the Australian New Zealand Clinical Trial 
Registry (ANZCTR) as well as under the TGA’s Clinical Trial Notification scheme. 
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Chapter 8 – Pilot study: operation, experience, baseline and 
preliminary safety data results 
This chapter provides a summary of the operation of the pilot study to date, including 
issues encountered, potential implications and limitations of results, adverse events and 
future study plan. Future improvements to CHM studies are discussed as well as the 
preliminary feasibility of the pilot study design for repeat in a large-scale study. 
Resources such as study personnel, equipment and site location are discussed in 
relation to budget and planning for a large-scale study. 
Due to the duration of treatment and follow-up required for each participant (6 
months), the pilot study was still ongoing at the time of thesis preparation. Full result 
analyses were not available at the time of thesis submission and nor were there any 
interim efficacy results due to the blinded nature of the study. When all participants 
have completed study requirements, the data will be analysed and a manuscript 
reporting results prepared for publication in a peer-reviewed journal.  
8.1 Recruitment 
It was determined early in the study that email response to people‘s email enquiries 
about the study rarely had a response back from interested participants, so instead they 
were phoned to discuss the trial further and screen for suitability. Throughout the 
recruitment phase, enquiry from potential participants was possible 24 hours 7 days a 
week; however, to ease scheduling and monitoring of participants, face-to-face 
assessments were only offered over six time periods (cohorts). Each of these face-to-
face assessment periods spanned a week and potential participants were able to book a 
convenient day and time for screening during that week. This method meant relevant 
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assessments coincided at each time point, which eased tracking and follow-up and 
simplified the management of assessments. For example, to spread the workload, 
screening was done in a week when mid-treatment or end of treatment assessments of 
other cohorts was not required.  
Following phone and/or face-to-face assessment there were two modes of 
exclusion possible: 
1) Permanent: Those who were clearly not eligible due to inclusion/exclusion 
criteria were documented with exclusion reason and no further evaluation was 
required. 
2) Temporary: Those who had potential to be eligible at future screening after 
change or clarification of their condition (see below) remained eligible for future 
participation and were invited to contact the research team when their condition 
may be suitable for inclusion. 
 
Temporary exclusion was granted if: disease severity was too severe or too mild; topical, 
systemic or UVA/UVB therapy had recently been used; previous liver function disorder 
required physician consultation and clearance for inclusion; psoriasis vulgaris had not 
yet been medically diagnosed. This meant in some instances potential participants were 
screened on multiple occasions, either face-to-face or via phone during the recruitment 
period. 
Face-to-face screening for the first cohort commenced on March 16th 2015 and the 
sixth and final cohort was screened on July 21st 2015. During this time there were 107 
enquiries to participate. Cohort numbers gradually declined as trial recruitment period 
progressed, with the final cohort booking only three people. Of the 107 enquiries, 25 
were unable to be reached for further screening, were uninterested in undergoing 
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further screening, or missed their screening appointment and were lost to further 
follow-up. The remaining 82 were screened further via phone and/or face-to-face 
assessment. Of these, 68 were excluded with the main reasons because: psoriasis 
symptoms were too mild (n=22); the location of the study site was too far (n=16); 
psoriasis was not vulgaris type (n=7); or they were unwilling or unable to stop current 
psoriasis-related medication (n=7) (Figure 8.1).  
Fourteen participants were deemed eligible for the study and commenced the run-
in phase. All fourteen participants had blood samples collected to assess their liver and 
kidney function. Of the fourteen, five returned abnormal liver function results and were 
referred to their treating physician for advice prior to continuing involvement in the 
study. After discussion with their physician, three of these participants withdrew during 
the run-in phase. After the run-in phase and baseline assessment, the remaining 11 
were randomised and commenced their treatment phase. There were two dropouts 
during treatment phase, one before the week 6 mid-treatment assessment (due to work 
commitments and lack of time), the other was lost before the week 12 end of treatment 
assessment (Figure 8.1).  
8.1.1 Advertisement 
To attract participants during the recruitment period, various advertisement methods 
were employed. Initially a webpage was set up through the RMIT University website 
(Appendix 6), which provided a brief overview of the study and contact information for 
those interested in involvement. The webpage aimed to be an information source 
available to the public 24 hours a day. Advertisements were then arranged for local 
newspapers, RMIT staff newsletters, Google ad words and via link to webpage on a 
number of social network applications (Facebook, Twitter and LinkedIn)(Appendix 6). 
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A press release was provided by RMIT University’s Marketing and Communication 
department, which was picked up by SBS radio and an online source providing further 
free exposure. An interview for SBS radio attracted a small influx of interest (n=3), 
however these were not located in the local area so were unable to participate. 
Overall, there were nine enquiries from Internet advertisements and other online 
sources, however again they were typically not from the local area. Further free 
exposure was gained through a number of local newsletters. Recruitment posters were 
also printed and displayed at RMIT University Bundoora and Melbourne city campuses, 
with tear-off tabs detailing email, phone and website link for further details about the 
study (see Table 8.1) (Appendix 10). 
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Figure 8.1: Recruitment and exclusion flow chart 
 
Where possible, on first contact participants were asked how they heard about the 
study. The majority did not supply further information or were unsure (n=48); however, 
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of those who did respond, newspaper advertisement (n=22) and recruitment posters 
(n=17) proved to be most effective. Five newspaper advertisement campaigns were run 
over the recruitment period targeting a variety of regional papers. Newspapers closest 
to the study site provided half the enquiries (n=9) with the remaining three campaigns 
attracting the rest. 
 
Table 8.1: Trial advertising strategy recruitment numbers 
 Newspa
per 
Social 
media 
Posters 
SBS 
radio 
Other Unsure Total 
Number of 
enquiries 
received 
22 9 17 3 10 46 107 
Number of 
potential 
eligible 
volunteers 
11* 2* 10* 0 4* 10* 37* 
Number of 
final included 
participants  
2 1 4 0 3 4 14 
*Booked for face-to-face screening 
8.2 Monitoring 
Participants were regularly monitored for relevant efficacy and safety assessment 
throughout the study, with communication at least fortnightly. Further communication 
between allocated assessments occurred via phone and email, with participants free to 
contact the study co-ordinator at any time. Before each face-to-face assessment 
participants were sent an email containing relevant information regarding their 
upcoming assessment, including appointment booking date, time and location as well as 
preparation instructions prior to assessment, such as fasting and completion of study 
diaries. A mobile phone text message reminder was also sent to participants the day 
before their assessment, ensuring appointment attendance and to remind them to bring 
their study diary, remaining medication, and/or fast for the 12 hours prior to their visit. 
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Regular monthly reports were prepared for study investigators informing them of 
recruitment numbers, dropouts and adverse events. Study investigators were contacted 
in instances where the protocol and/or standard operating procedures were breached 
to determine any necessary action. As discussed, participants who returned abnormal 
liver function pathology results were referred to their GP, who assessed their safe 
continuation in the study and monitored their follow-up blood tests (weeks 6, 12 and 
24). 
 
8.3 Adverse events 
Adverse events were self-reported daily in participant study diaries, as well as over the 
phone during compliance and safety assessments and fortnightly to assessors at face-to-
face assessments. At this stage no serious adverse events or incidences threatening 
participant safety have occurred, in which case information would be sent to the study 
investigators then, if deemed necessary, forwarded to the Data & Safety Monitoring 
Committee for recommended action, such as sending a report to the RMIT HREC and 
TGA (National Health and Medical Research Council, 2009). 
Adverse events were reported by participants during both the run-in phase and 
treatment phase (Table 8.2). Only two people rated their adverse event as severe, one 
during the run-in phase reporting severe stress for two days and another who reported 
instance of severe itch during the treatment phase that lasted one day, but did not 
require medical intervention. Itch was the most common AE reported by participants 
(n=4). Incidence of itchy rash may be related to the calcipotriol as it is indicated as a 
potential side effect of its use (Leo Pharmaceutical Products Ltd A/S, 2002).  
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Both participants who reported nausea experienced it in weeks 1 or 2 of 
treatment, with one reporting it moderate severity, however there were no further 
reported incidents of nausea during the treatment phase. Due to previous review of AE 
reports in CHM (see chapters 3 and 4), investigators considered the nausea could 
possibly be associated with the PSORI-CM01 intervention. Runny nose was reported by 
one participant that then progressed to hayfever symptoms. Participant report 
indicated all adverse events to be relatively short term and only one participant 
requiring medical intervention as a result of an adverse event. This participant reported 
a moderate burning skin sensation after applying calcipotriol for the first time however 
the symptoms subsided and did not reoccur with further calcipotriol use.   
 At this stage, due to the blinded nature of the study it is unclear whether adverse 
events are related to PSORI-CM01 or the placebo group.  
Table 8.2: Number of participants reporting adverse events during the run-in and 
treatment phase 
Reported adverse 
event 
Run-in phase (week -2 to 
week 0) 
Treatment phase (Week 1 to 
week 12) 
Headache 3 (2 mild, 1 moderate) 3 (2 mild, 1 moderate) 
Stress 1 severe - 
Itch 2 mild-moderate 4 (2 mild, 1 moderate, 1 severe) 
Dizziness 1 mild 3 mild 
Diarrhoea 1 mild 1 mild 
Insomnia 1 mild - 
Abdomen pain 1 mild - 
Constipation 1 mild - 
Nausea - 2 (1 mild, 1 moderate) 
Runny nose - 1 mild 
Hayfever - 1 mild-moderate 
Blurred vision - 1 mild 
Tiredness - 2 mild 
Thirst - 1 mild 
Sensation of burning 
skin 
- 1 moderate 
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8.4 Current progress report and ongoing operation 
Currently nine participants have completed the follow-up phase and all eleven 
participants have completed treatment phase. In November the Guangdong Provincial 
Academy of Chinese Medical Sciences commenced operation of a second site and will 
recruit remaining participant numbers. The protocols remain the same for the 
Guangdong site and data will be pooled for analyses. Participants will continue in the 
study until the last participant completes their follow-up phase, at which point data will 
be sent to a statistician who is blinded to group allocation for analysis. Blood samples 
will be further analysed for concentration changes in cytokines using the Bio-Plex® 
MAGPIX™ Multiplex Reader. Once all data have been analysed a manuscript reporting 
results of the study will be prepared and submitted to a peer-reviewed journal for 
publication. 
8.4.1 Participant characteristics at screening (week -2) and baseline (week 0) 
assessments 
Characteristics of participants assessed as eligible who undertook the run-in phase and 
those that continued on to randomization are shown in table 8.3. The average age of 
participants screened as suitable was 44.7±14 years of age and the male to female was 
50:50, with majority of participants being born in Australia (n=9) and one each from 
South Africa, South Korea, China, Malaysia and India. The average BMI of included 
participants at screening was 25.7±4.1. This BMI is classified by the WHO as overweight 
(World Health Organization, 2006). Mean systolic and diastolic blood pressure was 
130/82, which place the participant mean in to the prehypertension range according to 
NIH recommendations (National Institute of Health, 2015) (Table 8.3).  
 333 
For psoriasis severity the mean PASI score at screening was 8.7±1.3 and BSA was 
9.1±4, and at the end of the run-in phase PASI mean had risen to 9±2.4 whilst BSA had 
decreased to 7.8±3.3 Photographic examples of a participant’s lesion change are shown 
at screening (week -2), baseline (week 0), mid treatment (week 6) and end of treatment 
(week 12) in figure 8.2.  
 
Figure 8.2: Example lesion change photos 
A, Week -2; B, Week 0; C, Week 6; D, Week 12 
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The average age of onset at screening was 22.4±14.4 years of age, with the age of 
psoriasis diagnosis on average similar at 23.4±15 years. For QoL mean DLQI was 
8.7±1.3 at screening compared to 9±2.4 at week 0. For Skindex 29 the mean domain for 
symptoms reduced (week-2 = 398 vs. week 0 = 377) whilst means increased for both 
the emotions (487->507) and functioning (377->463) domains. 
Of the 14 participants screened as eligible, 10 had previously used Chinese 
medicine and of these seven had utilized it for their psoriasis. Of the 10 who had 
previously used Chinese medicine three had utilized acupuncture, two CHM and four 
had used a combination of the two modalities. Eight of the 14 eligible had no previous 
family history of psoriasis and eight had no previous history of smoking. Both family 
history and smoking have significant evidence to indicating they increase the likelihood 
of psoriasis development (Mahil et al., 2015) (Armstrong et al., 2013). Almost all the 
participants consumed alcohol (n=12) and five of these indicated 2-3 days per week or 
more alcohol consumption. Six of the eligible stated they had 3 or more standard drinks 
on each occasion of alcohol consumption. Three people reported having more than four 
standard drinks in a day at least once per week or more. Excessive alcohol consumption 
has also been linked to psoriasis development and symptom exacerbation (Richard et al., 
2013). 
 
Table 8.3: Participant characteristics at screening and baseline assessments 
 Screening (week -2) Baseline (week 0) 
Age (mean±SD) 45±13.9 45±14.4 
Gender M/F 7/7 6/5 
Country of birth Au=9, SA=1, SK=1, C=1, 
MA=1 
Au=6, SA=1, SK=1, C=1, 
MA=1 
Weight  (kg) (mean±SD) 73.8±9.4 73.3±9 
Height (cm) (mean±SD) 170±7.8 171±7.3 
Blood pressure systolic (mean±SD) 130±12.9 127±10.8 
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Blood pressure diastolic (mean±SD) 82±8.6 81±9.3 
Aortic systolic pressure (SP) (mean±SD) 113±31.3 117±10.6 
Aortic diastolic pressure (DP) (mean±SD) 83±9.4 82±9.6 
Aortic mean arterial pressure (MAP) 
(mean±SD) 
99±9.4 96±9.7 
Aortic pulse pressure (PP) (mean±SD) 37±6.5 34±7.1 
Aortic heart rate (HR) (mean±SD) 71±7.7 74±11.7 
Aortic augmented pressure (AP) 
(mean±SD) 
12±4.8 9±6.5 
Aortic augmentation index 
(AIx)(mean±SD) 
32±9.1 25±15.8 
Body Mass Index (BMI) (mean±SD) 26±4.1 25±3.5 
Psoriasis Area Severity Index (PASI) 
(mean±SD) 
8.7±1.3 9±2.4 
Body Surface area (BSA) (mean±SD) 9.2±4.1 7.9±3.3 
Dermatology Life Quality Index (DLQI) 
(mean±SD) 
8.3±5.6 10±7.6 
SKINDEX 29 - Symptoms 398±125 377±125.7 
- Emotions (mean±SD) 487±232 507±234.8 
- Functioning  (mean±SD) 377±284.1 463±301.1 
Previous use of Chinese medicine 
(Yes/No) 
10/4 8/3 
If yes, was it for psoriasis (Yes/No) 7/3 5/3 
Previous form of Chinese medicine 
(ACU/CHM/Both) 
3/2/4 3/2/3 
Age of onset of psoriasis (mean±SD) 22.4±14.4 22.4±13.6 
Age of diagnosis of psoriasis (mean±SD) 23.4±15 23.5±14.4 
Family history of psoriasis (Yes/No) 6/8 3/8 
Smoking status (Never/previous/current) 8/3/3 6/2/3 
Drinks alcohol (Yes/No) 12/2 10/1 
Drinking frequency (Daily or most days/2 
– 3 days per week/Once per week/2 – 3 
days a month/Less often) 
2/3/1/1/5 2/2/1/1/4 
Average drinks per drinking occasion (5 
or more/3 – 4 /1– 2) 
2/4/6 2/3/4 
Over the last 12 months or so, how often 
had more than 4 standard drinks in a day? 
(Daily or most days/2 – 3 days per 
week/Once per week/2 – 3 days a 
month/Less often) 
0/2/1/2/7 0/2/1/2/5 
Au, Australia; C, China; cm, centre mitre; F, female; kg, kilogram; M, male; MA, Malaysia; 
SA, South Africa; SD, standard deviation; SK, South Korea; 
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8.4.2 Medication use at screening and during the run-in phase 
At screening three included participants were taking other non-psoriasis related 
medication. One person was taking coveram 10mg per day and eutroxsig 150mg per 
day which are commonly prescribed for high blood pressure and hypothyroidism 
(Servier Research International, 2013, Therapeutic Goods Administration, 2015) 
However this participant dropped out during the run-in phase prior to randomization. 
Another person was taking anti-seizure (topomax 50mg per day)(JANSSEN-CILAG Pty 
Ltd, 2015), anti-depressant (lovan 60mg per day)(Alphapharm Pty Limited, 2013), 
antacids (zantac 120mg per day and pantorazole 40mg per day)(Aspen Pharmacare 
Australia Pty Ltd, 2012, Amneal Pharma Australia Pty Ltd, 2015). A third participant 
was taking thyroxine 75mg per day for hypothyroidism.  
Other medications used during the run-in phase included analgesics paracetamol, 
ibuprofen and codeine but were not administered for psoriasis related symptoms. Two 
participants utilized topical psoriasis related therapy during the run-in phase despite 
instruction not to. One applied hydrocortisone acetate 0.5 fingertips (day 11) to the face 
and groin area due to unhappiness with the appearance and another applied a 
combination of 50% topical corticosteroid with 50% savlon at day 6 (two fingertips), 7 
(three fingertips) and 8 (three fingertips) to groin area where skin was causing 
discomfort from cracking. 
During the run-in phase, prior to randomization and administration of any study 
drug, participants experienced various symptoms. One person reported difficulty 
sleeping but did not rate the severity, whilst another also reported difficult sleeping on 
one occasion due to pruritus. This same person reported pruritus regularly on various 
limbs throughout the run-in phase, which was reported as mild to moderate in severity. 
Other mild symptoms reported included headache by three people, diarrhoea by one 
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person and dizziness by one person. Only one person reported any abnormal symptoms 
as severe, reporting stress on days one and two of the run-in phase. 
8.4.3 Pathology results for blood samples at screening 
All participants assessed as eligible at screening had three blood samples collected. One 
sample had plasma separated and stored, to be analysed at a later date for cytokine 
concentrations. The other two samples were sent to a pathology laboratory where 
blood examination was undertaken, as well as examination of fasting glucose, liver 
function and kidney function. Results are presented in Table 8.4. Lipid concentrations 
were also assessed to evaluate cholesterol levels, as well as triglyceride, HDL, LDL, non 
HDL and the cholesterol to HDL ratio (Table 8.5).  
Blood tests at screening identified one participant diagnosed with mild anaemia at 
screening (Haemoglobobulin: 12.9, RCC: 4.38, MCHC: 31.2), but no added risk to 
participation was identified so they continued to randomization. Another participant 
was diagnosed with mild eosinophilia (eosinophils 1.2), but was also randomized 
following the run-in phase. Blood test results of five out of the 14 people reported 
abnormal liver function. Three of these became dropouts, which after discussing their 
abnormal liver function results with their treating physician elected not to continue in 
the study. However two participants after discussion with their physician continued the 
study to the randomization phase. All three dropouts during the run-in phase were due 
to abnormal liver function results. 
 
Table 8.4: Blood pathology analyses of participants at screening (week -2) 
(mean±SD) 
Test 
Mean (standard 
deviation) 
Test 
Mean (standard 
deviation) 
Sodium 141 mmol/L (2.4) 
Glucose mmol/L 
(fasting) 
5.2 (0.4) 
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Potassium 4 mmol/L (0.7) Haemoglobin g/dL 14.5 (1.5) 
Chloride 105 mmol/L (2.1) WCC (x109/L) 6.6 (1.5) 
Bicarbonate 30 mmol/L (1.7) Platelets (x109/L) 269 (46.3) 
Urea 5 mmol/L (1.4) PCV (%) 44 (3.9) 
eGFR 89 mL/min (2) RCC (x1012/L) 4.9 (0.5) 
Creatinine 66 umol/L (14.9) MCV (fL) 90 (3.8) 
Bilirubin 11 umol/L (3.6) MCH (pg) 29.8 (1.3) 
ALT 27 U/L (14) MCHC (g/dL) 33 (0.8) 
AST 24 U/L (5.5) RDW (%) 13.6 (0.8) 
ALP 79 U/L (26.4) Neutrophils (x109/L) 3.8 (1.2) 
GGT 34 U/L (30) Lymphocytes (x109/L) 2.1 (0.5) 
Total 
protein 
72.6 g/L (3.1) Monocytes (x109/L) 0.5 (0.2) 
Albumin 45.8 g/L (2) Eosinophils (x109/L) 0.2 (0.3) 
Globulin 27 g/L (2.1) Basophils (x109/L) 0.0 (0.0) 
ALP, Alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; eGFR, estimated glomerular filtration rate; GGT, gamma-glutamyl 
transferase; MCH, Mean corpuscular haemoglobin; MCHC, Mean corpuscular 
haemoglobin concentration; MCV, mean corpuscular volume; PCV, packed cell volume; 
RCC, red cell count; RDW, red cell distribution width; WCC, white cell count. 
 
Shown increasing evidence in recent years is a greater risk in psoriasis sufferers to 
metabolic disease comorbidities such as cardiovascular disease (Puig et al., 2014). 
Cholesterol was measured at screening for eligible participants to evaluate if cholesterol 
levels were within recommended levels. Mean total cholesterol was 5.6 (0.9) well above 
the recommended limit for primary cardiovascular disease prevention (<4.0) (Tonkin et 
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al., 2005), means were also elevated for LDL 3.3 (0.9) (<2.0) and Non-HDL 3.9 (1.0) 
(<2.5). Only HDL 1.7(0.4) was in the recommended range for primary prevention 
(≥1.0)(Tonkin et al., 2005)(Table 8.5). 
Table 8.5: Blood lipid analyses of participants at screening (week 0) mmol/L 
(mean±SD) 
Total Chol Triglyceride HDL LDL Non-HDL CHOL/HDL (Ratio) 
5.6 (0.9) 1.3 (0.6) 1.7 (0.4) 3.3 (0.9) 3.9 (1.0) 3.6 (1.3) 
Chol, cholesterol; HDL, high-density lipoproteins; LDL, low-density lipoproteins 
8.4.4 Preliminary analysis of Th-17 pathway cytokines 
As the study is ongoing not all participant plasma samples are yet collected. At the time 
of preparing this thesis the baseline samples had been analysed for the 11 participants 
randomised to date.  
Sample preparation involved collection of a 5mL blood sample collected in an 
ethylenediaminetetraacetic acid (EDTA) coated vacutainer. The vacutainer was stood at 
room temperature for 30 minutes before being centrifuged at 1000 revolutions per 
minute (rpm) at four degrees Celsius (C) for 15 minutes with deceleration set to six. The 
sample was then separated from the palate using a pipette into a sterile centrifuge tube 
and centrifuged again at 4C but for 10 minutes at 3000 rpm and deceleration 6. The 
plasma was then again separated from the palate using a pipette this time into 2mL 
cryovial tube where they were stored in the freezer at -80C until day of assay (Figure 
8.3). 
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Figure 8.3: Plasma sample pipette separation in the bio safety cabinet 
 
The assay was run in a 98 well Bio-Plex® 4-plex according to the Bio-Plex® 
protocols supplied with the assay kit. Samples were thawed, vortexed and kept on ice 
then 50 μL of each sample was pipetted to be run at three concentrations (1:1, 1:2 and 
1:4). Eight standards were used to develop the standard curve and two non-disease 
samples were used as controls, again at the three concentrations. Each standard, 
unknown and control was assayed in duplicate. The 4-plex consisted of Th17 pathway 
cytokines IL-17F, IL-21, IL-23 and IL-31. 
Wash step used the Bio-Plex Pro™ Wash Station and once plate shaking and 
incubation was complete results were read using MAGPIX™ Multiplex Reader and 
analysed using Bio-Plex Manager software using a detection target of 50 beads (Figure 
8.4). 
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Figure 8.4: Serum sample analysis using Bio-Plex® MAGPIX™ Multiplex Reader and Bio-
Plex Manager software 
 
Any points from the standard curve that had accuracy outside 70-130% range were 
excluded. Using the software’s optimization setting the curve was set to the standards 
(Figures 8.5 A-D). 
 
  
Figure 8.5A: Standard curve of sample results for IL-17F 
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Figure 8.5B: Standard curve of sample results for IL-21 
 
 
 
Figure 8.5C: Standard curve of sample results for IL-23 
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Figure 8.5D: Standard curve of sample results for IL-31 
 
Bead count for all samples was well over the required 50 with the mean bead count of 
the unknown samples 388 (87). All unknown samples had concentrations detected of 
the target cytokines at the lower end of their standard curves.  
For IL-17F two participant samples (both 1:1 concentration) presented an 
observed concentration over 100, remaining samples all had observed concentrations 
under 50 (Figure 8.6A). Three samples showed observed concentrations over 100 for 
IL-21 the rest were under 100 with two samples not reported having concentration 
within range. Only one sample had a concentration within detectable range at a 1:4 
dilution (Figure 8.6B). Two samples had observed concentrations above 100 for IL-23, 
whilst three samples did not have detectable observed concentrations (Figure 8.6C). All 
samples detected a relatively low observed concentration of IL-31, however no samples 
were outside the detected range at a 1:1 dilution ratio (Figure 8.7D). 
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Figure 8.6A: Observed concentration of IL17F in plasma samples 
IMPPS, study ID; C, control 
 
 
Figure 8.6B: Observed concentration of IL-21 in plasma samples 
IMPPS, study ID; C, control 
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Figure 8.6C: Observed concentration of IL-23 in plasma samples 
IMPPS, study ID; C, control 
 
Figure 8.6D: Observed concentration of IL-31 in plasma samples 
IMPPS, study ID; C, control 
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8.5 Feasibility of the trial protocol 
Full assessment of feasibility awaits conclusion of the pilot study, however early 
indication for large-scale study scope is positive. This section evaluates feasibility of the 
study to date. 
8.5.1 Advertising methods for recruitment and feasibility of inclusion/exclusion criteria  
Advertisement 
Advertisement for the pilot appeared suitable to attract interest, with the number of 
enquiries exceeding the target sample size by more than three times. It should be noted, 
though, that the enrolment rate (13%) was lower than anticipated, estimated on 
previous experience of psoriasis severity. To recruit 30 participants using the current 
protocol would require 231 enquiries. Like the pilot, a future large-scale study would 
best utilise a mixture of advertisement types, in particular local newspaper 
advertisements near to study sites, online social media and poster display at study site 
locations.  
Inclusion and exclusion 
The pilot study indicated restrictions (exclusion) and requirements (inclusion) for 
participant involvement in the study did not appear to greatly affect participants’ 
willingness to participate. However, for the majority of interested participants, 
inclusion/exclusion criteria were limiting factors, deeming many ineligible. For the 14 
who did remain eligible, over one-third (n=5) returned abnormal liver function results, 
and although two of the five were cleared to continue, in a large-scale study such liver 
function results would impact (on 20% of recruited participants) on retention and 
should be factored into sample size calculations.  
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There is concern over the current PASI severity for inclusion as discussed in more 
detail in 8.6: Study limitations and further improvement. To reach a larger sample 
target it is likely the PASI inclusion would need to be lowered slightly. 
8.5.2 Feasibility of the study protocol 
Study length and participant continuation 
With the addition of the follow-up period, participation in the study required 
participant commitment of over six months. So far from pilot assessment, long-term 
study commitment does not appear to be a factor reducing willingness to participate or 
impact retention, indicating the duration of the pilot is feasible. Assessment frequency 
and timing of such assessments also appear to be acceptable to participants. 
Throughout the pilot, in instances when participants were expected to be unavailable 
for assessment, their commencement and assessment dates were adjusted. A large-scale 
study should similarly allocate assessment dates early in the study so participants can 
arrange their work and holiday schedules around these dates. 
Tolerance of PSORI-CM01 and its placebo 
The granulated powder forms of PSORI-CM01 and placebo have been well tolerated 
through the study thus far. Some participants expressed mild distaste of the allocated 
oral formulation on initial consumption. The pilot is still currently blind, so we do not 
know which group these people were allocated to. Distaste, however, has not prevented 
participants from consuming their allocated oral formulations and generally after less 
than a week participants reported no further issue.  
Feasibility of the control 
Use of calcipotriol as the control for the study has not resulted in any withdrawals or 
refusals to therapy. The topical conventional therapy (calcipotriol) has been well 
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tolerated and appears to be suitable for future large-scale study use. There were some 
participants who expressed initial lack of confidence using calcipotriol, informing the 
dispenser that due to previous lack of efficacy in use they doubted it would have 
sufficient efficacy. Despite doubts, no participant refused calcipotriol use, and most 
applied it according to supplied instructions for recommended dosage and 
administration. 
It was noted during the study that sufferers commonly had psoriasis plaques 
located on their scalp and as calcipotriol cream is unsuitable for scalp application these 
lesions did not receive conventional treatment in either group. A large-scale study 
might consider addition of a scalp-suitable form of calcipotriol or another suitable 
intervention for participants affected by scalp lesions. However, the limitation of 
calcipotriol use did not impact on compliance, retention or willingness to participate. 
Feasibility of chosen outcome measures 
The instruments utilised by the pilot to measure outcomes were administered without 
issue; however, a full-scale study might consider inclusion of other secondary outcomes 
for psoriasis severity. While collection of plasma samples for analysis of cytokine 
changes was possible for the pilot, for a full-scale study the costs of running such a large 
analysis would restrict samples from undergoing the same level of assessment. A full-
scale study would need to receive considerable funding to carry out the same range of 
cytokine assessments as the pilot study. The solution may be to reduce the number of 
cytokines being measured, from the broad cytokine analysis in the pilot to one or two 
targeted cytokines evidenced from the pilot to have further investigation promise. 
Feasibility of cytokine testing 
Baseline assay results indicate a 1:4 dilution is not necessary due to the low 
concentrations of cytokines. Future assay of plasma should utilize 1:1 or 1:2 dilutions in 
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the assay. Due to the low concentrations 7-8 standards is most likely sufficient for the 
sample type and cytokine concentrations. Future assay should consider further 
centrifuge of the plasma samples after thawing with pipette separation prior to being 
added to the assay. 
8.5.3 Feasibility of trial operation, equipment and resources 
Site location and equipment 
The study site location, RMIT University School of Health Sciences Research Hub, 
Bundoora, Victoria, has been a suitable site location, having the necessary equipment 
and facilities to conduct the pilot. A private room was available to assess psoriasis 
severity and conduct assessments, with equipment on site to measure blood pressure, 
height, weight and to draw blood. It is unlikely a multiple-site, large-scale study would 
have the same level of facilities available at all sites, so logistics would need to be 
considered to ensure minimal inconvenience to participants and study staff at 
assessment time points. Considering the current pilot has only one site, additional study 
sites at other locations would attract greater participant numbers.  
If any physicians showed interest in being involved in the research, a large-scale 
study might consider potential study site extension to include dermatology and/or GP 
clinics. Such sites also have the potential to provide a further source of participants and 
could provide trained on-site staff with the skills required to undertake many of the 
study tasks. Chinese medicine clinics may also be considered as potential site 
recruitment and assessment centres.  
A second site at Guangdong University and Provincial hospital is being 
implemented to recuit the remaining subject numbers. Same protocol will be 
implemented at China site and all outcome measures will be identical. Sub group 
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analysis will be conducted to evaluate any site difference prior to pooling of data. A site 
visit will also be conducted at the China site to ensure it operates consistently with the 
Australian site and data is recorded correctly. Data from both sites will be merged into 
the same excel template. 
Study personnel 
Primarily, one research assistant performed all tasks for the current pilot study. Due to 
the amount of work required for phone follow-ups, face-to-face assessments, screenings, 
blood processing and other study-related activity, it is estimated that if there were 20 or 
more participants enrolled at any one point extra staff would be required. For a large, 
multi-site study, further research staff would be required based on the target sample 
and recruitment rate. Required skills of these additional staff would depend on the 
requirements of staff at each given site, which would relate to equipment available at 
and activities performed, i.e. venepuncture, blood centrifugation and transfer, 
medication dispensing. 
Some activities such as blood collection may be outsourced to external facilities 
such as pathology centres. Indeed, external site blood collection has occurred on 
occasion during the pilot. For example, if a participant forgot to fast or bloods were 
unable to be withdrawn at the time of assessment, participants were referred to their 
local pathology collection centre for blood drawing and results sent back to the research 
team. Assessment of each study visit takes between 1 and 2 hours, and blood sample 
separation and processing requires a further 1–2 hours. This reduces the number of 
participants a research assistant can process to approximately 2–3 per day. 
Budget feasibility 
The current pilot study has thus far been conducted below the anticipated budget, 
mostly due to the reduced sample size. So far there have been no unexpected costs, 
 351 
however advertising budget was increased slightly to attract further suitable 
participants. However, advertisement costs could be minimised if screening inclusion 
criteria for PASI were adjusted to include more potential participants.  
8.5.4 Conclusion of feasibility 
When the study is complete, further assessment of pilot data will be undertaken; 
however, preliminary findings suggest modifications to inclusion/exclusion criteria and 
an increase in staffing levels and site locations for full-scale study feasibility.  
8.6 Study limitations and further improvement 
The main limitation encountered during this study was difficulty achieving the 
recruitment target (n=30). While there was high interest and number of enquiries, the 
majority of those screened were not eligible. The most common reason for exclusion 
(n=27) was a failure to meet the required PASI score range (7–12), most (n=22) being 
too mild. Had this criterion been adjusted and the study open to all PASI score levels, 
the recruitment target would have been met with an enrolment rate of 38% (n=41). 
Allowing for 20% dropout, this would still have supplied the required target (n=32).  
In fact, during face-to-face screening, it became apparent that the sensitivity of 
PASI for mild conditions was poor, with many sufferers with substantial size lesions on 
one or two regions of the body not meeting the PASI minimum (PASI 7) required. 
Sufferers with large lesions on visible areas such as the lower arms or hands scored 
lower PASI than those with small, more hidden lesions on multiple body regions such as 
the back, upper legs and scalp. It was clear in some instances that sufferers with PASI 
scores not reaching the required threshold still had significant psoriasis severity. 
Further, it was noted that people more commonly presented with lesions on one body 
region than with smaller lesions on multiple body regions.  
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The required PASI range (7–12) appeared to be very sensitive, yet PASI lacked the 
same sensitivity below 7, with erythema, induration and scaling having less effect on 
overall PASI score. The sensitivity of the PASI 7–12 range seemed to make inclusion 
difficult, as changes in same symptoms had too great an effect, pushing people above the 
range. While PASI 12 seemed to be an appropriate maximum severity cut-off for this 
study intervention, minimum severity would have been more appropriately set to 
around PASI 4, as people with this score tended to report psoriasis impact similar to 
people in the PASI 7–12 range. For example, the most characteristic presentation of 
psoriasis vulgaris is plaques on the extensor surfaces of elbows and knees; however, 
such location with moderate to severe severity was not sufficient in PASI score to be 
included in the current pilot study (see Figure 8.7 example). 
 
Figure 8.7: Example PASI score of typical psoriasis located on elbows and knees with 
moderate to high scores for erythema, induration and scaling 
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Chapter 9 – Summary of main findings and discussion 
This chapter summarises the main findings of each chapter of the thesis. It details a 
summary first of the systematic review findings and their implications for clinical 
practice and research. It then provides a summary of conducting the pilot study to date 
and the implications of the study’s strengths and weaknesses for further research. 
9.1 Main findings of the systematic reviews 
9.1.1 Findings of systematic review one: oral CHM vs. placebo 
Results from the first systematic review indicated that oral CHM might bring mild to 
moderate improvement to psoriasis symptoms when compared with placebo. The 
general quality of the reviewed studies was low and reporting was poor. It was difficult 
to determine how each CHM intervention was selected and which were most effective. 
The most common CHM ingredients utilised in reviewed studies were salvia miltiorrhiza, 
angelica sinensis and rehmannia glutinosa. Use of oral CHM alone appears to be safe, 
with predominantly minor adverse events reported and moderate side effects rare. 
There was little follow-up data available to evaluate long-term effects of oral CHM for 
psoriasis.  
9.1.2 Findings of systematic review two: oral CHM combined with conventional therapy vs. 
conventional therapy 
The second systematic review and meta-analysis revealed an enhanced effect of oral 
CHM on psoriasis when combined with conventional therapy. The majority of trials 
investigating combined therapy utilised systemic drug acitretin or topical vitamin D 
analogue calcipotriol. Compared with conventional therapy alone, CHM appeared to 
increase therapeutic effects and reduce adverse effects. The most common herbs used 
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in combination with conventional therapy were rehmannia glutinosa (shu di/di huang), 
salvia miltiorrhiza (dan shen) and lithospermum erythrorhizon (zi cao). Chinese herbal 
medicine ingredients varied significantly and made it difficult to determine which have 
the greatest efficacy for psoriasis. Certain herbs (salvia miltiorrhiza (dan shen), angelica 
sinensis (dang gui) and rehmannia glutinosa (shu di/di huang) were utilised more often 
than others in interventions, indicating these herbs may have greater therapeutic effect 
than others. There was considerable variation between the reported participant 
syndrome types amongst the reviewed studies, but many studies did not stipulate how 
they determined syndrome, so results for syndrome efficacy had to be considered with 
caution.  
The review indicated that in some instances oral CHM has potential to impact liver 
function, with degree of risk likely dependent on the type of CHM being utilised. It was 
unclear from results which CHM ingredients have greatest risk. Otherwise, adverse 
event risk is mild to moderate and evidence suggests oral CHM may act as a 
preventative of side effects for some conventional therapies. 
9.1.3 Implications of the reviews for clinical practice  
Generally, there appears a benefit of adding CHM to conventional therapy and 
physicians should consider integrating oral CHM with ongoing conventional therapy. 
For instance, to enhance outcomes for patients, physicians who prescribe systemic drug 
acitretin or topical calcipotriol should consider referral for oral CHM therapy. Until 
long-term safety data are available, clinicians utilising oral CHM should consider short-
term (8–12 weeks) administration in patients for psoriasis. Similarly, until further 
toxicity data are available, physicians of psoriasis sufferers with decreased liver 
function should carefully consider use of specific CHM to minimise additional impact on 
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the liver. Where possible, through blood pathology, physicians are encouraged to 
monitor liver function and evaluate any changes, especially for people with a history of 
long-term use of systemic psoriasis treatments, such as methotrexate, which is known 
to directly damage liver function. 
9.1.4 Implications of the reviews for further research  
The quality of design of the reviewed studies was generally low, thus more high quality 
studies are needed. In addition, variation in outcome measures between studies meant 
some were unable to be pooled for meta-analysis. Future research studies should 
determine methodological design according to CONSORT recommendations to ensure 
repeatability of studies, minimise risk of bias and allow for meta-analysis. Only some 
conventional therapies combined with CHM have sufficient data to evaluate their 
efficacy and safety, highlighting the need for more research to evaluate further 
conventional therapies combined with oral CHM. 
The findings of the systematic reviews may help researchers identify previous 
CHM formulations that warrant further investigation for psoriasis for example Dai 
2014’s Yinxieling formulation, which in meta-analyses results compared to placebo had 
the strongest effect size of the CHM (Dai et al., 2014b). In addition, repeat studies of 
CHM interventions would aid pooling of results data for comparison. Such data 
comparisons may provide evidence to support or refute previous findings, and may 
eventually lead to broad conclusive findings and recommendations for oral CHM 
therapy in psoriasis.  
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9.2 Preliminary findings of the pilot study 
9.2.1 Findings from development of an oral CHM formulation for psoriasis vulgaris and the 
biological activity of its constituents  
While the first developed formulation had theoretical basis to support its use, it had no 
RCT trial clinical evidence indicating its potential benefits for psoriasis. Investigation of 
the constituent compounds confirmed the ingredients had biological actions with 
potential anti-psoriatic activity. Considering the limited available resources and 
unknown prevalence of Chinese medicine syndrome types in the target population, 
rather than restrict sample size on such basis, the formulation was made to be suitable 
for all syndrome types. However, consultation with experts yielded recommendations 
to use an existing formulation that has substantial clinical and laboratory evidence of its 
efficacy for psoriasis.  
Thus, the pre-existing formulation PSORI-CM01 was chosen for the pilot study 
intervention. Again, investigation of constituent compounds present in the seven 
included ingredients indicated potential actions similar to those of conventional anti-
psoriatic therapies. The chief herb, chi shao, is sourced predominantly from two peony 
species, P. lactiflora and P. veitchii. The Radix Paeoniae Rubra (chi shao) produced from 
P. veitchii was found to be the form needed for the proposed formulation. The primary 
Chinese medicine actions of chi shao are to cool heat, cool blood and move blood. The 
conventional medical benefits of chi shao relevant to psoriasis are that it inhibits 
epithelial cell mitosis, reduces proliferating cell nuclear antigen expression, promotes 
epidermal cell differentiation, and acts as a sedative, analgesic, antipyretic, anti-
inflammatory and vasodilator.  
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 Ongoing conjecture exists surrounding the correct botanical source of PSORI-
CM01’s principal CHM, chi shao. Furthermore, bai shao is often sold in the marketplace 
as chi shao, so distinguishing between each can be difficult. A review of the two common 
botanicals processed and sold as chi shao, P. lactiflora and P. veitchii, revealed they have 
some but not all constituents in common. Variation between the two species may have 
an intrinsic basis and/or be caused by environmental differences in the geographical 
regions of cultivation. The constituents of both botanicals showed evidence of anti-
inflammation, anti-tumour, antibacterial, anti-viral and antioxidant-like activity, which 
are all pathways that have been implicated in psoriasis pathogenesis. Historical records 
and constituent features both suggested P. veitchii should be the source for chi shao in 
the PSORI-CM01 formulation. 
9.2.2 Implication of the pilot study for further research  
Although the pilot study results may impart some insights into clinical use of CHM 
alongside conventional treatments, the primary aim of the pilot is to inform a future 
adequately powered study. Thus, the current, ongoing pilot study is in the process of 
evaluating the feasibility and practicality of a larger study. After completion of data 
collection and analysis, results are hoped to help predict resources, equipment and 
methodology for a subsequent study. Improvements already suggested include 
modifying PASI score (to PASI 4–12 to improve targeting of mild-moderate symptoms, 
and also allow inclusion of more participants, thus increasing chances of reaching 
sample size targets. Similarly, increasing the number of study site locations may 
improve recruitment success. 
Further research which might be prompted by the present pilot study results, 
include blood cytokine change with PSORI-CM01 treatment. Further scientific 
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investigation into the psoriasis-related biological pathway effects of cytokines may lead 
to development of new psoriasis drug treatments.  
 Further research is also needed into the effects of the sulphurisation process 
during bai shao processing. Evidence suggests that it does alter the constituent 
compounds; however, investigation is needed into how these changes affect the 
therapeutic and biological activity of bai shao for psoriasis disease, as well as safety to 
consumers. While a number of botanical species and interspecies variants have been 
evaluated for chi shao, research should continue to compare and evaluate botanical 
species for psoriasis efficacy. Further in vitro and in vivo investigation of botanical 
species may provide further indication of which is of most benefit to key psoriatic 
disease aspects such as inflammation and proliferation. There is also scope for 
investigating the potential benefits of these constituents for other diseases sharing 
similar pathways. Future studies should also investigate both granulated extracts and 
raw herb decoction to compare the efficacy and safety of each.  
Another area of research that warrants further research is the effect of syndrome 
type on psoriasis treatment selection and efficacy. The PSORI-CM01 formulation was 
originally developed to be applicable to all syndrome types. Indeed, there is no current 
reliable and validated Chinese medicine syndrome instrument available for psoriasis. 
Development of such an instrument, plus more investigation into the effect of syndrome 
type on efficacy and safety of various CHM interventions are needed.  
9.2.3 Strengths and limitations of the pilot study 
The double-blinded, randomised, placebo-controlled trial study design is the most 
rigorous method to evaluate an intervention with low risk of bias. The present pilot 
study attempted to match the look, taste and smell of CHM and placebo treatments to 
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ensure participant blinding throughout the study. Thus far, participants have reported 
their perceived treatment group allocation is based on change or lack of change to 
clinical symptoms, not the features of the provided granules.  
For CHM interventions, such rigorous RCT design can restrict potential efficacy of 
the intervention and may not reflect actual clinical effects. Allowing for syndrome in the 
study design allows Chinese medicine clinical relevance to be applied to results at 
analysis. Ideally, syndrome would be utilised to determine both CHM ingredient 
selection and dosage for each participant. With a much larger sample size and funding 
to develop and manufacture a range of formulations, such a study may be possible while 
maintaining rigour and minimising bias. 
Another feature of the pilot study is that there is no change to intervention during 
the treatment period, which keeps participants and dispensers blinded and reduces 
potential risk of bias to treatment allocation. However, this design may limit the 
potential efficacy of the oral CHM, as Chinese medicine theory indicates maximum 
efficacy requires ongoing formula modification according to disease and syndrome 
change. While such a design would provide maximum efficacy of CHM treatment, it 
would also increase risk of bias through treatment allocation.  
9.3 Conclusions 
The current study and its protocol development were based on a culmination of 
systematic review findings. Literature reviews were undertaken in Chinese medicine 
and conventional psoriasis disease and treatment, CHM plus conventional treatment for 
psoriasis, and biological activity of common CHM constituents in psoriasis. The reviews 
indicated that oral CHM has benefit for psoriasis, particularly when combined with 
conventional therapy. Deficiencies in the quality of previous research meant that 
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findings could not be considered conclusive. Safety data, although limited, indicated low 
risk of adverse events, however long-term data are lacking. 
 Mild–moderate severity psoriasis vulgaris is the most common type and has 
limited oral therapeutic options. Here, an oral CHM evidence-based intervention 
(PSORI-CM01) was combined with conventional therapy calcipotriol in a randomised, 
double-blinded, placebo-controlled pilot study designed according to the most rigorous 
methods possible. The pilot study is ongoing; however, preliminary reports indicate the 
study design is well suited for use in a full-scale study.   
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Appendices 
Appendix 1 –  Chinese medicine syndrome differentiation instrument  
CHINESE MEDICINE SYNDROME DIFFERENTIAL DIAGNOSIS 
QUESTIONNAIRE (to be completed by a Chinese medicine practitioner) 
 
 Differentiation of psoriasis Syndrome Yes No 
(A) 
Wind-heat with 
Blood dryness 
1. Plaques are in bright red colour   
2. Plaques are currently in emerging stage (recent 
exacerbation of the plaques) 
  
3. Increased erythema   
4. Skin lesions appear at the site of irritation (Koebner 
phenomenon) 
  
5. Irritability   
6. Dry mouth and thirsty   
7. Dry stool   
8. Dark colour urine   
(B) 
Blood 
Deficiency with 
Wind-dryness 
1. Plaques are in pale red colour   
2. Plaques may be in remission stage   
3. Large amount of scales   
4. Dry mouth   
5. Dry stool   
(C) 
Blood stasis 
1. Skin hypertrophy   
2. Plaques are in dark red/purple colour   
3. Plaques are prolonged   
Tongue  (A) Red tongue body, yellow or greasy tongue coating 
(B) Pink tongue body, thin and white tongue coating 
(C) Purple or dull tongue body, with dark purple patches 
or spots 
 
Pulse  (A) Taut and slippery or rapid pulse 
(B) Thin and slow pulse 
(C) Unsmooth/hesitant/choppy pulse or thin and slow 
pulse. 
 
Differentiation (please tick one of the three syndromes):  
(A) Wind-heat with Blood dryness  
(B) Blood Deficiency with Wind-dryness  
(C) Blood Stasis  
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Appendix 2 - Chinese database search strategy 
Search strategy for psoriasis 
CNKI 
1. Condition 
银屑病 牛皮癣 白庀 白庇 庀风 庇风 松皮癣  
2. Intervention  
中医 中医治疗 中医临床 中医辨证 中医干预 祖国医学 辨证施治 中西医 中西医学 中西
医结合 中西医治疗 中西医结合治疗 中西医结合疗法 中西医结合方法 
草药 中草药 中医药 中医药学 中医中药 中药治疗 中医药治疗 中医药疗法 中医药防治 
中医药研究 中医中药治疗 中草药治疗应用 
传统医学 传统医药 传统治疗 中国传统医学  
3. Study type 
随机临床观察 随机临床试验 临床随机研究 临床随机试验 临床观察 临床研究 临床疗效 
随机试验 疗效观察随机 随机 对照 单盲 双盲 系统评价 Meta 分析 
4. Strategy 
(SU%银屑病 or SU%牛皮癣 or SU%白疕 or SU%松皮癣) and  (SU%中医 or SU%中医临
床 or SU%中医辨证 or SU%祖国医学 or SU%辨证施治 or SU%中西医 or SU%中西医结
合 or SU%中西医结合疗法 or SU%草药 or SU%中草药 or SU%中医药 or SU%中医中药 
or SU%中药治疗 or SU%中医药防治 or SU%中医药研究 or SU%传统医学 or SU%传统
医药 or SU%传统治疗) and (SU%临床观察 or SU%随机临床试验 or SU%临床随机研究 
or SU%临床随机试验 or SU%临床研究 or SU%临床疗效 or SU%随机试验 or SU%系统
评价)  
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CQVIP: 
Keyword_C= ((银屑病+牛皮癣+白疕+松皮癣)*(中医+中医临床+中医辨证+祖国医学+辨
证施治+中西医+中西医结合+中西医结合疗法+草药+中草药+中医药+中医中药+中药治
疗+中医药防治+中医药研究+传统医学+传统医药+传统治疗)*(临床观察+随机临床试验
+临床随机研究+临床随机试验+临床研究+临床疗 效+随机试验+系统评
价))+Title_C=((银屑病+牛皮癣+白疕+松皮癣)*(中医+中医临床+中医辨证+祖国医学+辨
证施治+中西医+中西医结 合+中西医结合疗法+草药+中草药+中医药+中医中药+中药
治疗+中医药防治+中医药研究+传统医学+传统医药+传统治疗)*(临床观察+随机临床试
验+ 临床随机研究+临床随机试验+临床研究+临床疗效+随机试验+系统评价)) 
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Appendix 3 – Literature search list of Chinese herbs utilized for psoriasis 
Herb 
Herb 
name 
(Pinyin) 
Scientific/botanical 
name 
Herb 
Herb 
name 
(Pinyin) 
Scientific/botanical 
name 
1 Huang qi Astragali radix 59 
Bai zhi Angelicae dahuricae 
radix 
2 
Dang 
shen 
Codonopsis radix 60 
Fu ling 
Poria cocos 
3 Dan shen 
Salviae miltiorrhizae 
radix 
61 
Bai zhu  Atractylodis 
macrocephalae 
rhizoma 
4 Chi shao Paeoniae radix rubra 62 
Dong gu 
or xiang 
gu 
Lentinus edodes 
5 
Chuan 
xiong 
Rhizoma ligustici 
chuanxiong 
63 
Shui fei ji Fructus silybum 
marianum 
6 Di long 
Pheretima 
aspergillum 
64 
Jiang 
huang 
Curcumae longae 
rhizoma 
7 Niu xi 
Achyranthis 
bidentatae radix 
65 
Jiang can 
Bombyx batrycatus 
8 Zi cao 
Arnebiae/lithosperm
i radix 
66 
Cha ye 
Camellia sinensis 
9 Gan cao Glycyrrhizae radix 67 
Ling xiao 
hua  
Campsitis flos 
10 Ma huang Ephedrae herba 68 
She 
chuang zi  
Cnidii fructus 
11 Fu zi 
Aconiti radix 
lateralis praeparata 
69 
Huang 
lian 
Picrorhizae rhizoma 
12 Bai jie zi Sinapis albae semen 70 
King rat 
snake  
Elaphe carinata 
13 Rou gui 
Cinnamomi cassiae 
cortex 
71 
Tonburi 
(di fu zi) 
Kochia scoparia 
14 Gan jiang Zingiberis rhizoma 72 Ban mao  Mylabris 
15 Lu rong Cervi cornu 73 Sha shen Glehnia root 
16 Tu fu ling 
Smilacis glabrae 
rhizoma 
74 
Lu gen Common reed 
rhizome 
17 
Bai xian 
pi 
Dictamni cortex 75 
Yu zhu  Fragrant solomonseal 
rhizome 
18 
Bai mao 
gen 
Imperatae rhizoma 76 
Bai ji li  
Puncture-vine fruit 
19 
Ji xue 
teng 
Spatholobi caulis et 
radix 
77 
Di fu zi Fructus kochiae 
scopariae 
20 Huai hua Sophorae flos 78 
Quan 
shen 
Rhizoma bistortae 
21 Qing dai Indigo naturalis 79 Quan xie Scorpian 
22 Ku gua Momordica 80 Chai hu Radix bupleuri 
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charantia 
23 Bai liu pi 
 
81 Yu jin Radix curcumae 
24 
Qian cao 
gen 
Rubiae radix 82 
Xiang fu 
Rhizoma cyperi 
25 
Ren gong 
niu huang 
Calculus bovis 
artificial 
83 
Long dan 
cao 
Herba gentianae 
26 Gui zhi 
Cinnamomi cassiae 
ramulus 
84 
San leng 
Rhizoma sparganii 
27 Bai shao 
Paeoniae radix 
lactiflora 
85 
Tao ren 
Semen persicae 
28 Yi yi ren Coicis semen 86 
Gui jian 
yu 
Euonymi ramulus 
29 
Shui niu 
jiao 
Bubali cornu 87 
Chen po 
Pericarpium citri 
reticulatae 
30 
Bai hua 
she she 
cao 
Hedyotidis diffusae 
herba 
88 
Ju hua 
Tanacetum 
parthenium 
31 Huang bai Phellodendri cortex 89 Ji xue cao Herba centellae 
32 E zhu Curcumae rhizoma 90 Qian hu Radix peucedani 
33 Mu li Ostrea concha 91 
Sang ji 
sheng 
Ramulus visci 
34 
Xuan 
shen 
Scrophulariae radix 92 
Yin xing 
ye 
Folium ginkgo 
35 Dang gui 
Angelicae sinensis 
radix 
93 
Shang lu 
Radix phytolaccae 
36 
He shou 
wu 
Polygoni multiflori 
radix 
94 
San qi 
Notoginseng 
37 Di huang Rehmanniae radix 95 Bu gu zhi Fructus psoraleae 
38 
Pu gong 
ying 
Taraxaci herba 96 
Nan she 
teng 
Celatrus orbiculatus 
39 Lian qiao Forsythiae fructus 97 
Feng fang Hornets nest (nidus 
vespae) 
40 
Ban lan 
gen 
Isatidis/baphicacant
his radix 
98 
Tian men 
dong 
Radix asparagi 
41 
Da qing 
ye 
Isatidis folium 99 
Mai dong 
Radix ophiopogonis 
42 
Jin yin 
hua 
Lonicerae flos 100 
Chen pi Pericarpium citri 
reticulatae 
43 Xia ku cao Prunellae spica 101 Chan tui Periostracum cicadae 
44 Mu dan pi Moutan cortex 102 
Niu bang 
zi 
Fructus arctii 
45 
Shu di 
huang 
Rehmanniae radix 
praeparata 
103 
Liu yue 
xue (liu ji 
nu) 
Herba serissae 
46 Ling yang Cornu antelopis 104 Ru xiang Resina boswelliae 
 411 
jiao 
47 Zhi zi Gardeniae fructus 105 Mo yao Myrrha 
48 Huang qin Scutellariae radix 106 Wu mei Fructus mume 
49 Hong hua Carthami flos 107 
Ba qia Rhizoma smilacis 
chinensis 
50 Ku shen 
Sophorae 
flavescentis radix 
108 
Ci shi  
Magnetitum 
51 Fang feng Saposhnikoviae radix 109 
Zhen zhu 
mu 
Concha magaritifera 
usta 
52 
Bei dou 
gen 
Menispermi rhizoma 110 
Niu huang 
Calculus bovis 
53 Hu zhang 
Polygoni cuspidati 
rhizoma 
111 
Wu she 
Zaocys 
54 Jing jie Schizonepetae herba 112 
Cao he 
che 
Rhizoma paridis 
choglou 
55 
Sheng shi 
gao 
Gypsum fibrosum 113 
Ren dong 
tang 
Caulis lonicerae 
56 
Bai ying 
(long kui) 
Herba solani lyrati 114 
Shan dou 
gen 
Radix sophorae 
tonkinensis 
57 She mei 
Herba duchesneae 
indicae 
115 
Da huang Radix et rhizoma rhei 
recens 
58 
Lei gong 
teng 
Tripterygium 
wilfordii hook 
116 
Dai mao 
fen 
Carapax 
eretmochelydis 
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Appendix 4 – Dermatology life quality index instrument 
Note: Used with permission Dr Faraz Mahmood Ali (on behalf of Prof. Andrew Finlay)  
 413 
Appendix 5 – Skindex 29 Instrument 
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Note: User agreement signed with MAPI research trust for SKINDEX 29 use  
 415 
Appendix 6 – Study recruitment advertisements and recruitment poster 
 
Source RMIT Univeristy website (https://www.rmit.edu.au/.../chinese-herbal-
medicine-for-psoriasis-study/) 
 
 416 
 
Source: Linked In (https://www.linkedin.com/) 
 
Life News magazine 
 417 
 
          
 
 418 
 
Source: Example newspaper advertisement published in the Moreland Leader 
newspaper 
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Appendix 7 – Patient information and consent form 
 
 
 
 
 
 
 420 
 
 421 
 
 422 
 
 
 423 
 
 
 
 
 
 
 424 
 
 
 425 
Appendix 8 - Case Record Form example  
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Appendix 9 – Study medication instructions 
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Appendix 11 – Serious adverse events form 
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Appendix 14 - TGA Clinical Trial Notification letter 
 
 
